0001140361-24-03629910-Q FEMASYS INC 2024080820240808084536084536084536 0 0001140361-24-036299 10-Q 66 20240630 20240808 20240808 FEMASYS INC 0001339005 3841 113713499 DE 1231 10-Q 34 001-40492 241186263 3950 JOHNS CREEK COURT SUITE 100 SUWANEE GA 30024 770-500-3910 3950 JOHNS CREEK COURT SUITE 100 SUWANEE GA 30024 10-Q 1 ef20029680_10q.htm 10-Q false12-312024Q200013390052023-03-31NASDAQ2023-11-3000013390052024-01-012024-06-3000013390052024-08-0700013390052024-06-3000013390052023-12-3100013390052023-01-012023-06-3000013390052024-04-012024-06-3000013390052023-04-012023-06-300001339005us-gaap:CommonStockMember2023-03-310001339005us-gaap:AdditionalPaidInCapitalMember2023-06-3000013390052023-06-300001339005us-gaap:RetainedEarningsMember2023-03-3100013390052024-03-310001339005femy:EquityWarrantsMember2023-03-310001339005us-gaap:AdditionalPaidInCapitalMember2022-12-310001339005us-gaap:CommonStockMember2022-12-310001339005us-gaap:RetainedEarningsMember2022-12-3100013390052023-03-3100013390052022-12-310001339005femy:EquityWarrantsMember2023-06-300001339005us-gaap:CommonStockMember2024-03-310001339005us-gaap:CommonStockMember2023-06-300001339005us-gaap:AdditionalPaidInCapitalMember2023-03-310001339005us-gaap:RetainedEarningsMember2024-03-310001339005femy:EquityWarrantsMember2024-03-310001339005us-gaap:RetainedEarningsMember2023-06-300001339005us-gaap:AdditionalPaidInCapitalMember2024-03-310001339005femy:EquityWarrantsMember2022-12-310001339005us-gaap:CommonStockMember2024-06-300001339005us-gaap:TreasuryStockCommonMember2024-03-310001339005us-gaap:TreasuryStockCommonMember2023-12-310001339005us-gaap:TreasuryStockCommonMember2022-12-310001339005us-gaap:TreasuryStockCommonMember2023-03-310001339005us-gaap:TreasuryStockCommonMember2023-06-300001339005femy:EquityWarrantsMember2023-04-012023-06-300001339005femy:EquityWarrantsMember2023-01-012023-06-300001339005us-gaap:RetainedEarningsMember2023-01-012023-06-300001339005us-gaap:TreasuryStockCommonMember2023-04-012023-06-300001339005us-gaap:CommonStockMember2023-01-012023-06-300001339005us-gaap:TreasuryStockCommonMember2023-01-012023-06-300001339005us-gaap:AdditionalPaidInCapitalMember2023-01-012023-06-300001339005us-gaap:AdditionalPaidInCapitalMember2023-04-012023-06-300001339005us-gaap:RetainedEarningsMember2023-04-012023-06-300001339005us-gaap:CommonStockMember2023-04-012023-06-300001339005us-gaap:AdditionalPaidInCapitalMember2024-04-012024-06-300001339005us-gaap:CommonStockMember2024-01-012024-06-300001339005us-gaap:CommonStockMember2024-04-012024-06-300001339005femy:EquityWarrantsMember2024-04-012024-06-300001339005us-gaap:AdditionalPaidInCapitalMember2024-01-012024-06-300001339005us-gaap:RetainedEarningsMember2024-04-012024-06-300001339005us-gaap:RetainedEarningsMember2024-01-012024-06-300001339005us-gaap:TreasuryStockCommonMember2024-01-012024-06-300001339005us-gaap:TreasuryStockCommonMember2024-04-012024-06-300001339005femy:EquityWarrantsMember2024-01-012024-06-300001339005us-gaap:TreasuryStockCommonMember2024-06-300001339005us-gaap:CommonStockMember2023-12-310001339005femy:EquityWarrantsMember2024-06-300001339005us-gaap:RetainedEarningsMember2024-06-300001339005us-gaap:AdditionalPaidInCapitalMember2024-06-300001339005us-gaap:RetainedEarningsMember2023-12-310001339005us-gaap:AdditionalPaidInCapitalMember2023-12-310001339005femy:EquityWarrantsMember2023-12-310001339005femy:Two021StockOptionPlanMember2024-01-012024-06-300001339005femy:InducementGrantMember2024-01-012024-06-300001339005us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Member2024-06-300001339005us-gaap:FairValueInputsLevel1Memberus-gaap:MoneyMarketFundsMember2023-12-310001339005srt:MaximumMember2024-01-012024-06-300001339005srt:MinimumMember2024-01-012024-06-300001339005femy:FemVueMember2024-04-012024-06-300001339005country:USfemy:FemVueMember2023-01-012023-06-300001339005femy:FemVueMember2023-04-012023-06-300001339005femy:FemVueMembercountry:US2023-04-012023-06-300001339005femy:FemVueMemberus-gaap:NonUsMember2023-04-012023-06-300001339005femy:FemVueMember2023-01-012023-06-300001339005us-gaap:NonUsMemberfemy:FemVueMember2024-04-012024-06-300001339005country:USfemy:FemVueMember2024-01-012024-06-300001339005femy:FemVueMember2024-01-012024-06-300001339005femy:FemVueMemberus-gaap:NonUsMember2024-01-012024-06-300001339005us-gaap:NonUsMemberfemy:FemVueMember2023-01-012023-06-300001339005country:USfemy:FemVueMember2024-04-012024-06-300001339005femy:AFCOCreditCorporationMemberfemy:JunePromissoryNoteMember2022-06-012022-06-300001339005femy:JulyPromissoryNoteMemberfemy:AFCOCreditCorporationMember2023-07-012023-07-310001339005femy:AFCOCreditCorporationMemberfemy:JunePromissoryNoteMember2022-06-300001339005femy:AFCOCreditCorporationMemberfemy:JulyPromissoryNoteMember2023-07-310001339005femy:JulyPromissoryNoteMemberfemy:AFCOCreditCorporationMember2024-01-012024-06-300001339005femy:JunePromissoryNoteMemberfemy:AFCOCreditCorporationMember2024-01-012024-06-300001339005femy:AFCOCreditCorporationMemberfemy:JulyPromissoryNoteMember2023-12-310001339005femy:AFCOCreditCorporationMemberfemy:JulyPromissoryNoteMember2024-06-300001339005femy:AFCOCreditCorporationMemberfemy:JulyPromissoryNoteMember2024-04-012024-06-300001339005femy:JulyPromissoryNoteMemberfemy:AFCOCreditCorporationMember2023-01-012023-06-300001339005femy:AFCOCreditCorporationMemberfemy:JulyPromissoryNoteMember2023-04-012023-06-300001339005femy:November2023FinancingMemberus-gaap:CommonStockMemberus-gaap:ConvertibleDebtMember2023-11-210001339005femy:November2023FinancingMemberus-gaap:ConvertibleDebtMemberfemy:SeriesBWarrantsMember2023-11-210001339005femy:November2023FinancingMemberfemy:SeriesAWarrantsMember2023-11-210001339005femy:November2023FinancingMember2023-11-212023-11-210001339005femy:November2023FinancingMemberus-gaap:ConvertibleDebtMember2024-06-300001339005us-gaap:ConvertibleDebtMemberfemy:November2023FinancingMember2024-01-012024-06-300001339005femy:November2023FinancingMember2024-01-012024-06-300001339005femy:November2023FinancingMember2023-11-210001339005femy:November2023FinancingMemberfemy:SeriesAWarrantsMember2024-06-300001339005femy:November2023FinancingMemberfemy:SeriesBWarrantsMember2024-06-300001339005femy:SeriesBWarrantsMemberfemy:November2023FinancingMember2023-11-212023-11-210001339005femy:SeriesAWarrantsMemberfemy:November2023FinancingMember2023-11-212023-11-210001339005femy:November2023FinancingMemberfemy:SeriesBWarrantsMember2024-01-012024-06-300001339005femy:SeriesAWarrantsMemberfemy:November2023FinancingMember2024-01-012024-06-300001339005us-gaap:ConvertibleDebtMemberfemy:November2023FinancingMember2024-04-012024-06-300001339005femy:November2023FinancingMemberus-gaap:ConvertibleDebtMember2023-12-310001339005srt:MaximumMember2022-07-010001339005femy:EquityDistributionAgreementMembersrt:MaximumMember2023-10-310001339005us-gaap:CommonStockMember2023-04-012023-04-300001339005femy:EquityDistributionAgreementMember2024-01-012024-06-300001339005srt:MaximumMemberfemy:PlacementAgentWarrantsMember2023-04-300001339005femy:CommonWarrantsMembersrt:MaximumMember2023-04-300001339005femy:PreFundedWarrantsMembersrt:MaximumMember2023-04-300001339005femy:PreFundedWarrantsMember2023-04-300001339005us-gaap:CommonStockMember2023-04-3000013390052023-04-012023-04-300001339005femy:PlacementAgentWarrantsMember2023-09-012023-09-300001339005femy:PlacementAgentWarrantsMember2023-10-012023-10-310001339005femy:PlacementAgentWarrantsMember2024-06-300001339005femy:Two021StockOptionPlanMember2023-12-310001339005femy:Two021StockOptionPlanMemberus-gaap:ShareBasedPaymentArrangementNonemployeeMember2024-01-012024-06-300001339005us-gaap:ShareBasedPaymentArrangementEmployeeMemberfemy:Two021StockOptionPlanMember2024-01-012024-06-300001339005femy:Two021StockOptionPlanMember2024-06-300001339005femy:InducementGrantMember2024-02-122024-02-120001339005femy:InducementGrantMember2024-06-300001339005femy:InducementGrantMember2024-02-120001339005us-gaap:ResearchAndDevelopmentExpenseMember2023-01-012023-06-300001339005us-gaap:GeneralAndAdministrativeExpenseMember2024-04-012024-06-300001339005us-gaap:GeneralAndAdministrativeExpenseMember2024-01-012024-06-300001339005us-gaap:SellingAndMarketingExpenseMember2024-04-012024-06-300001339005us-gaap:SellingAndMarketingExpenseMember2023-01-012023-06-300001339005us-gaap:GeneralAndAdministrativeExpenseMember2023-04-012023-06-300001339005us-gaap:SellingAndMarketingExpenseMember2024-01-012024-06-300001339005us-gaap:ResearchAndDevelopmentExpenseMember2024-01-012024-06-300001339005us-gaap:GeneralAndAdministrativeExpenseMember2023-01-012023-06-300001339005us-gaap:ResearchAndDevelopmentExpenseMember2024-04-012024-06-300001339005us-gaap:ResearchAndDevelopmentExpenseMember2023-04-012023-06-300001339005us-gaap:SellingAndMarketingExpenseMember2023-04-012023-06-300001339005femy:EmployeeStockPurchasePlanMember2024-01-012024-06-300001339005femy:EmployeeStockPurchasePlanMember2023-01-012023-06-300001339005femy:EmployeeStockPurchasePlanMember2024-06-3000013390052023-04-202023-04-200001339005femy:CommonWarrantsMember2023-04-200001339005femy:PlacementAgentWarrantsMember2023-04-200001339005femy:PreFundedWarrantsMember2023-04-200001339005femy:CommonWarrantsMember2024-06-300001339005femy:PreFundedWarrantsMember2023-04-202023-04-200001339005femy:CommonWarrantsMember2023-04-202023-04-2000013390052023-11-012023-11-300001339005femy:WarrantsSevenMember2023-01-012023-06-300001339005femy:WarrantsSixMember2023-04-012023-06-300001339005femy:WarrantsSixMember2024-04-012024-06-300001339005femy:WarrantsSevenMember2024-01-012024-06-300001339005femy:WarrantsSevenMember2023-04-012023-06-300001339005femy:WarrantsSixMember2024-01-012024-06-300001339005femy:WarrantsSevenMember2024-04-012024-06-300001339005femy:WarrantsSixMember2023-01-012023-06-30xbrli:sharesiso4217:USDiso4217:USDxbrli:sharesfemy:Segmentfemy:Productfemy:Womenxbrli:pure UNITED STATES SECURITIES AND

EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) â˜‘ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR â˜ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____to_____ Commission file number: 001-40492 Femasys Inc. (Exact Name of Registrant as Specified in its Charter) Â Delaware 11-3713499 (State or other jurisdiction of incorporation or organization) (IRS Employer Identification No.) Â Â 3950 Johns Creek Court, Suite 100 Â Suwanee, GAÂ Â 30024 (Address of principal executive offices) (Zip Code) Â Â Â (770) 500-3910 Â Â (Registrantâ€™s telephone number, including area code) Â Â Â Â Â N/A Â Â (Former name, former address and former fiscal year, if changed since last report) Â Â Securities registered pursuant to Section 12(b) of the Act: Â Title of each class Trading symbol Name of each exchange on which registered Â Common stock, $0.001 par value FEMY The Nasdaq Capital Market Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes â˜‘ No â˜ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes â˜‘Â No â˜ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company, or an emerging growth company. See the definitions of â€œlarge accelerated filer,â€ â€œaccelerated filerâ€ and â€œsmaller reporting companyâ€ and â€œemerging growth companyâ€ in Rule 12b-2 of the Exchange Act. Large accelerated filer â˜ Accelerated filer â˜ Non-accelerated filer â˜‘ Smaller reporting company â˜‘ Emerging growth company â˜‘ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. â˜‘ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).Â Yes â˜ No â˜‘ The Registrant had 22,232,799 shares of common stock, $0.001 par value, outstanding as of August 7, 2024. Â Â TABLE OF CONTENTS Â Â Â Page Part I. Financial Information Item 1 Condensed Financial Statements 5 Â Condensed Balance Sheets as of June 30, 2024 and December 31, 2023 (unaudited) 6 Â Condensed Statements of Comprehensive Loss for the Three and Six months ended June 30, 2024 and 2023 (unaudited) 7 Â Condensed Statements of Stockholdersâ€™ Equity for the Three and Six months ended June 30, 2024 and 2023 (unaudited) 8 Â Condensed Statements of Cash Flows for the Six months ended June 30, 2024 and 2023 (unaudited) 10 Â Condensed Notes to Financial Statements (unaudited) 11 Item 2 Managementâ€™s Discussion and Analysis of Financial Condition and Results of Operations 18 Item 3 Quantitative and Qualitative Disclosures About Market Risk 26 Item 4 Controls and Procedures 26 Â Part II. Other Information Item 1 Legal Proceedings 27 Item 1A Risk Factors 28 Item 2 Unregistered Sales of Equity Securities and Use of Proceeds 28 Item 3 Defaults Upon Senior Securities 28 Item 4 Mine Safety Disclosures 28 Item 5 Other Information 28 Item 6 Exhibits 28 SIGNATURES 30 2 Table of Contents SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS This Quarterly Report on Form 10-Q contains forward-looking statements. All statements other than statements of historical facts contained in this Quarterly Report on Form 10-Q are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as â€œmay,â€ â€œwill,â€ â€œshould,â€ â€œexpect,â€ â€œplan,â€ â€œanticipate,â€ â€œcould,â€ â€œintend,â€ â€œtarget,â€ â€œproject,â€ â€œcontemplate,â€ â€œbelieve,â€ â€œestimate,â€ â€œpredict,â€ â€œpotentialâ€ or â€œcontinueâ€ or the negative of these terms or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements include, but are not limited to, statements concerning: Â â€¢ our ability to successfully initiate and grow the commercial launch of FemaSeedÂ®; â€¢ our ability to obtain additional financing to fund the clinical development and commercialization of our product candidate and products and fund our operations; â€¢ estimates regarding the total addressable market for our products and product candidate; â€¢ competitive companies and technologies in our industry; â€¢ our business model and strategic plans for our products, product candidate, technologies and business, including our implementation thereof; â€¢ commercial success and market acceptance of our products and product candidate; â€¢ our ability to achieve and maintain adequate levels of coverage or reimbursement for FemaSeed, FemBloc or any future product candidates, and our products we may seek to commercialize; â€¢ our ability to accurately forecast customer demand for our product candidates, and manage our inventory; â€¢ our ability to build, manage and maintain our direct sales and marketing organization, and to market and sell our artificial insemination product, permanent birth control system, and women-specific medical product solutions in markets in and outside of the United States; â€¢ our expectations about market trends â€¢ our ability to develop and advance our current product candidate, FemBlocÂ®Â and successfully initiate andÂ complete, clinical trials; â€¢ the ability of our clinical trials to demonstrate safety and effectiveness of our product candidate, FemBlocÂ and other positive results; â€¢ our ability to enroll subjects in the clinical trials for our product candidate, FemBloc in order to advance the development thereof on a timely basis; â€¢ our ability to obtain U.S. Food and Drug Administration (FDA) approval for our product candidate, FemBloc, for permanent birth control, ability to establish and expand sales of our women-specific medical products and develop and commercialize additional products; â€¢ our ability to obtain regulatory approvals for and commercialize our product candidate FemBloc, or the effect of delays in obtaining regulatory authorizations and commercialize; â€¢ our ability to manufacture our products and product candidates in compliance with applicable laws, regulations and requirements and to oversee third-party suppliers, service providers and vendors in the performance of any contracted activities in accordance with applicable laws, regulations and requirements; â€¢ our ability to hire and retain our senior management and other highly qualified personnel; â€¢ FDA or other U.S. or foreign regulatory or governmental actions affecting us or the healthcare industry generally, including healthcare reform measures in the United States and international markets; â€¢ the timing or likelihood of regulatory filings and approvals or clearances; â€¢ our ability to establish and maintain intellectual property protection for our product candidates and our ability to avoid claims of infringement; and â€¢ the volatility of the trading price of our common stock. 3 Table of Contents The forward-looking statements in this Quarterly Report on Form 10-Q are only predictions and are based largely on our current expectations and projections about future events and financial trends that we believe may affect our business, financial condition and results of operations. These forward-looking statements speak only as of the date of this Quarterly Report on Form 10-Q and are subject to a number of known and unknown risks, uncertainties and assumptions, including those described under the sections in this Quarterly Report on Form 10-Q entitled â€œRisk Factorsâ€ and â€œManagementâ€™s Discussion and Analysis of Financial Condition and Results of Operationsâ€ and elsewhere in this Quarterly Report on 10-Q. BecauseÂ forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified and some of which are beyond our control, you should not rely on these forward-looking statements as predictions of future events. The events and circumstances reflected in our forward-looking statements may not be achieved or occur and actual results could differ materially from those projected in the forward-looking statements. Moreover, we operate in an evolving environment. New risk factors and uncertainties may emerge from time to time, and it is not possible for management to predict all risk factors and uncertainties. You should read this Quarterly Report on FormÂ 10-QÂ and the documents that we reference in this Quarterly Report on FormÂ 10-QÂ and have filed with the Securities and Exchange Commission as exhibits hereto completely and with the understanding that our actual future results may be materially different from any future results expressed or implied by these forward-looking statements. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise. TheÂ forward-looking statements contained in this Quarterly Report on 10-Q are excluded from the safe harbor protection provided by the Private Securities Litigation Reform Act of 1995 and Section 27A of the Securities Act of 1933, as amended. 4 Table of Contents PART I. FINANCIAL INFORMATION ITEM I. Financial Statements FEMASYS INC. Condensed Balance Sheets (unaudited) Assets Â June 30, 2024 Â Â December 31, 2023 Â Current assets: Â Â Â Â Â Â Cash and cash equivalents Â $ 13,525,898 Â Â Â 21,716,077 Â Accounts receivable, net Â Â 92,535 Â Â Â 98,906 Â Inventory, net Â Â 1,315,580 Â Â Â 667,118 Â Prepaid and other current assets Â Â 997,623 Â Â Â 695,879 Â Total current assets Â Â 15,931,636 Â Â Â 23,177,980 Â Property and equipment, at cost: Â Â Â Â Â Â Â Leasehold improvements Â Â 1,212,417 Â Â Â 1,212,417 Â Office equipment Â Â 47,308 Â Â Â 47,308 Â Furniture and fixtures Â Â 429,933 Â Â Â 414,303 Â Machinery and equipment Â Â 2,599,994 Â Â Â 2,559,356 Â Construction in progress Â Â 651,157 Â Â Â 423,077 Â Â Â Â 4,940,809 Â Â Â 4,656,461 Â Less accumulated depreciation Â Â (3,678,450) Â Â (3,545,422) Net property and equipment Â Â 1,262,359 Â Â Â 1,111,039 Â Long-term assets: Â Â Â Â Â Â Â Lease right-of-use assets, net Â Â 2,081,054 Â Â Â 2,380,225 Â Intangible assets, net of accumulated amortization Â Â 44,317 Â Â Â â€” Â Other long-term assets Â Â 957,078 Â Â Â 1,086,581 Â Total long-term assets Â Â 3,082,449 Â Â Â 3,466,806 Â Â Â Â Â Â Â Â Total assets Â $ 20,276,444 Â Â Â 27,755,825 Â (continued) 5 Table of Contents FEMASYS INC. Condensed Balance Sheets (unaudited) Liabilities and Stockholdersâ€™ Equity Â June 30, 2024 Â Â December 31, 2023 Â Current liabilities: Â Â Â Â Â Â Accounts payable Â $ 951,510 Â Â Â 1,137,823 Â Accrued expenses Â Â 886,352 Â Â Â 1,444,296 Â Clinical holdback â€“ current portion Â Â 92,397 Â Â Â 65,300 Â Lease liabilities â€“ current portion Â Â 533,734 Â Â Â 406,636 Â Total current liabilities Â Â 2,463,993 Â Â Â 3,054,055 Â Long-term liabilities: Â Â Â Â Â Â Â Clinical holdback â€“ long-term portion Â Â 32,706 Â Â Â 54,935 Â Convertible notes payable, net (including related parties) Â Â 4,758,017 Â Â Â 4,258,179 Â Lease liabilities â€“ long-term portion Â Â 1,771,487 Â Â Â 2,036,067 Â Total long-term liabilities Â Â 6,562,210 Â Â Â 6,349,181 Â Total liabilities Â Â 9,026,203 Â Â Â 9,403,236 Â Commitments and contingencies Â Â Â Â Â Â Stockholdersâ€™ equity: Â Â Â Â Â Â Â Common stock, $0.001 par, 200,000,000 authorized, 22,350,022 shares issued and 22,232,799 outstanding as of June 30, 2024; and 21,774,604 shares issuedÂ and 21,657,381 outstanding as of December 31, 2023 Â Â 22,350 Â Â Â 21,775 Â Treasury stock, 117,223 common shares Â Â (60,000) Â Â (60,000) Warrants Â Â 2,608,642 Â Â Â 2,787,137 Â Additional paid-in-capital Â Â 125,344,962 Â Â Â 123,985,306 Â Accumulated deficit Â Â (116,665,713) Â Â (108,381,629) Total stockholdersâ€™ equity Â Â 11,250,241 Â Â Â 18,352,589 Â Â Â Â Â Â Â Â Total liabilities and stockholdersâ€™ equity Â $ 20,276,444 Â Â Â 27,755,825 Â Â The accompanying notes are an integral part of these condensed unaudited financial statements. 6 Table of Contents FEMASYS INC. Condensed Statements of Comprehensive Loss (unaudited) Â Â Three Months Ended June 30, Â Â Six Months Ended June 30, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Sales Â $ 221,484 Â Â Â 320,514 Â Â Â 492,624 Â Â Â 614,498 Â Cost of sales (excluding depreciation expense) Â Â 73,125 Â Â Â 110,469 Â Â Â 161,657 Â Â Â 215,589 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Operating expenses: Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Research and development Â Â 1,975,875 Â Â Â 1,527,172 Â Â Â 3,746,606 Â Â Â 3,064,611 Â Sales and marketing Â Â

975,190 Â Â Â 128,899 Â Â Â 1,275,677 Â Â Â 373,795 Â General and administrative Â Â 1,611,817 Â Â Â 1,356,637 Â Â Â 3,114,621 Â Â Â 2,671,774 Â Depreciation and amortization Â Â 67,628 Â Â Â 133,299 Â Â Â 138,856 Â Â Â 266,365 Â Total operating expenses Â Â 4,630,510 Â Â Â 3,146,007 Â Â Â 8,275,760 Â Â Â 6,376,545 Â Loss from operations Â Â (4,482,151) Â Â (2,935,962) Â Â (7,944,793) Â Â (5,977,636) Other income (expense): Â Â Â

insemination to market in the United States. A pivotal clinical trial was still ongoing at the time of receiving regulatory clearance, however, enrollment was completed in November 2023. In June 2024, the Company received European Union Medical Device Regulation (EU MDR) certificates and CE Mark certification for four products: FemaSeed, FemVue, FemCervÂ® and FemCathÂ®. FemVue, a solution that enables fallopian tube assessment with ultrasound as an alternative to the radiologic approach (hysterosalpingogram) for the diagnosis of infertility, is approved for sale in the U.S., Japan, and Canada. FemChecÂ® allows for fallopian tube evaluation after a FemBloc procedure to confirm occlusion (or procedure success). FemCerv is a solution for complete tissue sampling with minimal contamination of the endocervical canal in a virtually pain-free procedure as an alternative to the single biopsy method for diagnosis of cervical cancer and is approved for sale in the U.S. and Canada. FemCath, allows for selective evaluation of an individual fallopian tube as an alternative to the traditional intrauterine catheter that is undirected, is approved for sale in the U.S. and Canada. FemBlocÂ®, the Companyâ€™s solution for permanent birth control, is based on the Companyâ€™s platform technology for delivery and in June 2023 Femasys received FDA approval of our IDE to evaluate the safety and efficacy of FemBloc, our non-surgical, non-implant, non-hormonal in-office solution for permanent birth control in a pivotal clinical trial. In August 2023 Femasys announced the initiation of enrollment in the FINALE [Prospective Multi-Center Trial for FemBloc Intratubal Occlusion for TranscervicAL Permanent Birth Control] pivotal trial designed to evaluate the safety and efficacy of FemBloc. This prospective, multi-center, open-label, single-arm study design includes pregnancy rate as the primary endpoint, which will be analyzed once 401 women have relied on FemBloc for one year for permanent birth control. In addition, the study is designed as a roll-in beginning with enrollment of 50 women for a clinical readout primarily of preliminary safety data prior to enrolling the remaining subjects. An interim analysis of clinical data endpoints is planned once 300 women have used FemBloc for permanent birth control for one year. Follow-up will continue annually for five years post-market. Basis of Presentation Â The Company has prepared the accompanying condensed financial statements pursuant to the rules and regulations of the U.S. Securities and Exchange Commission (SEC). Certain information and footnote disclosures normally included in the annual financial statements prepared in accordance with accounting principles generally accepted in the United States of America (U.S. GAAP) have been condensed or omitted pursuant to these rules and regulations. These condensed financial statements should be read in conjunction with the Companyâ€™s audited financial statements and footnotes related thereto for the year ended December 31, 2023 included in our Annual Report on Form 10K filed with the SEC on March 28, 2024 (the Annual Report). There have been no material changes to the Companyâ€™s significant accounting policies described in Note 2 to the financial statements included in the Annual Report. Â In the opinion of management, the unaudited financial statements include all adjustments (consisting only of normal recurring adjustments) necessary to present fairly the Companyâ€™s financial position and the results of its operations and cash flows at the dates for periods presented. The results of operations for such interim periods are not necessarily indicative of the results to be expected for the full year. Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenue and expense during the reporting periods. Estimates for these and other items are subject to change and are reassessed by management in accordance with U.S. GAAP. Actual results could differ from those estimates. Liquidity Â As of June 30, 2024, the Company had cash and cash equivalents of $13,525,898. The Company plans to finance its operations and development needs with its existing cash and cash equivalents, additional equity and/or debt financing arrangements, and revenue primarily anticipated from the sale of FemVue and FemaSeed to support the Companyâ€™s research and development activities, primarily focused on FemBloc. There can be no assurance that the Company will be able to obtain additional financing on terms acceptable to the Company, on a timely basis, or at all. If the Company is not able to obtain sufficient funds on acceptable terms when needed, the Companyâ€™s business, results of operations, and financial condition could be materially adversely impacted. 11 Table of Contents FEMASYS INC. Condensed Notes to Financial Statements (unaudited) For the six months ended June 30, 2024, the Company generated a net loss of $8,284,084. The Company expects such losses to increase over the next few years as the Company advances FemBloc through clinical development if and until FDA approval is received and is available to be marketed. The financial statements have been prepared on a going-concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Company has incurred net operating losses in every year since inception and has an accumulated deficit as of June 30, 2024 of $116,665,713 and expects to incur additional losses and negative operating cash flows for at least the next twelve months. The Companyâ€™s ability to meet its obligations is dependent upon its ability to generate sufficient cash flows from operations and future financing transactions. Although management expects the Company will continue as a going concern, there is no assurance that managementâ€™s plans will be successful since the availability and amount of such funding is not certain. Accordingly, substantial doubt exists about the Companyâ€™s ability to continue as a going concern for at least one year from the issuance of these financial statements. The accompanying financial statements do not include any adjustments to reflect the possible future effects on the recoverability of assets or the amounts and classifications of liabilities that may result from the possible inability of the Company to continue as a going concern. Recently Issued Accounting Pronouncements â€“ Recently Adopted In November 2023, the FASB issued ASU No. 2023-07,Â Segment Reporting (Topic 28): Improvements to Reportable Segment Disclosures. The ASU improves reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment expenses. The ASU improves financial reporting by requiring disclosure of incremental segment information on an annual and interim basis for all public entities to enable investors to develop more decision-useful financial analyses. The amendments in this update are effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted. The Company will adopt the ASU for the fiscal year ended December 31, 2024 and interim periods in fiscal 2025. The adoption of the ASU will result in additional disclosures to the Companyâ€™s financial statements and footnote disclosures. Â Recently Issued Accounting Pronouncements â€“ Not Yet Adopted In December 2023, the FASB issued ASU 2023-09,Â Income Taxes (Topic 740): Improvements to Income Tax Disclosures. The ASU requires the annual financial statements to include consistent categories and greater disaggregation of information in the rate reconciliation, and income taxes paid disaggregated by jurisdiction. ASU 2023-09 is effective for the Companyâ€™s annual reporting periods beginning after December 15, 2024. Adoption is either with a prospective method or a fully retrospective method of transition. Early adoption is permitted. The Company is currently evaluating the effect that adoption of ASU 2023-09 will have on its financial statements and expects to adopt the ASU on January 1, 2025. No other new accounting pronouncement issued or effective has had, or is expected to have, a material impact on the Companyâ€™s financial statements. Â (2) Fair Value The Company applies a fair value hierarchy that requires the use of observable market data, when available, and prioritizes the inputs to valuation techniques used to measure fair value in the following categories: Level 1 â€“ Valuation is based upon quoted prices for identical instruments traded in active markets. Level 2 â€“ Valuation is based upon quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active, and modelâ€‘based valuation techniques for which all significant assumptions are observable in the market. Level 3 â€“ Valuation is generated from modelâ€‘based techniques that use significant assumptions not observable in the market. These unobservable assumptions reflect the Companyâ€™s own estimates of assumptions market participants would use in pricing the asset or liability. Certain of the Companyâ€™s financial instruments, including cash and other liabilities approximate their fair value because of the shortâ€‘term maturity of these financial instruments. The fair value of stock options, convertible notes and warrants are based on Level 3 inputs. (3) Cash and Cash Equivalents Â As of June 30, 2024 and December 31, 2023, money market funds included in cash and cash equivalents on the balance sheets were $12,686,738 and $21,278,895, respectively, which represent level 1 within the fair value hierarchy where there are quoted prices in active markets for identical assets. (4) Inventories Â Inventory stated at cost, net of reserve, consisted of the following: Â Â June 30, Â Â December 31, Â Â Â 2024 Â Â 2023 Â Materials Â $ 792,365 Â Â Â 367,934 Â Work in progress Â Â 229,045 Â Â Â 128,993 Â Finished goods Â Â 294,170 Â Â Â 170,191 Â Inventory, net Â $ 1,315,580 Â Â Â 667,118 Â 12 Table of Contents FEMASYS INC. Condensed Notes to Financial Statements (unaudited) (5) Accrued Expenses Â Accrued expenses consisted of the following: Â Â June 30, Â Â December 31, Â Â Â 2024 Â Â 2023 Â Clinical trial costs Â $ 334,799 Â Â Â 276,141 Â Accrued interest Â Â 250,025 Â Â Â â€” Â Incentive and other compensation costs Â Â 170,328 Â Â Â 1,082,606 Â Director fees Â Â 70,000 Â Â Â 60,210 Â Franchise taxes Â Â 3,150 Â Â Â 12,160 Â Other Â Â 58,050 Â Â Â 13,179 Â Accrued expenses Â $ 886,352 Â Â Â 1,444,296 Â (6) Clinical Holdback Â The following table shows the activity within the clinical holdback liability accounts for the six months ended June 30, 2024: Â Balance at December 31, 2023 Â $ 120,235 Â Clinical holdback retained Â Â 5,990 Â Clinical holdback paid Â Â (1,122) Balance at June 30, 2024 Â $ 125,103 Â Less: clinical holdback - current portion Â Â (92,397) Clinical holdback - long-term portion Â $ 32,706 Â (7) Revenue Recognition Â Revenue is recognized upon shipment of our goods based upon contractually stated pricing at standard payment terms ranging from 30 to 60 days. All revenue is recognized point in time and no revenue is recognized over time. For the three and six months ended June 30, 2024 and 2023, there was no revenue recognized from performance obligations satisfied or partially satisfied in prior periods, nor were there any unsatisfied performance obligations as of June 30, 2024 or 2023. Â The majority of products sold directly to U.S customers are shipped via common carrier, and the customer pays for shipping and handling and assumes control Free on Board (FOB) shipping point. Products shipped to our international distributors are in accordance with their respective agreements; however, the shipping terms are generally EX-Works, reflecting that control is assumed by the distributor at the shipping point. Returns are only accepted with prior authorization from the Company. Items to be returned must be in original unopened cartons and are subject to a 30% restocking fee. Throughout the periods presented, the Company has not had a history of significant returns. Â The following table summarizes our sales, primarily from FemVue, by geographic region as follows: Â Â Three Months Ended June 30, Â Â Six Months Ended June 30, Â Primary geographical markets Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â U.S. Â $ 221,484 Â Â Â 262,469 Â Â Â 492,624 Â Â Â 556,453 Â International Â Â â€” Â Â Â 58,045 Â Â Â â€” Â Â Â 58,045 Â Total Â $ 221,484 Â Â Â 320,514 Â Â Â 492,624 Â Â Â 614,498 Â (8) Commitments and Contingencies Legal Claims Â Occasionally, the Company may be a party to legal claims or proceedings of which the outcomes are subject to significant uncertainty. In accordance with Accounting Standards Codification (ASC) 450, Contingencies, the Company will assess the likelihood of an adverse judgment for any outstanding claim as well as ranges of probable losses. When it has been determined that a loss is probable and the amount can be reasonably estimated, the Company will record a liability. For both periods presented, there were no material legal contingencies requiring accrual or disclosure. The Company, as permitted under Delaware law and in accordance with its bylaws, indemnifies its officers and directors for

certain events or occurrences, subject to certain limits, while the officer or director is or was serving at the Companyâ€™s request in such capacity. The Company entered into employment agreements with its officers, which provides for indemnification protection in the executiveâ€™s capacity as an officer for actions taken within the scope of employment. The maximum amount of potential future indemnification is unlimited; however, the Company has obtained director and officer insurance that limits its exposure. The Company believes the fair value for these indemnification obligations is minimal. Accordingly, the Company has not recognized any liabilities relating to these obligations as of June 30, 2024 and December 31, 2023. 13 Table of Contents FEMASYS INC. Condensed Notes to Financial Statements (unaudited) (9) Notes Payable AFCO Credit Corporation (AFCO) Â In June 2022, the Company executed a Promissory Note with AFCO to finance certain insurance premiums totaling $465,380, requiring the Company to pay $47,539 in a down payment and make monthly installment payments. The annual interest rate was 5.7% and the monthly installment payment was $47,539, which represents principal and interest. The final installment payment was paid in March of 2023. In July 2023, the Company executed a Promissory Note with AFCO to finance certain insurance premiums totaling $469,042, requiring the Company to pay $48,423 in a down payment and make monthly installment payments. The annual interest rate was 8.6% and the monthly installment is $48,423, which represents principal and interest. The Promissory Note was paid in full without penalty in November 2023. As of June 30,Â 2024, and December 31,Â 2023, there was no principal balance on the AFCO note in the accompanying balance sheets. Interest expense in connection with the AFCO promissory notes was $0 and $1,319 for the three and six months ended June 30,Â 2024 and 2023, respectively. (10) Convertible Notes with Warrants (November 2023 Financing) On November 21, 2023, the Company issued (i) senior unsecured convertible notes in an aggregate principal amount of $6,850,000, convertible into shares of common stock at a conversion price of $1.18 per share, (ii) Series A Warrants to purchase up to an aggregate of 5,805,083 shares of common stock at an exercise price of $1.18 per share, and (iii) Series B Warrants, together with the Series A Warrants, and, together with the convertible notes, to purchase up to an aggregate of 5,805,083 shares of common stock at an exercise price of $1.475 per share. The financing resulted in aggregate gross proceeds of $6,850,000, before $525,144 of transaction costs. The Notes accrue interest at a rate of 6.0% per annum, payable annually, in cash or shares of common stock at the Companyâ€™s option, and mature on November 21, 2025, unless earlier converted or redeemed. The Notes are convertible into shares of common stock at the election of the holder at any time at an initial conversion price of $1.18. The Company has agreed not to issue or sell any equity securities of the Company at a price below the then-current conversion price for a period of 18 months after closing, subject to certain exceptions. Beginning six months after issuance, the Company may require holders to convert their Notes into conversion shares if the closing price of the common stock exceeds $2.36 per share for 10 consecutive trading days and the daily dollar trading volume of the common stock exceeds $1,000,000 per day during the same period and certain equity conditions described in the Notes are satisfied. The Notes provide for certain events of default, whereby each holder of Notes will be able to require the Company to redeem in cash any or all of the holderâ€™s Notes at a premium of 115%. The conversion feature did not meet the requirements for separate accounting and is not accounted for as a derivative instrument. As of June 30, 2024, the Convertible Notes have not been converted into shares of common stock. The Warrants The Series A Warrants are exercisable immediately and expire five years from the date of issuance. The Company has the right to call the exercise of the Series A Warrants if the closing price of the common stock exceeds 200% of the Series A Exercise Price for 10 consecutive trading days and the daily dollar trading volume of the common stock exceeds $1,000,000 per day during the same period and certain equity conditions are satisfied. The Series B Warrants are exercisable immediately, together with the Series A Warrant Shares, and expire one year from the date of issuance. The Company has the right to call the exercise of the Series B Warrants if the closing price of the common stock exceeds 200% of the Series B exercise price for 10 consecutive trading days and the daily dollar trading volume of the common stock exceeds $1,000,000 per day during the same period and certain equity conditions are satisfied. There is no established public trading market for the warrants and the Company does not intend to list the Warrants on any national securities exchange or nationally recognized trading system. The Series A Warrants and Series B Warrants are classified as a component of permanent equity because they are freestanding financial instruments that are legally detachable and separately exercisable from the shares of common stock from which they are issued, are immediately exercisable, do not embody an obligation for the Company to repurchase its shares, and permit the holders to receive a fixed number of shares of common stock upon exercise. 14 Table of Contents FEMASYS INC. Condensed Notes to Financial Statements (unaudited) For the convertible notes for the three months ended June 30, 2024, the Company recognized total interest expense of $388,311, including coupon interest expense of $102,750 and amortization of debt discount and issuance costs of $285,561. For the six months ended June 30, 2024, the Company recognized total interest expense of $749,863, including coupon interest expense of $205,500 and amortization of debt discount and issuance costs of $544,363. As of December 31, 2023, the Notes principal balance as $6,850,000, unamortized discount was $2,636,346 and accrued interest was $44,525. As of June 30, 2024, the Notes principal balance as $6,850,000, unamortized discount was $2,091,983 and accrued interest was $250,025. The fair value of the convertible notes on June 30, 2024, calculated using a discounted cash flow analysis, was $6,307,258. (11) Stockholdersâ€™ Equity On July 1, 2022, we filed shelf registration statement to sell up to $150 million in common and preferred stock, debt securities and warrants. Additionally, we entered into an Equity Distribution Agreement (the â€œEquity Distribution Agreementâ€) with Piper Sandler & Co. (â€œPiper Sandlerâ€ or the â€œSales Agentâ€) and filed a related prospectus establishing an â€œat-the-marketâ€ facility, pursuant to which we may offer and sell shares of our common stock from time to time through the Sales Agent. In October 2023, the Sales Agent was authorized to sell shares for aggregate proceeds up to $16.7 million at current market prices until all shares are sold. As of June 30, 2024, 3.9 million shares of common stock have been sold for aggregate proceeds of approximately $8.7 million under the Equity Distribution Agreement pursuant to the prospectus. As of June 30, 2024, the amount we are authorized to sell is subject to baby-shelf limitations. In April 2023, the Company sold an aggregate of (i) 1,318,000 shares of common stock and (ii) pre-funded warrants to purchase up to 1,878,722 shares of common stock in a registered direct offering (â€œpre-funded warrantsâ€) and, in a concurrent private placement, warrants to purchase up to 3,196,722 shares of common stock (â€œcommon warrantsâ€). Additionally, common warrants were issued to the placement agent to purchase up to 191,803 shares of common stock as compensation for services (â€œplacement agent warrantsâ€), collectively the (â€œApril 2023 Financingâ€). The purchase price per share for the common stock, pre-funded warrants was $1.22 and $1.2199, respectively. The gross proceeds from the offering were $3,899,813, less placement agent fees and offering expenses of $547,764. In June 2023, all pre-funded warrants were exercised for shares of common stock. In September and October 2023, all common warrants and 122,994 placement agent warrants were exercised for cash proceeds of $3,687,976. As of June 30, 2024, 68,809 placement agent warrants remain outstanding. As of June 30, 2024, the Company had 22,232,799 shares of common stock outstanding, and no dividends have been declared or paid. (12) Equity Incentive Plans and Warrants Stock-Based Awards (a) Stock Option Plans Â Activity under the Companyâ€™s stock option plans for the six months ended June 30, 2024 was as follows: Â Â Number of options Â Â Weighted average exercise price Â Outstanding at December 31, 2023 Â Â 2,102,030 Â Â $ 2.00 Â Granted Â Â 1,062,421 Â Â Â 1.06 Â Forfeited Â Â (243,312) Â Â 2.09 Â Outstanding at June 30, 2024 Â Â 2,921,139 Â Â $ 1.65 Â Â Â Â Â Â Â Â Â Â Vested and exercisable at June 30, 2024 Â Â 1,207,595 Â Â $ 2.53 Â Options granted under our 2021 Stock Option Plan for the six months ended June 30, 2024 to employees and nonemployees were 1,059,921 and 2,500, respectively and the weighted average exercise prices were $1.06 and $0.79, respectively. The weighted-average fair values of the options granted to employees and nonemployees were $0.90 and $0.39, respectively and were estimated using the following Black-Scholes assumptions: Â Â Employee Â Â Nonemployee Â Expected term (in years) Â 6.25 Â Â Â 1.50 Â Riskâ€‘free interest rate Â Â 4.06 % Â Â 4.53 % Dividend yield Â Â â€” % Â Â â€” % Expected volatility Â Â 110.40 % Â Â 105.34 % Â No options were exercised for the six months ended June 30, 2024 under our stock option plans. As of June 30, 2024, the total number of shares of common stock reserved for future awards under the 2021 Stock Option Plan was 676,741. (b) Inducement Grants On February 12, 2024, the Company awarded, outside the 2021 Plan, our Chief Commercial Officer a stock option grant for the right to purchase 100,000 shares of common stock at an exercise price of $1.10 per share (inducement grant), which was approved by the Compensation committee. The inducement grant will vest in equal installments over four years provided the employee remains employed by the Company on the vesting date. The fair value of the inducement grant was $0.94 and was estimated using the following assumptions: Â Â Inducement Â Expected term (in years) Â 6.25 Â Riskâ€‘free interest rate Â Â 4.10 % Dividend yield Â Â â€” % Expected volatility Â Â 109.64 % As of June 30, 2024, inducement grant awards of 250,000 shares were outstanding with a weighted average exercise price of $1.89, and 62,500 shares were vested and exercisable with a weighted average exercise price of $2.64. 15 Table of Contents FEMASYS INC. Condensed Notes to Financial Statements (unaudited) (c) Share-Based Compensation Expense The following table shows the share-based compensation expense related to vested stock option grants to employees and nonemployees by financial statement line item on the accompanying condensed statement of comprehensive loss: Â Â Three Months Ended June 30, Â Â Six Months Ended June 30, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Research and development Â $ 34,629 Â Â Â 27,192 Â Â Â 64,637 Â Â Â 52,251 Â Sales and marketing Â Â 18,246 Â Â Â 602 Â Â Â 24,764 Â Â Â (1,942) General and administrative Â Â 51,138 Â Â Â 37,422 Â Â Â 92,197 Â Â Â 71,861 Â Total share-based compensation expense Â $ 104,013 Â Â Â 65,216 Â Â Â 181,598 Â Â Â 122,170 Â As of June 30, 2024, the remaining share-based compensation expense that is expected to be recognized in future periods for employees and nonemployees is $1,516,737, which includes $155,222 of compensation expense to be recognized upon achieving certain performance conditions. For service-based awards, the $1,361,515 of unrecognized expense is expected to be recognized over a weighted average period of 3.3 years. Â Â (d) Employee Stock Purchase Plan (ESPP) Â For the six months ended June 30, 2024, 12,081 shares of common stock were issued under the Companyâ€™s ESPP Plan at a fair value of $10,390. For the six months ended June 30, 2023, 3,858 shares of common stock were issued under the ESPP plan at a fair value of $1,697. As of June 30, 2024, the total number of shares of common stock reserved for future awards under the ESPP Plan was 591,437. (e) April 2023 Financing Â Â On April 20, 2023, the Company entered into a securities purchase agreement pursuant to which the Company sold (i) 1,318,000 shares of common stock (see Note 11, Stockholdersâ€™ Equity), (ii) pre-funded warrants to purchase 1,878,722 shares of common stock, (iii) common warrants to purchase 3,196,722 shares of common stock. Additionally, common warrants to purchase 191,803 shares of common stock were issued to the placement agent compensation for services performed. The pre-funded warrants, common warrants and placement agent warrants were exercisable immediately following the closing date of the offering. The pre-funded warrants have an unlimited term and an exercise price of $0.0001 per share. The common warrants have a 5.5 year term and an exercise price of $1.095 per share. The placement agent warrants have a 5 year term and

exercise price of $1.525 per share. The offering resulted in aggregate gross proceeds of $3,899,813, before $547,764 of transaction costs. The pre-funded warrants and common warrants are classified as a component of permanent equity because they are freestanding financial instruments that are legally detachable and separately exercisable from the shares of common stock with which they were issued, are immediately exercisable, do not embody an obligation for the Company to repurchase its shares, and permit the holders to receive a fixed number of shares of common stock upon exercise. The common stock was valued at $1,133,480, based on the Companyâ€™s stock price. The pre-funded warrants and common warrants were valued at $1,615,701 and $1,854,099, respectively, using the following Black-Scholes assumptions: Â Â Pre-funded warrants Â Â Common warrants Â Expected term (in years) Â 4 Â Â Â 4 Â Riskâ€‘free interest rate Â Â 3.83 % Â Â 3.83 % Dividend yield Â Â â€” % Â Â â€” % Expected volatility Â Â 100.25 % Â Â 100.25 % Exercise price Â $ 0.0001 Â Â $ 1.095 Â Stock price Â $ 0.86 Â Â $ 0.86 Â Black-Scholes value Â $ 0.86 Â Â $ 0.58 Â The net proceeds of $3,352,049 were allocated to the common stock, pre-funded warrants and common warrants using the relative fair value method. The valuations were recorded to stockholdersâ€™ equity. Â In June 2023, all pre-funded warrants were exercised for shares of common stock. In September and October 2023, all common warrants and 122,994 placement agent warrants were exercised for cash proceeds of $3,687,976. As of June 30, 2024, 68,809 placement agent warrants remain outstanding. (13) Relatedâ€‘Party Transactions In November 2023, the Company issued unsecured convertible notes and accompanying Series A and Series B Warrants (see Note 10). The transaction included issuance of a $5 million convertible note and Series A and Series B Warrants to PharmaCyte Biotech, Inc. The interim CEO, President and Director of PharmaCyte Biotech, Inc., Joshua Silverman, serves on the Companyâ€™s board of directors. In addition, during the year ended December 31, 2023 and six months ended June 30, 2024 and 2023, a family member of the CEO was employed by the Company. 16 Table of Contents FEMASYS INC. Condensed Notes to Financial Statements (unaudited) (14) Net Loss per Share Attributable to Common Stockholders Â The following table sets forth the computation of the basic and diluted net loss per share: Â Â Three Months Ended June 30, Â Â Six Months Ended June 30, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Net loss attributable to common stockholders, basic & diluted Â $ (4,684,574) Â Â (2,893,508) Â Â (8,284,084) Â Â (5,839,765) Â Weighted average number of shares used in computing net loss per share attributable to common stockholders, basic and diluted Â Â 22,215,516 Â Â Â 13,107,590 Â Â Â 21,995,436 Â Â Â 12,493,334 Â Net loss per share attributable to common stockholders, basic and diluted Â $ (0.21) Â Â (0.22) Â Â (0.38) Â Â (0.47) The following potentially dilutive securities have been excluded from the computations of diluted weighted average shares outstanding because they would be anti-dilutive: Â Â Â Three Months Ended June 30, Â Â Six Months Ended June 30, Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Options to purchase common stock Â Â 3,171,139 Â Â Â 1,169,671 Â Â Â 3,171,139 Â Â Â 1,169,671 Â Warrants to purchase common stock, in connection with April 2023 financing Â Â 68,809 Â Â Â 3,388,525 Â Â Â 68,809 Â Â Â 3,388,525 Â Warrants to purchase common stock, in connection with November 2023 financing Â Â 11,610,166 Â Â Â â€” Â Â Â 11,610,166 Â Â Â â€” Â Warrants to purchase common stock Â Â 196,816 Â Â Â 233,460 Â Â Â 196,816 Â Â Â 233,460 Â Total potential shares Â Â 15,046,930 Â Â Â 4,791,656 Â Â Â 15,046,930 Â Â Â 4,791,656 Â (15) Income Taxes The effective tax rate of 0% for the three and six months ended June 30, 2024 and 2023 was lower than the statutory rate due to the Company remaining in a full valuation allowance position. 17 Table of Contents Item 2. Managementâ€™s Discussion and Analysis of Financial Condition and Results of Operations The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our financial statements and related notes included elsewhere in this in this Quarterly Report on Form 10-Q and our Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission, or the SEC, on March 28, 2024. This Quarterly Report on Form 10-Q contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the â€œsafe harborâ€ created by those sections. Forward-looking statements are based on our managementâ€™s beliefs and assumptions and on information currently available to our management. In some cases, you can identify forward-looking statements by terms such as â€œmay,â€ â€œwill,â€ â€œshould,â€ â€œcould,â€ â€œgoal,â€ â€œwould,â€ â€œexpect,â€ â€œplan,â€ â€œanticipate,â€ â€œbelieve,â€ â€œestimate,â€ â€œproject,â€ â€œpredict,â€ â€œpotentialâ€ and similar expressions intended to identify forward-looking statements and reflect our beliefs and opinions on the relevant subject. Our actual results could differ materially from those discussed in the forward-looking statements. Factors that could cause or contribute to these differences include those discussed below and elsewhere in this Quarterly Report on Form 10-Q. The forward-looking statements included in this Quarterly Report on Form 10-Q are made only as of the date hereof. These statements are based upon information available to us as of the filing date of this Quarterly Report on Form 10-Q, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain, and investors are cautioned not to unduly rely upon these statements. Overview We are a leading biomedical company focused on addressing significant unmet needs for women worldwide with a broad portfolio of in-office, accessible, and innovative therapeutic and diagnostic solutions, including a lead revolutionary product candidate and FDA-cleared, and Canadian and European Union approved products. Our mission is to provide women with superior minimally-invasive, non-surgical product technologies, accessible in the office, improving patient care and overall health economics focused on servicing the reproductive health needs for those seeking solutions for infertility issues (FemaSeed and FemVue) or permanent birth control (FemBloc). We are a woman-founded and led company with an expansive, internally created intellectual property portfolio with over 180 patents globally, in- house chemistry, manufacturing, and controls (CMC) and device manufacturing capabilities and proven ability to develop and commercialize products. Our suite of products and product candidates address what we believe are multi-billion dollar global market segments in which there has been little advancement for many years, helping women avoid pharmaceutical solutions, implants and surgery that can be expensive and expose women to harm. Corporate Update On November 15, 2023, we secured a $6.85 million financing with a strategic investment from investors led by PharmaCyte Biotech. On November 28, 2023, we announced the completion of enrollment of FemaSeed pivotal trial in support of commercial launch. On November 30, 2023, we announced the appointment of James Liu, M.D. as Chief Medical Officer. On January 23, 2024 and January 26, 2024, we announced initiation of enrollment in pivotal trial (NCT05977751) of our permanent birth control candidate FemBloc at two academic sites, for a total of six active sites, the maximum number permitted in the first stage. On February 6, 2024, we announced the appointment of Richard Spector to new position of Chief Commercial Officer. 18 Table of Contents On March 6, 2024, we announced the first in-office commercial procedure with FDA-cleared FemaSeed infertility solution at a former investigative site. On March 20, 2024, we announced positive topline data from pivotal trial for FDA-cleared FemaSeed for the treatment of infertility. On April 18, 2024, we announced that our CEO, met with members of Congress to raise awareness of the Company and discuss womenâ€™s healthcare initiatives. On May 16, 2024, we announced that our CEO, met with the White Houseâ€™s Gender Policy Council. On May 17,Â 2024, we announced that our CEO, met with the White Houseâ€™s Office of Science and Technology to discuss the Cancer Moonshot initiative. On June 20, 2024, we announced receipt of European Union Medical Device Regulation (EU MDR) and CE Mark certification for FemaSeed, FemVue, FemCerv and FemCath. Clinical Update FemaSeed â€“ Our Intratubal Artificial Insemination Solution. In September 2023 we announced 510(k) clearance from the FDA for FemaSeed for intratubal insemination. The clinical trial was still ongoing at the time of receiving U.S. regulatory clearance from the FDA, however, the study was concluded with enrollment completed in November 2023. Topline results of the clinical trial were announced in March 2024. The trial demonstrated that 24% of women became pregnant after FemaSeed with male factor infertility (1 million to 20 million total motile sperm count (TMSC)). In contrast, the historical control indicated a 6.7% pregnancy rate by cycle for intrauterine insemination (IUI) with male factor infertility (greater than 1 million TMSC). Although subjects were permitted to have multiple FemaSeed attempts, the majority of women who became pregnant did so after the first FemaSeed procedure. The majority of adverse events were reported as mild (n=127 subjects, 216 cycles). No new safety concerns were observed through the seven-week follow-up. All adverse events were consistent with those known for IUI. The approved labeling includes women or couples wishing to become pregnant by way of intratubal insemination. The recruitment of the commercial team began with the hire of the Chief Commercial Officer in February 2024. In March 2024, the first commercial use of FemaSeed at a former investigative site was announced. Build-out of our initial commercial team in the United States, the focus of our primary market efforts was completed in June 2024. In June 2024, we received EU MDR and CE Mark certification for FemaSeed and concurrently are exploring potential strategic partners for distribution in Europe and internationally. FemBloc â€“ Our Permanent Birth Control Solution. In June 2023 we received FDA approval of our IDE to evaluate the safety and efficacy of FemBloc, our non-surgical, non-implant, in-office solution for permanent birth control in a pivotal clinical trial. In August 2023 we announced the initiation of enrollment in the FINALE [Prospective Multi-Center Trial for FemBloc INtratubal Occlusion for TranscervicAL PErmanent Birth Control] pivotal trial designed to evaluate the safety and efficacy of FemBloc. This prospective, multi-center, open-label, single-arm study design includes pregnancy rate as the primary endpoint, which will be analyzed once 401 women have used FemBloc for one year for permanent birth control. In addition, the study is designed as a roll-in beginning with enrollment of 50 women for a clinical readout primarily of preliminary safety data prior to enrolling the remaining subjects. An interim analysis of clinical data endpoints is planned once 300 women have used FemBloc for permanent birth control for one year. Follow-up will continue annually for five years post-market. All six sites permitted in the initial stage of the trial were announced as actively enrolling subjects in January 2024. 19 Table of Contents Results of Operations Comparison of the Three Months Ended June 30, 2024 and 2023 The following table shows our results of operations for the three months ended June 30, 2024 and 2023: Â Â Three Months Ended June 30, Â Â Â Â Â Â Â Â Â 2024 Â Â 2023 Â Â Change Â Â % Change Â Sales Â $ 221,484 Â Â Â 320,514 Â Â Â (99,030) Â Â -30.9 % Cost of sales (excluding depreciation expense) Â Â 73,125 Â Â Â 110,469 Â Â Â (37,344) Â Â -33.8 % Â Operating expenses: Â Research and development Â Â 1,975,875 Â Â Â 1,527,172 Â Â Â 448,703 Â Â Â 29.4 % Sales and marketing Â Â 975,190 Â Â 128,899 Â Â Â 846,291 Â Â Â 656.6 % General and administrative Â Â 1,611,817 Â Â Â 1,356,637 Â Â Â 255,180 Â Â Â 18.8 % Depreciation and amortization Â Â 67,628 Â Â Â 133,299 Â Â Â (65,671) Â Â -49.3 % Total operating expenses Â Â 4,630,510 Â Â Â 3,146,007 Â Â Â 1,484,503 Â Â Â 47.2 % Loss from operations Â Â (4,482,151) Â Â (2,935,962) Â Â (1,546,189) Â Â 52.7 % Other income (expense): Â Interest income Â Â 184,138 Â Â Â 42,652 Â Â Â 141,486 Â Â Â 331.7 % Interest expense Â Â (388,311) Â Â (198) Â Â (388,113) Â Â 196016.7 % Other income (expense), net Â Â (204,173) Â Â 42,454 Â Â Â (246,627) Â Â -580.9 % Loss before

income taxes Â Â (4,686,324) Â Â (2,893,508) Â Â (1,792,816) Â Â 62.0 % Income tax benefit Â Â (1,750) Â Â â€” Â Â Â (1,750) Â Â -100.0 % Net loss Â $ (4,684,574) Â Â (2,893,508) Â Â (1,791,066) Â Â 61.9 % Sales Sales decreased by $99,030, or 30.9%, to $221,484 for the three months ended June 30, 2024 from $320,514 for the three months ended June 30, 2023, primarily due to the timing of international sales year over year. Units sold decreased by 41.7% for the comparable periods, while maintaining a consistent average selling price. FemaSeed sales are expected to commence in the second half of 2024. Cost of sales Cost of sales decreased by $37,344 or 33.8%, to $73,125 for the three months ended June 30, 2024 from $110,469 for the three months ended June 30, 2023. The decrease is primarily attributed to reduced sales and certain manufacturing efficiencies. Research and development The following table summarizes our R&D expenses incurred during the periods presented: Â Â Three Months Ended June 30, Â Â Â 2024 Â Â 2023 Â Compensation and related personnel costs Â $ 974,880 Â Â Â 840,506 Â Clinical-related costs Â Â 435,588 Â Â Â 361,578 Â Material and development costs Â Â 389,129 Â Â Â 205,095 Â Professional and outside consultant costs Â Â 118,477 Â Â Â 120,527 Â Other costs Â Â 57,801 Â Â Â (534) Total research and development expenses Â $ 1,975,875 Â Â Â 1,527,172 Â R&D expenses increased by $448,703 or 29.4%, to 1,975,875 for the three months ended June 30, 2024 from $1,527,172 for the three months ended June 30, 2023. The increase relates primarily to increased material and development costs, clinical- related costs and compensation. 20 Table of Contents Sales and marketing Sales and marketing expenses increased by $846,291 or 656.6%, to $975,190 for the three months ended June 30, 2024 from $128,899 for the three months ended June 30, 2023. The increase is largely due to increased compensation costs and sales expenses as we recruited and hired commercial team members in connection with the initiation of commercialization of FemaSeed. General and administrative General and administrative expenses increased by $255,180, or 18.8%, to $1,611,817 for the three months ended June 30, 2024 from $1,356,637 for the three months ended June 30, 2023. The increase was largely due to increased facility, overhead and compensation costs. Depreciation and amortization Depreciation and amortization expenses decreased by $65,671, or 49.3%, to $67,628 for the three months ended June 30, 2024 from $133,299 for the three months ended June 30, 2023. The decrease is due to a reduction of depreciation expense associated with our fixed assets. Other income (expense), net Other income (expense), net decreased by $246,627, or 580.9%, to $204,173 of expense for the three months ended June 30, 2024 from $42,454 of income for the three months ended June 30, 2023. The decrease relates to interest expense and non-cash discount amortization related to the convertible notes payable, partially offset by an increase in interest income. Results of Operations Comparison of the Six Months Ended June 30, 2024 and 2023 The following table shows our results of operations for the six months ended June 30, 2024 and 2023: Â Â Six Months Ended June 30, Â Â Â Â Â Â Â Â Â 2024 Â Â 2023 Â Â Change Â Â % Change Â Sales Â $ 492,624 Â Â Â 614,498 Â Â Â (121,874) Â Â -19.8 % Cost of sales (excluding depreciation expense) Â Â 161,657 Â Â Â 215,589 Â Â Â (53,932) Â Â -25.0 % Â Operating expenses: Â Research and development Â Â 3,746,606 Â Â Â 3,064,611 Â Â Â 681,995 Â Â Â 22.3 % Sales and marketing Â Â 1,275,677 Â Â Â 373,795 Â Â Â 901,882 Â Â Â 241.3 % General and administrative Â Â 3,114,621 Â Â Â 2,671,774 Â Â Â 442,847 Â Â Â 16.6 % Depreciation and amortization Â Â 138,856 Â Â Â 266,365 Â Â Â (127,509) Â Â -47.9 % Total operating expenses Â Â 8,275,760 Â Â Â 6,376,545 Â Â Â 1,899,215 Â Â Â 29.8 % Loss from operations Â Â (7,944,793) Â Â (5,977,636) Â Â (1,967,157) Â Â 32.9 % Other income (expense): Â Interest income Â Â 408,822 Â Â Â 139,741 Â Â Â 269,081 Â Â Â 192.6 % Interest expense Â Â (749,863) Â Â (1,870) Â Â (747,993) Â Â 39999.6 % Other income (expense), net Â Â (341,041) Â Â 137,871 Â Â Â (478,912) Â Â -347.4 % Loss before income taxes Â Â (8,285,834) Â Â (5,839,765) Â Â (2,446,069) Â Â 41.9 % Income tax benefit Â Â (1,750) Â Â â€” Â Â Â (1,750) Â Â -100.0 % Net loss Â $ (8,284,084) Â Â (5,839,765) Â Â (2,444,319) Â Â 41.9 % 21 Table of Contents Sales Sales decreased by $121,874, or 19.8%, to $492,624 for the six months ended June 30, 2024 from $614,498 for the six months ended June 30, 2023, attributable primarily to international sales. Units sold decreased by 25.7% for the comparable periods, while maintaining a consistent average selling price. FemaSeed sales are expected to commence in the second half of 2024. Cost of sales Cost of sales decreased by $53,932 or 25.0%, to $161,657 for the six months ended June 30, 2024 from $215,589 for the six months ended June 30, 2023. The decrease is primarily attributed to reduced sales and certain manufacturing efficiencies. Research and development The following table summarizes our R&D expenses incurred during the periods presented: Â Â Six Months Ended June 30, Â Â Â 2024 Â Â 2023 Â Compensation and related personnel costs Â $ 1,963,937 Â Â Â 1,740,794 Â Clinical-related costs Â Â 874,363 Â Â Â 727,938 Â Material and development costs Â Â 532,828 Â Â Â 372,256 Â Professional and outside consultant costs Â Â 286,659 Â Â Â 212,462 Â Other costs Â Â 88,819 Â Â Â 11,161 Â Total research and development expenses Â $ 3,746,606 Â Â Â 3,064,611 Â R&D expenses increased by $681,995 or 22.3%, to $3,746,606 for the six months ended June 30, 2024 from $3,064,611 for the six months ended June 30, 2023. The increase relates primarily to increased material and development costs, clinical-related costs, compensation costs and professional and outside consultant costs. Sales and marketing Sales and marketing expenses increased by $901,882 or 241.3%, to $1,275,677 for the six months ended June 30, 2024 from $373,795 for the six months ended June 30, 2023. The increase is largely due to increased compensation costs and sales expenses as we recruited and hired commercial team members in connection with the initiation of commercialization of FemaSeed. General and administrative General and administrative expenses increased by $442,847, or 16.6%, to $3,114,621 for the six months ended June 30, 2024 from $2,671,774 for the six months ended June 30, 2023. The increase was largely due to increased facility, overhead and compensation costs. Depreciation and amortization Depreciation and amortization expenses decreased by $127,509, or 47.9%, to $138,856 for the six months ended June 30, 2024 from $266,365 for the six months ended June 30, 2023. The decrease is due to a reduction of depreciation expense associated with our fixed assets. Other income (expense), net Other income (expense), net decreased by $478,912, or 347.4%, to $341,041 of expense for the six months ended June 30, 2024 from $137,871 of income for the six months ended June 30, 2023. The decrease relates to interest expense and non-cash discount amortization related to the convertible notes payable, partially offset by an increase in interest income. 22 Table of Contents Liquidity and Capital Resources Sources of liquidity Since our inception through June 30, 2024, our operations have been financed primarily by net proceeds from the sale of our common stock and convertible preferred stock, indebtedness and, to a lesser extent, product revenue. As of June 30, 2024, we had $13,525,898 of cash and cash equivalents and an accumulated deficit of $116,665,713. On July 1, 2022, we entered into an Equity Distribution Agreement (the â€œEquity Distribution Agreementâ€) with Piper Sandler & Co. (the â€œSales Agentâ€) and filed a related prospectus establishing an â€œat-the-marketâ€ facility, pursuant to which we may offer and sell shares of our common stock from time to time through the Sales Agent. In October 2023, the Sales Agent was authorized to sell shares of common stock for an aggregate price up to $16.7 million pursuant to the prospectus. As of June 30, 2024, approximately 3.9 million shares of common stock have been sold for aggregate proceeds of approximately $8.7 million under the Equity Distribution Agreement pursuant to the prospectus. As of June 30, 2024, the amount we are authorized to sell is subject to baby-shelf limitations. In April 2023, we sold an aggregate of (i) 1,318,000 shares of common stock and (ii) pre-funded warrants to purchase up to 1,878,722 shares of common stock in a registered direct offering and, in a concurrent private placement, warrants to purchase up to 3,196,722 shares of common stock. Additionally, common warrants were issued to the placement agent in this transaction to purchase up to 191,803 shares of common stock as compensation for services, collectively the (â€œApril 2023 Financingâ€). The purchase price per share for the common stock, pre-funded warrants was $1.22 and $1.2199, respectively. The net proceeds from the April 2023 Financing at closing were approximately $3.4 million. The pre-funded and common warrants in the April 2023 Financing were fully exercised for cash for additional proceeds of $3.5 million. Placement agent warrants of 68,809 remain outstanding as of June 30, 2024. In November 2023, we entered into a securities purchase agreement with certain accredited investors pursuant to which we sold (i) senior unsecured convertible notes in an aggregate principal amount of $6,850,000, convertible into shares of common stock at a conversion price of $1.18 per share, (ii) Series A Warrants to purchase up to an aggregate of 5,805,083 shares of common stock at an exercise price of $1.18 per share, and (iii) Series B Warrants to purchase up to an aggregate of 5,805,083 shares of common stock at an exercise price of $1.475 per share (collectively, the â€œNovember Private Placementâ€). Net proceeds from the November Private Placement were $6.3 million. If exercised for cash, the warrants issued in the November Private Placement could result in proceeds of up to an additional $15.4 million. Funding requirements Based on our current operating plan, our current cash and cash equivalents is sufficient into July 2025.Â However, it is not sufficient to fund our ongoing operations for twelve months from the date of these financial statements and we will need to obtain additional financing to fund our ongoing operations. Our estimate as to how long we expect our existing cash and cash equivalents to be able to continue to fund our operations is based on assumptions that may prove to be wrong, and we could use our available capital resources sooner than we currently expect. Changing circumstances, some of which may be beyond our control, could cause us to consume capital significantly faster than we currently anticipate. As a result of our current limited financial liquidity, we have concluded that substantial doubt exists about our ability to continue as a going concern. Our cash and cash equivalents as of June 30, 2024 will not be sufficient to fund our product candidate FemBloc through regulatory approval, and we anticipate needing to raise additional capital to complete the development and commercialization of our product candidate. However, we can give no assurances that we will be able to secure additional sources of funds to support our operations, or if such funds will be available to us, that such additional financing will be sufficient to meet our needs or be on terms acceptable to us. This risk may increase if economic and market conditions deteriorate. If we are unable to obtain additional financing when needed, we may need to terminate, significantly modify, or delay the development of our product candidate, or we may need to obtain funds through collaborations or otherwise on terms that may require us to relinquish rights to our technologies or product candidates that we might otherwise seek to develop or commercialize independently. If we are unable to raise adequate additional capital as and when required in the future, we could be forced to cease development activities and terminate our operations, and you could experience a complete loss of your investment. 23 Table of Contents Cash Flows Comparison of the Six months ended June 30, 2024 and 2023 The following table summarizes our cash flows for the six months ended June 30, 2024 and 2023: Â Â Six Months Ended June 30, Â Â Â Â 2024 Â Â 2023 Â Net cash used in operating activities Â $ (8,894,780) Â Â (5,388,824) Net cash used in investing activities Â Â (297,123) Â Â (71,849) Net cash provided by financing activities Â Â 1,001,724 Â Â Â 3,203,754 Â Net change in cash and cash equivalents Â $ (8,190,179) Â Â (2,256,919) Operating activities For the six months ended June 30, 2024, cash used in operating activities was $8,894,780, attributable to a net loss of $8,284,084 and a net change in our net operating assets and liabilities of $1,777,514, partially offset by non-cash charges of $1,166,618. Non-cash charges primarily consisted of $544,363 in amortization of the discount on convertible notes, $299,171 in right-of-use amortization, $181,598 in share-based compensation and $138,856 in depreciation and amortization. The change in our net operating

assets and liabilities was primarily due to decreases in accounts payable and accrued expenses of $781,626, lease liabilities of $137,482 and increases in inventory of $651,292 and prepaid and other assets of $173,828. For the six months ended June 30, 2023, cash used in operating activities was $5,388,824, attributable to a net loss of $5,839,765 and a net change in our net operating assets and liabilities of $132,443, partially offset by non-cash charges of $583,384. Non-cash charges largely consisted of $266,365 in depreciation and amortization, $148,541 in right-of-use amortization, $122,170 in stock-based compensation and $44,538 for loss on disposal of assets. The change in our net operating assets and liabilities was primarily due to decreases of $181,065 in lease liabilities and increases of $146,521 in inventory and $78,276 in accounts receivable, partially offset by decreases in prepaid and other assets of $154,065 and increases of $116,235 in accounts payable and accrued expenses. Investing activities For the six months ended June 30, 2024, cash used in investing activities for the purchase of property and equipment and acquisition of patents was $297,123. For the six months ended June 30, 2023, cash used in investing activities for the purchase of property and equipment was $71,849. Financing activities For the six months ended June 30, 2024, cash provided by financing activities was $1,001,724, attributable to proceeds from sales under the at-the-market facility, net of issuance costs and proceeds from the issuance of shares under the ESPP plan. For the six months ended June 30, 2023, cash used in financing activities was $3,203,754, attributable to proceeds from the issuance of common stock and warrants of $3,905,071, partially offset by financing offering costs of $547,764, repayments on notes payable of $141,298 and payments under lease obligations of $12,255. Critical Accounting Estimates Managementâ€™s discussion and analysis of our financial condition and results of operations is based on our financial statements, which have been prepared in accordance with U.S. generally accepted accounting principles, or GAAP. The preparation of these financial statements requires us to make estimates and assumptions for the reported amounts of assets, liabilities, revenue, expenses and related disclosures. Our estimates are based on our historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions and any such differences may be material. 24 Table of Contents While our significant accounting policies are more fully described in Note 2 to our financial statements appearing the Annual Report on Form 10-K for the year ended December 31, 2023 as filed on March 28, 2024, we believe the following discussion addresses our most critical accounting policies, which are those that are most important to our financial condition and results of operations and require our most difficult, subjective and complex judgments. Revenue recognition Our policy is to recognize revenue when a customer obtains control of the promised goods under Accounting Standards Update (ASU) 2020-05, Revenue from Contracts with Customers (Topic 606), which we adopted effective January 1, 2018. The amount of revenue recognized reflects the consideration to which we expect to be entitled to receive in exchange for these goods, and we have elected to exclude amounts collected from customers for all sales (and other similar) taxes from the transaction price. We do not have multiple performance obligations in our customer orders, so revenue is recognized upon shipment of our goods based upon contractually stated pricing at standard payment terms ranging from 30 to 60 days. All revenue is recognized point in time and no revenue is recognized over time. The majority of products sold directly to U.S. customers are shipped via common carrier, and the customer pays for shipping and handling and assumes control Free on Board (FOB) shipping point. Products shipped to our international distributors are in accordance with their respective agreements; however, the shipping terms are generally EX-Works, reflecting that control is assumed by the distributor at the shipping point. Returns are only accepted with prior authorization from the Company. Items to be returned must be in original unopened cartons and are subject to a 30% restocking fee. As of June 30, 2024, we have not had a history of significant returns. 25 Table of Contents Accrued expenses We accrue expenses for estimated costs of R&D activities conducted by our third-party service providers, which include the conduct of preclinical studies and clinical trials. We record the estimated costs of R&D activities based upon the estimated amount of services provided but not yet invoiced. These costs, at times, may be a significant component of the research and development expenses and the Company makes estimates in determining the accrued expense each period. As actual costs become known, the Company adjusts its accrual. These accrued R&D costs are included in accrued expenses on the balance sheet and within R&D expense on the statement of comprehensive loss. Item 3. Quantitative and Qualitative Disclosures About Market Risk Not applicable. Item 4. Controls and Procedures Evaluation of Disclosure Controls and Procedures We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in the reports that we file or submit under the Exchange Act are (1) recorded, processed, summarized and reported within the time periods specified in the SECâ€™s rules and forms, and (2) accumulated and communicated to our management, including to our principal executive officer and principal financial officer, to allow timely decisions regarding required disclosure. Our management, with the participation of our Chief Executive Officer (principal executive officer) and Chief Financial Officer (principal financial and accounting officer), has evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended) as of the end of the period covered by this Quarterly Report on Form 10-Q. Based on such evaluation, our management has concluded that our disclosure controls and procedures were effective at a reasonable assurance level as of June 30, 2024. Changes in Internal Control over Financial Reporting There were no changes in our internal control over financial reporting identified in connection with the evaluation required by Rule 13a-15(d) and 15d-15(d) of the Exchange Act that occurred during the quarter ended June 30, 2024 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. Inherent Limitations on Effectiveness of Controls Our management, including our Chief Executive Officer and Chief Financial Officer (principal financial and accounting officer), does not expect that our disclosure controls and procedures or internal control over financial reporting will prevent all errors and all fraud. A control system, no matter how well designed and implemented, can provide only reasonable, not absolute, assurance that the control systemâ€™s objectives will be met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues within a company are detected. The inherent limitations include the realities that judgments in decision-making can be faulty and that breakdowns can occur because of simple errors or mistakes. Controls can also be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of the controls. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions or that the degree of compliance with the policies or procedures may deteriorate. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and may not be detected. 26 Table of Contents PART II OTHER INFORMATION Item 1. Legal Proceedings From time to time we may be involved in legal proceedings arising in connection with our business. As of June 30, 2024, we have not had a history of significant legal proceedings and there no currently pending actions against us. We believe that any amount, or range, of reasonably possible losses in connection with any potential actions against us in excess of established reserves, in the aggregate, will not be not material to our financial condition or cash flows. However, losses may be material to our operating results for any particular future period, depending on the level of income for such period and the significance of any actions against us. 27 Table of Contents Item 1A. Risk Factors As of the date of this report, there are no material changes to our risk factors as previously disclosed in Part I, Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2023 except as noted below. There is substantial doubt about our ability to continue as a going concern There is substantial doubt about our ability to continue as a going concern. If we are unable to raise sufficient capital in this offering or otherwise as and when needed, our business, financial condition and results of operations will be materially and adversely affected, and we will need to significantly modify our operational plans to continue as a going concern. If we are unable to continue as a going concern, we may have to liquidate our assets, and the values we receive for our assets in liquidation or dissolution could be significantly lower than the values reflected in our financial statements. Our lack of cash resources and our potential inability to continue as a going concern may materially adversely affect our share price and our ability to raise new capital, enter into critical contractual relations with third parties and otherwise execute our development strategy. Item 2. Unregistered Sales of Equity Securities, Use of Proceeds, and Issuer Purchases of Equity Securities None. Item 3. Defaults Upon Senior Securities None. Item 4. Mine Safety Disclosures Not applicable. Item 5. Other Information During the period covered by this Quarterly Report, none of the Companyâ€™s directors or executive officers have adopted or terminated a Rule 10b5-1 trading arrangement or a non-Rule 10b5-1 trading arrangement (each as defined in Item 408 of Regulation S-K under the Securities Exchange Act of 1934, as amended). Item 6. Exhibits Â Â Incorporated by Reference Â Â Â Â Exhibit Number Description of Document Schedule/Form File Number Exhibit Filing Date Â Â Â Â Â 3.1 Eleventh Amended and Restated Certificate of Incorporation of Femasys Inc. Form 8-K 001- 40492 3.1 June 22, 2021 Â Â Â Â Â Â 3.2 Amended and Restated Bylaws of Femasys Inc. Form 8-K 001- 40492 3.2 June 22, 2021 Â Â Â Â Â Â 3.3 First Amendment to the Amended and Restated Bylaws of Femasys Inc. Form 8-K 001- 40492 3.1 March 30, 2023 Â Â Â Â Â 31.1* Certification of Principal Executive Officer Pursuant to Securities Exchange Act Rules 13a-14(a), as adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 Â Â Â Â Â Â Â Â Â 31.2* Â Certification of Principal Financial Officer Pursuant to Securities Exchange Act Rules 13a-14(a), as adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 Â Â Â Â Â Â Â Â Â 32.1* Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 Â Â Â Â 28 Table of Contents 32.2* Â Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 Â Â Â Â Â Â Â Â Â Â 101.INS* Inline XBRL Instance Document (the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document) Â Â Â Â Â Â Â Â Â Â 101.SCH* Inline XBRL Taxonomy Extension Schema Document Â Â Â Â Â Â Â Â Â Â 101.CAL Inline XBRL Taxonomy Extension Calculation Linkbase Document Â Â Â Â Â Â Â Â Â Â 101.DEF* Inline XBRL Taxonomy Definition Linkbase Document Â Â Â Â Â Â Â Â Â Â 101.LAB* Inline XBRL Taxonomy Extension Label Linkbase Document Â Â Â Â Â Â Â Â Â Â 101.PRE* Inline XBRL Taxonomy Extension Presentation Linkbase Document Â Â Â Â Â Â Â Â Â Â 104* Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101) Â Â Â Â *Filed herewith 29 Table of Contents SIGNATURES Pursuant to the requirements of the Securities Act, the registrant has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Suwanee, State of Georgia, on this 8th day of August 2024. FEMASYS INC. Dated: August 8, 2024 By: /s/ Kathy Lee-Sepsick Â Kathy Lee-Sepsick Â Chief Executive Officer and President Dated: August 8, 2024 Â Â By: /s/ Dov Elefant Â Dov Elefant Â Chief Financial Officer 30 EX-31.1 2 ef20029680_ex31-1.htm EXHIBIT 31.1 Exhibit 31.1 CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER PURSUANT TO SECURITIES EXCHANGE

ACT RULES 13a-14(a) AND 15(d)-14(a), AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Kathy Lee-Sepsick, certify that: 1. I have reviewed this Report on Form 10-Q for Femasys Inc; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; 3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; 4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant is made known to us by others within those entities, particularly during the period in which this report is being prepared; b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; c. Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and d. Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and 5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions): a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and b. Any fraud, whether or not material, which involves management or other employees who have a significant role in the registrant's internal control over financial reporting. Â FEMASYS INC. Â Â Date: August 8, 2024 By: /s/ Kathy Lee-Sepsick Â Â Kathy Lee-Sepsick Â Â Chief Executive Officer and President Â Â (principal executive officer) EX-31.2 3 ef20029680_ex31-2.htm EXHIBIT 31.2 Exhibit 31.2 CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER PURSUANT TO SECURITIES EXCHANGE ACT RULES 13a-14(a) AND 15(d)-14(a), AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Dov Elefant, certify that: 1. I have reviewed this Report on Form 10-Q for Femasys Inc; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; 3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; 4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant is made known to us by others within those entities, particularly during the period in which this report is being prepared; b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; c. Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and d. Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and 5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions): a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and b. Any fraud, whether or not material, which involves management or other employees who have a significant role in the registrant's internal control over financial reporting. Â FEMASYS INC. Â Â Date:Â August 8, 2024 By: /s/ Dov Elefant Â Â Dov Elefant Â Â Chief Financial Officer Â Â (principal financial and accounting officer) EX-32.1 4 ef20029680_ex32-1.htm EXHIBIT 32.1 Exhibit 32.1 CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350 ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the Quarterly Report of Femasys Inc., a Delaware Corporation, (the â€œCompanyâ€) on Form 10-Q for the quarter ended June 30, 2024, as filed with the Securities and Exchange Commission on the date hereof (the â€œReportâ€), the undersigned certify the following pursuant to Section 18, U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002: 1. The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and 2. The information contained in the report fairly presents, in all material respects, the financial condition and results of operations of the Company. Â FEMASYS INC. Â Â Â Â Date:Â August 8, 2024 By: /s/ Kathy Lee-Sepsick Â Â Kathy Lee-Sepsick Â Â Chief Executive Officer and President Â Â (principal executive officer) EX-32.2 5 ef20029680_ex32-2.htm EXHIBIT 32.2 Exhibit 32.2 CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350 ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the Quarterly Report of Femasys Inc., a Delaware Corporation, (the â€œCompanyâ€) on Form 10-Q for the quarter ended June 30, 2024, as filed with the Securities and Exchange Commission on the date hereof (the â€œReportâ€), the undersigned certify the following pursuant to Section 18, U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002: 1. The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and 2. The information contained in the report fairly presents, in all material respects, the financial condition and results of operations of the Company. Â FEMASYS INC. Â Â Â Â Date:Â August 8, 2024 By: /s/ Dov Elefant Â Â Dov Elefant Â Â Chief Financial Officer Â Â (principal financial and accounting officer) EX-101.SCH 6 femy-20240630.xsd XBRL TAXONOMY EXTENSION SCHEMA 000100 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 010000 - Statement - Condensed Balance Sheets link:presentationLink link:calculationLink link:definitionLink 010100 - Statement - Condensed Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 020000 - Statement - Condensed Statements of Comprehensive Loss link:presentationLink link:calculationLink link:definitionLink 030000 - Statement - Condensed Statements of Stockholders' Equity link:presentationLink link:calculationLink link:definitionLink 040000 - Statement - Condensed Statements of Cash Flows link:presentationLink link:calculationLink link:definitionLink 060100 - Disclosure - Organization, Nature of Business, and Liquidity link:presentationLink link:calculationLink link:definitionLink 060200 - Disclosure - Fair Value link:presentationLink link:calculationLink link:definitionLink 060300 - Disclosure - Cash and Cash Equivalents link:presentationLink link:calculationLink link:definitionLink 060400 - Disclosure - Inventories link:presentationLink link:calculationLink link:definitionLink 060500 - Disclosure - Accrued Expenses link:presentationLink link:calculationLink link:definitionLink 060600 - Disclosure - Clinical Holdback link:presentationLink link:calculationLink link:definitionLink 060700 - Disclosure - Revenue Recognition link:presentationLink link:calculationLink link:definitionLink 060800 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 060900 - Disclosure - Notes Payable link:presentationLink link:calculationLink link:definitionLink 061000 - Disclosure - Convertible Notes with Warrants (November 2023 Financing) link:presentationLink link:calculationLink link:definitionLink 061100 - Disclosure - Stockholders' Equity link:presentationLink link:calculationLink link:definitionLink 061200 - Disclosure - Equity Incentive Plans and Warrants link:presentationLink link:calculationLink link:definitionLink 061300 - Disclosure - Related-Party Transactions link:presentationLink link:calculationLink link:definitionLink 061400 - Disclosure - Net Loss per Share Attributable to Common Stockholders link:presentationLink link:calculationLink link:definitionLink 061500 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 061600 - Disclosure - Insider Trading Arrangements link:presentationLink link:calculationLink link:definitionLink 070100 - Disclosure - Organization, Nature of Business, and Liquidity (Policies) link:presentationLink link:calculationLink link:definitionLink 080400 - Disclosure - Inventories (Tables) link:presentationLink link:calculationLink link:definitionLink 080500 - Disclosure - Accrued Expenses (Tables) link:presentationLink link:calculationLink link:definitionLink 080600 - Disclosure - Clinical Holdback (Tables) link:presentationLink link:calculationLink link:definitionLink 080700 - Disclosure - Revenue Recognition (Tables) link:presentationLink link:calculationLink link:definitionLink 081200 - Disclosure - Equity Incentive Plans and Warrants (Tables) link:presentationLink link:calculationLink link:definitionLink 081400 - Disclosure - Net Loss per Share Attributable to Common Stockholders (Tables) link:presentationLink link:calculationLink link:definitionLink 090100 - Disclosure - Organization, Nature of Business, and Liquidity (Details) link:presentationLink link:calculationLink link:definitionLink 090300 - Disclosure - Cash and Cash Equivalents (Details) link:presentationLink link:calculationLink link:definitionLink 090400 - Disclosure - Inventories (Details) link:presentationLink link:calculationLink link:definitionLink 090500 - Disclosure - Accrued Expenses (Details) link:presentationLink link:calculationLink link:definitionLink 090600 - Disclosure - Clinical Holdback (Details) link:presentationLink link:calculationLink link:definitionLink 090700 - Disclosure - Revenue Recognition (Details) link:presentationLink link:calculationLink link:definitionLink 090900 - Disclosure - Notes Payable (Details) link:presentationLink link:calculationLink link:definitionLink 091000 - Disclosure - Convertible Notes with Warrants (November 2023 Financing), Summary (Details) link:presentationLink link:calculationLink link:definitionLink 091002 - Disclosure - Convertible Notes with Warrants (November 2023 Financing), Warrants (Details) link:presentationLink link:calculationLink link:definitionLink 091004 - Disclosure - Convertible Notes with Warrants (November 2023 Financing), Convertible Notes Payable (Details) link:presentationLink link:calculationLink link:definitionLink 091100 - Disclosure - Stockholders' Equity (Details) link:presentationLink link:calculationLink link:definitionLink

091200 - Disclosure - Equity Incentive Plans and Warrants, Stock Option Plan, Activity (Details) link:presentationLink link:calculationLink link:definitionLink 091202 - Disclosure - Equity Incentive Plans and Warrants, Inducement Grant (Details) link:presentationLink link:calculationLink link:definitionLink 091204 - Disclosure - Equity Incentive Plans and Warrants, Share-Based Compensation Expense (Details) link:presentationLink link:calculationLink link:definitionLink 091206 - Disclosure - Equity Incentive Plans and Warrants, Employee Stock Purchase Plan (Details) link:presentationLink link:calculationLink link:definitionLink 091208 - Disclosure - Equity Incentive Plans and Warrants, April 2023 Financing (Details) link:presentationLink link:calculationLink link:definitionLink 091300 - Disclosure - Related-Party Transactions (Details) link:presentationLink link:calculationLink link:definitionLink 091400 - Disclosure - Net Loss per Share Attributable to Common Stockholders (Details) link:presentationLink link:calculationLink link:definitionLink 091500 - Disclosure - Income Taxes (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 7 femy-20240630_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 8 femy-20240630_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 9 femy-20240630_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Insider Trading Arrangements [Line Items] Rule 10b5-1 Arrangement Adopted Rule 10b5-1 Arrangement Adopted [Flag] Rule 10b5-1 Arrangement Terminated Rule 10b5-1 Arrangement Terminated [Flag] Non-Rule 10b5-1 Arrangement Adopted Non-Rule 10b5-1 Arrangement Adopted [Flag] Non-Rule 10b5-1 Arrangement Terminated Non-Rule 10b5-1 Arrangement Terminated [Flag] Accrued Expenses Accounts Payable and Accrued Liabilities Disclosure [Text Block] Accounts receivable, net Less accumulated depreciation Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Additional paid-in-capital Amortization of debt issuance costs and discount Amortization of debt discount and issuance costs Depreciation Depreciation Amortization Amortization of Intangible Assets Balance Sheets [Abstract] Net loss per share attributable to common stockholders, basic (in dollars per share) Net loss per share attributable to common stockholders, basic (in dollars per share) Cash and cash equivalents Interest Accounts receivable Increase (Decrease) in Accounts Receivable Inventory Increase (Decrease) in Inventories Changes in operating assets and liabilities: Accounts payable Increase (Decrease) in Accounts Payable Accrued expenses Increase (Decrease) in Accrued Liabilities Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block] Common stock, authorized (in shares) Common stock, issued (in shares) Balance (in shares) Balance (in shares) Common stock, outstanding (in shares) Common stock, $.001 par, 200,000,000 authorized, 22,350,022 shares issued and 22,232,799 outstanding as of June 30, 2024; and 21,774,604 shares issued and 21,657,381 outstanding as of December 31, 2023 Construction in progress Convertible Notes [Member] Convertible notes payable, net (including related parties) Cost of sales (excluding depreciation expense) Total current liabilities Liabilities, Current Current liabilities: Maturity date Notes Payable Debt Disclosure [Text Block] Notes principal balance Aggregate principal amount Frequency of installment payments Interest rate Convertible note accrue interest rate Maturity date of loan Debt Instrument, Maturity Date Debt Instrument, Name [Domain] Monthly principal and interest payments Notes Payable [Abstract] Convertible Notes [Abstract] Debt Instrument [Axis] Debt Instrument [Line Items] Schedule of Long-Term Debt Instruments [Table] Transaction costs Payments of Debt Issuance Costs Depreciation and amortization Cash and Cash Equivalents Cash and Cash Equivalents Disclosure [Text Block] Net loss per share attributable to common stockholders, diluted (in dollars per share) Net loss per share attributable to common stockholders, diluted (in dollars per share) Effective tax rate Effective Income Tax Rate Reconciliation, Percent [Abstract] Share-based compensation expense Share-Based Payment Arrangement, Expense Share-based compensation expense Share-Based Payment Arrangement, Noncash Expense Employee Stock Ownership Plan (ESOP), Plan [Domain] Employee Stock Ownership Plan (ESOP) Name [Axis] Employee Stock Ownership Plan (ESOP) Disclosures [Line Items] Schedule of Employee Stock Ownership Plan (ESOP) Disclosures [Table] Furniture and fixtures General and administrative General and Administrative [Member] Statements of Comprehensive Loss [Abstract] Income Taxes [Text Block] Taxes Prepaid and other assets Increase (Decrease) in Other Operating Assets Warrants to purchase common stock (in shares) Options to purchase common stock (in shares) Intangible assets, net of accumulated amortization Interest expense on loan Interest expense Interest Expense, Debt Finished goods Inventory, net Inventory, net Materials Work in progress Leasehold improvements Total liabilities Liabilities Total liabilities and stockholders' equity Liabilities and Equity Liabilities and Stockholders' Equity Liabilities and Equity [Abstract] Line of Credit Facility, Lender [Domain] Lender Name [Axis] Money Market Funds [Member] Net cash provided by financing activities Net Cash Provided by (Used in) Financing Activities Cash flows from financing activities: Net cash used in investing activities Net Cash Provided by (Used in) Investing Activities Cash flows from investing activities: Net cash used in operating activities Net Cash Provided by (Used in) Operating Activities Cash flows from operating activities: Net loss Net loss Net loss attributable to common stockholders, basic Net loss attributable to common stockholders, basic Total other income (expense), net Nonoperating Income (Expense) Other income (expense): Long-term assets: Total long-term liabilities Liabilities, Noncurrent Long-term liabilities: Note payable Loss from operations Operating Income (Loss) Organization, Nature of Business, and Liquidity Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] Prepaid and other current assets Proceeds from convertible notes Proceeds from Convertible Debt Proceeds from at-the-market sales of common stock Proceeds from Issuance of Common Stock Proceeds from Issuance of Common Stock Gross proceeds from offering Proceeds from Issuance or Sale of Equity Proceeds from the issuance of common stock and warrants in April 2023 Financing Proceeds to pay insurance premiums Proceeds from Notes Payable Property and equipment, gross Property, Plant and Equipment, Gross Net property and equipment Property, Plant and Equipment, Net Acquisition of patents Payments to Acquire Intangible Assets Purchases of property and equipment Payments to Acquire Property, Plant, and Equipment Related-party transaction Related-Party Transactions Down payments Repayment of note payable Repayments of Notes Payable Issuance costs for at-the-market sales of common stock Payments for Repurchase of Common Stock Accumulated deficit Sale of Stock [Domain] Purchase price (in dollars per share) Net proceeds from issuance of common stock and warrants Sale of Stock, Consideration Received on Transaction Inventories Share-based Compensation Expense Disclosure of Share-Based Compensation Arrangements by Share-Based Payment Award [Table Text Block] Sales and marketing Sales and Marketing [Member] Share-based compensation expense expected to be recognized for employees and nonemployees Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount Forfeited (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period Weighted-average fair values of options granted (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Ending balance (in shares) Beginning balance (in shares) Shares outstanding (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Beginning balance (in dollars per share) Ending balance (in dollars per share) Weighted average exercise price (in dollars per share) Dividend yield Expected volatility Risk free interest rate Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Statements of Cash Flows [Abstract] Statements of Stockholders' Equity [Abstract] Stockholders' equity: Stockholders Equity [Abstract] Warrants outstanding (in shares) Stockholders' Equity Equity [Text Block] Warrants issued to purchase common stock (in shares) Warrants purchase shares of common stock (in shares) Warrants issued to purchase common stock (in shares) Sale of Stock [Axis] Supplemental cash flow information Total current assets Assets, Current Current assets: Warrants Weighted-average shares used in computing net loss per share attributable to common stockholders, diluted (in shares) Weighted average number of shares used in computing net loss per share attributable to common stockholders, diluted (in shares) Total potential shares (in shares) Weighted Average Number of Shares Outstanding, Diluted, Adjustment Weighted-average shares used in computing net loss per share attributable to common stockholders, basic (in shares) Weighted average number of shares used in computing net loss per share attributable to common stockholders, basic (in shares) Common Stock [Member] Property and equipment, at cost: Research and development Total assets Assets Interest income Investment Income, Interest Cash and cash equivalent Cash and Cash Equivalents, Fair Value Disclosure Statement [Table] Machinery and equipment Assets Assets [Abstract] Statement [Line Items] Net Income (Loss) Available to Common Stockholders, Basic [Abstract] Class of Warrant or Right [Table] Class of Warrant or Right [Axis] Class of Warrant or Right [Domain] Level 1 [Member] Fair Value, Inputs, Level 1 [Member] Stockholders' Equity [Abstract] Fair Value Class of Warrant or Right [Line Items] Class of Stock [Domain] Increase (Decrease) in Stockholders' Equity [Roll Forward] Other long-term assets Operating expenses: Total operating expenses Operating Expenses Net Loss per Share Attributable to Common Stockholders [Abstract] Other liabilities Class of Stock [Axis] Common stock, par value (in dollars per share) Common stock reserved for issuance (in shares) Common Stock, Capital Shares Reserved for Future Issuance Total stockholders' equity Balance Balance Equity, Attributable to Parent Income tax benefit Income Tax Expense (Benefit) Office equipment Property, Plant and Equipment, Other, Gross Equity Components [Axis] Additional Paid-in Capital [Member] Accumulated Deficit [Member] Equity Component [Domain] Common stock value Stock Issued During Period, Value, New Issues Issuance of common stock in connection with ESPP Stock issued, fair value Common stock sold (in shares) Issuance and sale of common stock (in shares) Issuance of common stock in connection with ESPP (in shares) Stock issued (in shares) Options exercised (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period Net loss attributable to common stockholders, diluted Net loss attributable to common stockholders, diluted Number of Options [Roll Forward] Options vested and exercisable [Abstract] Options vested and exercisable, Exercise price (in dollars per share) Options vested and exercisable, Weighted average exercise price (in dollars per shares) Options vested and exercisable, Number of option vested (in shares) Estimated Fair Value Assumptions [Abstract] Estimated Fair Value Assumptions [Abstract] Convertible note, fair value Convertible Debt, Fair Value Disclosures Dividends declared or paid Net Loss per Share Attributable to Common Stockholders Weighted Average Number of Shares Outstanding [Abstract] Parent [Member] Class of Stock [Line Items] Schedule of Stock by Class [Table] Commitments and contingencies Commitments and Contingencies Adjustments to reconcile net loss to net cash used in operating activities: Long-Term Debt, Type [Axis] Accounts payable Accrued expenses Accrued expenses Director fees Accrued Professional Fees, Current Accrued and unpaid interest Accrued interest Interest Payable, Current Other Long-Term Debt, Type [Domain] Share-based compensation expense Proceeds from common stock issued through ESPP and exercised options Loss before income taxes Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Inventory reserve write-off Coupon interest expense Fair Value Hierarchy and NAV [Domain] Proceeds from exercise of pre-funded warrants Asset Class [Domain] Cash and Cash Equivalents [Abstract] Accrued Expenses [Abstract] Organization, Nature of Business, and Liquidity [Abstract] Asset Class [Axis] Fair Value Hierarchy and NAV [Axis] Accrued Expenses Schedule of Accrued Liabilities [Table Text Block] Computations of Diluted Weighted Average Shares Outstanding Inventory Stated

at Cost, Net of Reserve Commitments and Contingencies [Abstract] Income Taxes [Abstract] Fair Value [Abstract] Inventories [Abstract] Notes Payable [Abstract] Total long-term assets Assets, Noncurrent, Other than Noncurrent Investments and Property, Plant and Equipment Estimated Using Assumptions Stock Option Plan Activity Share-Based Compensation Expense [Abstract] Salary and Wage, Excluding Cost of Good and Service Sold [Abstract] Equity Incentive Plans and Warrants Shareholders' Equity and Share-Based Payments [Text Block] Use of Estimates Use of Estimates, Policy [Policy Text Block] Assets, Fair Value Disclosure [Abstract] Assets, Fair Value Disclosure [Abstract] Fair Value, Recurring and Nonrecurring [Table] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Research and Development [Member] Related-Party Transactions [Abstract] Granted (in shares) Non-cash investing and financing activities: Computation of Basic and Diluted Net Loss Per Share Basis of Presentation Unrecognized expenses Stock price (in dollars per share) Share Price Weighted Average Exercise Price [Abstract] Granted (in dollars per share) Forfeited (in dollars per share) Income Statement Location [Axis] Income Statement Location [Domain] Recently Issued Accounting Pronouncements Adopted and Not Yet Adopted Expected term (in years) Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term Vesting period Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period Weighted-average period over which unrecognized compensation is expected to be recognized Number of operating segments Number of Operating Segments Exercise price (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Exercise Price Conversion price (in dollars per share) Sales by Geographic Region Loss on disposal of assets Gain (Loss) on Disposition of Assets Notes redeem at premium, percentage Warrants exercise price (in dollars per share) Warrants exercise price (In dollars per share) International [Member] Unamortized discount and debt issuance costs Convertible Notes Payable [Abstract] Treasury Common Stock [Member] Treasury stock, common shares (in shares) Treasury stock, common shares (in shares) Treasury stock, common shares (in shares) Treasury stock, 117,223 common shares Treasury stock, common value Treasury stock, common value Treasury Stock, Common, Value Revenue Recognition [Abstract] Disaggregation of Revenue [Abstract] Disaggregation of Revenue [Table] Disaggregation of Revenue [Line Items] Revenue Recognition [Abstract] Revenue Recognition Revenue from Contract with Customer [Text Block] Sales Net change in cash and cash equivalents Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect End of period Beginning of period Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Cash and cash equivalents: Payments under lease obligations Finance Lease, Principal Payments Revenue recognized from performance obligations in prior periods Contract with Customer, Performance Obligation Satisfied in Previous Period Warrants term Warrants term Grantee Status [Axis] Grantee Status [Domain] Employees [Member] Nonemployee [Member] Amortization of right-of-use assets Lease liabilities Interest expense Interest Expense, Nonoperating Geographical [Domain] Geographical [Axis] Statistical Measurement [Axis] Statistical Measurement [Domain] Maximum [Member] Minimum [Member] Product and Service [Domain] Product and Service [Axis] U.S. [Member] Cover [Abstract] Document Type Document Quarterly Report Document Transition Report Entity Interactive Data Current Amendment Flag Document Fiscal Year Focus Document Fiscal Period Focus Document Period End Date Entity Registrant Name Entity Central Index Key Entity File Number Entity Tax Identification Number Entity Incorporation, State or Country Code Current Fiscal Year End Date Entity Current Reporting Status Entity Shell Company Entity Filer Category Entity Small Business Entity Emerging Growth Company Entity Ex Transition Period Entity Address, Address Line One Entity Address, Address Line Two Entity Address, City or Town Entity Address, State or Province Entity Address, Postal Zip Code City Area Code Local Phone Number Title of 12(b) Security Trading Symbol Security Exchange Name Entity Common Stock, Shares Outstanding Borrowing supported by a written promise to pay an obligation in June of 2022. June Promissory Note [Member] Borrowing supported by a written promise to pay an obligation in July of 2023. July Promissory Note [Member] July Promissory Note [Member] AFCO Credit Corporation, doing business as AFCO Insurance Premium Finance, provides premium financing services. The Company offers loans for businesses, finance property, and casualty insurance premiums. Afco Insurance Premium Finance serves clients worldwide. AFCO Credit Corporation [Member] AFCO Credit Corporation [Member] Amount of clinical holdback expected to be paid during the following twelve months or within one business cycle, if longer. Clinical Holdback Current Clinical holdback - current portion Less: clinical holdback - current portion Present value of lessee's discounted obligation for lease payments from operating and finance lease, classified as current. Operating and Finance Lease, Liability, Current Lease liabilities - current portion Amount of right-of-use asset from operating and finance lease. Operating Lease and Finance Lease, Right-of-Use Asset Lease right-of-use assets, net Amount of clinical holdback, due after one year or beyond the normal operating cycle, if longer. Clinical Holdback, Noncurrent Clinical holdback - long-term portion Present value of lessee's discounted obligation for lease payments from operating and finance lease, classified as noncurrent. Operating and Finance Lease, Liability, Noncurrent Lease liabilities - long-term portion Equity Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount. Equity Warrants [Member] Warrants [Member] Number of new stock issued in connection with the at-the-market program during the period. Stock Issued During Period, Shares, At-The-Market Offering, Net of issuance Costs Issuance of common stock in connection with at-the-market offering, net of issuance costs (in shares) Equity impact of the value in issuance of common stock and warrants, in connection with "April 2023 Financing", net of issuance costs. Stock Issued During Period, Value, Issuance of Common Stock and Warrants Issuance of common stock and warrants in connection with April 2023 Financing, net of issuance costs The warrants expired during the period. Expiration of Warrant Number of common stock and warrants, in connection with "April 2023 Financing" during the period. Stock Issued During Period, Shares, Issuance of Common Stock and Warrants Issuance of common stock and warrants in connection with April 2023 Financing, net of issuance costs (in shares) Number of pre-funded warrants exercise. Stock Issued During Period, Shares, Exercise of Pre-funded Warrants Exercise of pre-funded warrants (in shares) Aggregate value of issuance of common stock from exercise of pre-funded warrants issued during the period. Stock Issued During Period, Value, Exercise of Pre-funded Warrants Exercise of pre-funded warrants Equity impact of the value of new stock issued in connection with at-the-market program during the period. Stock Issued During Period, Value, At-The-Market Offering, Net of Issuance Costs Issuance of common stock in connection with at-the-market offering, net of issuance costs A pre-funded warrant that allows the warrant holder to purchase a specified number of a company's securities at a nominal exercise price. Pre Funded Warrants [Member] Pre-funded Warrants [Member] The member stands common stock issued to the placement agent as compensation for services ("placement agent warrants"). Placement Agent Warrants [Member] Placement Agent Warrants [Member] The cash inflow associated with the amount received from holders exercising their common stock warrants. Proceeds from Exercise of Common Stock Warrants Cash proceeds from warrants exercised The authorized offering amount of securities. Authorized Offering Amount of Securities Authorized offering amount of securities Number of warrants exercised during the period. Number of Warrants Exercised Warrants exercised (in shares) Amount of placement agent fees expense and offering expenses related to common stock and warrants. Placement Agent Fees Expenses and Offering Expenses Placement agent fees expenses and offering expenses A common warrant represents the right to purchase a company's stock at a specific price and at a specific date. Common Warrants [Member] Common Warrants [Member] Amount of common stock authorized value to be issued by Sales Agent to sell maximum shares at current market prices until all shares all sold. Common Stock, Authorized Value to be Issued by Sales Agent Common stock authorized value to be issued by Sales Agent Equity distribution agreement is one under which a supplier or manufacturer of goods agrees that an independent third party will market and sell the goods. Equity Distribution Agreement [Member] The amount of offering costs from noncash transactions included in deferred offering costs reclassified to additional paid-in-capital. Deferred Offering Costs Reclassified to Additional Paid-In-Capital Deferred offering costs reclassified to additional paid-in-capital Value of property and equipment costs included in accounts payable and accrued expense as a noncash or partial noncash transaction. Property and Equipment Costs, Included in Accounts Payable and Accrued Expense Property and equipment costs included in accounts payable and accrued expense The amount of commission costs relating to certain proceeds from issuance of common stock incurred as a noncash or partial noncash transaction. Commission Costs Relating to Certain Proceeds From Issuance of Common Stock Commissions costs relating to certain proceeds from issuance of common stock Cash Paid For [Abstract] Cash paid for: Value of acquisition of patents included in accounts payable as a noncash or partial noncash transaction.. Acquisition of Patents Included in Accounts Payable Acquisition of patents included in accounts payable The cash outflow for cost incurred directly with the issuance of an equity security. Payments of Equity Issuance Costs Equity issuance costs for April 2023 Financing Transaction costs Convertible Notes with Warrants (November 2023 Financing) [Abstract] The entire disclosure for information about convertible notes with warrants financing. Convertible Notes with Warrants November 2023 Financing [Text Block] Convertible Notes with Warrants (November 2023 Financing) The November 2023 financing. November 2023 Financing [Member] November 2023 Financing [Member] A classification of Information by type of warrant or right issued, for example Series B Warrants. Series B Warrants [Member] Series B Warrants [Member] A classification of Information by type of warrant or right issued, for example Series A Warrants. Series A Warrants [Member] Series A Warrants [Member] Warrants Transactions [Abstract] Warrants [Abstract] Percentage of warrant has the right to call the exercise, if the closing price of the common stock exceeds. Percentage of Warrant Closing Price of Common Stock Exceeds, Percentage Percentage of warrant closing price of common stock exceeds The consecutive trading days, in which common stock exceeds the conversion price, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Consecutive Trading Days, Common Stock Exceeds the Conversion Price Consecutive trading days The amount of daily dollar trading volume of the common stock exceeds per day during the same period and certain equity conditions. Daily Dollar Trading Volume of Common Stock Exceeds per Day Daily dollar trading volume of common stock exceeds per day Organization and Nature of Business [Abstract] Organization and Nature of Business [Abstract] Number of year where women's used for permanent birth control. Number of Year Where Women's Used for Permanent Birth Control Number of year where women's used for permanent birth control. Number of products received European Union Medical Device Regulation (EU MDR) certificates and CE Mark certifications during the period. Number of Products Received EU MDR and CE Mark Certifications Number of products received EU MDR and CE Mark certifications Follow-up period for interim analysis of clinical data for permanent birth control Follow-up Period for Interim Analysis of Clinical Data Follow-up period for interim analysis of clinical data for permanent birth control Number of women need to use for interim analysis of clinical data for permanent birth control Number of Women Need to Use for Interim Analysis of Clinical Data Number of women need to use for interim analysis of clinical data for permanent birth control Period for analysis of clinical data for permanent birth control. Period for analysis of clinical data Period for analysis of clinical data for permanent birth control Number of women used FemBloc for

permanent birth control Number of Women Used FemBloc for Permanent Birth Control Number of women used FemBloc for permanent birth control Liquidity [Abstract] Liquidity [Abstract] Number of additional women enrolled for a clinical readout. Number of Women Enrolled for Clinical Readout Number of women enrolled for a clinical readout Clinical Holdback [Abstract] The entire disclosure of clinical holdback. Clinical Holdback [Text Block] Clinical Holdback A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period. Clinical Holdback Liability [Roll Forward] Clinical Holdback Liability [Roll Forward] Amount of clinical holdback retained during the period. Clinical Holdback Retained Clinical holdback retained Amount of cash outflow reducing clinical holdback liability. Clinical Holdback Paid Clinical holdback paid Amount of clinical holdback liability. Clinical Holdback Liability Balance Balance Period of conversion price for a period after closing, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Period of Conversion Price Conversion price, period The closing price per share of the common stock exceeds of the conversion feature embedded in the debt instrument. Debt Instrument, Convertible, Conversion Price of Common Stock Exceeds Conversion price of common stock exceeds (in dollars per share) Tabular disclosure of clinical holdback liability account. Schedule Of Clinical Holdback Liability Account [Table Text Block] Clinical Holdback Liability Primary Geographical Markets [Abstract] Primary Geographical Markets [Abstract] Revenue recognition payment period term, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment. Revenue Recognition, Payment Term of Period Revenue recognition payment period term The percentage of restocking fee on items to be returned. Percentage of Restocking Fee Percentage of restocking fee Pressure management device evaluates the women's fallopian tubes after a FemBloc procedure and is part of the FemBloc validation study. FemVue [Member] FemVue [Member] Warrants and rights represent derivative securities that give the holder the right to purchase securities. Warrants Six [Member] April 2023 Financing [Member] Warrants and rights represent derivative securities that give the holder the right to purchase securities. Warrants Seven [Member] November 2023 Financing [Member] Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of pre-funded warrants, common warrants and placement agent warrants using the treasury stock method. Incremental Common Shares Attributable to Dilutive Effect of Pre-Funded Warrants, Common Warrants and Placement Agent Warrants Warrants to purchase common stock in connection financing (in shares) Equity Incentive Plans and Warrants [Abstract] Warrants [Abstract] Warrants [Abstract] Price of a single share of a number of saleable stocks of a company under Black-Scholes assumptions. Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Black-Scholes Value Black-Scholes value (in dollars per share) Tabular disclosure of the significant assumptions used during the year to estimate the fair value of warrants, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions. Schedule of Share Based Payment Award, Fair Value Warrant Liability, Valuation Assumptions [Table Text Block] Warrants Valuation Assumptions Inducement grants are a type of equity award to newly hired personnel. Inducement Grant [Member] Inducement Grant [Member] Name of the stock-based compensation arrangement option plan. 2021 Stock Option Plan [Member] 2021 Stock Option Plan [Member] Employee Stock Purchase Plan [Abstract] Employee Stock Purchase Plan [Abstract] The Employee Stock Purchase Plan (the "ESPP") allows eligible full-time employees to purchase shares of common stock at 90 percent of the lower of the fair market value of a share of common stock on the first or last day of the quarter. Employee Stock Purchase Plan [Member] Employee Stock Purchase Plan [Member] Disclosure of accounting policy for the liquidity. Liquidity [Policy Text Block] Liquidity Disclosure of accounting policy for the organization and nature of business. Organization and Nature of Business [Policy Text Block] Organization and Nature of Business Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to clinical trial cost. Accrued Clinical Trial Cost Clinical trail costs Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to franchise taxes. Franchise Taxes Franchise taxes The carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to incentive and other compensation costs. Incentive and Other Compensation Costs, Current Incentive and other compensation costs Inducement Grant [Abstract] Amount of expense for award under share-based payment arrangement to be recognized upon achieving certain performance condition. Share-based Compensation Expense to be Recognized upon Achieving Certain Performance Condition Compensation expense to be recognized upon achieving certain performance condition Stock-based Compensation Expense [Abstract] Share-based Compensation Expense [Abstract] EX-101.PRE 10 femy-20240630_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 12 R1.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Document and Entity Information - shares 6 Months Ended Jun. 30, 2024 Aug. 07, 2024 Cover [Abstract] Â Â Document Type 10-Q Â Amendment Flag false Â Document Quarterly Report true Â Document Period End Date Jun. 30, 2024 Â Current Fiscal Year End Date --12-31 Â Document Fiscal Year Focus 2024 Â Document Fiscal Period Focus Q2 Â Document Transition Report false Â Entity File Number 001-40492 Â Entity Registrant Name Femasys Inc. Â Entity Central Index Key 0001339005 Â Entity Incorporation, State or Country Code DE Â Entity Tax Identification Number 11-3713499 Â Entity Address, Address Line One 3950 Johns Creek Court Â Entity Address, Address Line Two Suite 100 Â Entity Address, City or Town Suwanee Â Entity Address, State or Province GA Â Entity Address, Postal Zip Code 30024 Â City Area Code 770 Â Local Phone Number 500-3910 Â Title of 12(b) Security Common stock, $0.001 par value Â Trading Symbol FEMY Â Security Exchange Name NASDAQ Â Entity Current Reporting Status Yes Â Entity Interactive Data Current Yes Â Entity Filer Category Non-accelerated Filer Â Entity Small Business true Â Entity Emerging Growth Company true Â Entity Ex Transition Period true Â Entity Shell Company false Â Entity Common Stock, Shares Outstanding Â 22,232,799 X - DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission. + ReferencesNo definition available. + Details Name: dei_AmendmentFlag Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionArea code of city + ReferencesNo definition available. + Details Name: dei_CityAreaCode Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionCover page. + ReferencesNo definition available. + Details Name: dei_CoverAbstract Namespace Prefix: dei_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionEnd date of current fiscal year in the format --MM-DD. + ReferencesNo definition available. + Details Name: dei_CurrentFiscalYearEndDate Namespace Prefix: dei_ Data Type: xbrli:gMonthDayItemType Balance Type: na Period Type: duration X - DefinitionFiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY. + ReferencesNo definition available. + Details Name: dei_DocumentFiscalPeriodFocus Namespace Prefix: dei_ Data Type: dei:fiscalPeriodItemType Balance Type: na Period Type: duration X - DefinitionThis is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006. + ReferencesNo definition available. + Details Name: dei_DocumentFiscalYearFocus Namespace Prefix: dei_ Data Type: xbrli:gYearItemType Balance Type: na Period Type: duration X - DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD. + ReferencesNo definition available. + Details Name: dei_DocumentPeriodEndDate Namespace Prefix: dei_ Data Type: xbrli:dateItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true only for a form used as an quarterly report. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Form 10-Q -Number 240 -Section 308 -Subsection a + Details Name: dei_DocumentQuarterlyReport Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true only for a form used as a transition report. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Forms 10-K, 10-Q, 20-F -Number 240 -Section 13 -Subsection a-1 + Details Name: dei_DocumentTransitionReport Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'. + ReferencesNo definition available. + Details Name: dei_DocumentType Namespace Prefix: dei_ Data Type: dei:submissionTypeItemType Balance Type: na Period Type: duration X - DefinitionAddress Line 1 such as Attn, Building Name, Street Name + ReferencesNo definition available. + Details Name: dei_EntityAddressAddressLine1 Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionAddress Line 2 such as Street or Suite number + ReferencesNo definition available. + Details Name: dei_EntityAddressAddressLine2 Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionName of the City or Town + ReferencesNo definition available. + Details Name: dei_EntityAddressCityOrTown Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionCode for the postal or zip code + ReferencesNo definition available. + Details Name: dei_EntityAddressPostalZipCode Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionName of the state or province. + ReferencesNo definition available. + Details Name: dei_EntityAddressStateOrProvince Namespace Prefix: dei_ Data Type: dei:stateOrProvinceItemType Balance Type: na Period Type: duration X - DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityCentralIndexKey Namespace Prefix: dei_ Data Type: dei:centralIndexKeyItemType Balance Type: na Period Type: duration X - DefinitionIndicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument. + ReferencesNo definition available. + Details Name: dei_EntityCommonStockSharesOutstanding Namespace Prefix: dei_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionIndicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure. + ReferencesNo definition available. + Details Name: dei_EntityCurrentReportingStatus Namespace Prefix: dei_ Data Type: dei:yesNoItemType Balance Type: na Period Type: duration X - DefinitionIndicate

if registrant meets the emerging growth company criteria. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityEmergingGrowthCompany Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionIndicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Securities Act -Number 7A -Section B -Subsection 2 + Details Name: dei_EntityExTransitionPeriod Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen. + ReferencesNo definition available. + Details Name: dei_EntityFileNumber Namespace Prefix: dei_ Data Type: dei:fileNumberItemType Balance Type: na Period Type: duration X - DefinitionIndicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityFilerCategory Namespace Prefix: dei_ Data Type: dei:filerCategoryItemType Balance Type: na Period Type: duration X - DefinitionTwo-character EDGAR code representing the state or country of incorporation. + ReferencesNo definition available. + Details Name: dei_EntityIncorporationStateCountryCode Namespace Prefix: dei_ Data Type: dei:edgarStateCountryItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-T -Number 232 -Section 405 + Details Name: dei_EntityInteractiveDataCurrent Namespace Prefix: dei_ Data Type: dei:yesNoItemType Balance Type: na Period Type: duration X - DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityRegistrantName Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityShellCompany Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionIndicates that the company is a Smaller Reporting Company (SRC). + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntitySmallBusiness Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityTaxIdentificationNumber Namespace Prefix: dei_ Data Type: dei:employerIdItemType Balance Type: na Period Type: duration X - DefinitionLocal phone number for entity. + ReferencesNo definition available. + Details Name: dei_LocalPhoneNumber Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionTitle of a 12(b) registered security. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b + Details Name: dei_Security12bTitle Namespace Prefix: dei_ Data Type: dei:securityTitleItemType Balance Type: na Period Type: duration X - DefinitionName of the Exchange on which a security is registered. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1 + Details Name: dei_SecurityExchangeName Namespace Prefix: dei_ Data Type: dei:edgarExchangeCodeItemType Balance Type: na Period Type: duration X - DefinitionTrading symbol of an instrument as listed on an exchange. + ReferencesNo definition available. + Details Name: dei_TradingSymbol Namespace Prefix: dei_ Data Type: dei:tradingSymbolItemType Balance Type: na Period Type: duration XML 13 R2.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Condensed Balance Sheets - USD ($) Jun. 30, 2024 Dec. 31, 2023 Current assets: Â Â Cash and cash equivalents $ 13,525,898 $ 21,716,077 Accounts receivable, net 92,535 98,906 Inventory, net 1,315,580 667,118 Prepaid and other current assets 997,623 695,879 Total current assets 15,931,636 23,177,980 Property and equipment, at cost: Â Â Leasehold improvements 1,212,417 1,212,417 Office equipment 47,308 47,308 Furniture and fixtures 429,933 414,303 Machinery and equipment 2,599,994 2,559,356 Construction in progress 651,157 423,077 Property and equipment, gross 4,940,809 4,656,461 Less accumulated depreciation (3,678,450) (3,545,422) Net property and equipment 1,262,359 1,111,039 Long-term assets: Â Â Lease right-of-use assets, net 2,081,054 2,380,225 Intangible assets, net of accumulated amortization 44,317 0 Other long-term assets 957,078 1,086,581 Total long-term assets 3,082,449 3,466,806 Total assets 20,276,444 27,755,825 Current liabilities: Â Â Accounts payable 951,510 1,137,823 Accrued expenses 886,352 1,444,296 Clinical holdback - current portion 92,397 65,300 Lease liabilities - current portion 533,734 406,636 Total current liabilities 2,463,993 3,054,055 Long-term liabilities: Â Â Clinical holdback - long-term portion 32,706 54,935 Convertible notes payable, net (including related parties) 4,758,017 4,258,179 Lease liabilities - long-term portion 1,771,487 2,036,067 Total long-term liabilities 6,562,210 6,349,181 Total liabilities 9,026,203 9,403,236 Commitments and contingencies Stockholders' equity: Â Â Common stock, $.001 par, 200,000,000 authorized, 22,350,022 shares issued and 22,232,799 outstanding as of June 30, 2024; and 21,774,604 shares issued and 21,657,381 outstanding as of December 31, 2023 22,350 21,775 Treasury stock, 117,223 common shares (60,000) (60,000) Warrants 2,608,642 2,787,137 Additional paid-in-capital 125,344,962 123,985,306 Accumulated deficit (116,665,713) (108,381,629) Total stockholders' equity 11,250,241 18,352,589 Total liabilities and stockholders' equity $ 20,276,444 $ 27,755,825 X - DefinitionAmount of clinical holdback expected to be paid during the following twelve months or within one business cycle, if longer. + ReferencesNo definition available. + Details Name: femy_ClinicalHoldbackCurrent Namespace Prefix: femy_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of clinical holdback, due after one year or beyond the normal operating cycle, if longer. + ReferencesNo definition available. + Details Name: femy_ClinicalHoldbackNoncurrent Namespace Prefix: femy_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating and finance lease, classified as current. + ReferencesNo definition available. + Details Name: femy_OperatingAndFinanceLeaseLiabilityCurrent Namespace Prefix: femy_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating and finance lease, classified as noncurrent. + ReferencesNo definition available. + Details Name: femy_OperatingAndFinanceLeaseLiabilityNoncurrent Namespace Prefix: femy_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of right-of-use asset from operating and finance lease. + ReferencesNo definition available. + Details Name: femy_OperatingLeaseAndFinanceLeaseRightOfUseAsset Namespace Prefix: femy_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10 + Details Name: us-gaap_AccountsPayableCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2 + Details Name: us-gaap_AccountsReceivableNetCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_AccruedLiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(14)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1 + Details Name: us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -

SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_AdditionalPaidInCapital Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of asset recognized for present right to economic benefit. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 12: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 13: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(12)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 19: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 30: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(11)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 + Details Name: us-gaap_Assets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of asset recognized for present right to economic benefit, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 10: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name

Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7 + Details Name: us-gaap_AssetsCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_AssetsCurrentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_AssetsNoncurrentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionSum of the carrying amounts as of the balance sheet date of all assets, excluding property, plant, and equipment and other property and investments, that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer. Alternate captions include Total Deferred Charges and Other Assets. + ReferencesNo definition available. + Details Name: us-gaap_AssetsNoncurrentOtherThanNoncurrentInvestmentsAndPropertyPlantAndEquipment Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4 + Details Name: us-gaap_CashAndCashEquivalentsAtCarryingValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionRepresents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(15)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 + Details Name: us-gaap_CommitmentsAndContingencies Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1 + Details Name: us-gaap_CommonStockValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1 + Details Name: us-gaap_ConstructionInProgressGross Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of long-term debt (with maturities initially due after one year or beyond the operating cycle if longer) identified as Convertible Notes Payable, excluding current portion. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_ConvertibleLongTermNotesPayable Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 926 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5 + Details Name: us-gaap_FiniteLivedIntangibleAssetsNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount before accumulated depreciation of equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1 + Details Name: us-gaap_FurnitureAndFixturesGross Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_InventoryNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount before accumulated depreciation of additions or improvements to assets held under a lease arrangement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1 + Details Name: us-gaap_LeaseholdImprovementsGross Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(26)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name

Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(21)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 15: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(14)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 29: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30 + Details Name: us-gaap_Liabilities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(32)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LiabilitiesAndStockholdersEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionTotal obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(21)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI

https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7 + Details Name: us-gaap_LiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_LiabilitiesCurrentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of obligation due after one year or beyond the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(26)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 13: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 22: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7 + Details Name: us-gaap_LiabilitiesNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_LiabilitiesNoncurrentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount before accumulated depreciation of tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1 + Details Name: us-gaap_MachineryAndEquipmentGross Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of current assets classified as other. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_OtherAssetsCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of noncurrent assets classified as other. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_OtherAssetsNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(13)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1 + Details Name: us-gaap_PropertyPlantAndEquipmentGross Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 360 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7AReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 360 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1 + Details Name: us-gaap_PropertyPlantAndEquipmentNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_PropertyPlantAndEquipmentNetAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount before accumulated depreciation, depletion and amortization of other physical assets used in the normal conduct of business to produce goods and services and not intended for resale. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 360 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1 + Details Name: us-gaap_PropertyPlantAndEquipmentOther Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of accumulated undistributed earnings (deficit). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -

Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(23)(a)(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_RetainedEarningsAccumulatedDeficit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 4.E) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2 + Details Name: us-gaap_StockholdersEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_StockholdersEquityAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount allocated to previously issued common shares repurchased by the issuing entity and held in treasury. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 505 -SubTopic 30 -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481520/505-30-50-4Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 505 -SubTopic 30 -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481549/505-30-45-1 + Details Name: us-gaap_TreasuryStockCommonValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionValue of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_WarrantsAndRightsOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant XML 14 R3.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Condensed Balance Sheets (Parenthetical) - $ / shares Jun. 30, 2024 Dec. 31, 2023 Stockholders' equity: Â Â Common stock, par value (in dollars per share) $ 0.001 $ 0.001 Common stock, authorized (in shares) 200,000,000 200,000,000 Common stock, issued (in shares) 22,350,022 21,774,604 Common stock, outstanding (in shares) 22,232,799 21,657,381 Treasury stock, common shares (in shares) 117,223 117,223 X - DefinitionFace amount or stated value per share of common stock. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockParOrStatedValuePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe maximum number of common shares permitted to be issued by an entity's charter and bylaws. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 + Details Name: us-gaap_CommonStockSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionTotal number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockSharesIssued Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of shares of common stock outstanding. Common stock represent the ownership interest in a corporation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3 + Details Name: us-gaap_CommonStockSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_StockholdersEquityAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionNumber of previously issued common shares repurchased by the issuing entity and held in treasury. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 505 -SubTopic 30 -

Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481549/505-30-45-1 + Details Name: us-gaap_TreasuryStockCommonShares Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant XML 15 R4.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Condensed Statements of Comprehensive Loss - USD ($) 3 Months Ended 6 Months Ended Jun. 30, 2024 Jun. 30, 2023 Jun. 30, 2024 Jun. 30, 2023 Statements of Comprehensive Loss [Abstract] Â Â Â Â Sales $ 221,484 $ 320,514 $ 492,624 $ 614,498 Cost of sales (excluding depreciation expense) 73,125 110,469 161,657 215,589 Operating expenses: Â Â Â Â Research and development 1,975,875 1,527,172 3,746,606 3,064,611 Sales and marketing 975,190 128,899 1,275,677 373,795 General and administrative 1,611,817 1,356,637 3,114,621 2,671,774 Depreciation and amortization 67,628 133,299 138,856 266,365 Total operating expenses 4,630,510 3,146,007 8,275,760 6,376,545 Loss from operations (4,482,151) (2,935,962) (7,944,793) (5,977,636) Other income (expense): Â Â Â Â Interest income 184,138 42,652 408,822 139,741 Interest expense (388,311) (198) (749,863) (1,870) Total other income (expense), net (204,173) 42,454 (341,041) 137,871 Loss before income taxes (4,686,324) (2,893,508) (8,285,834) (5,839,765) Income tax benefit (1,750) 0 (1,750) 0 Net loss (4,684,574) (2,893,508) (8,284,084) (5,839,765) Net loss attributable to common stockholders, basic (4,684,574) (2,893,508) (8,284,084) (5,839,765) Net loss attributable to common stockholders, diluted $ (4,684,574) $ (2,893,508) $ (8,284,084) $ (5,839,765) Net loss per share attributable to common stockholders, basic (in dollars per share) $ (0.21) $ (0.22) $ (0.38) $ (0.47) Net loss per share attributable to common stockholders, diluted (in dollars per share) $ (0.21) $ (0.22) $ (0.38) $ (0.47) Weighted-average shares used in computing net loss per share attributable to common stockholders, basic (in shares) 22,215,516 13,107,590 21,995,436 12,493,334 Weighted-average shares used in computing net loss per share attributable to common stockholders, diluted (in shares) 22,215,516 13,107,590 21,995,436 12,493,334 X - DefinitionThe aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(2)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(2)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1 + Details Name: us-gaap_CostOfGoodsAndServicesSold Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1 + Details Name: us-gaap_DepreciationAndAmortization Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7 + Details Name: us-gaap_EarningsPerShareBasic Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionThe amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI

https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7 + Details Name: us-gaap_EarningsPerShareDiluted Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionThe aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1 + Details Name: us-gaap_GeneralAndAdministrativeExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(11)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 9: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(10)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(15)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_IncomeStatementAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 231 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 6.I.7) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Subparagraph (a) -SubTopic 20 -Topic 740 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(h)) -SubTopic 10 -Topic 235 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1 + Details Name: us-gaap_IncomeTaxExpenseBenefit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of interest expense classified as nonoperating. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_InterestExpenseNonoperating Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(7)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 + Details Name: us-gaap_InvestmentIncomeInterest Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -

Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 5 -Subparagraph (SAB Topic 6.B) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-5Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B + Details Name: us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 5 -Subparagraph (SAB Topic 6.B) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-5Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 16 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 40 -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-40Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 40 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-40Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 40 -

Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-40Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 40 -Subparagraph (b)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-40 + Details Name: us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_NonoperatingIncomeExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NonoperatingIncomeExpenseAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionGenerally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense. + ReferencesNo definition available. + Details Name: us-gaap_OperatingExpenses Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_OperatingExpensesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe net result for the period of deducting operating expenses from operating revenues. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31 + Details Name: us-gaap_OperatingIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 730 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 912 -SubTopic 730 -Name Accounting Standards Codification -Section 25 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1 + Details Name: us-gaap_ResearchAndDevelopmentExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4 + Details Name: us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe aggregate total amount of expenses directly related to the marketing or selling of products or services. + ReferencesNo definition available. + Details Name: us-gaap_SellingAndMarketingExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 16 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16 + Details Name: us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10 + Details Name: us-gaap_WeightedAverageNumberOfSharesOutstandingBasic Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration XML 16 R5.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Condensed Statements of Stockholders' Equity - USD ($) Common Stock [Member] Treasury Common Stock [Member] Warrants [Member] Additional Paid-in Capital [Member] Accumulated Deficit [Member] Total Balance at Dec. 31, 2022 $ 11,987 Â $ 567,972 $ 108,857,065 $ (94,134,505) $ 15,242,519 Balance (in shares) at Dec. 31, 2022 11,986,927 Â Â Â Â Â Treasury stock, common value at Dec. 31, 2022 Â $ (60,000) Â Â Â Â Treasury stock, common shares (in shares) at Dec. 31, 2022 Â 117,223 Â Â Â Â Increase (Decrease) in Stockholders' Equity [Roll Forward] Â Â Â Â Â Â Issuance of common stock and warrants in connection with April 2023 Financing, net of issuance costs $ 1,318 $ 0 2,526,664 818,014 0 3,345,996 Issuance of common stock and warrants in connection with April 2023 Financing, net of issuance costs (in shares) 1,318,000 Â Â Â Â Â Issuance of common stock in connection with at-the-market offering, net of issuance costs $ 3 $ 0 0 3,365 0 3,368 Issuance of common stock in connection with at-the-market offering, net of issuance costs (in shares) 2,869 0 Â Â Â Â Issuance of common stock in connection with ESPP $ 3 $ 0 0 1,694 0 1,697 Issuance of common stock in connection with ESPP (in shares) 3,858 0 Â Â Â Â Exercise of pre-funded warrants $ 1,879 $ 0 (1,176,533) 1,174,842 0 188 Exercise of pre-funded warrants (in shares) 1,878,722 0 Â Â Â Â Share-based compensation expense $ 0 $ 0 0 122,170 0 122,170 Net loss 0 0 0 0 (5,839,765) (5,839,765) Treasury stock, common value at Jun. 30, 2023 Â $ (60,000) Â Â Â Â Treasury stock, common

shares (in shares) at Jun. 30, 2023 Â 117,223 Â Â Â Â Balance at Jun. 30, 2023 $ 15,190 Â 1,918,103 110,977,150 (99,974,270) 12,876,173 Balance (in shares) at Jun. 30, 2023 15,190,376 Â Â Â Â Â Balance at Mar. 31, 2023 $ 11,990 Â 567,972 108,917,384 (97,080,762) 12,356,584 Balance (in shares) at Mar. 31, 2023 11,989,796 Â Â Â Â Â Treasury stock, common value at Mar. 31, 2023 Â $ (60,000) Â Â Â Â Treasury stock, common shares (in shares) at Mar. 31, 2023 Â 117,223 Â Â Â Â Increase (Decrease) in Stockholders' Equity [Roll Forward] Â Â Â Â Â Â Issuance of common stock and warrants in connection with April 2023 Financing, net of issuance costs $ 1,318 $ 0 2,526,664 818,014 0 3,345,996 Issuance of common stock and warrants in connection with April 2023 Financing, net of issuance costs (in shares) 1,318,000 Â Â Â Â Â Issuance of common stock in connection with ESPP $ 3 $ 0 0 1,694 0 1,697 Issuance of common stock in connection with ESPP (in shares) 3,858 0 Â Â Â Â Exercise of pre-funded warrants $ 1,879 $ 0 (1,176,533) 1,174,842 0 188 Exercise of pre-funded warrants (in shares) 1,878,722 0 Â Â Â Â Share-based compensation expense $ 0 $ 0 0 65,216 0 65,216 Net loss 0 0 0 0 (2,893,508) (2,893,508) Treasury stock, common value at Jun. 30, 2023 Â $ (60,000) Â Â Â Â Treasury stock, common shares (in shares) at Jun. 30, 2023 Â 117,223 Â Â Â Â Balance at Jun. 30, 2023 $ 15,190 Â 1,918,103 110,977,150 (99,974,270) 12,876,173 Balance (in shares) at Jun. 30, 2023 15,190,376 Â Â Â Â Â Balance at Dec. 31, 2023 $ 21,775 Â 2,787,137 123,985,306 (108,381,629) $ 18,352,589 Balance (in shares) at Dec. 31, 2023 21,774,604 Â Â Â Â 21,774,604 Treasury stock, common value at Dec. 31, 2023 Â $ (60,000) Â Â Â $ (60,000) Treasury stock, common shares (in shares) at Dec. 31, 2023 Â 117,223 Â Â Â 117,223 Increase (Decrease) in Stockholders' Equity [Roll Forward] Â Â Â Â Â Â Issuance of common stock in connection with at-the-market offering, net of issuance costs $ 563 $ 0 0 989,185 0 $ 989,748 Issuance of common stock in connection with at-the-market offering, net of issuance costs (in shares) 563,337 0 Â Â Â Â Issuance of common stock in connection with ESPP $ 12 $ 0 0 10,378 0 10,390 Issuance of common stock in connection with ESPP (in shares) 12,081 0 Â Â Â Â Expiration of Warrant $ 0 $ 0 (178,495) 178,495 0 0 Share-based compensation expense 0 0 0 181,598 0 181,598 Net loss 0 0 0 0 (8,284,084) (8,284,084) Treasury stock, common value at Jun. 30, 2024 Â $ (60,000) Â Â Â $ (60,000) Treasury stock, common shares (in shares) at Jun. 30, 2024 Â 117,223 Â Â Â 117,223 Balance at Jun. 30, 2024 $ 22,350 Â 2,608,642 125,344,962 (116,665,713) $ 11,250,241 Balance (in shares) at Jun. 30, 2024 22,350,022 Â Â Â Â 22,350,022 Balance at Mar. 31, 2024 $ 22,217 Â 2,631,838 124,994,678 (111,981,139) $ 15,607,594 Balance (in shares) at Mar. 31, 2024 22,216,570 Â Â Â Â Â Treasury stock, common value at Mar. 31, 2024 Â $ (60,000) Â Â Â Â Treasury stock, common shares (in shares) at Mar. 31, 2024 Â 117,223 Â Â Â Â Increase (Decrease) in Stockholders' Equity [Roll Forward] Â Â Â Â Â Â Issuance of common stock in connection with at-the-market offering, net of issuance costs $ 121 $ 0 0 212,697 0 212,818 Issuance of common stock in connection with at-the-market offering, net of issuance costs (in shares) 121,371 0 Â Â Â Â Issuance of common stock in connection with ESPP $ 12 $ 0 0 10,378 0 10,390 Issuance of common stock in connection with ESPP (in shares) 12,081 0 Â Â Â Â Expiration of Warrant $ 0 $ 0 (23,196) 23,196 0 0 Share-based compensation expense 0 0 0 104,013 0 104,013 Net loss 0 0 0 0 (4,684,574) (4,684,574) Treasury stock, common value at Jun. 30, 2024 Â $ (60,000) Â Â Â $ (60,000) Treasury stock, common shares (in shares) at Jun. 30, 2024 Â 117,223 Â Â Â 117,223 Balance at Jun. 30, 2024 $ 22,350 Â $ 2,608,642 $ 125,344,962 $ (116,665,713) $ 11,250,241 Balance (in shares) at Jun. 30, 2024 22,350,022 Â Â Â Â 22,350,022 X - DefinitionThe warrants expired during the period. + ReferencesNo definition available. + Details Name: femy_ExpirationOfWarrant Namespace Prefix: femy_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionNumber of new stock issued in connection with the at-the-market program during the period. + ReferencesNo definition available. + Details Name: femy_StockIssuedDuringPeriodSharesAtTheMarketOfferingNetOfIssuanceCosts Namespace Prefix: femy_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of pre-funded warrants exercise. + ReferencesNo definition available. + Details Name: femy_StockIssuedDuringPeriodSharesExerciseOfPreFundedWarrants Namespace Prefix: femy_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of common stock and warrants, in connection with "April 2023 Financing" during the period. + ReferencesNo definition available. + Details Name: femy_StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndWarrants Namespace Prefix: femy_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionEquity impact of the value of new stock issued in connection with at-the-market program during the period. + ReferencesNo definition available. + Details Name: femy_StockIssuedDuringPeriodValueAtTheMarketOfferingNetOfIssuanceCosts Namespace Prefix: femy_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAggregate value of issuance of common stock from exercise of pre-funded warrants issued during the period. + ReferencesNo definition available. + Details Name: femy_StockIssuedDuringPeriodValueExerciseOfPreFundedWarrants Namespace Prefix: femy_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionEquity impact of the value in issuance of common stock and warrants, in connection with "April 2023 Financing", net of issuance costs. + ReferencesNo definition available. + Details Name: femy_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrants Namespace Prefix: femy_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 20 -Section 55 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481089/718-20-55-13Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 20 -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481089/718-20-55-12 + Details Name: us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionTotal number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockSharesIssued Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionA roll forward is a reconciliation of a concept from the beginning of a period to the end of a period. + ReferencesNo definition available. + Details Name: us-gaap_IncreaseDecreaseInStockholdersEquityRollForward Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -

Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionNumber of shares issued during the period as a result of an employee stock purchase plan. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionAggregate change in value for stock issued during the period as a result of employee stock purchase plan. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 4.E) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2 + Details Name: us-gaap_StockholdersEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionNumber of previously issued common shares repurchased by the issuing entity and held in treasury. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 505 -SubTopic 30 -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481549/505-30-45-1 + Details Name: us-gaap_TreasuryStockCommonShares Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionAmount allocated to previously issued common shares repurchased by the issuing entity and held in treasury. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 505 -SubTopic 30 -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481520/505-30-50-4Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 505 -SubTopic 30 -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481549/505-30-45-1 + Details Name: us-gaap_TreasuryStockCommonValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant XML 17 R6.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Condensed Statements of Cash Flows - USD ($) 6 Months Ended Jun. 30, 2024 Jun. 30, 2023 Cash flows from operating activities: Â Â Net loss $ (8,284,084) $

(5,839,765) Adjustments to reconcile net loss to net cash used in operating activities: Â Â Depreciation 133,028 264,040 Amortization 5,828 2,325 Amortization of right-of-use assets 299,171 148,541 Loss on disposal of assets 0 44,538 Inventory reserve write-off 2,830 1,770 Share-based compensation expense 181,598 122,170 Amortization of debt issuance costs and discount 544,363 0 Changes in operating assets and liabilities: Â Â Accounts receivable 6,371 (78,276) Inventory (651,292) (146,521) Prepaid and other assets (173,828) 154,065 Accounts payable (223,682) 36,119 Accrued expenses (557,944) 80,116 Lease liabilities (137,482) (181,065) Other liabilities (39,657) 3,119 Net cash used in operating activities (8,894,780) (5,388,824) Cash flows from investing activities: Â Â Acquisition of patents (50,145) 0 Purchases of property and equipment (246,978) (71,849) Net cash used in investing activities (297,123) (71,849) Cash flows from financing activities: Â Â Proceeds from the issuance of common stock and warrants in April 2023 Financing 0 3,899,813 Equity issuance costs for April 2023 Financing 0 (547,764) Proceeds from exercise of pre-funded warrants 0 188 Proceeds from common stock issued through ESPP and exercised options 10,390 1,697 Proceeds from at-the-market sales of common stock 1,021,994 3,373 Issuance costs for at-the-market sales of common stock (30,660) 0 Repayment of note payable 0 (141,298) Payments under lease obligations 0 (12,255) Net cash provided by financing activities 1,001,724 3,203,754 Net change in cash and cash equivalents (8,190,179) (2,256,919) Cash and cash equivalents: Â Â Beginning of period 21,716,077 12,961,936 End of period 13,525,898 10,705,017 Cash paid for: Â Â Interest 0 1,870 Taxes 4,550 Â Non-cash investing and financing activities: Â Â Property and equipment costs included in accounts payable and accrued expense 37,370 0 Commissions costs relating to certain proceeds from issuance of common stock 0 6,163 Deferred offering costs reclassified to additional paid-in-capital $ 1,586 $ 0 X - ReferencesNo definition available. + Details Name: femy_CashPaidForAbstract Namespace Prefix: femy_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe amount of commission costs relating to certain proceeds from issuance of common stock incurred as a noncash or partial noncash transaction. + ReferencesNo definition available. + Details Name: femy_CommissionCostsRelatingToCertainProceedsFromIssuanceOfCommonStock Namespace Prefix: femy_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe amount of offering costs from noncash transactions included in deferred offering costs reclassified to additional paid-in-capital. + ReferencesNo definition available. + Details Name: femy_DeferredOfferingCostsReclassifiedToAdditionalPaidInCapital Namespace Prefix: femy_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash outflow for cost incurred directly with the issuance of an equity security. + ReferencesNo definition available. + Details Name: femy_PaymentsOfEquityIssuanceCosts Namespace Prefix: femy_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionValue of property and equipment costs included in accounts payable and accrued expense as a noncash or partial noncash transaction. + ReferencesNo definition available. + Details Name: femy_PropertyAndEquipmentCostsIncludedInAccountsPayableAndAccruedExpense Namespace Prefix: femy_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of amortization expense attributable to debt discount (premium) and debt issuance costs. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69E -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69EReference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69F -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69FReference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-3 + Details Name: us-gaap_AmortizationOfFinancingCostsAndDiscounts Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482686/350-30-45-2 + Details Name: us-gaap_AmortizationOfIntangibleAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4 + Details Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 1 -SubTopic 230 -Topic 830 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1 + Details Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1 + Details Name: us-gaap_Depreciation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cash outflow for principal payment on finance lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5 + Details Name: us-gaap_FinanceLeasePrincipalPayments Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_GainLossOnDispositionOfAssets1 Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount, after refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2AReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 23 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-23Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-22Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 2 -

Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2 + Details Name: us-gaap_IncomeTaxesPaidNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInAccountsPayable Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInAccountsReceivable Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInAccruedLiabilities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInInventories Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_IncreaseDecreaseInOperatingCapitalAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of increase (decrease) in obligation for operating lease. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(1) -SubTopic 20 -Topic 842 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_IncreaseDecreaseInOperatingLeaseLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of increase (decrease) in operating assets classified as other. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInOtherOperatingAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of increase (decrease) in operating liabilities classified as other. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInOtherOperatingLiabilities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 17 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-17Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2 + Details Name: us-gaap_InterestPaidNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe change in the inventory reserve representing the cumulative difference in cost between the first in, first out and the last in, first out inventory valuation methods, which change has been reflected in the statement of income during the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 330 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 5.L) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480581/330-10-S99-1 + Details Name: us-gaap_InventoryLIFOReservePeriodCharge Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24 + Details Name: us-gaap_NetCashProvidedByUsedInFinancingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24 + Details Name: us-gaap_NetCashProvidedByUsedInInvestingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25 + Details Name: us-gaap_NetCashProvidedByUsedInOperatingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -

Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NoncashInvestingAndFinancingItemsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash outflow to reacquire common stock during the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 15 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15 + Details Name: us-gaap_PaymentsForRepurchaseOfCommonStock Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 13 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13 + Details Name: us-gaap_PaymentsToAcquireIntangibleAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 13 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13 + Details Name: us-gaap_PaymentsToAcquirePropertyPlantAndEquipment Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash inflow from the additional capital contribution to the entity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromIssuanceOfCommonStock Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2A -Subparagraph (a) -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2A + Details Name: us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromIssuanceOfWarrants Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash inflow associated with the amount received from holders exercising their stock warrants. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromWarrantExercises Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash outflow for a borrowing supported by a written promise to pay an obligation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 15 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15 + Details Name: us-gaap_RepaymentsOfNotesPayable Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of noncash expense for share-based payment arrangement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_ShareBasedCompensation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration XML 18 R7.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Organization, Nature of Business, and Liquidity 6 Months Ended Jun. 30, 2024 Organization, Nature of Business, and Liquidity [Abstract] Â Organization, Nature of Business, and Liquidity (1) Organization, Nature of Business, and Liquidity Â Organization and Nature of Business Â Femasys Inc. (the Company or Femasys) was incorporated in Delaware on February 19, 2004 and is headquartered in Suwanee, Georgia. The Company is a leading biomedical company focused on addressing significant unmet needs for women worldwide with a broad portfolio of in-office, accessible, and innovative therapeutic and diagnostic products, including a lead revolutionary product candidate and FDA-cleared products.Â The Companyâ€™s mission is to provide women with superior minimally-invasive, non-surgical product

technologies, accessible in the office, improving patient care and overall health economics focused on servicing the reproductive health needs for those seeking solutions for infertility issues (FemaSeedÂ® and FemVueÂ®) or permanent birth control (FemBlocÂ®).Â The Company currently operates as one segment with an initial focus on servicing the reproductive health needs for those seeking solutions for infertility issues or permanent birth control. Femasys has an expansive intellectual property portfolio which covers both design and utility patents in the U.S. and significant ex-U.S. markets for each product initiative. Femasys has taken concepts internally conceived and protected through development, including domestic and foreign regulatory approvals, and production, through in-house manufacturing.Â FemaSeed, a solution which enables directed intratubal insemination to improve on traditional intrauterine insemination (IUI) and provides a lower cost and safer option to in vitro fertilization methods, received approval to sell FemaSeed in Canada in April 2023. In September 2023, the Company received 510(k) clearance from the FDA for FemaSeed for intratubal insemination to market in the United States. A pivotal clinical trial was still ongoing at the time of receiving regulatory clearance, however, enrollment was completed in November 2023. In June 2024, the Company received European Union Medical Device Regulation (EU MDR) certificates and CE Mark certification for four products: FemaSeed, FemVue, FemCervÂ® and FemCathÂ®. FemVue, a solution that enables fallopian tube assessment with ultrasound as an alternative to the radiologic approach (hysterosalpingogram) for the diagnosis of infertility, is approved for sale in the U.S., Japan, and Canada. FemChecÂ® allows for fallopian tube evaluation after a FemBloc procedure to confirm occlusion (or procedure success). FemCerv is a solution for complete tissue sampling with minimal contamination of the endocervical canal in a virtually pain-free procedure as an alternative to the single biopsy method for diagnosis of cervical cancer and is approved for sale in the U.S. and Canada. FemCath, allows for selective evaluation of an individual fallopian tube as an alternative to the traditional intrauterine catheter that is undirected, is approved for sale in the U.S. and Canada. FemBlocÂ®, the Companyâ€™s solution for permanent birth control, is based on the Companyâ€™s platform technology for delivery and in June 2023 Femasys received FDA approval of our IDE to evaluate the safety and efficacy of FemBloc, our non-surgical, non-implant, non-hormonal in-office solution for permanent birth control in a pivotal clinical trial. In August 2023 Femasys announced the initiation of enrollment in the FINALE [Prospective Multi-Center Trial for FemBloc Intratubal Occlusion for TranscervicAL Permanent Birth Control] pivotal trial designed to evaluate the safety and efficacy of FemBloc. This prospective, multi-center, open-label, single-arm study design includes pregnancy rate as the primary endpoint, which will be analyzed once 401 women have relied on FemBloc for one year for permanent birth control. In addition, the study is designed as a roll-in beginning with enrollment of 50 women for a clinical readout primarily of preliminary safety data prior to enrolling the remaining subjects. An interim analysis of clinical data endpoints is planned once 300 women have used FemBloc for permanent birth control for one year. Follow-up will continue annually for five years post-market. Basis of Presentation Â The Company has prepared the accompanying condensed financial statements pursuant to the rules and regulations of the U.S. Securities and Exchange Commission (SEC). Certain information and footnote disclosures normally included in the annual financial statements prepared in accordance with accounting principles generally accepted in the United States of America (U.S. GAAP) have been condensed or omitted pursuant to these rules and regulations. These condensed financial statements should be read in conjunction with the Companyâ€™s audited financial statements and footnotes related thereto for the year ended December 31, 2023 included in our Annual Report on Form 10K filed with the SEC on March 28, 2024 (the Annual Report). There have been no material changes to the Companyâ€™s significant accounting policies described in Note 2 to the financial statements included in the Annual Report. Â In the opinion of management, the unaudited financial statements include all adjustments (consisting only of normal recurring adjustments) necessary to present fairly the Companyâ€™s financial position and the results of its operations and cash flows at the dates for periods presented. The results of operations for such interim periods are not necessarily indicative of the results to be expected for the full year. Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenue and expense during the reporting periods. Estimates for these and other items are subject to change and are reassessed by management in accordance with U.S. GAAP. Actual results could differ from those estimates. Liquidity Â As of June 30, 2024, the Company had cash and cash equivalents of $13,525,898. The Company plans to finance its operations and development needs with its existing cash and cash equivalents, additional equity and/or debt financing arrangements, and revenue primarily anticipated from the sale of FemVue and FemaSeed to support the Companyâ€™s research and development activities, primarily focused on FemBloc. There can be no assurance that the Company will be able to obtain additional financing on terms acceptable to the Company, on a timely basis, or at all. If the Company is not able to obtain sufficient funds on acceptable terms when needed, the Companyâ€™s business, results of operations, and financial condition could be materially adversely impacted. For the six months ended June 30, 2024, the Company generated a net loss of $8,284,084. The Company expects such losses to increase over the next few years as the Company advances FemBloc through clinical development if and until FDA approval is received and is available to be marketed. The financial statements have been prepared on a going-concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Company has incurred net operating losses in every year since inception and has an accumulated deficit as of June 30, 2024 of $116,665,713 and expects to incur additional losses and negative operating cash flows for at least the next twelve months. The Companyâ€™s ability to meet its obligations is dependent upon its ability to generate sufficient cash flows from operations and future financing transactions. Although management expects the Company will continue as a going concern, there is no assurance that managementâ€™s plans will be successful since the availability and amount of such funding is not certain. Accordingly, substantial doubt exists about the Companyâ€™s ability to continue as a going concern for at least one year from the issuance of these financial statements. The accompanying financial statements do not include any adjustments to reflect the possible future effects on the recoverability of assets or the amounts and classifications of liabilities that may result from the possible inability of the Company to continue as a going concern. Recently Issued Accounting Pronouncements â€“ Recently Adopted In November 2023, the FASB issued ASU No. 2023-07,Â Segment Reporting (Topic 28): Improvements to Reportable Segment Disclosures. The ASU improves reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment expenses. The ASU improves financial reporting by requiring disclosure of incremental segment information on an annual and interim basis for all public entities to enable investors to develop more decision-useful financial analyses. The amendments in this update are effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted. The Company will adopt the ASU for the fiscal year ended December 31, 2024 and interim periods in fiscal 2025. The adoption of the ASU will result in additional disclosures to the Companyâ€™s financial statements and footnote disclosures. Â Recently Issued Accounting Pronouncements â€“ Not Yet Adopted In December 2023, the FASB issued ASU 2023-09,Â Income Taxes (Topic 740): Improvements to Income Tax Disclosures. The ASU requires the annual financial statements to include consistent categories and greater disaggregation of information in the rate reconciliation, and income taxes paid disaggregated by jurisdiction. ASU 2023-09 is effective for the Companyâ€™s annual reporting periods beginning after December 15, 2024. Adoption is either with a prospective method or a fully retrospective method of transition. Early adoption is permitted. The Company is currently evaluating the effect that adoption of ASU 2023-09 will have on its financial statements and expects to adopt the ASU on January 1, 2025. No other new accounting pronouncement issued or effective has had, or is expected to have, a material impact on the Companyâ€™s financial statements. X - ReferencesNo definition available. + Details Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480424/946-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480424/946-10-50-2Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 810 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/810/tableOfContentReference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/205/tableOfContent + Details Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 19 R8.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Fair Value 6 Months Ended Jun. 30, 2024 Fair Value [Abstract] Â Fair Value (2) Fair Value The Company applies a fair value hierarchy that requires the use of observable market data, when available, and prioritizes the inputs to valuation techniques used to measure fair value in the following categories: Level 1 â€“ Valuation is based upon quoted prices for identical instruments traded in active markets. Level 2 â€“ Valuation is based upon quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active, and modelâ€‘based valuation techniques for which all significant assumptions are observable in the market. Level 3 â€“ Valuation is generated from modelâ€‘based techniques that use significant assumptions not observable in the market. These unobservable assumptions reflect the Companyâ€™s own estimates of assumptions market participants would use in pricing the asset or liability. Certain of the Companyâ€™s financial instruments, including cash and other liabilities approximate their fair value because of the shortâ€‘term maturity of these financial instruments. The fair value of stock options, convertible notes and warrants are based on Level 3 inputs. X - ReferencesNo definition available. + Details Name: us-gaap_FairValueDisclosuresAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and

(d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 107 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-107Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6AReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2E -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2EReference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6AReference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6AReference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6AReference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6AReference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 940 -SubTopic 820 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478119/940-820-50-1 + Details Name: us-gaap_FairValueDisclosuresTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 20 R9.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Cash and Cash Equivalents 6 Months Ended Jun. 30, 2024 Cash and Cash Equivalents [Abstract] Â Cash and Cash Equivalents (3) Cash and Cash Equivalents Â As of June 30, 2024 and December 31, 2023, money market funds included in cash and cash equivalents on the balance sheets were $12,686,738 and $21,278,895, respectively, which represent level 1 within the fair value hierarchy where there are quoted prices in active markets for identical assets. X - ReferencesNo definition available. + Details Name: us-gaap_CashAndCashEquivalentsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for cash and cash equivalent footnotes, which may include the types of deposits and money market instruments, applicable carrying amounts, restricted amounts and compensating balance arrangements. Cash and equivalents include: (1) currency on hand (2) demand deposits with banks or financial institutions (3) other kinds of accounts that have the general characteristics of demand deposits (4) short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Generally, only investments maturing within three months from the date of acquisition qualify. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1 + Details Name: us-gaap_CashAndCashEquivalentsDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 21 R10.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Inventories 6 Months Ended Jun. 30, 2024 Inventories [Abstract] Â Inventories (4) Inventories Â Inventory stated at cost, net of reserve, consisted of the following: Â Â June 30, Â Â December 31, Â Â Â 2024 Â Â 2023 Â Materials Â $ 792,365 Â Â Â 367,934 Â Work in progress Â Â 229,045 Â Â Â 128,993 Â Finished goods Â Â 294,170 Â Â Â 170,191 Â Inventory, net Â $ 1,315,580 Â Â Â 667,118 Â X - ReferencesNo definition available. + Details Name: us-gaap_InventoryDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 330 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/330/tableOfContent + Details Name: us-gaap_InventoryDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 22 R11.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Accrued Expenses 6 Months Ended Jun. 30, 2024 Accrued Expenses [Abstract] Â Accrued Expenses (5) Accrued Expenses Â Accrued expenses consisted of the following: Â Â June 30, Â Â December 31, Â Â Â 2024 Â Â 2023 Â Clinical trial costs Â $ 334,799 Â Â Â 276,141 Â Accrued interest Â Â 250,025 Â Â Â â€” Â Incentive and other compensation costs Â Â 170,328 Â Â Â 1,082,606 Â Director fees Â Â 70,000 Â Â Â 60,210 Â Franchise taxes Â Â 3,150 Â Â Â 12,160 Â Other Â Â 58,050 Â Â Â 13,179 Â Accrued expenses Â $ 886,352 Â Â Â 1,444,296 Â X - DefinitionThe entire disclosure for accounts payable and accrued liabilities at the end of the reporting period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 720 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483384/720-30-45-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_PayablesAndAccrualsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 23 R12.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Clinical Holdback 6 Months Ended Jun. 30, 2024 Clinical Holdback [Abstract] Â Clinical Holdback (6) Clinical Holdback Â The following table shows the activity within the clinical holdback liability accounts for the six months ended June 30, 2024: Â Balance at December 31, 2023 Â $ 120,235 Â Clinical holdback retained Â Â 5,990 Â Clinical holdback paid Â Â (1,122) Balance at June 30, 2024 Â $ 125,103 Â Less: clinical holdback - current portion Â Â (92,397) Clinical holdback - long-term portion Â $ 32,706 Â X - ReferencesNo definition available. + Details Name: femy_ClinicalHoldbackAbstract Namespace Prefix: femy_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure of clinical holdback. + ReferencesNo definition available. + Details Name: femy_ClinicalHoldbackTextBlock Namespace Prefix: femy_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 24 R13.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Revenue Recognition 6 Months Ended Jun. 30, 2024 Revenue Recognition [Abstract] Â Revenue Recognition (7) Revenue Recognition Â Revenue is recognized upon shipment of our goods based upon contractually stated pricing at standard payment terms ranging from 30 to 60 days. All revenue is recognized point in time and no revenue is recognized over time. For the three and six months ended June 30, 2024 and 2023, there was no revenue recognized from performance obligations satisfied or partially satisfied in prior periods, nor were there any unsatisfied performance obligations as of June 30, 2024 or 2023. Â The majority of products sold directly to U.S customers are shipped via common carrier, and the customer pays for shipping and handling and assumes control Free on Board (FOB) shipping point. Products shipped to our international distributors are in accordance with their respective agreements; however, the shipping terms are generally EX-Works, reflecting that control is assumed by the distributor at the shipping point. Returns are only accepted with prior authorization from the Company. Items to be returned must be in original unopened cartons and are subject to a 30% restocking fee. Throughout the periods presented, the Company has not had a history of significant returns. Â The following table summarizes our sales, primarily from FemVue, by geographic region as follows: Â Â Three Months Ended June 30, Â Â Six Months Ended June 30, Â Primary geographical markets Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â U.S. Â $ 221,484 Â Â Â 262,469 Â Â Â 492,624 Â Â Â 556,453 Â International Â Â â€” Â Â Â 58,045 Â Â Â â€” Â Â Â 58,045 Â Total Â $ 221,484 Â Â Â 320,514 Â Â Â 492,624 Â Â Â 614,498 Â X - ReferencesNo definition available. + Details Name: us-gaap_RevenueFromContractWithCustomerAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-9Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -

Name Accounting Standards Codification -Section 50 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-15Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-13Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Topic 606 -Publisher FASB -URI https://asc.fasb.org/606/tableOfContent + Details Name: us-gaap_RevenueFromContractWithCustomerTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 25 R14.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Commitments and Contingencies 6 Months Ended Jun. 30, 2024 Commitments and Contingencies [Abstract] Â Commitments and Contingencies (8) Commitments and Contingencies Legal Claims Â Occasionally, the Company may be a party to legal claims or proceedings of which the outcomes are subject to significant uncertainty. In accordance with Accounting Standards Codification (ASC) 450, Contingencies, the Company will assess the likelihood of an adverse judgment for any outstanding claim as well as ranges of probable losses. When it has been determined that a loss is probable and the amount can be reasonably estimated, the Company will record a liability. For both periods presented, there were no material legal contingencies requiring accrual or disclosure. The Company, as permitted under Delaware law and in accordance with its bylaws, indemnifies its officers and directors for certain events or occurrences, subject to certain limits, while the officer or director is or was serving at the Companyâ€™s request in such capacity. The Company entered into employment agreements with its officers, which provides for indemnification protection in the executiveâ€™s capacity as an officer for actions taken within the scope of employment. The maximum amount of potential future indemnification is unlimited; however, the Company has obtained director and officer insurance that limits its exposure. The Company believes the fair value for these indemnification obligations is minimal. Accordingly, the Company has not recognized any liabilities relating to these obligations as of June 30, 2024 and December 31, 2023. X - ReferencesNo definition available. + Details Name: us-gaap_CommitmentsAndContingenciesDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for commitments and contingencies. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 405 -SubTopic 30 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/405-30/tableOfContentReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 440 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/450/tableOfContentReference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 954 -SubTopic 440 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 440 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 440 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/440/tableOfContent + Details Name: us-gaap_CommitmentsAndContingenciesDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 26 R15.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Notes Payable 6 Months Ended Jun. 30, 2024 Notes Payable [Abstract] Â Notes Payable (9) Notes Payable AFCO Credit Corporation (AFCO) Â In June 2022, the Company executed a Promissory Note with AFCO to finance certain insurance premiums totaling $465,380, requiring the Company to pay $47,539 in a down payment and make monthly installment payments. The annual interest rate was 5.7% and the monthly installment payment was $47,539, which represents principal and interest. The final installment payment was paid in March of 2023. In July 2023, the Company executed a Promissory Note with AFCO to finance certain insurance premiums totaling $469,042, requiring the Company to pay $48,423 in a down payment and make monthly installment payments. The annual interest rate was 8.6% and the monthly installment is $48,423, which represents principal and interest. The Promissory Note was paid in full without penalty in November 2023. As of June 30,Â 2024, and December 31,Â 2023, there was no principal balance on the AFCO note in the accompanying balance sheets. Interest expense in connection with the AFCO promissory notes was $0 and $1,319 for the three and six months ended June 30,Â 2024 and 2023, respectively. X - ReferencesNo definition available. + Details Name: us-gaap_DebtDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 405 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 405 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 405 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 405 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 405 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(c)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 470 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/470/tableOfContentReference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1C -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1CReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1C -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1CReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1C -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1CReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1I -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1IReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1I -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1IReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1I -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I + Details Name: us-gaap_DebtDisclosureTextBlock

Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 27 R16.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Convertible Notes with Warrants (November 2023 Financing) 6 Months Ended Jun. 30, 2024 Convertible Notes with Warrants (November 2023 Financing) [Abstract] Â Convertible Notes with Warrants (November 2023 Financing) (10) Convertible Notes with Warrants (November 2023 Financing) On November 21, 2023, the Company issued (i) senior unsecured convertible notes in an aggregate principal amount of $6,850,000, convertible into shares of common stock at a conversion price of $1.18 per share, (ii) Series A Warrants to purchase up to an aggregate of 5,805,083 shares of common stock at an exercise price of $1.18 per share, and (iii) Series B Warrants, together with the Series A Warrants, and, together with the convertible notes, to purchase up to an aggregate of 5,805,083 shares of common stock at an exercise price of $1.475 per share. The financing resulted in aggregate gross proceeds of $6,850,000, before $525,144 of transaction costs. The Notes accrue interest at a rate of 6.0% per annum, payable annually, in cash or shares of common stock at the Companyâ€™s option, and mature on November 21, 2025, unless earlier converted or redeemed. The Notes are convertible into shares of common stock at the election of the holder at any time at an initial conversion price of $1.18. The Company has agreed not to issue or sell any equity securities of the Company at a price below the then-current conversion price for a period of 18 months after closing, subject to certain exceptions. Beginning six months after issuance, the Company may require holders to convert their Notes into conversion shares if the closing price of the common stock exceeds $2.36 per share for 10 consecutive trading days and the daily dollar trading volume of the common stock exceeds $1,000,000 per day during the same period and certain equity conditions described in the Notes are satisfied. The Notes provide for certain events of default, whereby each holder of Notes will be able to require the Company to redeem in cash any or all of the holderâ€™s Notes at a premium of 115%. The conversion feature did not meet the requirements for separate accounting and is not accounted for as a derivative instrument. As of June 30, 2024, the Convertible Notes have not been converted into shares of common stock. The Warrants The Series A Warrants are exercisable immediately and expire five years from the date of issuance. The Company has the right to call the exercise of the Series A Warrants if the closing price of the common stock exceeds 200% of the Series A Exercise Price for 10 consecutive trading days and the daily dollar trading volume of the common stock exceeds $1,000,000 per day during the same period and certain equity conditions are satisfied. The Series B Warrants are exercisable immediately, together with the Series A Warrant Shares, and expire one year from the date of issuance. The Company has the right to call the exercise of the Series B Warrants if the closing price of the common stock exceeds 200% of the Series B exercise price for 10 consecutive trading days and the daily dollar trading volume of the common stock exceeds $1,000,000 per day during the same period and certain equity conditions are satisfied. There is no established public trading market for the warrants and the Company does not intend to list the Warrants on any national securities exchange or nationally recognized trading system. The Series A Warrants and Series B Warrants are classified as a component of permanent equity because they are freestanding financial instruments that are legally detachable and separately exercisable from the shares of common stock from which they are issued, are immediately exercisable, do not embody an obligation for the Company to repurchase its shares, and permit the holders to receive a fixed number of shares of common stock upon exercise. For the convertible notes for the three months ended June 30, 2024, the Company recognized total interest expense of $388,311, including coupon interest expense of $102,750 and amortization of debt discount and issuance costs of $285,561. For the six months ended June 30, 2024, the Company recognized total interest expense of $749,863, including coupon interest expense of $205,500 and amortization of debt discount and issuance costs of $544,363. As of December 31, 2023, the Notes principal balance as $6,850,000, unamortized discount was $2,636,346 and accrued interest was $44,525. As of June 30, 2024, the Notes principal balance as $6,850,000, unamortized discount was $2,091,983 and accrued interest was $250,025. The fair value of the convertible notes on June 30, 2024, calculated using a discounted cash flow analysis, was $6,307,258. X - ReferencesNo definition available. + Details Name: femy_ConvertibleNotesWithWarrantsNovember2023FinancingAbstract Namespace Prefix: femy_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for information about convertible notes with warrants financing. + ReferencesNo definition available. + Details Name: femy_ConvertibleNotesWithWarrantsNovember2023FinancingTextBlock Namespace Prefix: femy_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 28 R17.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Stockholders' Equity 6 Months Ended Jun. 30, 2024 Stockholders' Equity [Abstract] Â Stockholders' Equity (11) Stockholdersâ€™ Equity On July 1, 2022, we filed shelf registration statement to sell up to $150 million in common and preferred stock, debt securities and warrants. Additionally, we entered into an Equity Distribution Agreement (the â€œEquity Distribution Agreementâ€) with Piper Sandler & Co. (â€œPiper Sandlerâ€ or the â€œSales Agentâ€) and filed a related prospectus establishing an â€œat-the-marketâ€ facility, pursuant to which we may offer and sell shares of our common stock from time to time through the Sales Agent. In October 2023, the Sales Agent was authorized to sell shares for aggregate proceeds up to $16.7 million at current market prices until all shares are sold. As of June 30, 2024, 3.9 million shares of common stock have been sold for aggregate proceeds of approximately $8.7 million under the Equity Distribution Agreement pursuant to the prospectus. As of June 30, 2024, the amount we are authorized to sell is subject to baby-shelf limitations. In April 2023, the Company sold an aggregate of (i) 1,318,000 shares of common stock and (ii) pre-funded warrants to purchase up to 1,878,722 shares of common stock in a registered direct offering (â€œpre-funded warrantsâ€) and, in a concurrent private placement, warrants to purchase up to 3,196,722 shares of common stock (â€œcommon warrantsâ€). Additionally, common warrants were issued to the placement agent to purchase up to 191,803 shares of common stock as compensation for services (â€œplacement agent warrantsâ€), collectively the (â€œApril 2023 Financingâ€). The purchase price per share for the common stock, pre-funded warrants was $1.22 and $1.2199, respectively. The gross proceeds from the offering were $3,899,813, less placement agent fees and offering expenses of $547,764. In June 2023, all pre-funded warrants were exercised for shares of common stock. In September and October 2023, all common warrants and 122,994 placement agent warrants were exercised for cash proceeds of $3,687,976. As of June 30, 2024, 68,809 placement agent warrants remain outstanding. As of June 30, 2024, the Company had 22,232,799 shares of common stock outstanding, and no dividends have been declared or paid. X - ReferencesNo definition available. + Details Name: us-gaap_EquityAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for equity. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-6Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480237/815-40-50-6Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(e)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/505/tableOfContentReference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 16 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18 + Details Name: us-gaap_StockholdersEquityNoteDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 29 R18.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Equity Incentive Plans and Warrants 6 Months Ended Jun. 30, 2024 Equity Incentive Plans and Warrants [Abstract] Â Equity Incentive Plans and Warrants (12) Equity Incentive Plans and Warrants Stock-Based Awards (a) Stock Option

Plans Â Activity under the Companyâ€™s stock option plans for the six months ended June 30, 2024 was as follows: Â Â Number of options Â Â Weighted average exercise price Â Outstanding at December 31, 2023 Â Â 2,102,030 Â Â $ 2.00 Â Granted Â Â 1,062,421 Â Â Â 1.06 Â Forfeited Â Â (243,312) Â Â 2.09 Â Outstanding at June 30, 2024 Â Â 2,921,139 Â Â $ 1.65 Â Â Â Â Â Â Â Â Â Â Â Â Vested and exercisable at June 30, 2024 Â Â 1,207,595 Â Â $ 2.53 Â Options granted under our 2021 Stock Option Plan for the six months ended June 30, 2024 to employees and nonemployees were 1,059,921 and 2,500, respectively and the weighted average exercise prices were $1.06 and $0.79, respectively. The weighted-average fair values of the options granted to employees and nonemployees were $0.90 and $0.39, respectively and were estimated using the following Black-Scholes assumptions: Â Â Employee Â Â Nonemployee Â Expected term (in years) Â 6.25 Â Â Â 1.50 Â Riskâ€‘free interest rate Â Â 4.06 % Â Â 4.53 % Dividend yield Â Â â€” % Â Â â€” % Expected volatility Â Â 110.40 % Â Â 105.34 % Â No options were exercised for the six months ended June 30, 2024 under our stock option plans. As of June 30, 2024, the total number of shares of common stock reserved for future awards under the 2021 Stock Option Plan was 676,741. (b) Inducement Grants On February 12, 2024, the Company awarded, outside the 2021 Plan, our Chief Commercial Officer a stock option grant for the right to purchase 100,000 shares of common stock at an exercise price of $1.10 per share (inducement grant), which was approved by the Compensation committee. The inducement grant will vest in equal installments over four years provided the employee remains employed by the Company on the vesting date. The fair value of the inducement grant was $0.94 and was estimated using the following assumptions: Â Â Inducement Â Expected term (in years) Â 6.25 Â Riskâ€‘free interest rate Â Â 4.10 % Dividend yield Â Â â€” % Expected volatility Â Â 109.64 % As of June 30, 2024, inducement grant awards of 250,000 shares were outstanding with a weighted average exercise price of $1.89, and 62,500 shares were vested and exercisable with a weighted average exercise price of $2.64. (c) Share-Based Compensation Expense The following table shows the share-based compensation expense related to vested stock option grants to employees and nonemployees by financial statement line item on the accompanying condensed statement of comprehensive loss: Â Â Three Months Ended June 30, Â Â Six Months Ended June 30, Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Research and development Â $ 34,629 Â Â Â 27,192 Â Â Â 64,637 Â Â Â 52,251 Â Sales and marketing Â Â 18,246 Â Â Â 602 Â Â Â 24,764 Â Â Â (1,942) General and administrative Â Â 51,138 Â Â Â 37,422 Â Â Â 92,197 Â Â Â 71,861 Â Total share-based compensation expense Â $ 104,013 Â Â Â 65,216 Â Â Â 181,598 Â Â Â 122,170 Â As of June 30, 2024, the remaining share-based compensation expense that is expected to be recognized in future periods for employees and nonemployees is $1,516,737, which includes $155,222 of compensation expense to be recognized upon achieving certain performance conditions. For service-based awards, the $1,361,515 of unrecognized expense is expected to be recognized over a weighted average period of 3.3 years. Â Â (d) Employee Stock Purchase Plan (ESPP) Â For the six months ended June 30, 2024, 12,081 shares of common stock were issued under the Companyâ€™s ESPP Plan at a fair value of $10,390. For the six months ended June 30, 2023, 3,858 shares of common stock were issued under the ESPP plan at a fair value of $1,697. As of June 30, 2024, the total number of shares of common stock reserved for future awards under the ESPP Plan was 591,437. (e) April 2023 Financing Â Â On April 20, 2023, the Company entered into a securities purchase agreement pursuant to which the Company sold (i) 1,318,000 shares of common stock (see Note 11, Stockholdersâ€™ Equity), (ii) pre-funded warrants to purchase 1,878,722 shares of common stock, (iii) common warrants to purchase 3,196,722 shares of common stock. Additionally, common warrants to purchase 191,803 shares of common stock were issued to the placement agent compensation for services performed. The pre-funded warrants, common warrants and placement agent warrants were exercisable immediately following the closing date of the offering. The pre-funded warrants have an unlimited term and an exercise price of $0.0001 per share. The common warrants have a 5.5 year term and an exercise price of $1.095 per share. The placement agent warrants have a 5 year term and exercise price of $1.525 per share. The offering resulted in aggregate gross proceeds of $3,899,813, before $547,764 of transaction costs. The pre-funded warrants and common warrants are classified as a component of permanent equity because they are freestanding financial instruments that are legally detachable and separately exercisable from the shares of common stock with which they were issued, are immediately exercisable, do not embody an obligation for the Company to repurchase its shares, and permit the holders to receive a fixed number of shares of common stock upon exercise. The common stock was valued at $1,133,480, based on the Companyâ€™s stock price. The pre-funded warrants and common warrants were valued at $1,615,701 and $1,854,099, respectively, using the following Black-Scholes assumptions: Â Â Pre-funded warrants Â Â Common warrants Â Expected term (in years) Â 4 Â Â Â 4 Â Riskâ€‘free interest rate Â Â 3.83 % Â Â 3.83 % Dividend yield Â Â â€” % Â Â â€” % Expected volatility Â Â 100.25 % Â Â 100.25 % Exercise price Â $ 0.0001 Â Â $ 1.095 Â Stock price Â $ 0.86 Â Â $ 0.86 Â Black-Scholes value Â $ 0.86 Â Â $ 0.58 Â The net proceeds of $3,352,049 were allocated to the common stock, pre-funded warrants and common warrants using the relative fair value method. The valuations were recorded to stockholdersâ€™ equity. Â In June 2023, all pre-funded warrants were exercised for shares of common stock. In September and October 2023, all common warrants and 122,994 placement agent warrants were exercised for cash proceeds of $3,687,976. As of June 30, 2024, 68,809 placement agent warrants remain outstanding. X - ReferencesNo definition available. + Details Name: femy_EquityIncentivePlansAndWarrantsAbstract Namespace Prefix: femy_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for shareholders' equity and share-based payment arrangement. Includes, but is not limited to, disclosure of policy and terms of share-based payment arrangement, deferred compensation arrangement, and employee stock purchase plan (ESPP). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef - Topic 505 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/505/tableOfContentReference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/718/tableOfContent + Details Name: us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 30 R19.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Related-Party Transactions 6 Months Ended Jun. 30, 2024 Related-Party Transactions [Abstract] Â Related-Party Transactions (13) Relatedâ€‘Party Transactions In November 2023, the Company issued unsecured convertible notes and accompanying Series A and Series B Warrants (see Note 10). The transaction included issuance of a $5 million convertible note and Series A and Series B Warrants to PharmaCyte Biotech, Inc. The interim CEO, President and Director of PharmaCyte Biotech, Inc., Joshua Silverman, serves on the Companyâ€™s board of directors. In addition, during the year ended December 31, 2023 and six months ended June 30, 2024 and 2023, a family member of the CEO was employed by the Company. X - ReferencesNo definition available. + Details Name: us-gaap_RelatedPartyTransactionsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-5Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-6Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 850 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(g)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(c)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(e)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 850 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/850/tableOfContentReference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 850 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483326/850-10-50-6Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 850 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 850 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1 + Details Name: us-gaap_RelatedPartyTransactionsDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 31 R20.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Net Loss per Share Attributable to Common Stockholders 6 Months Ended Jun. 30, 2024 Net Loss per Share Attributable to Common Stockholders [Abstract] Â Net Loss per Share Attributable to Common Stockholders (14) Net Loss per Share Attributable to Common Stockholders Â The following table sets forth the computation of the basic and diluted net loss per share: Â Â Three Months Ended June 30, Â Â Six Months Ended June 30, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Â Â Â Â Â Â Â Â Â Â Â Net loss attributable to common stockholders, basic & diluted Â $ (4,684,574) Â Â (2,893,508) Â Â (8,284,084) Â Â (5,839,765) Â Â Â Â Â Â Â Â Â Â Â Â

1,169,671 Â Warrants to purchase common stock, in connection with April 2023 financing Â Â 68,809 Â Â Â 3,388,525 Â Â Â 68,809 Â Â Â 3,388,525 Â Warrants to purchase common stock, in connection with November 2023 financing Â Â 11,610,166 Â Â Â â€” Â Â Â 11,610,166 Â Â Â â€” Â Warrants to purchase common stock Â Â 196,816 Â Â Â 233,460 Â Â Â 196,816 Â Â Â 233,460 Â Total potential shares Â Â 15,046,930 Â Â Â 4,791,656 Â Â Â 15,046,930 Â Â Â 4,791,656 Â X - ReferencesNo definition available. + Details Name: us-gaap_EarningsPerShareAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for earnings per share. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/260/tableOfContentReference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-3 + Details Name: us-gaap_EarningsPerShareTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 32 R21.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Income Taxes 6 Months Ended Jun. 30, 2024 Income Taxes [Abstract] Â Income Taxes [Text Block] (15) Income Taxes The effective tax rate of 0% for the three and six months ended June 30, 2024 and 2023 was lower than the statutory rate due to the Company remaining in a full valuation allowance position. X - ReferencesNo definition available. + Details Name: us-gaap_IncomeTaxDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for income tax. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 231 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12C -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12CReference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12B -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12BReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 270 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477891/740-270-50-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 6.I.5.Q1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-13Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(h)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/740/tableOfContentReference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-14Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 21 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-21Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 17 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 11.C) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482603/740-30-50-2 + Details Name: us-gaap_IncomeTaxDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 33 R22.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Insider Trading Arrangements 3 Months Ended Jun. 30, 2024 Insider Trading Arrangements [Line Items] Â Rule 10b5-1 Arrangement Adopted false Non-Rule 10b5-1 Arrangement Adopted false Rule 10b5-1 Arrangement Terminated false Non-Rule 10b5-1 Arrangement Terminated false X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a + Details Name: ecd_InsiderTradingArrLineItems Namespace Prefix: ecd_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_NonRule10b51ArrAdoptedFlag Namespace Prefix: ecd_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_NonRule10b51ArrTrmntdFlag Namespace Prefix: ecd_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_Rule10b51ArrAdoptedFlag Namespace Prefix: ecd_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_Rule10b51ArrTrmntdFlag Namespace Prefix: ecd_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration XML 34 R23.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Organization, Nature of Business, and Liquidity (Policies) 6 Months Ended Jun. 30, 2024 Organization, Nature of Business, and Liquidity [Abstract] Â Organization and Nature of Business Organization and Nature of Business Â Femasys Inc. (the Company or Femasys) was incorporated in Delaware on February 19, 2004 and is headquartered in Suwanee, Georgia. The Company is a leading biomedical company focused on addressing significant unmet needs for women worldwide with a broad portfolio of in-office, accessible, and innovative therapeutic and diagnostic products, including a lead revolutionary product candidate and FDA-cleared products.Â The Companyâ€™s mission is to provide women with superior minimally-invasive, non-surgical product technologies, accessible in the office, improving patient care and overall health economics focused on servicing the reproductive health needs for those seeking solutions for infertility issues (FemaSeedÂ® and FemVueÂ®) or permanent birth control (FemBlocÂ®).Â The Company currently operates as one segment with an initial focus on servicing the reproductive health needs for those seeking solutions for infertility issues or permanent birth control. Femasys has an expansive intellectual property portfolio which covers both design and utility patents in the U.S. and significant ex-U.S. markets for each product initiative. Femasys has taken concepts internally conceived and protected through development, including domestic and foreign regulatory approvals, and production, through in-house manufacturing.Â FemaSeed, a solution which enables directed intratubal insemination to improve on traditional intrauterine insemination (IUI) and provides a lower cost and safer option to in vitro fertilization methods, received approval to sell FemaSeed in Canada in April 2023. In September 2023, the Company received 510(k) clearance from the FDA for FemaSeed for intratubal insemination to market in the United States. A pivotal clinical trial was still ongoing at the time of receiving regulatory clearance, however, enrollment was completed in November 2023. In June 2024, the Company received European Union Medical Device Regulation (EU MDR) certificates and CE Mark certification for four products: FemaSeed, FemVue, FemCervÂ® and FemCathÂ®. FemVue, a solution that enables fallopian tube assessment with ultrasound as an alternative to the radiologic approach (hysterosalpingogram) for the diagnosis of infertility, is approved for sale in the U.S., Japan, and Canada. FemChecÂ® allows for fallopian tube evaluation after a FemBloc procedure to confirm occlusion (or procedure success). FemCerv is a solution for complete tissue sampling with minimal contamination of the endocervical canal in a virtually pain-free procedure as an alternative to the single biopsy method for diagnosis of cervical cancer and is approved for sale in the U.S. and Canada. FemCath, allows for selective evaluation of an individual fallopian tube as an alternative to the traditional intrauterine catheter that is undirected, is approved for sale in the U.S. and Canada. FemBlocÂ®, the Companyâ€™s solution for permanent birth control, is based on the Companyâ€™s platform technology for delivery and in June 2023 Femasys received FDA approval of our IDE to evaluate the safety and efficacy of FemBloc, our non-surgical, non-implant, non-hormonal in-office solution for permanent birth control in a pivotal clinical trial. In August 2023 Femasys announced the initiation of enrollment in the FINALE [Prospective Multi-Center Trial for FemBloc Intratubal Occlusion for TranscervicAL Permanent Birth Control] pivotal trial designed to evaluate the safety and efficacy of FemBloc. This prospective, multi-center, open-label, single-arm study design includes pregnancy rate as the primary endpoint, which will be analyzed once 401 women have relied on FemBloc for one year for permanent birth control. In addition, the study is designed as a roll-in beginning with enrollment of 50 women for a clinical readout primarily of preliminary safety data prior to enrolling the remaining subjects. An interim analysis of clinical data endpoints is planned once 300 women have used FemBloc for permanent birth control for one year. Follow-up will continue annually for five years post-market. Basis of Presentation Basis of Presentation Â The Company has prepared the accompanying condensed financial statements pursuant to the rules and regulations of the U.S. Securities and Exchange Commission (SEC). Certain information and footnote disclosures normally included in the annual financial statements prepared in accordance with accounting principles generally accepted in the United States of America (U.S. GAAP) have been condensed or omitted pursuant to these rules and regulations. These condensed financial statements should be read in conjunction with the Companyâ€™s audited financial statements and footnotes related thereto for the year ended December 31, 2023 included in our Annual Report on Form 10K filed with the SEC on March 28, 2024 (the Annual Report). There have been no material changes to the Companyâ€™s significant accounting policies described in Note 2 to the financial statements included in the Annual Report. Â In the opinion of management, the unaudited financial statements include all adjustments (consisting only of normal recurring adjustments) necessary to present fairly the Companyâ€™s financial position and the results of its operations and cash flows at the dates for periods presented. The results of operations for such interim periods are not necessarily indicative of the results to be

expected for the full year. Use of Estimates Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenue and expense during the reporting periods. Estimates for these and other items are subject to change and are reassessed by management in accordance with U.S. GAAP. Actual results could differ from those estimates. Liquidity Liquidity Â As of June 30, 2024, the Company had cash and cash equivalents of $13,525,898. The Company plans to finance its operations and development needs with its existing cash and cash equivalents, additional equity and/or debt financing arrangements, and revenue primarily anticipated from the sale of FemVue and FemaSeed to support the Companyâ€™s research and development activities, primarily focused on FemBloc. There can be no assurance that the Company will be able to obtain additional financing on terms acceptable to the Company, on a timely basis, or at all. If the Company is not able to obtain sufficient funds on acceptable terms when needed, the Companyâ€™s business, results of operations, and financial condition could be materially adversely impacted. For the six months ended June 30, 2024, the Company generated a net loss of $8,284,084. The Company expects such losses to increase over the next few years as the Company advances FemBloc through clinical development if and until FDA approval is received and is available to be marketed. The financial statements have been prepared on a going-concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Company has incurred net operating losses in every year since inception and has an accumulated deficit as of June 30, 2024 of $116,665,713 and expects to incur additional losses and negative operating cash flows for at least the next twelve months. The Companyâ€™s ability to meet its obligations is dependent upon its ability to generate sufficient cash flows from operations and future financing transactions. Although management expects the Company will continue as a going concern, there is no assurance that managementâ€™s plans will be successful since the availability and amount of such funding is not certain. Accordingly, substantial doubt exists about the Companyâ€™s ability to continue as a going concern for at least one year from the issuance of these financial statements. The accompanying financial statements do not include any adjustments to reflect the possible future effects on the recoverability of assets or the amounts and classifications of liabilities that may result from the possible inability of the Company to continue as a going concern. Recently Issued Accounting Pronouncements Adopted and Not Yet Adopted Recently Issued Accounting Pronouncements â€“ Recently Adopted In November 2023, the FASB issued ASU No. 2023-07,Â Segment Reporting (Topic 28): Improvements to Reportable Segment Disclosures. The ASU improves reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment expenses. The ASU improves financial reporting by requiring disclosure of incremental segment information on an annual and interim basis for all public entities to enable investors to develop more decision-useful financial analyses. The amendments in this update are effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted. The Company will adopt the ASU for the fiscal year ended December 31, 2024 and interim periods in fiscal 2025. The adoption of the ASU will result in additional disclosures to the Companyâ€™s financial statements and footnote disclosures. Â Recently Issued Accounting Pronouncements â€“ Not Yet Adopted In December 2023, the FASB issued ASU 2023-09,Â Income Taxes (Topic 740): Improvements to Income Tax Disclosures. The ASU requires the annual financial statements to include consistent categories and greater disaggregation of information in the rate reconciliation, and income taxes paid disaggregated by jurisdiction. ASU 2023-09 is effective for the Companyâ€™s annual reporting periods beginning after December 15, 2024. Adoption is either with a prospective method or a fully retrospective method of transition. Early adoption is permitted. The Company is currently evaluating the effect that adoption of ASU 2023-09 will have on its financial statements and expects to adopt the ASU on January 1, 2025. No other new accounting pronouncement issued or effective has had, or is expected to have, a material impact on the Companyâ€™s financial statements. X - DefinitionDisclosure of accounting policy for the liquidity. + ReferencesNo definition available. + Details Name: femy_LiquidityPolicyTextBlock Namespace Prefix: femy_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for the organization and nature of business. + ReferencesNo definition available. + Details Name: femy_OrganizationAndNatureOfBusinessPolicyTextBlock Namespace Prefix: femy_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). + ReferencesNo definition available. + Details Name: us-gaap_BasisOfAccountingPolicyPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact. + ReferencesNo definition available. + Details Name: us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 11 -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-11Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 12 -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-8 + Details Name: us-gaap_UseOfEstimates Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 35 R24.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Inventories (Tables) 6 Months Ended Jun. 30, 2024 Inventories [Abstract] Â Inventory Stated at Cost, Net of Reserve Inventory stated at cost, net of reserve, consisted of the following: Â Â June 30, Â Â December 31, Â Â Â 2024 Â Â 2023 Â Materials Â $ 792,365 Â Â Â 367,934 Â Work in progress Â Â 229,045 Â Â Â 128,993 Â Finished goods Â Â 294,170 Â Â Â 170,191 Â Inventory, net Â $ 1,315,580 Â Â Â 667,118 Â X - ReferencesNo definition available. + Details Name: us-gaap_InventoryDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)(c)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483489/210-10-50-1 + Details Name: us-gaap_ScheduleOfInventoryCurrentTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 36 R25.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Accrued Expenses (Tables) 6 Months Ended Jun. 30, 2024 Accrued Expenses [Abstract] Â Accrued Expenses Accrued expenses consisted of the following: Â Â June 30, Â Â December 31, Â Â Â 2024 Â Â 2023 Â Clinical trial costs Â $ 334,799 Â Â Â 276,141 Â Accrued interest Â Â 250,025 Â Â Â â€” Â Incentive and other compensation costs Â Â 170,328 Â Â Â 1,082,606 Â Director fees Â Â 70,000 Â Â Â 60,210 Â Franchise taxes Â Â 3,150 Â Â Â 12,160 Â Other Â Â 58,050 Â Â Â 13,179 Â Accrued expenses Â $ 886,352 Â Â Â 1,444,296 Â X - ReferencesNo definition available. + Details Name: us-gaap_PayablesAndAccrualsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the components of accrued liabilities. + ReferencesNo definition available. + Details Name: us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 37 R26.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Clinical Holdback (Tables) 6 Months Ended Jun. 30, 2024 Clinical Holdback [Abstract] Â Clinical Holdback Liability The following table shows the activity within the clinical holdback liability accounts for the six months ended June 30, 2024: Â Balance at December 31, 2023 Â $ 120,235 Â Clinical holdback retained Â Â 5,990 Â Clinical holdback paid Â Â (1,122) Balance at June 30, 2024 Â $ 125,103 Â Less: clinical holdback - current portion Â Â (92,397) Clinical holdback - long-term portion Â $ 32,706 Â X - ReferencesNo definition available. + Details Name: femy_ClinicalHoldbackAbstract Namespace Prefix: femy_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of clinical holdback liability account. + ReferencesNo definition available. + Details Name: femy_ScheduleOfClinicalHoldbackLiabilityAccountTableTextBlock Namespace Prefix: femy_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 38 R27.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Revenue Recognition (Tables) 6 Months Ended Jun. 30, 2024 Revenue Recognition [Abstract] Â Sales by Geographic Region The following table summarizes our sales, primarily from FemVue, by geographic region as follows: Â Â Three Months Ended June 30, Â Â Six Months Ended June 30, Â Primary geographical markets Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â U.S. Â $ 221,484 Â Â Â 262,469 Â Â Â 492,624 Â Â Â 556,453 Â International Â Â â€” Â Â Â 58,045 Â Â Â â€” Â Â Â 58,045 Â Total Â $ 221,484 Â Â Â 320,514 Â Â Â 492,624 Â Â Â 614,498 Â X - ReferencesNo definition available. + Details Name: us-gaap_RevenueFromContractWithCustomerAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type:

duration X - DefinitionTabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41 + Details Name: us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 39 R28.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Equity Incentive Plans and Warrants (Tables) 6 Months Ended Jun. 30, 2024 Equity Incentive Plans and Warrants [Abstract] Â Stock Option Plan Activity Activity under the Companyâ€™s stock option plans for the six months ended June 30, 2024 was as follows: Â Â Number of options Â Â Weighted average exercise price Â Outstanding at December 31, 2023 Â Â 2,102,030 Â Â $ 2.00 Â Granted Â Â 1,062,421 Â Â Â 1.06 Â Forfeited Â Â (243,312) Â Â 2.09 Â Outstanding at June 30, 2024 Â Â 2,921,139 Â Â $ 1.65 Â Â Â Â Â Â Â Â Â Â Â Â Vested and exercisable at June 30, 2024 Â Â 1,207,595 Â Â $ 2.53 Â Share-based Compensation Expense The following table shows the share-based compensation expense related to vested stock option grants to employees and nonemployees by financial statement line item on the accompanying condensed statement of comprehensive loss: Â Â Three Months Ended June 30, Â Â Six Months Ended June 30, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Research and development Â $ 34,629 Â Â Â 27,192 Â Â Â 64,637 Â Â Â 52,251 Â Sales and marketing Â Â 18,246 Â Â Â 602 Â Â Â 24,764 Â Â Â (1,942) General and administrative Â Â 51,138 Â Â Â 37,422 Â Â Â 92,197 Â Â Â 71,861 Â Total share-based compensation expense Â $ 104,013 Â Â Â 65,216 Â Â Â 181,598 Â Â Â 122,170 Â Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Â Warrants Valuation Assumptions The common stock was valued at $1,133,480, based on the Companyâ€™s stock price. The pre-funded warrants and common warrants were valued at $1,615,701 and $1,854,099, respectively, using the following Black-Scholes assumptions: Â Â Pre-funded warrants Â Â Common warrants Â Expected term (in years) Â 4 Â Â Â 4 Â Riskâ€‘free interest rate Â Â 3.83 % Â Â 3.83 % Dividend yield Â Â â€” % Â Â â€” % Expected volatility Â Â 100.25 % Â Â 100.25 % Exercise price Â $ 0.0001 Â Â $ 1.095 Â Stock price Â $ 0.86 Â Â $ 0.86 Â Black-Scholes value Â $ 0.86 Â Â $ 0.58 Â 2021 Stock Option Plan [Member] Â Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Â Estimated Using Assumptions Options granted under our 2021 Stock Option Plan for the six months ended June 30, 2024 to employees and nonemployees were 1,059,921 and 2,500, respectively and the weighted average exercise prices were $1.06 and $0.79, respectively. The weighted-average fair values of the options granted to employees and nonemployees were $0.90 and $0.39, respectively and were estimated using the following Black-Scholes assumptions: Â Â Employee Â Â Nonemployee Â Expected term (in years) Â 6.25 Â Â Â 1.50 Â Riskâ€‘free interest rate Â Â 4.06 % Â Â 4.53 % Dividend yield Â Â â€” % Â Â â€” % Expected volatility Â Â 110.40 % Â Â 105.34 % Inducement Grant [Member] Â Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Â Estimated Using Assumptions On February 12, 2024, the Company awarded, outside the 2021 Plan, our Chief Commercial Officer a stock option grant for the right to purchase 100,000 shares of common stock at an exercise price of $1.10 per share (inducement grant), which was approved by the Compensation committee. The inducement grant will vest in equal installments over four years provided the employee remains employed by the Company on the vesting date. The fair value of the inducement grant was $0.94 and was estimated using the following assumptions: Â Â Inducement Â Expected term (in years) Â 6.25 Â Riskâ€‘free interest rate Â Â 4.10 % Dividend yield Â Â â€” % Expected volatility Â Â 109.64 % X - ReferencesNo definition available. + Details Name: femy_EquityIncentivePlansAndWarrantsAbstract Namespace Prefix: femy_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the significant assumptions used during the year to estimate the fair value of warrants, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions. + ReferencesNo definition available. + Details Name: femy_ScheduleOfShareBasedPaymentAwardFairValueWarrantLiabilityValuationAssumptionsTableTextBlock Namespace Prefix: femy_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of share-based payment arrangement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d) -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e) -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the significant assumptions used during the year to estimate the fair value of employee stock purchase plans, including, but not limited to: (a) expected term, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Subparagraph (f)(2) -Name Accounting Standards Codification -Paragraph 2 -Section 50 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 1D -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1DReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -

Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(v) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis=femy_Two021StockOptionPlanMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis=femy_InducementGrantMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 40 R29.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Net Loss per Share Attributable to Common Stockholders (Tables) 6 Months Ended Jun. 30, 2024 Net Loss per Share Attributable to Common Stockholders [Abstract] Â Computation of Basic and Diluted Net Loss Per Share The following table sets forth the computation of the basic and diluted net loss per share: Â Â Three Months Ended June 30, Â Â Six Months Ended June 30, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Â Â Â Â Â Â Â Â Â Â Â Â Net loss attributable to common stockholders, basic & diluted Â $ (4,684,574) Â Â (2,893,508) Â Â (8,284,084) Â Â (5,839,765) Â Weighted average number of shares used in computing net loss per share attributable to common stockholders, basic and diluted Â Â 22,215,516 Â Â Â 13,107,590 Â Â Â 21,995,436 Â Â Â 12,493,334 Â Net loss per share attributable to common stockholders, basic and diluted Â $ (0.21) Â Â (0.22) Â Â (0.38) Â Â (0.47) Computations of Diluted Weighted Average Shares Outstanding The following potentially dilutive securities have been excluded from the computations of diluted weighted average shares outstanding because they would be anti-dilutive: Â Â Â Three Months Ended June 30, Â Â Six Months Ended June 30, Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Options to purchase common stock Â Â 3,171,139 Â Â Â 1,169,671 Â Â Â 3,171,139 Â Â Â 1,169,671 Â Warrants to purchase common stock, in connection with April 2023 financing Â Â 68,809 Â Â Â 3,388,525 Â Â Â 68,809 Â Â Â 3,388,525 Â Warrants to purchase common stock, in connection with November 2023 financing Â Â 11,610,166 Â Â Â â€” Â Â Â 11,610,166 Â Â Â â€” Â Warrants to purchase common stock Â Â 196,816 Â Â Â 233,460 Â Â Â 196,816 Â Â Â 233,460 Â Total potential shares Â Â 15,046,930 Â Â Â 4,791,656 Â Â Â 15,046,930 Â Â Â 4,791,656 Â X - ReferencesNo definition available. + Details Name: us-gaap_EarningsPerShareAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1 + Details Name: us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the weighted average number of shares used in calculating basic net earnings per share (or unit) and diluted earnings per share (or unit). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1 + Details Name: us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 41 R30.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Organization, Nature of Business, and Liquidity (Details) 3 Months Ended 6 Months Ended Jun. 30, 2024 USD ($) Women Jun. 30, 2023 USD ($) Jun. 30, 2024 USD ($) Product Women Segment Jun. 30, 2023 USD ($) Dec. 31, 2023 USD ($) Organization and Nature of Business [Abstract] Â Â Â Â Â Number of operating segments | Segment Â Â 1 Â Â Number of products received EU MDR and CE Mark certifications | Product Â Â 4 Â Â Number of women used FemBloc for permanent birth control | Women 401 Â 401 Â Â Number of year where women's used for permanent birth control. Â Â 1 year Â Â Number of women enrolled for a clinical readout | Women Â Â 50 Â Â Number of women need to use for interim analysis of clinical data for permanent birth control | Women Â Â 300 Â Â Period for analysis of clinical data for permanent birth control Â Â 1 year Â Â Follow-up period for interim analysis of clinical data for permanent birth control Â Â 5 years Â Â Liquidity [Abstract] Â Â Â Â Â Cash and cash equivalents | $ $ 13,525,898 Â $ 13,525,898 Â $ 21,716,077 Net loss | $ (4,684,574) $ (2,893,508) (8,284,084) $ (5,839,765) Â Accumulated deficit | $ $ (116,665,713) Â $ (116,665,713) Â $ (108,381,629) X - DefinitionFollow-up period for interim analysis of clinical data for permanent birth control + ReferencesNo definition available. + Details Name: femy_FollowUpPeriodForInterimAnalysisOfClinicalData Namespace Prefix: femy_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: femy_LiquidityAbstract Namespace Prefix: femy_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionNumber of products received European Union Medical Device Regulation (EU MDR) certificates and CE Mark certifications during the period. + ReferencesNo definition available. + Details Name: femy_NumberOfProductsReceivedEUMDRAndCEMarkCertifications Namespace Prefix: femy_ Data Type: xbrli:integerItemType Balance Type: na Period Type: duration X - DefinitionNumber of additional women enrolled for a clinical readout. + ReferencesNo definition available. + Details Name: femy_NumberOfWomenEnrolledForClinicalReadout Namespace Prefix: femy_ Data Type: xbrli:integerItemType Balance Type: na Period Type: duration X - DefinitionNumber of women need to use for interim analysis of clinical data for permanent birth control + ReferencesNo definition available. + Details Name: femy_NumberOfWomenNeedToUseForInterimAnalysisOfClinicalData Namespace Prefix: femy_ Data Type: xbrli:integerItemType Balance Type: na Period Type: duration X - DefinitionNumber of women used FemBloc for permanent birth control + ReferencesNo definition available. + Details Name: femy_NumberOfWomenUsedFemBlocForPermanentBirthControl Namespace Prefix: femy_ Data Type: xbrli:integerItemType Balance Type: na Period Type: instant X - DefinitionNumber of year where women's used for permanent birth control. + ReferencesNo definition available. + Details Name: femy_NumberOfYearWhereWomenSUsedForPermanentBirthControl Namespace Prefix: femy_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: femy_OrganizationAndNatureOfBusinessAbstract Namespace Prefix: femy_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionPeriod for analysis of clinical data for permanent birth control. + ReferencesNo definition available. + Details Name: femy_PeriodForAnalysisOfClinicalData Namespace Prefix: femy_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionAmount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4 + Details Name: us-gaap_CashAndCashEquivalentsAtCarryingValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -

Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionNumber of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18 + Details Name: us-gaap_NumberOfOperatingSegments Namespace Prefix: us-gaap_ Data Type: xbrli:integerItemType Balance Type: na Period Type: duration X - DefinitionAmount of accumulated undistributed earnings (deficit). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(23)(a)(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_RetainedEarningsAccumulatedDeficit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant XML 42 R31.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Cash and Cash Equivalents (Details) - USD ($) Jun. 30, 2024 Dec. 31, 2023 Level 1 [Member] | Money Market Funds [Member] Â Â Assets, Fair Value Disclosure [Abstract] Â Â Cash and cash equivalent $ 12,686,738 $ 21,278,895 X - ReferencesNo definition available. + Details Name: us-gaap_AssetsFairValueDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionFair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -

Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_CashAndCashEquivalentsFairValueDisclosure Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - Details Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 43 R32.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Inventories (Details) - USD ($) Jun. 30, 2024 Dec. 31, 2023 Inventories [Abstract] Â Â Materials $ 792,365 $ 367,934 Work in progress 229,045 128,993 Finished goods 294,170 170,191 Inventory, net $ 1,315,580 $ 667,118 X - ReferencesNo definition available. + Details Name: us-gaap_InventoryDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_InventoryFinishedGoods Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_InventoryNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)(a)(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_InventoryRawMaterials Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)(a)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_InventoryWorkInProcess Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant XML 44 R33.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Accrued Expenses (Details) - USD ($) Jun. 30, 2024 Dec. 31, 2023 Accrued Expenses [Abstract] Â Â Clinical trail costs $ 334,799 $ 276,141 Accrued interest 250,025 0 Incentive and other compensation costs 170,328 1,082,606 Director fees 70,000 60,210 Franchise taxes 3,150 12,160 Other 58,050 13,179 Accrued expenses $ 886,352 $ 1,444,296 X - DefinitionCarrying value as of the balance sheet date of obligations incurred and payable, pertaining to clinical trial cost. + ReferencesNo definition available. + Details Name: femy_AccruedClinicalTrialCost Namespace Prefix: femy_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of obligations incurred and payable, pertaining to franchise taxes. + ReferencesNo definition available. + Details Name: femy_FranchiseTaxes Namespace Prefix: femy_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionThe carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to incentive and other compensation costs. + ReferencesNo definition available. + Details Name: femy_IncentiveAndOtherCompensationCostsCurrent Namespace Prefix: femy_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_AccruedLiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_AccruedProfessionalFeesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_InterestPayableCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_OtherAccruedLiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_PayablesAndAccrualsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 45 R34.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Clinical Holdback (Details) - USD ($) 6 Months Ended Jun. 30, 2024 Dec. 31, 2023 Clinical Holdback Liability [Roll Forward] Â Â Balance $ 120,235 Â Clinical holdback retained 5,990 Â Clinical holdback paid (1,122) Â Balance 125,103 Â Less: clinical holdback - current portion (92,397) $ (65,300) Clinical holdback - long-term portion $ 32,706 $ 54,935 X - DefinitionAmount of clinical holdback expected to be paid during the following twelve months or within one business cycle, if longer. + ReferencesNo definition available. + Details Name: femy_ClinicalHoldbackCurrent Namespace Prefix: femy_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of clinical holdback liability. + ReferencesNo definition available. + Details Name: femy_ClinicalHoldbackLiability Namespace Prefix: femy_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionA roll forward is a reconciliation of a concept from the beginning of a period to the end of a period. + ReferencesNo definition available. + Details Name: femy_ClinicalHoldbackLiabilityRollForward Namespace Prefix: femy_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of clinical holdback, due after one year or beyond the normal operating cycle, if longer. + ReferencesNo definition available. + Details Name: femy_ClinicalHoldbackNoncurrent Namespace Prefix: femy_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of cash outflow reducing clinical holdback liability. + ReferencesNo definition available. + Details Name: femy_ClinicalHoldbackPaid Namespace Prefix: femy_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of clinical holdback retained during the period. + ReferencesNo definition available. + Details Name: femy_ClinicalHoldbackRetained Namespace Prefix: femy_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration XML 46 R35.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Revenue Recognition (Details) - USD ($) 3 Months Ended 6 Months Ended Jun. 30, 2024 Jun. 30, 2023 Jun. 30, 2024 Jun. 30, 2023 Revenue Recognition [Abstract] Â Â Â Â Revenue recognized from performance obligations in prior periods $ 0 $ 0 $ 0 $ 0 Percentage of restocking fee Â Â 30.00% Â Primary Geographical Markets [Abstract] Â Â Â Â Sales 221,484 320,514 $ 492,624 614,498 FemVue [Member] Â Â Â Â Primary Geographical Markets [Abstract] Â Â Â Â Sales 221,484 320,514 492,624 614,498 FemVue [Member] | U.S. [Member] Â Â Â Â Primary Geographical Markets [Abstract] Â Â Â Â Sales 221,484 262,469 492,624 556,453 FemVue [Member] | International [Member] Â Â Â Â Primary Geographical Markets [Abstract] Â Â Â Â Sales $ 0 $ 58,045 $ 0 $ 58,045 Minimum [Member] Â Â Â Â Revenue Recognition [Abstract] Â Â Â Â Revenue recognition payment period term Â Â 30 days Â Maximum [Member] Â Â Â Â Revenue Recognition [Abstract] Â Â Â Â Revenue recognition payment period term Â Â 60 days Â X - DefinitionThe percentage of restocking fee on items to be returned. + ReferencesNo definition available. + Details Name: femy_PercentageOfRestockingFee Namespace Prefix: femy_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: femy_PrimaryGeographicalMarketsAbstract Namespace Prefix: femy_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionRevenue recognition payment period term, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment. + ReferencesNo definition available. + Details Name: femy_RevenueRecognitionPaymentTermOfPeriod Namespace Prefix: femy_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionAmount of revenue recognized from performance obligation satisfied or partially satisfied in previous reporting periods. Includes, but is not limited to, change in transaction price. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12A -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12A + Details Name: us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_DisaggregationOfRevenueAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or

service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4 + Details Name: us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Details Name: srt_ProductOrServiceAxis=femy_FemVueMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_StatementGeographicalAxis=country_US Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_StatementGeographicalAxis=us-gaap_NonUsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MinimumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 47 R36.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Notes Payable (Details) - USD ($) 1 Months Ended 3 Months Ended 6 Months Ended Jul. 31, 2023 Jun. 30, 2022 Jun. 30, 2024 Jun. 30, 2023 Jun. 30, 2024 Jun. 30, 2023 Dec. 31, 2023 Notes Payable [Abstract] Â Â Â Â Â Â Â Down payments Â Â Â Â $ 0 $ 141,298 Â July Promissory Note [Member] | AFCO Credit Corporation [Member] Â Â Â Â Â Â Â Notes Payable [Abstract] Â Â Â Â Â Â Â Proceeds to pay insurance premiums $ 469,042 Â Â Â Â Â Â Down payments $ 48,423 Â Â Â Â Â Â Interest rate 8.60% Â Â Â Â Â Â Frequency of installment payments Â Â Â Â monthly Â Â Monthly principal and interest payments $ 48,423 Â Â Â Â Â Â Maturity date of loan Nov. 30, 2023 Â Â Â Â Â Â Note payable Â Â $ 0 Â $ 0 Â $ 0 Interest expense on loan Â Â $ 0 $ 1,319 $ 0 $ 1,319 Â June Promissory Note [Member] | AFCO Credit Corporation [Member] Â Â Â Â Â Â Â Notes Payable [Abstract] Â Â Â Â Â Â Â Proceeds to pay insurance premiums Â $ 465,380 Â Â Â Â Â Down payments Â $ 47,539 Â Â Â Â Â Interest rate Â 5.70% Â Â Â Â Â Frequency of installment payments Â Â Â Â monthly Â Â Monthly principal and interest payments Â $ 47,539 Â Â Â Â Â Maturity date of loan Â Mar. 31, 2023 Â Â Â Â Â X - DefinitionDescription of the frequency of periodic payments (monthly, quarterly, annual). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 942 -SubTopic 470 -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477734/942-470-50-3 + Details Name: us-gaap_DebtInstrumentFrequencyOfPeriodicPayment Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionContractual interest rate for funds borrowed, under the debt agreement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B + Details Name: us-gaap_DebtInstrumentInterestRateStatedPercentage Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionDate when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)(a)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B + Details Name: us-gaap_DebtInstrumentMaturityDate Namespace Prefix: us-gaap_ Data Type: xbrli:dateItemType Balance Type: na Period Type: duration X - DefinitionAmount of the required periodic payments including both interest and principal payments. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 942 -SubTopic 470 -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477734/942-470-50-3 + Details Name: us-gaap_DebtInstrumentPeriodicPayment Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_DebtInstrumentsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of the cost of borrowed funds accounted for as interest expense for debt. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69E -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69EReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69F -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69FReference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-6 + Details Name: us-gaap_InterestExpenseDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionSum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_NotesPayableCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionThe cash inflow from a borrowing supported by a written promise to pay an obligation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromNotesPayable Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash outflow for a borrowing supported by a written promise to pay an obligation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 15 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15 + Details Name: us-gaap_RepaymentsOfNotesPayable Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Details Name: us-gaap_DebtInstrumentAxis=femy_JulyPromissoryNoteMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_LineOfCreditFacilityAxis=femy_AFCOCreditCorporationMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=femy_JunePromissoryNoteMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 48 R37.htm IDEA:

XBRL DOCUMENT v3.24.2.u1 Convertible Notes with Warrants (November 2023 Financing), Summary (Details) - November 2023 Financing [Member] - USD ($) 6 Months Ended Nov. 21, 2023 Jun. 30, 2024 Dec. 31, 2023 Convertible Notes [Abstract] Â Â Â Proceeds from convertible notes $ 6,850,000 Â Â Transaction costs $ 525,144 Â Â Conversion price, period Â 18 months Â Conversion price of common stock exceeds (in dollars per share) $ 2.36 Â Â Consecutive trading days Â 10 days Â Daily dollar trading volume of common stock exceeds per day $ 1,000,000 Â Â Notes redeem at premium, percentage 115.00% Â Â Series A Warrants [Member] Â Â Â Convertible Notes [Abstract] Â Â Â Warrants purchase shares of common stock (in shares) 5,805,083 Â Â Warrants exercise price (in dollars per share) $ 1.18 Â Â Consecutive trading days Â 10 days Â Daily dollar trading volume of common stock exceeds per day $ 1,000,000 Â Â Series B Warrants [Member] Â Â Â Convertible Notes [Abstract] Â Â Â Consecutive trading days Â 10 days Â Daily dollar trading volume of common stock exceeds per day $ 1,000,000 Â Â Convertible Notes [Member] Â Â Â Convertible Notes [Abstract] Â Â Â Aggregate principal amount Â $ 6,850,000 $ 6,850,000 Convertible note accrue interest rate Â 6.00% Â Maturity date Â Nov. 21, 2025 Â Convertible Notes [Member] | Series B Warrants [Member] Â Â Â Convertible Notes [Abstract] Â Â Â Warrants purchase shares of common stock (in shares) 5,805,083 Â Â Warrants exercise price (in dollars per share) $ 1.475 Â Â Convertible Notes [Member] | Common Stock [Member] Â Â Â Convertible Notes [Abstract] Â Â Â Aggregate principal amount $ 6,850,000 Â Â Conversion price (in dollars per share) $ 1.18 Â Â X - DefinitionThe consecutive trading days, in which common stock exceeds the conversion price, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesNo definition available. + Details Name: femy_ConsecutiveTradingDaysCommonStockExceedsTheConversionPrice Namespace Prefix: femy_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionThe amount of daily dollar trading volume of the common stock exceeds per day during the same period and certain equity conditions. + ReferencesNo definition available. + Details Name: femy_DailyDollarTradingVolumeOfCommonStockExceedsPerDay Namespace Prefix: femy_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe closing price per share of the common stock exceeds of the conversion feature embedded in the debt instrument. + ReferencesNo definition available. + Details Name: femy_DebtInstrumentConvertibleConversionPriceOfCommonStockExceeds Namespace Prefix: femy_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionPeriod of conversion price for a period after closing, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesNo definition available. + Details Name: femy_PeriodOfConversionPrice Namespace Prefix: femy_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionExercise price per share or per unit of warrants or rights outstanding. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3 + Details Name: us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionNumber of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3 + Details Name: us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionExpiration, mandatory redemption, or due date, in YYYY-MM-DD format, of the financial instrument issued in exchange for the original debt being converted in a noncash or part noncash transaction. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5 + Details Name: us-gaap_DebtConversionConvertedInstrumentExpirationOrDueDateDayMonthAndYear Namespace Prefix: us-gaap_ Data Type: xbrli:dateItemType Balance Type: na Period Type: duration X - DefinitionAmount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(16)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4 + Details Name: us-gaap_DebtInstrumentCarryingAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionThe price per share of the conversion feature embedded in the debt instrument. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-5 + Details Name: us-gaap_DebtInstrumentConvertibleConversionPrice1 Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionContractual interest rate for funds borrowed, under the debt agreement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B + Details Name: us-gaap_DebtInstrumentInterestRateStatedPercentage Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionPercentage price of original principal amount of debt at which debt can be redeemed by the issuer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 470 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477734/942-470-50-3 + Details Name: us-gaap_DebtInstrumentRedemptionPricePercentage Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_DebtInstrumentsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 15 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15 + Details Name: us-gaap_PaymentsOfDebtIssuanceCosts Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromConvertibleDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Details Name: us-gaap_DebtInstrumentAxis=femy_November2023FinancingMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementClassOfStockAxis=femy_SeriesAWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementClassOfStockAxis=femy_SeriesBWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 49 R38.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Convertible Notes with Warrants (November 2023 Financing), Warrants (Details) - November 2023 Financing [Member] - USD ($) 6 Months Ended Nov. 21, 2023 Jun. 30, 2024 Warrants [Abstract] Â Â Consecutive trading days Â 10 days Daily dollar trading volume of common stock exceeds per day $ 1,000,000 Â Series A Warrants [Member] Â Â Warrants [Abstract] Â Â Warrants term Â 5 years Percentage of warrant closing price of common stock exceeds 200.00% Â Consecutive trading days Â 10 days Daily dollar trading volume of common stock exceeds per day $ 1,000,000 Â Series B Warrants [Member] Â Â Warrants [Abstract] Â Â Warrants term Â 1 year Percentage of warrant closing price of common stock exceeds 200.00% Â Consecutive trading days Â 10 days Daily dollar trading volume of common stock exceeds per day $ 1,000,000 Â X - DefinitionThe consecutive trading days, in which common stock exceeds the conversion price, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesNo definition available. + Details Name: femy_ConsecutiveTradingDaysCommonStockExceedsTheConversionPrice Namespace Prefix: femy_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionThe amount of daily dollar trading volume of the common stock exceeds per day during the same period and certain equity conditions. + ReferencesNo definition available. + Details Name: femy_DailyDollarTradingVolumeOfCommonStockExceedsPerDay Namespace Prefix: femy_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionPercentage of warrant has the right to call the exercise, if the closing price of the common stock exceeds. + ReferencesNo definition available. + Details Name: femy_PercentageOfWarrantClosingPriceOfCommonStockExceedsPercentage Namespace Prefix: femy_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: femy_WarrantsTransactionsAbstract Namespace Prefix: femy_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionPeriod between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. +

ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_WarrantsAndRightsOutstandingTerm Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: instant X - Details Name: us-gaap_DebtInstrumentAxis=femy_November2023FinancingMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementClassOfStockAxis=femy_SeriesAWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementClassOfStockAxis=femy_SeriesBWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 50 R39.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Convertible Notes with Warrants (November 2023 Financing), Convertible Notes Payable (Details) - USD ($) 3 Months Ended 6 Months Ended Jun. 30, 2024 Jun. 30, 2024 Jun. 30, 2023 Dec. 31, 2023 Convertible Notes [Abstract] Â Â Â Â Amortization of debt discount and issuance costs Â $ 544,363 $ 0 Â Convertible Notes Payable [Abstract] Â Â Â Â Accrued and unpaid interest $ 250,025 250,025 Â $ 0 November 2023 Financing [Member] | Convertible Notes [Member] Â Â Â Â Convertible Notes [Abstract] Â Â Â Â Interest expense 388,311 749,863 Â Â Coupon interest expense 102,750 205,500 Â Â Amortization of debt discount and issuance costs 285,561 544,363 Â Â Convertible Notes Payable [Abstract] Â Â Â Â Notes principal balance 6,850,000 6,850,000 Â 6,850,000 Accrued and unpaid interest 250,025 250,025 Â 44,525 Unamortized discount and debt issuance costs 2,091,983 2,091,983 Â $ 2,636,346 Convertible note, fair value $ 6,307,258 $ 6,307,258 Â Â X - DefinitionAmount of amortization expense attributable to debt discount (premium) and debt issuance costs. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69E -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69EReference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69F -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69FReference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-3 + Details Name: us-gaap_AmortizationOfFinancingCostsAndDiscounts Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionFair value portion of borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2E -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2EReference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_ConvertibleDebtFairValueDisclosures Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(16)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4 + Details Name: us-gaap_DebtInstrumentCarryingAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of unamortized debt discount (premium) and debt issuance costs. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69BReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69CReference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-1A + Details Name: us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNetAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_DebtInstrumentsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of the cost of borrowed funds accounted for as interest expense for debt. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69E -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69EReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69F -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69FReference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-6 + Details Name: us-gaap_InterestExpenseDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionRepresents the portion of interest incurred in the period on debt arrangements that was charged against earnings, excluding amortization of debt discount (premium) and financing costs. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69E -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69EReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69F -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69FReference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F + Details Name: us-gaap_InterestExpenseDebtExcludingAmortization Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionCarrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_InterestPayableCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Details Name: us-gaap_DebtInstrumentAxis=femy_November2023FinancingMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-

gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 51 R40.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Stockholders' Equity (Details) - USD ($) 1 Months Ended 6 Months Ended Apr. 20, 2023 Oct. 31, 2023 Sep. 30, 2023 Apr. 30, 2023 Jun. 30, 2024 Jun. 30, 2023 Dec. 31, 2023 Jul. 01, 2022 Stockholders Equity [Abstract] Â Â Â Â Â Â Â Â Common stock sold (in shares) 1,318,000 Â Â Â Â Â Â Â Proceeds from Issuance of Common Stock Â Â Â Â $ 1,021,994 $ 3,373 Â Â Gross proceeds from offering $ 3,899,813 Â Â $ 3,899,813 Â Â Â Â Placement agent fees expenses and offering expenses Â Â Â $ 547,764 Â Â Â Â Common stock, outstanding (in shares) Â Â Â Â 22,232,799 Â 21,657,381 Â Dividends declared or paid Â Â Â Â $ 0 Â Â Â Maximum [Member] Â Â Â Â Â Â Â Â Stockholders Equity [Abstract] Â Â Â Â Â Â Â Â Authorized offering amount of securities Â Â Â Â Â Â Â $ 150,000,000 Pre-funded Warrants [Member] Â Â Â Â Â Â Â Â Stockholders Equity [Abstract] Â Â Â Â Â Â Â Â Warrants issued to purchase common stock (in shares) 1,878,722 Â Â Â Â Â Â Â Â Purchase price (in dollars per share) Â Â Â $ 1.2199 Â Â Â Â Pre-funded Warrants [Member] | Maximum [Member] Â Â Â Â Â Â Â Â Stockholders Equity [Abstract] Â Â Â Â Â Â Â Â Warrants issued to purchase common stock (in shares) Â Â Â 1,878,722 Â Â Â Â Common Warrants [Member] Â Â Â Â Â Â Â Â Stockholders Equity [Abstract] Â Â Â Â Â Â Â Â Warrants issued to purchase common stock (in shares) 3,196,722 Â Â Â Â Â Â Â Common Warrants [Member] | Maximum [Member] Â Â Â Â Â Â Â Â Stockholders Equity [Abstract] Â Â Â Â Â Â Â Â Warrants issued to purchase common stock (in shares) Â Â Â 3,196,722 Â Â Â Â Placement Agent Warrants [Member] Â Â Â Â Â Â Â Â Stockholders Equity [Abstract] Â Â Â Â Â Â Â Â Warrants issued to purchase common stock (in shares) 191,803 Â Â Â Â Â Â Â Warrants exercised (in shares) Â 122,994 122,994 Â Â Â Â Â Cash proceeds from warrants exercised Â $ 3,687,976 $ 3,687,976 Â Â Â Â Â Warrants outstanding (in shares) Â Â Â Â 68,809 Â Â Â Placement Agent Warrants [Member] | Maximum [Member] Â Â Â Â Â Â Â Â Stockholders Equity [Abstract] Â Â Â Â Â Â Â Â Warrants issued to purchase common stock (in shares) Â Â Â 191,803 Â Â Â Â Equity Distribution Agreement [Member] Â Â Â Â Â Â Â Â Stockholders Equity [Abstract] Â Â Â Â Â Â Â Â Common stock sold (in shares) Â Â Â Â 3,900,000 Â Â Â Proceeds from Issuance of Common Stock Â Â Â Â $ 8,700,000 Â Â Â Equity Distribution Agreement [Member] | Maximum [Member] Â Â Â Â Â Â Â Â Stockholders Equity [Abstract] Â Â Â Â Â Â Â Â Common stock authorized value to be issued by Sales Agent Â $ 16,700,000 Â Â Â Â Â Â Common Stock [Member] Â Â Â Â Â Â Â Â Stockholders Equity [Abstract] Â Â Â Â Â Â Â Â Common stock sold (in shares) Â Â Â 1,318,000 Â Â Â Â Purchase price (in dollars per share) Â Â Â $ 1.22 Â Â Â Â X - DefinitionThe authorized offering amount of securities. + ReferencesNo definition available. + Details Name: femy_AuthorizedOfferingAmountOfSecurities Namespace Prefix: femy_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of common stock authorized value to be issued by Sales Agent to sell maximum shares at current market prices until all shares all sold. + ReferencesNo definition available. + Details Name: femy_CommonStockAuthorizedValueToBeIssuedBySalesAgent Namespace Prefix: femy_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionNumber of warrants exercised during the period. + ReferencesNo definition available. + Details Name: femy_NumberOfWarrantsExercised Namespace Prefix: femy_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionAmount of placement agent fees expense and offering expenses related to common stock and warrants. + ReferencesNo definition available. + Details Name: femy_PlacementAgentFeesExpensesAndOfferingExpenses Namespace Prefix: femy_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash inflow associated with the amount received from holders exercising their common stock warrants. + ReferencesNo definition available. + Details Name: femy_ProceedsFromExerciseOfCommonStockWarrants Namespace Prefix: femy_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionNumber of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3 + Details Name: us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of warrants or rights outstanding. + ReferencesNo definition available. + Details Name: us-gaap_ClassOfWarrantOrRightOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of shares of common stock outstanding. Common stock represent the ownership interest in a corporation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3 + Details Name: us-gaap_CommonStockSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionAmount of paid and unpaid common stock dividends declared with the form of settlement in cash, stock and payment-in-kind (PIK). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 2 -SubTopic 405 -Topic 942 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477787/942-405-45-2 + Details Name: us-gaap_DividendsCommonStock Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash inflow from the additional capital contribution to the entity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromIssuanceOfCommonStock Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3 + Details Name: us-gaap_ProceedsFromIssuanceOrSaleOfEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionPer share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction. + ReferencesNo definition available. + Details Name: us-gaap_SaleOfStockPricePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionNumber of new stock issued during the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_StockholdersEquityNoteAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=femy_PreFundedWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=femy_CommonWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=femy_PlacementAgentWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SubsidiarySaleOfStockAxis=femy_EquityDistributionAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 52 R41.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Equity Incentive Plans and Warrants, Stock Option Plan, Activity (Details) - 2021 Stock Option Plan [Member] 6 Months Ended Jun. 30, 2024 $ / shares shares Number of Options [Roll Forward] Â Beginning balance (in shares) | shares

2,102,030 Granted (in shares) | shares 1,062,421 Forfeited (in shares) | shares (243,312) Ending balance (in shares) | shares 2,921,139 Weighted Average Exercise Price [Abstract] Â Beginning balance (in dollars per share) | $ / shares $ 2 Granted (in dollars per share) | $ / shares 1.06 Forfeited (in dollars per share) | $ / shares 2.09 Ending balance (in dollars per share) | $ / shares $ 1.65 Options vested and exercisable [Abstract] Â Options vested and exercisable, Number of option vested (in shares) | shares 1,207,595 Options vested and exercisable, Exercise price (in dollars per share) | $ / shares $ 2.53 Estimated Fair Value Assumptions [Abstract] Â Options exercised (in shares) | shares 0 Common stock reserved for issuance (in shares) | shares 676,741 Employees [Member] Â Number of Options [Roll Forward] Â Granted (in shares) | shares 1,059,921 Weighted Average Exercise Price [Abstract] Â Granted (in dollars per share) | $ / shares $ 1.06 Options vested and exercisable [Abstract] Â Weighted-average fair values of options granted (in dollars per share) | $ / shares $ 0.9 Estimated Fair Value Assumptions [Abstract] Â Expected term (in years) 6 years 3 months Risk free interest rate 4.06% Dividend yield 0.00% Expected volatility 110.40% Nonemployee [Member] Â Number of Options [Roll Forward] Â Granted (in shares) | shares 2,500 Weighted Average Exercise Price [Abstract] Â Granted (in dollars per share) | $ / shares $ 0.79 Options vested and exercisable [Abstract] Â Weighted-average fair values of options granted (in dollars per share) | $ / shares $ 0.39 Estimated Fair Value Assumptions [Abstract] Â Expected term (in years) 1 year 6 months Risk free interest rate 4.53% Dividend yield 0.00% Expected volatility 105.34% X - DefinitionAggregate number of common shares reserved for future issuance. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockCapitalSharesReservedForFutureIssuance Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionThe estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionThe risk-free interest rate assumption that is used in valuing an option on its own shares. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionThe number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionGross number of share options (or share units) granted during the period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionThe weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionNumber of options outstanding, including both vested and non-vested options. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionA roll forward is a reconciliation of a concept from the beginning of a period to the end of a period. + ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionWeighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionNumber of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionWeighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionWeighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionWeighted average per share amount at which grantees can acquire shares of common stock by exercise of options. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionExpected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-

gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionNumber of share options (or share units) exercised during the current period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis=femy_Two021StockOptionPlanMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementEmployeeMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementNonemployeeMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 53 R42.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Equity Incentive Plans and Warrants, Inducement Grant (Details) - Inducement Grant [Member] - $ / shares Feb. 12, 2024 Jun. 30, 2024 Inducement Grant [Abstract] Â Â Granted (in shares) 100,000 Â Weighted average exercise price (in dollars per share) $ 1.1 $ 1.89 Vesting period 4 years Â Weighted-average fair values of options granted (in dollars per share) $ 0.94 Â Estimated Fair Value Assumptions [Abstract] Â Â Expected term (in years) 6 years 3 months Â Risk free interest rate 4.10% Â Dividend yield 0.00% Â Expected volatility 109.64% Â Shares outstanding (in shares) Â 250,000 Options vested and exercisable, Number of option vested (in shares) Â 62,500 Options vested and exercisable, Weighted average exercise price (in dollars per shares) Â $ 2.64 X - ReferencesNo definition available. + Details Name: femy_InducementGrantAbstract Namespace Prefix: femy_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionPeriod over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionThe estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionThe risk-free interest rate assumption that is used in valuing an option on its own shares. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionGross number of share options (or share units) granted during the period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionThe weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionNumber of options outstanding, including both vested and non-vested options. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionWeighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionNumber of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionWeighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionExpected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis=femy_InducementGrantMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 54 R43.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Equity Incentive Plans and Warrants, Share-Based Compensation Expense (Details) - USD ($) 3 Months Ended 6 Months Ended Jun. 30, 2024 Jun. 30, 2023 Jun. 30, 2024 Jun. 30, 2023 Share-based Compensation Expense [Abstract] Â Â Â Â Share-based compensation expense $ 104,013 $ 65,216 $ 181,598 $ 122,170 Share-based compensation expense expected to be recognized for employees and nonemployees 1,516,737 Â 1,516,737 Â Compensation expense to be recognized upon achieving certain performance condition Â Â 155,222 Â Unrecognized expenses 1,361,515 Â $ 1,361,515 Â Weighted-average period over which unrecognized compensation is expected to be

recognized Â Â 3 years 3 months 18 days Â Research and Development [Member] Â Â Â Â Share-based Compensation Expense [Abstract] Â Â Â Â Share-based compensation expense 34,629 27,192 $ 64,637 52,251 Sales and Marketing [Member] Â Â Â Â Share-based Compensation Expense [Abstract] Â Â Â Â Share-based compensation expense 18,246 602 24,764 (1,942) General and Administrative [Member] Â Â Â Â Share-based Compensation Expense [Abstract] Â Â Â Â Share-based compensation expense $ 51,138 $ 37,422 $ 92,197 $ 71,861 X - DefinitionAmount of expense for award under share-based payment arrangement to be recognized upon achieving certain performance condition. + ReferencesNo definition available. + Details Name: femy_ShareBasedCompensationExpenseToBeRecognizedUponAchievingCertainPerformanceCondition Namespace Prefix: femy_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: femy_StockBasedCompensationExpenseAbstract Namespace Prefix: femy_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of expense for award under share-based payment arrangement. Excludes amount capitalized. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 14.F) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_AllocatedShareBasedCompensationExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cost not yet recognized for nonvested award under share-based payment arrangement. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionWeighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionAmount of cost to be recognized for option under share-based payment arrangement. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - Details Name: us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_IncomeStatementLocationAxis=us-gaap_SellingAndMarketingExpenseMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 55 R44.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Equity Incentive Plans and Warrants, Employee Stock Purchase Plan (Details) - USD ($) 3 Months Ended 6 Months Ended Jun. 30, 2024 Jun. 30, 2023 Jun. 30, 2024 Jun. 30, 2023 Employee Stock Purchase Plan [Abstract] Â Â Â Â Stock issued, fair value $ 10,390 $ 1,697 $ 10,390 $ 1,697 Employee Stock Purchase Plan [Member] Â Â Â Â Employee Stock Purchase Plan [Abstract] Â Â Â Â Stock issued (in shares) Â Â 12,081 3,858 Stock issued, fair value Â Â $ 10,390 $ 1,697 Common stock reserved for issuance (in shares) 591,437 Â 591,437 Â X - ReferencesNo definition available. + Details Name: femy_EmployeeStockPurchasePlanAbstract Namespace Prefix: femy_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAggregate number of common shares reserved for future issuance. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockCapitalSharesReservedForFutureIssuance Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of shares issued during the period as a result of an employee stock purchase plan. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionAggregate change in value for stock issued during the period as a result of employee stock purchase plan. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Details Name: us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis=femy_EmployeeStockPurchasePlanMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 56 R45.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Equity Incentive Plans and Warrants, April 2023 Financing (Details) - USD ($) 1 Months Ended 6 Months Ended Apr. 20, 2023 Oct. 31, 2023 Sep. 30, 2023 Apr. 30, 2023 Jun. 30, 2024 Jun. 30, 2023 Warrants [Abstract] Â Â Â Â Â Â Issuance and sale of common stock (in shares) 1,318,000 Â Â Â Â Â Gross proceeds from offering $ 3,899,813 Â Â $ 3,899,813 Â Â Transaction costs 547,764 Â Â Â $ 0 $ 547,764 Common stock value 1,133,480 Â Â Â Â Â Estimated Fair Value Assumptions [Abstract] Â Â Â Â Â Â Net proceeds from issuance of common stock and warrants $ 3,352,049 Â Â Â Â Â Pre-funded Warrants [Member] Â Â Â Â Â Â Warrants [Abstract] Â Â Â Â Â Â Warrants issued to purchase common stock (in shares) 1,878,722 Â Â Â Â Â Warrants exercise price (In dollars per share) $ 0.0001 Â Â Â Â Â Common stock value $ 1,615,701 Â Â Â Â Â Estimated Fair Value Assumptions [Abstract] Â Â Â Â Â Â Expected term (in years) 4 years Â Â Â Â Â Risk free interest rate 3.83% Â Â Â Â Â Dividend yield 0.00% Â Â Â Â Â Expected volatility 100.25% Â Â Â Â Â Exercise price (in dollars per share) $ 0.0001 Â Â Â Â Â Stock price (in dollars per share) 0.86 Â Â Â Â Â Black-Scholes value (in dollars per share) $ 0.86 Â Â Â Â Â Common Warrants [Member] Â Â Â Â Â Â Warrants [Abstract] Â Â Â Â Â Â Warrants issued to purchase common stock (in shares) 3,196,722 Â Â Â Â Â Warrants term Â Â Â Â 5 years 6 months Â Warrants exercise price (In dollars per share) $ 1.095 Â Â Â Â Â Common stock value $ 1,854,099 Â Â Â Â Â Estimated Fair Value Assumptions [Abstract] Â Â Â Â Â Â Expected term (in years) 4 years Â Â Â Â Â Risk free interest rate 3.83% Â Â Â Â Â Dividend yield 0.00% Â Â Â Â Â Expected volatility 100.25% Â Â Â Â Â Exercise price (in dollars per share) $ 1.095 Â Â Â Â Â Stock price (in dollars per share) 0.86 Â Â Â Â Â Black-Scholes value (in dollars per share) $ 0.58 Â Â Â Â Â Placement Agent Warrants [Member] Â Â Â Â Â Â Warrants [Abstract] Â Â Â Â Â Â Warrants issued to purchase common stock (in shares) 191,803 Â Â Â Â Â Warrants term Â Â Â Â 5 years Â Warrants exercise price (In dollars per share) $ 1.525 Â Â Â Â Â Estimated Fair Value Assumptions [Abstract] Â Â Â Â Â Â Warrants exercised (in shares) Â 122,994 122,994 Â Â Â Cash proceeds from warrants exercised Â $ 3,687,976 $ 3,687,976 Â Â Â Warrants outstanding (in shares) Â Â Â Â 68,809 Â X - DefinitionNumber of warrants exercised during the period. + ReferencesNo definition available. + Details Name: femy_NumberOfWarrantsExercised Namespace Prefix: femy_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionThe cash outflow for cost incurred directly with the issuance of an equity security. + ReferencesNo definition available. + Details Name: femy_PaymentsOfEquityIssuanceCosts Namespace Prefix: femy_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash inflow associated with the amount received from holders exercising their common stock warrants. + ReferencesNo definition available. + Details Name: femy_ProceedsFromExerciseOfCommonStockWarrants Namespace Prefix: femy_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionPrice of a single share of a number of saleable stocks of a company under Black-Scholes assumptions. + ReferencesNo definition available. + Details Name: femy_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsBlackScholesValue Namespace Prefix: femy_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - ReferencesNo definition available. + Details Name: femy_WarrantsAbstract Namespace Prefix: femy_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionExercise price per share or per unit of warrants or rights outstanding. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3 + Details Name: us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionNumber of securities into which the class of warrant or right may be converted. For example, but

not limited to, 500,000 warrants may be converted into 1,000,000 shares. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3 + Details Name: us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of warrants or rights outstanding. + ReferencesNo definition available. + Details Name: us-gaap_ClassOfWarrantOrRightOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionThe cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3 + Details Name: us-gaap_ProceedsFromIssuanceOrSaleOfEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionCash received on stock transaction after deduction of issuance costs. + ReferencesNo definition available. + Details Name: us-gaap_SaleOfStockConsiderationReceivedOnTransaction Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAgreed-upon price for the exchange of the underlying asset relating to the share-based payment award. + ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionThe estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionThe risk-free interest rate assumption that is used in valuing an option on its own shares. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionPrice of a single share of a number of saleable stocks of a company. + ReferencesNo definition available. + Details Name: us-gaap_SharePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionExpected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionNumber of new stock issued during the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionEquity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodValueNewIssues Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionPeriod between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_WarrantsAndRightsOutstandingTerm Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: instant X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=femy_PreFundedWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=femy_CommonWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=femy_PlacementAgentWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 57 R46.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Related-Party Transactions (Details) $ in Millions 1 Months Ended Nov. 30, 2023 USD ($) Related-Party Transactions [Abstract] Â Related-party transaction $ 5 X - DefinitionAmount of transactions with related party during the financial reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 850 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 850 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483326/850-10-50-3 + Details Name: us-gaap_RelatedPartyTransactionAmountsOfTransaction Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_RelatedPartyTransactionsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML

58 R47.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Net Loss per Share Attributable to Common Stockholders (Details) - USD ($) 3 Months Ended 6 Months Ended Jun. 30, 2024 Jun. 30, 2023 Jun. 30, 2024 Jun. 30, 2023 Net Income (Loss) Available to Common Stockholders, Basic [Abstract] Â Â Â Â Net loss attributable to common stockholders, basic $ (4,684,574) $ (2,893,508) $ (8,284,084) $ (5,839,765) Net loss attributable to common stockholders, diluted $ (4,684,574) $ (2,893,508) $ (8,284,084) $ (5,839,765) Weighted average number of shares used in computing net loss per share attributable to common stockholders, basic (in shares) 22,215,516 13,107,590 21,995,436 12,493,334 Weighted average number of shares used in computing net loss per share attributable to common stockholders, diluted (in shares) 22,215,516 13,107,590 21,995,436 12,493,334 Net loss per share attributable to common stockholders, basic (in dollars per share) $ (0.21) $ (0.22) $ (0.38) $ (0.47) Net loss per share attributable to common stockholders, diluted (in dollars per share) $ (0.21) $ (0.22) $ (0.38) $ (0.47) Weighted Average Number of Shares Outstanding [Abstract] Â Â Â Â Options to purchase common stock (in shares) 3,171,139 1,169,671 3,171,139 1,169,671 Warrants to purchase common stock (in shares) 196,816 233,460 196,816 233,460 Total potential shares (in shares) 15,046,930 4,791,656 15,046,930 4,791,656 April 2023 Financing [Member] Â Â Â Â Weighted Average Number of Shares Outstanding [Abstract] Â Â Â Â Warrants to purchase common stock in connection financing (in shares) 68,809 3,388,525 68,809 3,388,525 November 2023 Financing [Member] Â Â Â Â Weighted Average Number of Shares Outstanding [Abstract] Â Â Â Â Warrants to purchase common stock in connection financing (in shares) 11,610,166 0 11,610,166 0 X - DefinitionAdditional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of pre-funded warrants, common warrants and placement agent warrants using the treasury stock method. + ReferencesNo definition available. + Details Name: femy_IncrementalCommonSharesAttributableToDilutiveEffectOfPreFundedWarrantsCommonWarrantsAndPlacementAgentWarrants Namespace Prefix: femy_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionThe amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7 + Details Name: us-gaap_EarningsPerShareBasic Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionThe amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7 + Details Name: us-gaap_EarningsPerShareDiluted Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionAdditional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of call options and warrants using the treasury stock method. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -

Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-22Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 23 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-23Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 26 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-26 + Details Name: us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionAdditional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480454/718-10-45-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-22Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 23 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-23Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-28A + Details Name: us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionAmount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 5 -Subparagraph (SAB Topic 6.B) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-5Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B + Details Name: us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 5 -Subparagraph (SAB Topic 6.B) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-5Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 16 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 40 -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-40Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 40 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-40Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 40 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-40Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 40 -Subparagraph (b)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-40 + Details Name: us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1 + Details Name: us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionThe average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 16 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16 + Details Name: us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10 + Details Name: us-gaap_WeightedAverageNumberOfSharesOutstandingBasic Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=femy_WarrantsSixMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=femy_WarrantsSevenMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 59 R48.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Income Taxes (Details) 3 Months Ended 6 Months Ended Jun. 30, 2024 Jun. 30, 2023 Jun. 30, 2024 Jun. 30, 2023 Effective Income Tax Rate Reconciliation, Percent [Abstract] Â Â Â Â Effective tax rate 0.00% 0.00% 0.00% 0.00% X - DefinitionPercentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 231 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231 + Details Name: us-gaap_EffectiveIncomeTaxRateContinuingOperations Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration EXCEL 60 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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

;'EDD81_OTV23;J;/ 0LZ?O.14?GZ#AY\^XN8NB&B)3R M> +]O6N[!3+ MUES@6QHO(];JM-O=5H1I;*$81V1@?5XL:$#05%%:;U\@M.4?,_@5RU2-9:,!M$U=!)KF(M/+Y;,7\VMX^9< I.ATR@6XP&U@@?\YOI^1.6HCA5,+$P&IG/U9K MQ]'22(""R7V4!;I)]J/3%0@R#3LZG5C.=GSVQ.V?
C,K:=#1M&N#C\7@XMLO2 MBW A(5M>5 TR M6'!VULS2 Y9>*?IUE!K9';O=05SP6.XYB1'^QL4$UFG2&98T1G*=D 4. #?$ MT4Q0?
*]!MHK@PI+27)#6SRFU4!H(FLB!J4>"(<7K;YH] M5Z%82=J$^!!&&N*<<^9ST6S[!Z5&T?95O-RCEU@5 9<8WS2J-2S%UGB5P/&M MG#P=$Q+-E
L&08:7)"82J3E^34@3_BNEVOZKR2.FJW"$2M"/F(9 M-AIRM1:!MG&IA&!:$L;1>$[2M!'\6:PUDSY@R.S-D77.UI$.$9)>-T(^8LZ+
MD!&_'H8X2IKMHG%8!/V>7L-)P>B"RV;]N'Z&U3-L+([W1]072N0/)J<_Z3(T M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-*K^(+
M.7\N?<^E[[GT/:'2MSAD6R4)RU3393>* M$IY"&V[I4_5*E=?EK[DHN#Q;Y.FOH70^+,_Y/%_GM,T+,T.WF)&Y M"M-
2D&_#^>G%>!KB.=D$N7V85VWGV-'1^^?!4;"C[SR6'<>(\J(A[J&&F,_# M0X=Y>U^89Y7&4#04;6RL)"Q&MV"XU_$L%.!D8"V@!X.O40+R4E5@,5O&
RN0 MHGQ,C$7H<.>77%_CT9+CVZ9EM6ZO*7<9;2)2.<)IF!-GJ\K>9;'!51W/55OR
ML+YJ/;053L_^6:W(GPP13A8+$DACE!>F2J+S&5.^YRM)Q%4XOT4SMA*7&+SC MYL=Q3E.X$G:V#P(RN;LYJ7IE,6>F\M\M#
DL6XA9$N)-7>W5YYNTB42%(JP# 4A M%W+C[^^3:G>,U_HL@6V$5#)DU1?*0XG!/3-R0]A4)?.NVB8+A=OB5,V[&KXF M8$O#>FZ=+2?
VU[4/;07/4;SHYG@'K.' MYA,L0Z1^P7V*BH 1JV*^NJ]/^26<.[1[\8$@F_S6VZ3VW> ,?-2K6J5D*Q$ M2P=\'Y(&8XQ;]#1?
CQ1BK::QK<;:,0QY@%CS#*%F.-^'19H:,]6+K#F-"F]! MU4#E/]O4#6CV#30,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04 M" "P10A9;S87X_X% "B(&
'AL+W=O([AR1=NC9-XVR[;KOFVUTO]A8AY M>BJ7(H%?9E+%7,.FFO?2I1(\R(OBJ,Y^)07F2\MELW 87'<>T2$3"UR:"PY^5\$04F21H MQ]=M:*
<\IBG<_[Q+O\GA >:)I*3T5]AH!<7G3<=$H@9SR+](->_B2W0P.3Y M,DKS?\FZV+??[Q _2[6,M\70@CA,BK_\97LB]@I<6E/ M@7L50&M.X*[+7!S
MT*)E.=85UWQ\KN2:*+,WI)D/^;G)JX$F3$PW3K6"7T.HT^,KZ6?0*YKP)"#7 MB0[UAMPFQ? PI[E+T@57(CWO:3B:J>GYV^3+(IG5))^1CS+1BQ12
Q%\6]^# M5I9-9;NF7C(T\'V6G!+7.2',87U+>SR\?)+-3XDSM)5_TQRW/'-NGN?6Y'ER M)13Y9_*4:@6#\5_;&2H2^O8$L;0-?6A\V>%9=)Z)5#?
FH4SU;G?]%N!VUM8P' MXCXS&R)>U)1QSQ_HD4\&Q4'NAK'!XB./0;M_IC^R]B-8V!:Q: T$WYBUC MDX)#^J=6SC8LAE8:0W$1V7)Z,&
57)"WH*8OY'>QL9+B40[TI^N.'&=@Y6Q# M;6CE-A27D]+D?:G@6LQ=_H1,-3P_B%3$DQF< #@/,K!W,IY^=6U%;D-\:&4^ M%/>5+?(C?R&W ?1O.
O]XAT&N6+Q2$J[[I"Z_='(RMN&"=%*A2AN,%>21! M>GJR^T ^P'[D4V+O5SS2'0T<\EXNDI1X2HAG,TZL]W$/#VK*7ND1Q8T&97]< M2RL['CG-
0K@VJ.-8<=OP)%J)$L7MYC6N9[;@,GZ4Z\2*BL=-LS5/A/TYVX8P ML4J8&&XXKT'+&]:]DJLP\:V#^D#FNXEUKJ -:V*5-3%<=%Z#WLM4P_/H[W!9
M>T\^D.@Z=;,B;:@3J]2)X=:3C]6)$KP># \8#JV7)%[5%*L2)H9[S@>9"_U" M)I@1'@@9.$['7'5$[7QNBQ"I18KC=/(8:7%?."&4_/_U"IL+/%/2D%1)/\F0<
MPT,XU=)_/B$_.J?@360)KWHK'MEG&/# INB5.S'<;N!%)@B3.9ENXB<968GQ M@)OKCU^L7&T(JLB>$VL^M#U*\AN9="
<\1^ROW@<0OUIEO#Z]JREGI#SM*?VX3+52Q#F)FAO@.W,J) M)]9QMN$]K/(>=I3WF-
=N>&R"G;NH6+VN*5TF/>Y3T7,="SHV:+KE_TYL6+NSPJ)I]5"MB% [M[JUU$S1M.%@+&* M=2$>4SOCA]F(DP4K\G?1E>QZ*M$&>
M9A;E5V/&F,N&9E)BM<_8VUL%-I=8OCB>$M_,]10+PN6WY0+\)%]V[E6[%ZOW
M'[FY0E,2B1F4.J=#.+PJ%L2+#2V7^9KRD]1:QOG'A>"!4&8'^'TFI=YMF .4 M_RUA_!]02P,$% @ L$4(6?9#HGG@!P RB(!@
!X;"]W;W)KW9G.E&UODEHU0=V4I33/[U6AGZX7=/'UP>_YP]ZZ!^O-U4$^J#ME_SC< M&KAG[QL\U)5=:ZKP*C=]>(=?
7LCN&O06OP_5T_UV77@0KG7^K.[^;B]7A"' M2!4JL\Z%A'^/ZD85A?,$./XZ.EV M)(M@JW:R*>SO^ND_ZAA0Z/QENJC;O\'3T98L@JRIK2Z/C0%!F5?=?
_GEV!%G M#:B8:<".#=BE#?BQ0=MSZPY9&]8':>7FRNBGP#AK\.8NVKYI6T,T>>6&\#H' G?@5M+;^B S=;V I5(K\Z@6FW]]1R/R$Q;=*SD;Q,I/L7*?
M]\V-K/>1K+9!YB[47TW^* L(OL:B[EQ%K2NWW!\WE(U"Z*8DH3'%]TPA=Y\=T:=9#Y MMAUW;??* '&<3WD,<33MJ#2.W'H;)Z:16F8Q"D..#X!CKV
_Z>M+"X &4^[M-4PYC7@T@CDU9)S&<7HV .@R0EHXJ6.6P-Z:>QSV[5N-1U P>PRD#;(=&U1
M+DE>DTM>R=D@^/04?.H=I4*Y'&OBVV0EP>C'U4Y1R3I=)P898+&HV%ZV6X ME))>Q(@7ZG]WNQRDZS1"J&:1R;>+F),QU[UH-
H1XIK/4"_'GQE2Y;8QJY](N M_^*NT=X\.AH@8&G*QVL3LZ."$SX#M==+ZI6HS:\RV\,C,YKV*%8V77EA"C]B M#!8SA,4_3]"9D&YG3=D4 MTD*FN%7 -
EDN78^CF*H92A"P=@,ZEX3J5\4?X,2Z(#V-@IY M*G24@1R&DVY&#.&'\!E)I+TFTMBK-9]T];"RRI2^1)5ZA?5;U>6UO TC[L65 M>N6K$YC
N$)KI7>K!FZZT&?SK*/# 8N0A))P0C>((4\(8^',,/6B2/VJ^+&R MLGK((54]!QOHW6")R%(;F_\]OT2F4B@$GP@F8C:3T;!>*]D+6MEFB,5HMJ%5 MT50*TS
F\5@R$3M*DBA,9JB']:+)_*+9)8H789V*(8@V$V*\@#%#$47)7)' MSLI,OVQV8#T0$0DD+
(Z$&,]>S#*.H9Z8F[ZL5TO&+RJ&BUS>YT5NH0=R^1S"^1PTKY##^*%A$]$7$H'<9PIX8<-)2$<_32JR-++TQB M7B08K\Q^,\&\DK?
AIENOJ=ROJ=BBZ%7+,\'X5#HYB\EX?P,Q"T7*9X:+]_K* M_?H*M=,C),AM-E-IJTX,V24U/^955C3;O'H(C.H2FX,T;DC176&.%*1QF)!)
M6H,9,D@7YO:5>*_!W*_!V#J_;""FDDOCF(ID@AU3<1Z1:*8VY&=;M_Y"=ISL MO+#:.5;+1HQ-% LSY"*E<^D9[W65^W7UB/@%G(BP$JBMR)B5,$-
!.)MC4=XK M*_^LSCX[M.E*F_J$M?NTS2L3UR\+4(19Q]4ILI[J,OPZ!%SJSG%6>;7*Y"$';D4/PI!JFX4<*MUH#!DUY6D"&?4,IXH^=1#^U.'= M8$-
PEV6QZ_2 M/.15'11J!TW)FQBZP70O3G0W5A_:=P_NM;6Z;"_W2@)T9P"?[S1DG<<;]SK# MZ?65S3]02P,$% @ L$4(6>\9^X6] @]0< !@ !X;"]W;W)K5
M>0D5EB->]-WEEQ46.FN6+FR%H +*ZJ8K&WC>V*TP84Z6VK&YR%+>*$H8S 62 M355A\7@)E&^FCN]L!V[(JE1FP,W2&J]@ >I7/1>ZY_8N!:F
2<(9$K"<.E_\ MR2PQ];;@-X&-W&DCD^26\SO3^59,'<\ 85<&0>L+VN8 :7&2&/<=YY./Z41 M[K:W[M$RC0)::8Y8 6QDNBDSD6P%0)BN28GJ)/
MZ#URD2SUJ$Q=I:37/93A,,TE#OO$X4ON>IVK2G\UT@0_0S46:(UI ^B$,%1P M2K&0J ;1+O#IT*-H_1/K;_:&=>:-/,]/W?5NQF-5>_!1#Q^]
1XWJN2"_-7O MK*%O7\E!Y-8UWH'1FUO[>X+]FLH]]+A'C]^ 3J1LCF/'SV&",/:\('A"/5#H M)TDT]J)AZ'$//7X#M-[[I<*L(&QUC'P\0!Z$07)Q\81\H- ?QTEX?
N!-27KR MY$7RG_HDDXUXW++G71*+?(P^>0;E^TE@-IP]]J-E+;F[LRF;_$'%BO")**P MU$)OE&@'T1XR;4?QVN[3MUSI7=\V2WTN@S
%^OZ2<[7MF*V_/^FS?U!+ P04 M " "P10A94+\0XID& ?'P & 'AL+W=OD4?BY8,N[LNU4L9[S-
\O!JMC=EJ'JQ$9'2Z\3^[6IKHPGEQNXCMUH\R'S;L"OHW;+,LD M4WF9Z-PKU.IJ](I+Z]&?C4CE:J%J5+$ M\&^GIBI-JTPPC[^;I-
VS"KP^/,A^X\U>2!S&Y=JJM./R=*LKT;AR%NJ5;Q- MS7O]\+-J"-437.BTK/]Z#PW6'WF+;6ETU@3##+(DW_^/'QLAC@(@#QY FP!J M!_"> -8$L.>.P)L
MP1@B:@IC[>2 M5XUR8PKX-8$X,YGJ? EE5TOOQL1&00N8TM,K;ZHS:+QUU1$[Y?VJR](\S[< MS+P7WWY.38PX#5^5A/OD]6_L]7 MMZ4IX)
[^"RO]/CG'DU<+W46YB1?J:@1I2U7LU&CRW3=$^#]@NI\RV>R4R>8G M2O:D0KRM$!_*/KF)4U5BVN_#1!U6[0F[":6$A]!4NV-571BC?D LV,R%\8@*
M:L'F+DP0SJ.PA3WA&+0<@T&.4UV:JO_*BJOW0CTNTNTRR>]@V0=%%TE<;RSJ M<5,M5^@:M,\?',U+,D(#2PL718C/161I@< $$8&TM'!AE
1!&.%:B%8+,7A' MOMVH O@"^89O>8$1%J>\\TZ9;';*9/,3)7M2"=E60@YVY7O(&!>+M1?G2^C$
M'3BK3;548N60;LM$,@BEW8$(+J"22&JUH(MCD@OA"ZL'$9PON" $;*PI1Y^ M>M&I>8.%O%=5.V*L0V=T($TBWR+MP@@-P\B^[3"8#
(2T[SL7QR2348!3CEK* MT2#EGU0.-UY:DXZ78+>2:M^KK"S&/,*6"!(2:ZY3!,<"(9B%F[DX1@@7E%C< M71P5T#Z2X^2)WWE!?Y#^['BEK37(=&&2?
^L+J.OSG:D(*6AH"8# "&/4*3Z* M"\/ ;G@$1T%/T5-][G#D#+B7$;.YH\@@TA*:($> 3HK3(:]\%NS5H67Y N=JI")Q6 M1&!^&%)J-R(R+(LD[]EY2>>%R;
9;BDW'8AR=KWG&:R6C#BW((D46AS1E 2 M7+UP[CXL72C]'LZ=YR6#1NZP^*(WX$LO5ZCG:G(^75Y\3B2S17"!G/+ ?@3" M\C$.#PCV)HP
"9.A["M]9SC)L..LE^!;M=*%.LA@XL>>/=ORG@IU!PEZ%J]JKX\D$Y]$61/?1$DU!?6 M-Z>^"'*POK1SFG38:1Y(>[$Q17*[-?%M"N76'I0]
_-9&KVX7^MTJ8KR9?4F M.%E@^E#7"/;H@R%Q?3 DK@^&'-:G,Z)TV(A^GC[+)-T:]+WJ=3..>(9""+)' M(039HQ^'':HY'DWE*G:5P<)4!?*C73"(\I M^.?
V,]FT!V8;"QQFVY0Y#N.R1[3.W=)!I_;%HC4-]CFRL>?)AL,[_K^]Q M P\IC+S.[5$8>3_OR<64(-=GY&*^/ZOMTN^/CM_$Q5V2EUZJ5C"4?RYANL7^-
';_Q>A- M?=QXJXW16?UQK6(H0P6 WU=:F\.7:H#V3'SR'U!+ P04 " "P10A9$6P- MOFT- #;?@ & 'AL+W=O9Z?>C< R/1L2:2Z))TG/[[V5%$(E
M(*I[2?,02_:'#^3N @*_74 W3TW[OKNOZS[ZN-WLNI=7]WW_\.WU=;>\K[=5 M]Z)YJ'?J+W=-NZUZ];9]=]T]M'6UVC?:;JYI'(OK;;7>7=W>['_WNKV]:1[[
MS7I7OVZC[G&[K=K?7]6;YNGE%;GZ](N?UN_N^^$7U[U]=W+J^_(MU+D0X,]XC_K^JD[>1T-M_*V:=X/;WY8O;R* MARNJ-_6R'R@J]>-
#/:\WFX%)7<=O!]*K8Y]#P]/7G]C+_N;[:&QNH+=P_NM>O?\L_IX,,1) TI'&M!# VHU8&2D 3LT8%8#DHTT2 X-$KL',=* 'QIP^Q[R
MD0;BT$#8E\1&&J2'!NG>6<_6W;MF4?75[4W;/$7M@%9LPXN]?_>ME4?6NR$4 MW_2M^NM:M>MOY\UNI0*K7D5O^JJO59#U7=3A?-JX=U
MK]Y[2,L Z7+YN'W<*(^LHD5]MUZN>Q^;#%BM45=C-KM6<7(,%GH,%KKG249X M7E6;:K>LHZI7%[5\$3'R341C2J%P>&82>Z9A/OQP2TB>I3?7'TZ]
[>UOF(:_ M[1ZJ9?WR2LVS7=U^J*]N__87(N)_0*YVN^0BS5-J]ED 5Q9G&4]CP4UDZ2)G
M>4)8PF,+*0%.3A/*27X$&A9G1XNSLRS^E8JJ[KY21OCZ+.L_LW++^B*GM@.\ MW4]U "99@4E68I)))#(C())C0"3>@#A.@-TP\WT3+9_GP0_5YO&\
<>FEGVB) M>>(.$!&K?V:0+3#[+##)2DPRB41FQ 4_Q@6_)"Z>YXS)TX>WKZE!PH&Y**64 M64&"V6>!259BDDDD,B-(Q#%(Q)Z=C03)#
[OE$";JXT1%P/[5U]%Z!Z_U?OVI MV6PBM=Q_JMH5M.9X)3"#!)-L@4E68)*5F&02BO<&;+6^F#N(NQ!G8=&
M8>$B&'.>^H(T$J3)X)%,8JW$Q%_&WJ$!?+@N8S94SXJ6_0&4[0#_#4X=E:AL M)2J;Q&(S0^5$M"-HH5*\>?T:]#H)#CD XKBZ7:Z[M?
02H#F9WC[M5K==/H).9NQ#-4F?.=%&.DUVI;J:>CP5GS!Y'D*B7)EE"[:'D M IVA!'!E8Y]@6ILB?G$J8,?@P$F BTJSE%+;K"[0,2NJYH3*5J*R22PVT^=:
M=R)^X>G-X,_9D U<#;/G0[WKJOU\67\<7M>@HWEH6,S#D 5QA27GHP?0GB@E M:6R/F""5#%.9!M2:#/$^I]_^2RW9-DT'SS(B=%WS,&01AA1A2 E
9CQC>6HO MH.4Y2--86G4@?MDA)'__\W'W(F+Q7MEDH$6]_%-5*^(J#: CMIK@'.-.Y"9WF>IPFU/Q4E MQ$JS5)"4P?,XU5H']6L=
(WGMH!NH*T+LW\XAYK2(:]X H90ZU)GN;.D,2M]D%5 M1U#92E0VB<5F!H961ZA?'0FMN<,1@EE],Z>NI@*NN5%[+5#92E0VB<5FQH=6 M?
>A%)4GPFCL<+*@%2A20E* U-VJO!2I;BIE<#4* 3+40"< M_6P'0+P%*51+=/3+5P:%,@G4+;>!:U+\]SJYR*/*?*AL)2J;Q&(S8TS+?/3" MLJ<)^>]#%[[\-
P!QQJXKZMG:.@ !\M]A(@D3C>2_J9;!*%Z=SSGY;PJ4Q[CY M;P#EV!933"M0V4I4-HG%9NXQT6H<\ZMQ%^2_#XR!_#> LIW,7$5O)/\-(.'\ M-
P"TAQ+$-9;_9EJ\8G[QZ@_FOQD@[H#Y;P#HF!53]"I0V4I4-HG%9OIV$2ABQ8L(*H """4R+L 1-DDD$FTWPG^]O\XI(O^\V"=2SS M,&01AA1A2 E
9C3+&8\SVU)G($UC::6%7:2TG)_]]O-/?5X^L 65.-1>"U2V M$I5-8K&9\:'%%8:X"2P<+*CB"CMS&QAJKP4J6XG*)K'8SL@GSRR93LM\, MD#J
[+>_Q\F[B5V) LY^0\"1[#< '[#?3$@GS2R279K\9(&O V6__ M!4SV!*JN@@%@>ALA6H;"4JFSS'PN9A"EKY2/S*QY3C%$#O^_DGGZ?@
MZB7P@0JHY4BH;"4JFPQ;Q/2\UFH2OU9S\8$)@$L^YGCLJV0&4K4-E*5#:)Q6:&E):T$K^D]5GW32=N M-107=AX+ #F?*&&5#
(#DF7H@L_=/AZDD<$%#Q6 RHI E)Z2?V:,OO)4-9LK'EE1:44HN+,2Y,)&<0 I,G!';O.$=< 5+F,HT
MH!9O$K]XXTLC)L%*DWD8L@A#BC"D!""SC&9);&*D><@S9,"M>C!_YCH<:I# M)Y!%_?R3SP<\4_1 [;5 92M1V638(J;GM>C!$46/^R%VJL/\%S#9
M%:C;J%#92E0V>8Z%3:=K68+[98F17:VPH]VJ&CH<-&)[&?>)?,%=68(*1C*6 MV0/.!1*:Y'DBG"=1 *H&',DS0IB=UP-NFG 1ISP?6^V<'(SL?\H_8U\K[?W
M*7GP@YHNG+D/==\0*EN!RE:BLDDL-C,PM%S!_7+%E'VM<(2@GH#,W1H;>!F, MJF6@LI6H;!*+S8P/K67PB\X:"N]KA8,%]> A#N@9X&
(9M7('E:U$99-8;&:P M: 6'9Y\QC\A1#QY"95N@LA6H;"4JF\1B,T-*:UK\3W3^,@?.-Z*VT@Z G$^G ML$P&0"BAIQO9#LX,'\0,4V5D1$\46B(3?]*SF
6P,8D2EMJN '"V*_RW.'6@ MHK*5J&P2B\T,%JVJB?__:UA@:5K41EDUAL9@AHE4R$3F0^,X\H@J4M\S!D(:] M6XS8)U@5 Z
E0#,&3L^B&DTX3()O\IT2191!.M1YF'((@PI B)D]B67LLP ME0Q3F0;44I'P2T6^+*((UE7,PY!%&%*$(24 F24B2WAJ9Q'/09K&.ODNJ3\F
MGP05;3__U(<<<:9\@MIK@,7J>)HG[])_?E-WSSLO\C[;=/WS7;_\KZN5G4[-3?[YJF__1F M^&[PX_?9W_X/4$L#!!0 (+!%"%E_P<8C,P@ *&PO=V]R M:W-
H965T&ULM5II<^.X$?TK+&4KE51%(^+@Y=BNLCTSM9/: MG76-=[.?81*2D*$(+0CYR*]/@Y1%B3@DI[1?;(IJ-%\?Z-<-\?)9JN_MDG,=
MO:SJIKV:++5>7\QF;;GD*]9^D&O>P#=SJ59,PT>UF+5KQ5G5+5K5,QS'Z6S% M1#.YONSNW:OK2[G1M6CXO8K:S6K%U.LMK^7SU01-WFY\$XNE-
C=FUY=KMN / M7/^VOE?P:;;34HD5;UHAFTCQ^=7D!EWI?QN/GRI MKB:Q0<1K7FJC@L&_)W['ZIH AQ_;)5.=L\T"_>OW[1_[HP'8QY9R^]D_;NH
M]/)JDD^BBL_9IM;?Y/./?&M08O25LFZ[O]'S5C:>1.6FU7*U70P(5J+I_[.7 MK2/V%H >]P*\78#'"ZAG =DN()VA/;+.K(],L^M+)9\C9:1!F[GH?-.M!FM$

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

M69MI!D_L_P - \ !D ("!L.0 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ L$4(69\-9_DP"0 -F M !D ("!= $ 'AL+W=O^@ M>&PO=V]R:W-H965T&UL4$L! A0#% @ L$4(6:.UC[5Y @ KP< !D M ("!J (! 'AL+W=O&PO&PO7W)E;',O=V]R:V)O M;VLN>&UL+G)E;'-02P$"% ,4 " "P10A9C$_JC[H! #N' $P M @ 'Q#P$ 6T-O;G1E;G1?5'EP97-=+GAM;%!+!08 . X #\/ (#<0 ! end XML 61 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show= {};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p ;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 62 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ .report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } .report table.authRefData a { display: block; font-weight: bold; } .report table.authRefData p { margin-top: 0px; } .report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } .report table.authRefData .hide a:hover { background-color: #2F4497; } .report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } .report table.authRefData table{ font-size: 1em; } /* Report Styles */ .pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ .report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } .report hr { border: 1px solid #acf; } /* Top labels */ .report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } .report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } .report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } .report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } .report td.pl div.a { width: 200px; } .report td.pl a:hover { background-color: #ffc; } /* Header rows... */ .report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ .report .rc { background-color: #f0f0f0; } /* Even rows... */ .report .re, .report .reu { background-color: #def; } .report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ .report .ro, .report .rou { background-color: white; } .report .rou td { border-bottom: 1px solid black; } .report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ .report .fn { white-space: nowrap; } /* styles for numeric types */ .report .num, .report .nump { text-align: right; white-space: nowrap; } .report .nump { padding-left: 2em; } .report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ .report .text { text-align: left; white-space: normal; } .report .text .big { margin-bottom: 1em; width: 17em; } .report .text .more { display: none; } .report .text .note { font-style: italic; font-weight: bold; } .report .text .small { width: 10em; } .report sup { font-style: italic; } .report .outerFootnotes { font-size: 1em; } XML 64 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.2.u1 html 157 260 1 false 33 0 false 7 false false R1.htm 000100 - Document - Document and Entity Information Sheet http://femasys.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 010000 - Statement - Condensed Balance Sheets Sheet http://femasys.com/role/CondensedBalanceSheets Condensed Balance Sheets Statements 2 false false R3.htm 010100 - Statement - Condensed Balance Sheets (Parenthetical) Sheet http://femasys.com/role/CondensedBalanceSheetsParenthetical Condensed Balance Sheets (Parenthetical) Statements 3 false false R4.htm 020000 - Statement - Condensed Statements of Comprehensive Loss Sheet http://femasys.com/role/CondensedStatementsOfComprehensiveLoss Condensed Statements of Comprehensive Loss Statements 4 false false R5.htm 030000 - Statement - Condensed Statements of Stockholders' Equity Sheet http://femasys.com/role/CondensedStatementsOfStockholdersEquity Condensed Statements of Stockholders' Equity Statements 5 false false R6.htm 040000 - Statement - Condensed Statements of Cash Flows Sheet http://femasys.com/role/CondensedStatementsOfCashFlows Condensed Statements of Cash Flows Statements 6 false false R7.htm 060100 - Disclosure - Organization, Nature of Business, and Liquidity Sheet http://femasys.com/role/OrganizationNatureOfBusinessAndLiquidity Organization, Nature of Business, and Liquidity Notes 7 false false R8.htm 060200 - Disclosure - Fair Value Sheet http://femasys.com/role/FairValue Fair Value Notes 8 false false R9.htm 060300 - Disclosure - Cash and Cash Equivalents Sheet http://femasys.com/role/CashAndCashEquivalents Cash and Cash Equivalents Notes 9 false false R10.htm 060400 - Disclosure - Inventories Sheet http://femasys.com/role/Inventories Inventories Notes 10 false false R11.htm 060500 - Disclosure - Accrued Expenses Sheet http://femasys.com/role/AccruedExpenses Accrued Expenses Notes 11 false false R12.htm 060600 - Disclosure - Clinical Holdback Sheet http://femasys.com/role/ClinicalHoldback Clinical Holdback Notes 12 false false R13.htm 060700 - Disclosure - Revenue Recognition Sheet http://femasys.com/role/RevenueRecognition Revenue Recognition Notes 13 false false R14.htm 060800 - Disclosure - Commitments and Contingencies Sheet http://femasys.com/role/CommitmentsAndContingencies Commitments and Contingencies Notes 14 false false R15.htm 060900 - Disclosure - Notes Payable Notes http://femasys.com/role/NotesPayable Notes Payable Notes 15 false false R16.htm 061000 - Disclosure - Convertible Notes with Warrants (November 2023 Financing) Notes http://femasys.com/role/ConvertibleNotesWithWarrantsNovember2023Financing Convertible Notes with Warrants (November 2023 Financing) Notes 16 false false R17.htm 061100 - Disclosure - Stockholders' Equity Sheet http://femasys.com/role/StockholdersEquity Stockholders' Equity Notes 17 false false R18.htm 061200 - Disclosure - Equity Incentive Plans and Warrants Sheet http://femasys.com/role/EquityIncentivePlansAndWarrants Equity Incentive Plans and Warrants Notes 18 false false R19.htm 061300 - Disclosure - Related-Party Transactions Sheet http://femasys.com/role/RelatedpartyTransactions Related-Party Transactions Notes 19 false false R20.htm 061400 - Disclosure - Net Loss per Share Attributable to Common Stockholders Sheet http://femasys.com/role/NetLossPerShareAttributableToCommonStockholders Net Loss per Share Attributable to Common Stockholders Notes 20 false false R21.htm 061500 - Disclosure - Income Taxes Sheet http://femasys.com/role/IncomeTaxes Income Taxes Notes 21 false false R22.htm 061600 - Disclosure - Insider Trading Arrangements Sheet http://femasys.com/role/InsiderTradingArrangements Insider Trading Arrangements Notes 22 false false R23.htm 070100 - Disclosure - Organization, Nature of Business, and Liquidity (Policies) Sheet http://femasys.com/role/OrganizationNatureOfBusinessAndLiquidityPolicies Organization, Nature of Business, and Liquidity (Policies) Policies 23 false false R24.htm 080400 - Disclosure - Inventories (Tables) Sheet http://femasys.com/role/InventoriesTables Inventories (Tables) Tables http://femasys.com/role/Inventories 24 false false R25.htm 080500 - Disclosure - Accrued Expenses (Tables) Sheet http://femasys.com/role/AccruedExpensesTables Accrued Expenses (Tables) Tables http://femasys.com/role/AccruedExpenses 25 false false R26.htm 080600 - Disclosure - Clinical Holdback (Tables) Sheet http://femasys.com/role/ClinicalHoldbackTables Clinical Holdback (Tables) Tables http://femasys.com/role/ClinicalHoldback 26 false false R27.htm 080700 - Disclosure - Revenue Recognition (Tables) Sheet http://femasys.com/role/RevenueRecognitionTables Revenue Recognition (Tables) Tables http://femasys.com/role/RevenueRecognition 27 false false R28.htm 081200 - Disclosure - Equity Incentive Plans and Warrants (Tables) Sheet http://femasys.com/role/EquityIncentivePlansAndWarrantsTables Equity Incentive Plans and Warrants (Tables) Tables http://femasys.com/role/EquityIncentivePlansAndWarrants 28 false false R29.htm 081400 - Disclosure - Net Loss per Share Attributable to Common Stockholders (Tables) Sheet http://femasys.com/role/NetLossPerShareAttributableToCommonStockholdersTables Net Loss per Share Attributable to Common Stockholders (Tables) Tables http://femasys.com/role/NetLossPerShareAttributableToCommonStockholders 29 false false R30.htm 090100 - Disclosure - Organization, Nature of Business, and Liquidity (Details) Sheet http://femasys.com/role/OrganizationNatureOfBusinessAndLiquidityDetails Organization, Nature of Business, and Liquidity (Details) Details http://femasys.com/role/OrganizationNatureOfBusinessAndLiquidityPolicies 30 false false R31.htm 090300 - Disclosure - Cash and Cash Equivalents (Details) Sheet http://femasys.com/role/CashAndCashEquivalentsDetails Cash and Cash Equivalents (Details) Details http://femasys.com/role/CashAndCashEquivalents 31 false false R32.htm 090400 - Disclosure - Inventories (Details) Sheet http://femasys.com/role/InventoriesDetails Inventories (Details) Details http://femasys.com/role/InventoriesTables 32 false false R33.htm 090500 - Disclosure - Accrued Expenses (Details) Sheet http://femasys.com/role/AccruedExpensesDetails Accrued Expenses (Details) Details http://femasys.com/role/AccruedExpensesTables 33 false false R34.htm 090600 - Disclosure - Clinical Holdback (Details) Sheet http://femasys.com/role/ClinicalHoldbackDetails Clinical Holdback (Details) Details http://femasys.com/role/ClinicalHoldbackTables 34 false false R35.htm 090700 - Disclosure - Revenue Recognition (Details) Sheet http://femasys.com/role/RevenueRecognitionDetails Revenue Recognition (Details) Details http://femasys.com/role/RevenueRecognitionTables 35 false false R36.htm 090900 - Disclosure - Notes Payable (Details) Notes http://femasys.com/role/NotesPayableDetails Notes Payable (Details) Details http://femasys.com/role/NotesPayable 36 false false R37.htm 091000 - Disclosure - Convertible Notes with Warrants (November 2023 Financing), Summary (Details) Notes http://femasys.com/role/ConvertibleNotesWithWarrantsNovember2023FinancingSummaryDetails Convertible Notes with Warrants (November 2023 Financing), Summary (Details) Details http://femasys.com/role/ConvertibleNotesWithWarrantsNovember2023Financing 37 false false R38.htm 091002 - Disclosure - Convertible Notes with Warrants (November 2023 Financing), Warrants (Details) Notes http://femasys.com/role/ConvertibleNotesWithWarrantsNovember2023FinancingWarrantsDetails Convertible Notes with Warrants (November 2023 Financing), Warrants (Details) Details http://femasys.com/role/ConvertibleNotesWithWarrantsNovember2023Financing 38 false false R39.htm 091004 - Disclosure - Convertible Notes with Warrants (November 2023 Financing), Convertible Notes Payable (Details) Notes http://femasys.com/role/ConvertibleNotesWithWarrantsNovember2023FinancingConvertibleNotesPayableDetails Convertible Notes with Warrants (November 2023 Financing), Convertible Notes Payable (Details) Details http://femasys.com/role/ConvertibleNotesWithWarrantsNovember2023Financing 39 false false R40.htm 091100 - Disclosure - Stockholders' Equity (Details) Sheet http://femasys.com/role/StockholdersEquityDetails Stockholders' Equity (Details) Details http://femasys.com/role/StockholdersEquity 40 false false R41.htm 091200 - Disclosure - Equity Incentive Plans and Warrants, Stock Option Plan, Activity (Details) Sheet http://femasys.com/role/EquityIncentivePlansAndWarrantsStockOptionPlanActivityDetails Equity Incentive Plans and Warrants, Stock Option Plan, Activity (Details) Details 41 false false R42.htm 091202 - Disclosure - Equity Incentive Plans and Warrants, Inducement Grant (Details) Sheet http://femasys.com/role/EquityIncentivePlansAndWarrantsInducementGrantDetails Equity Incentive Plans and Warrants, Inducement Grant (Details) Details 42 false false R43.htm 091204 - Disclosure - Equity Incentive Plans and Warrants, Share-Based Compensation Expense (Details) Sheet http://femasys.com/role/EquityIncentivePlansAndWarrantsSharebasedCompensationExpenseDetails Equity Incentive Plans and Warrants, Share-Based Compensation Expense (Details) Details 43 false false R44.htm 091206 - Disclosure - Equity Incentive Plans and Warrants, Employee Stock Purchase Plan (Details) Sheet http://femasys.com/role/EquityIncentivePlansAndWarrantsEmployeeStockPurchasePlanDetails Equity Incentive Plans and Warrants, Employee Stock Purchase Plan (Details) Details 44 false false R45.htm 091208 - Disclosure - Equity Incentive Plans and Warrants, April 2023 Financing (Details) Sheet http://femasys.com/role/EquityIncentivePlansAndWarrantsApril2023FinancingDetails Equity Incentive Plans and Warrants, April 2023 Financing (Details) Details 45 false false R46.htm 091300 - Disclosure - Related-Party Transactions (Details) Sheet http://femasys.com/role/RelatedpartyTransactionsDetails Related-Party Transactions (Details) Details http://femasys.com/role/RelatedpartyTransactions 46 false false R47.htm 091400 - Disclosure - Net Loss per Share Attributable to Common Stockholders (Details) Sheet http://femasys.com/role/NetLossPerShareAttributableToCommonStockholdersDetails Net Loss per Share Attributable to Common Stockholders (Details) Details http://femasys.com/role/NetLossPerShareAttributableToCommonStockholdersTables 47 false false R48.htm 091500 - Disclosure - Income Taxes (Details) Sheet http://femasys.com/role/IncomeTaxesDetails Income Taxes (Details) Details http://femasys.com/role/IncomeTaxes 48 false false All Reports Book All Reports ef20029680_10q.htm femy-20240630.xsd femy-20240630_cal.xml femy-20240630_def.xml femy-20240630_lab.xml femy-20240630_pre.xml http://fasb.org/us-gaap/2024 http://xbrl.sec.gov/dei/2024 http://xbrl.sec.gov/ecd/2024 true true JSON 67 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "ef20029680_10q.htm": { "nsprefix": "femy", "nsuri": "http://femasys.com/20240630", "dts": { "inline": { "local": ["ef20029680_10q.htm"] }, "schema": { "local": ["femy-20240630.xsd"], "remote": ["http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2004/ref-2004-08-10.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-

```
12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/2023/calculation-1.1.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd", "https://xbrl.sec.gov/country/2024/country-2024.xsd", "https://xbrl.sec.gov/currency/2024/currency-2024.xsd", "https://xbrl.sec.gov/dei/2024/dei-2024.xsd", "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd", "https://xbrl.sec.gov/exch/2024/exch-2024.xsd", "https://xbrl.sec.gov/naics/2024/naics-2024.xsd", "https://xbrl.sec.gov/sic/2024/sic-2024.xsd", "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd" ] }, "calculationLink": { "local": [ "femy-20240630_cal.xml" ] }, "definitionLink": { "local": [ "femy-20240630_def.xml" ] }, "labelLink": { "local": [ "femy-20240630_lab.xml" ] }, "presentationLink": { "local": [ "femy-20240630_pre.xml" ] } }, "keyStandard": 210, "keyCustom": 50, "axisStandard": 15, "axisCustom": 0, "memberStandard": 16, "memberCustom": 17, "hidden": { "total": 10, "http://xbrl.sec.gov/dei/2024": 6, "http://fasb.org/us-gaap/2024": 4 }, "contextCount": 157, "entityCount": 1, "segmentCount": 33, "elementCount": 404, "unitCount": 7, "baseTaxonomies": { "http://fasb.org/us-gaap/2024": 609, "http://xbrl.sec.gov/dei/2024": 31, "http://xbrl.sec.gov/ecd/2024": 4 }, "report": { "R1": { "role": "http://femasys.com/role/DocumentAndEntityInformation", "longName": "000100 - Document - Document and Entity Information", "shortName": "Document and Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "c20240101to20240630", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ef20029680_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c20240101to20240630", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ef20029680_10q.htm", "first": true, "unique": true } }, "R2": { "role": "http://femasys.com/role/CondensedBalanceSheets", "longName": "010000 - Statement - Condensed Balance Sheets", "shortName": "Condensed Balance Sheets", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "c20240630", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "U002", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "div", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ef20029680_10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "c20240630", "name": "us-gaap:AccountsReceivableNetCurrent", "unitRef": "U002", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "div", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ef20029680_10q.htm", "unique": true } }, "R3": { "role": "http://femasys.com/role/CondensedBalanceSheetsParenthetical", "longName": "010100 - Statement - Condensed Balance Sheets (Parenthetical)", "shortName": "Condensed Balance Sheets (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "c20240630", "name": "us-gaap:CommonStockParOrStatedValuePerShare", "unitRef": "U003", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": [ "us-gaap:CommonStockParOrStatedValuePerShare", "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ef20029680_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c20240630", "name": "us-gaap:CommonStockParOrStatedValuePerShare", "unitRef": "U003", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": [ "us-gaap:CommonStockParOrStatedValuePerShare", "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ef20029680_10q.htm", "first": true, "unique": true } }, "R4": { "role": "http://femasys.com/role/CondensedStatementsOfComprehensiveLoss", "longName": "020000 - Statement - Condensed Statements of Comprehensive Loss", "shortName": "Condensed Statements of Comprehensive Loss", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "c20240401to20240630", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "U002", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "div", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ef20029680_10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "c20240401to20240630", "name": "us-gaap:CostOfGoodsAndServicesSold", "unitRef": "U002", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "div", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ef20029680_10q.htm", "unique": true } }, "R5": { "role": "http://femasys.com/role/CondensedStatementsOfStockholdersEquity", "longName": "030000 - Statement - Condensed Statements of Stockholders' Equity", "shortName": "Condensed Statements of Stockholders' Equity", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "c20221231_StatementEquityComponentsAxis_CommonStockMember", "name": "us-gaap:StockholdersEquity", "unitRef": "U002", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ef20029680_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c20221231_StatementEquityComponentsAxis_CommonStockMember", "name": "us-gaap:StockholdersEquity", "unitRef": "U002", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ef20029680_10q.htm", "first": true, "unique": true } }, "R6": { "role": "http://femasys.com/role/CondensedStatementsOfCashFlows", "longName": "040000 - Statement - Condensed Statements of Cash Flows", "shortName": "Condensed Statements of Cash Flows", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "c20240101to20240630", "name": "us-gaap:NetIncomeLoss", "unitRef": "U002", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "div", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ef20029680_10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "c20240101to20240630", "name": "us-gaap:Depreciation", "unitRef": "U002", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "div", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ef20029680_10q.htm", "unique": true } }, "R7": { "role": "http://femasys.com/role/OrganizationNatureOfBusinessAndLiquidity", "longName": "060100 - Disclosure - Organization, Nature of Business, and Liquidity", "shortName": "Organization, Nature of Business, and Liquidity", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "7", "firstAnchor": { "contextRef": "c20240101to20240630", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ef20029680_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c20240101to20240630", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ef20029680_10q.htm", "first": true, "unique": true } }, "R8": { "role": "http://femasys.com/role/FairValue", "longName": "060200 - Disclosure - Fair Value", "shortName": "Fair Value", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "8", "firstAnchor": { "contextRef": "c20240101to20240630", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ef20029680_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c20240101to20240630", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ef20029680_10q.htm", "first": true, "unique": true } }, "R9": { "role": "http://femasys.com/role/CashAndCashEquivalents", "longName": "060300 - Disclosure - Cash and Cash Equivalents", "shortName": "Cash and Cash Equivalents", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "c20240101to20240630", "name": "us-gaap:CashAndCashEquivalentsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ef20029680_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c20240101to20240630", "name": "us-gaap:CashAndCashEquivalentsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ef20029680_10q.htm", "first": true, "unique": true } }, "R10": { "role": "http://femasys.com/role/Inventories", "longName": "060400 - Disclosure - Inventories", "shortName": "Inventories", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "c20240101to20240630", "name": "us-gaap:InventoryDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ef20029680_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c20240101to20240630", "name": "us-gaap:InventoryDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ef20029680_10q.htm", "first": true, "unique": true } }, "R11": { "role": "http://femasys.com/role/AccruedExpenses", "longName": "060500 - Disclosure - Accrued Expenses", "shortName": "Accrued Expenses", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "c20240101to20240630", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ef20029680_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c20240101to20240630", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ef20029680_10q.htm", "first": true, "unique": true } }, "R12": { "role": "http://femasys.com/role/ClinicalHoldback", "longName": "060600 - Disclosure - Clinical Holdback", "shortName": "Clinical Holdback", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "c20240101to20240630", "name": "femy:ClinicalHoldbackTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ef20029680_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c20240101to20240630", "name": "femy:ClinicalHoldbackTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ef20029680_10q.htm", "first": true, "unique": true } }, "R13": { "role": "http://femasys.com/role/RevenueRecognition", "longName": "060700 - Disclosure - Revenue Recognition", "shortName": "Revenue Recognition", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "c20240101to20240630", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ef20029680_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c20240101to20240630", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ef20029680_10q.htm", "first": true, "unique": true } }, "R14": { "role": "http://femasys.com/role/CommitmentsAndContingencies", "longName": "060800 - Disclosure - Commitments and Contingencies", "shortName": "Commitments and Contingencies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "c20240101to20240630", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ef20029680_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c20240101to20240630", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ef20029680_10q.htm", "first": true, "unique": true } }, "R15": { "role": "http://femasys.com/role/NotesPayable", "longName": "060900 - Disclosure - Notes Payable", "shortName": "Notes Payable", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "c20240101to20240630", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ef20029680_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c20240101to20240630", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ],
```

```
"reportCount": 1, "baseRef": "ef20029680_10q.htm", "first": true, "unique": true } }, "R16": { "role":
"http://femasys.com/role/ConvertibleNotesWithWarrantsNovember2023Financing", "longName": "061000 - Disclosure - Convertible Notes with Warrants (November 2023
Financing)", "shortName": "Convertible Notes with Warrants (November 2023 Financing)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "",
"menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "c20240101to20240630", "name":
"femy:ConvertibleNotesWithWarrantsNovember2023FinancingTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [
"div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ef20029680_10q.htm", "first": true, "unique": true }, "uniqueAnchor": {
"contextRef": "c20240101to20240630", "name": "femy:ConvertibleNotesWithWarrantsNovember2023FinancingTextBlock", "unitRef": null, "xsiNil": "false", "lang":
"en-US", "decimals": null, "ancestors": [ "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ef20029680_10q.htm", "first":
true, "unique": true } }, "R17": { "role": "http://femasys.com/role/StockholdersEquity", "longName": "061100 - Disclosure - Stockholders' Equity",
"shortName": "Stockholders' Equity", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": {
"contextRef": "c20240101to20240630", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US",
"decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ef20029680_10q.htm", "first": true, "unique": true },
"uniqueAnchor": { "contextRef": "c20240101to20240630", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false",
"lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ef20029680_10q.htm", "first": true, "unique":
true } }, "R18": { "role": "http://femasys.com/role/EquityIncentivePlansAndWarrants", "longName": "061200 - Disclosure - Equity Incentive Plans and Warrants",
"shortName": "Equity Incentive Plans and Warrants", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "18",
"firstAnchor": { "contextRef": "c20240101to20240630", "name": "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false",
"lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ef20029680_10q.htm", "first":
true, "unique": true }, "uniqueAnchor": { "contextRef": "c20240101to20240630", "name": "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock", "unitRef":
null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef":
"ef20029680_10q.htm", "first": true, "unique": true } }, "R19": { "role": "http://femasys.com/role/RelatedpartyTransactions", "longName": "061300 - Disclosure
- Related-Party Transactions", "shortName": "Related-Party Transactions", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat":
"Notes", "order": "19", "firstAnchor": { "contextRef": "c20240101to20240630", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "unitRef": null,
"xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ef20029680_10q.htm",
"first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c20240101to20240630", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
"unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef":
"ef20029680_10q.htm", "first": true, "unique": true } }, "R20": { "role": "http://femasys.com/role/NetLossPerShareAttributableToCommonStockholders",
"longName": "061400 - Disclosure - Net Loss per Share Attributable to Common Stockholders", "shortName": "Net Loss per Share Attributable to Common
Stockholders", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "20", "firstAnchor": { "contextRef":
"c20240101to20240630", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [
"div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ef20029680_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef":
"c20240101to20240630", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [
"div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ef20029680_10q.htm", "first": true, "unique": true } }, "R21": { "role":
"http://femasys.com/role/IncomeTaxes", "longName": "061500 - Disclosure - Income Taxes", "shortName": "Income Taxes", "isDefault": "false", "groupType":
"disclosure", "subGroupType": "", "menuCat": "Notes", "order": "21", "firstAnchor": { "contextRef": "c20240101to20240630", "name": "us-
gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "div", "body",
"html" ], "reportCount": 1, "baseRef": "ef20029680_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c20240101to20240630", "name":
"us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "div",
"body", "html" ], "reportCount": 1, "baseRef": "ef20029680_10q.htm", "first": true, "unique": true } }, "R22": { "role":
"http://femasys.com/role/InsiderTradingArrangements", "longName": "061600 - Disclosure - Insider Trading Arrangements", "shortName": "Insider Trading
Arrangements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "22", "firstAnchor": { "contextRef":
"c20240401to20240630", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [
"ecd:NonRule10b51ArrAdoptedFlag", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ef20029680_10q.htm", "first": true, "unique": true },
"uniqueAnchor": { "contextRef": "c20240401to20240630", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals":
null, "ancestors": [ "ecd:NonRule10b51ArrAdoptedFlag", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ef20029680_10q.htm", "first":
true, "unique": true } }, "R23": { "role": "http://femasys.com/role/OrganizationNatureOfBusinessAndLiquidityPolicies", "longName": "070100 - Disclosure -
Organization, Nature of Business, and Liquidity (Policies)", "shortName": "Organization, Nature of Business, and Liquidity (Policies)", "isDefault": "false",
"groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "23", "firstAnchor": { "contextRef": "c20240101to20240630", "name":
"femy:OrganizationAndNatureOfBusinessPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [
"ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ef20029680_10q.htm", "first": true, "unique": true }, "uniqueAnchor": {
"contextRef": "c20240101to20240630", "name": "femy:OrganizationAndNatureOfBusinessPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US",
"decimals": null, "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ef20029680_10q.htm", "first": true,
"unique": true } }, "R24": { "role": "http://femasys.com/role/InventoriesTables", "longName": "080400 - Disclosure - Inventories (Tables)", "shortName":
"Inventories (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "24", "firstAnchor": {
"contextRef": "c20240101to20240630", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US",
"decimals": null, "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ef20029680_10q.htm", "first": true,
"unique": true }, "uniqueAnchor": { "contextRef": "c20240101to20240630", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "unitRef": null,
"xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef":
"ef20029680_10q.htm", "first": true, "unique": true } }, "R25": { "role": "http://femasys.com/role/AccruedExpensesTables", "longName": "080500 - Disclosure -
Accrued Expenses (Tables)", "shortName": "Accrued Expenses (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat":
"Tables", "order": "25", "firstAnchor": { "contextRef": "c20240101to20240630", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "unitRef": null,
"xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ef20029680_10q.htm",
"first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c20240101to20240630", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
"unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef":
"ef20029680_10q.htm", "first": true, "unique": true } }, "R26": { "role": "http://femasys.com/role/ClinicalHoldbackTables", "longName": "080600 - Disclosure -
Clinical Holdback (Tables)", "shortName": "Clinical Holdback (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat":
"Tables", "order": "26", "firstAnchor": { "contextRef": "c20240101to20240630", "name": "femy:ScheduleOfClinicalHoldbackLiabilityAccountTableTextBlock",
"unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef":
"ef20029680_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c20240101to20240630", "name":
"femy:ScheduleOfClinicalHoldbackLiabilityAccountTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div",
"div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ef20029680_10q.htm", "first": true, "unique": true } }, "R27": { "role":
"http://femasys.com/role/RevenueRecognitionTables", "longName": "080700 - Disclosure - Revenue Recognition (Tables)", "shortName": "Revenue Recognition
(Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "27", "firstAnchor": { "contextRef":
"c20240101to20240630", "name": "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US",
"decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ef20029680_10q.htm", "first": true, "unique": true },
"uniqueAnchor": { "contextRef": "c20240101to20240630", "name": "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock", "unitRef": null,
"xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ef20029680_10q.htm",
"first": true, "unique": true } }, "R28": { "role": "http://femasys.com/role/EquityIncentivePlansAndWarrantsTables", "longName": "081200 - Disclosure - Equity
Incentive Plans and Warrants (Tables)", "shortName": "Equity Incentive Plans and Warrants (Tables)", "isDefault": "false", "groupType": "disclosure",
"subGroupType": "tables", "menuCat": "Tables", "order": "28", "firstAnchor": { "contextRef": "c20240101to20240630", "name": "us-
gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors":
[ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ef20029680_10q.htm", "first": true, "unique": true }, "uniqueAnchor": {
"contextRef": "c20240101to20240630", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "unitRef": null, "xsiNil": "false",
"lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ef20029680_10q.htm", "first":
true, "unique": true } }, "R29": { "role": "http://femasys.com/role/NetLossPerShareAttributableToCommonStockholdersTables", "longName": "081400 - Disclosure -
Net Loss per Share Attributable to Common Stockholders (Tables)", "shortName": "Net Loss per Share Attributable to Common Stockholders (Tables)", "isDefault":
"false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "29", "firstAnchor": { "contextRef": "c20240101to20240630",
"name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors":
[ "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ef20029680_10q.htm", "first": true, "unique": true }, "uniqueAnchor": {
"contextRef": "c20240101to20240630", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang":
"en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ef20029680_10q.htm", "first": true,
"unique": true } }, "R30": { "role": "http://femasys.com/role/OrganizationNatureOfBusinessAndLiquidityDetails", "longName": "090100 - Disclosure -
Organization, Nature of Business, and Liquidity (Details)", "shortName": "Organization, Nature of Business, and Liquidity (Details)", "isDefault": "false",
"groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "30", "firstAnchor": { "contextRef": "c20240101to20240630", "name": "us-
gaap:NumberOfOperatingSegments", "unitRef": "U004", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation",
"ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ef20029680_10q.htm", "first": true, "unique": true }, "uniqueAnchor": {
"contextRef": "c20240101to20240630", "name": "us-gaap:NumberOfOperatingSegments", "unitRef": "U004", "xsiNil": "false", "lang": null, "decimals": "INF",
"ancestors": [ "span", "div", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ef20029680_10q.htm",
"first": true, "unique": true } }, "R31": { "role": "http://femasys.com/role/CashAndCashEquivalentsDetails", "longName": "090300 - Disclosure - Cash and Cash
Equivalents (Details)", "shortName": "Cash and Cash Equivalents (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details",
"menuCat": "Details", "order": "31", "firstAnchor": { "contextRef":
"c20240630_FairValueByAssetClassAxis_MoneyMarketFundsMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member", "name": "us-
gaap:CashAndCashEquivalentsFairValueDisclosure", "unitRef": "U002", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "div", "ix:continuation",
"div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ef20029680_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef":
"c20240630_FairValueByAssetClassAxis_MoneyMarketFundsMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member", "name": "us-
```

gaap:CashAndCashEquivalentsFairValueDisclosure", "unitRef": "U002", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["div", "ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ef20029680_10q.htm", "first": true, "unique": true } }, "R32": { "role": "http://femasys.com/role/InventoriesDetails", "longName": "090400 - Disclosure - Inventories (Details)", "shortName": "Inventories (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "32", "firstAnchor": { "contextRef": "c20240630", "name": "us-gaap:InventoryRawMaterials", "unitRef": "U002", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["div", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ef20029680_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c20240630", "name": "us-gaap:InventoryRawMaterials", "unitRef": "U002", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["div", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ef20029680_10q.htm", "first": true, "unique": true } }, "R33": { "role": "http://femasys.com/role/AccruedExpensesDetails", "longName": "090500 - Disclosure - Accrued Expenses (Details)", "shortName": "Accrued Expenses (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "33", "firstAnchor": { "contextRef": "c20240630", "name": "femy:AccruedClinicalTrialCost", "unitRef": "U002", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["div", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ef20029680_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c20240630", "name": "femy:AccruedClinicalTrialCost", "unitRef": "U002", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["div", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ef20029680_10q.htm", "first": true, "unique": true } }, "R34": { "role": "http://femasys.com/role/ClinicalHoldbackDetails", "longName": "090600 - Disclosure - Clinical Holdback (Details)", "shortName": "Clinical Holdback (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "34", "firstAnchor": { "contextRef": "c20231231", "name": "femy:ClinicalHoldbackLiability", "unitRef": "U002", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["div", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ef20029680_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c20231231", "name": "femy:ClinicalHoldbackLiability", "unitRef": "U002", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["div", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ef20029680_10q.htm", "first": true, "unique": true } }, "R35": { "role": "http://femasys.com/role/RevenueRecognitionDetails", "longName": "090700 - Disclosure - Revenue Recognition (Details)", "shortName": "Revenue Recognition (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "35", "firstAnchor": { "contextRef": "c20240401to20240630", "name": "us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod", "unitRef": "U002", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["div", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ef20029680_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c20240401to20240630", "name": "us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod", "unitRef": "U002", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["div", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ef20029680_10q.htm", "first": true, "unique": true } }, "R36": { "role": "http://femasys.com/role/NotesPayableDetails", "longName": "090900 - Disclosure - Notes Payable (Details)", "shortName": "Notes Payable (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "36", "firstAnchor": { "contextRef": "c20240101to20240630", "name": "us-gaap:RepaymentsOfNotesPayable", "unitRef": "U002", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["div", "td", "tr", "table", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ef20029680_10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "c20230701to20230731_DebtInstrumentAxis_JulyPromissoryNoteMember_LineOfCreditFacilityAxis_AFCOCreditCorporationMember", "name": "us-gaap:ProceedsFromNotesPayable", "unitRef": "U002", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["span", "div", "ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ef20029680_10q.htm", "unique": true } }, "R37": { "role": "http://femasys.com/role/ConvertibleNotesWithWarrantsNovember2023FinancingSummaryDetails", "longName": "091000 - Disclosure - Convertible Notes with Warrants (November 2023 Financing), Summary (Details)", "shortName": "Convertible Notes with Warrants (November 2023 Financing), Summary (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "37", "firstAnchor": { "contextRef": "c20231121to20231121_DebtInstrumentAxis_November2023FinancingMember", "name": "us-gaap:ProceedsFromConvertibleDebt", "unitRef": "U002", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["span", "div", "ix:continuation", "div", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ef20029680_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c20231121to20231121_DebtInstrumentAxis_November2023FinancingMember", "name": "us-gaap:ProceedsFromConvertibleDebt", "unitRef": "U002", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["span", "div", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ef20029680_10q.htm", "first": true, "unique": true } }, "R38": { "role": "http://femasys.com/role/ConvertibleNotesWithWarrantsNovember2023FinancingWarrantsDetails", "longName": "091002 - Disclosure - Convertible Notes with Warrants (November 2023 Financing), Warrants (Details)", "shortName": "Convertible Notes with Warrants (November 2023 Financing), Warrants (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "38", "firstAnchor": { "contextRef": "c20240101to20240630_DebtInstrumentAxis_November2023FinancingMember", "name": "femy:ConsecutiveTradingDaysCommonStockExceedsTheConversionPrice", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "ix:continuation", "div", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ef20029680_10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "c20240630_DebtInstrumentAxis_November2023FinancingMember_StatementClassOfStockAxis_SeriesAWarrantsMember", "name": "us-gaap:WarrantsAndRightsOutstandingTerm", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "ix:continuation", "div", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ef20029680_10q.htm", "unique": true } }, "R39": { "role": "http://femasys.com/role/ConvertibleNotesWithWarrantsNovember2023FinancingConvertibleNotesPayableDetails", "longName": "091004 - Disclosure - Convertible Notes with Warrants (November 2023 Financing), Convertible Notes Payable (Details)", "shortName": "Convertible Notes with Warrants (November 2023 Financing), Convertible Notes Payable (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "39", "firstAnchor": { "contextRef": "c20240101to20240630", "name": "us-gaap:AmortizationOfFinancingCostsAndDiscounts", "unitRef": "U002", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["td", "tr", "table", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ef20029680_10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "c20240401to20240630_DebtInstrumentAxis_November2023FinancingMember_LongtermDebtTypeAxis_ConvertibleDebtMember", "name": "us-gaap:InterestExpenseDebt", "unitRef": "U002", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["span", "span", "div", "ix:continuation", "div", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ef20029680_10q.htm", "unique": true } }, "R40": { "role": "http://femasys.com/role/StockholdersEquityDetails", "longName": "091100 - Disclosure - Stockholders' Equity (Details)", "shortName": "Stockholders' Equity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "40", "firstAnchor": { "contextRef": "c20230420to20230420", "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues", "unitRef": "U001", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["span", "div", "ix:continuation", "div", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ef20029680_10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "c20230401to20230430", "name": "femy:PlacementAgentFeesExpensesAndOfferingExpenses", "unitRef": "U002", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["span", "div", "ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ef20029680_10q.htm", "unique": true } }, "R41": { "role": "http://femasys.com/role/EquityIncentivePlansAndWarrantsStockOptionPlanActivityDetails", "longName": "091200 - Disclosure - Equity Incentive Plans and Warrants, Stock Option Plan, Activity (Details)", "shortName": "Equity Incentive Plans and Warrants, Stock Option Plan, Activity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "41", "firstAnchor": { "contextRef": "c20231231_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_Two021StockOptionPlanMember", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "U001", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["td", "tr", "table", "div", "ix:continuation", "ix:continuation", "div", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ef20029680_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c20231231_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_Two021StockOptionPlanMember", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "U001", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["td", "tr", "table", "div", "ix:continuation", "ix:continuation", "div", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ef20029680_10q.htm", "first": true, "unique": true } }, "R42": { "role": "http://femasys.com/role/EquityIncentivePlansAndWarrantsInducementGrantDetails", "longName": "091202 - Disclosure - Equity Incentive Plans and Warrants, Inducement Grant (Details)", "shortName": "Equity Incentive Plans and Warrants, Inducement Grant (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "42", "firstAnchor": { "contextRef": "c20240212to20240212_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_InducementGrantMember", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "unitRef": "U001", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["span", "div", "ix:continuation", "us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock", "div", "div", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ef20029680_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c20240212to20240212_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_InducementGrantMember", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "unitRef": "U001", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["span", "div", "ix:continuation", "us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock", "div", "div", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ef20029680_10q.htm", "first": true, "unique": true } }, "R43": { "role": "http://femasys.com/role/EquityIncentivePlansAndWarrantsSharebasedCompensationExpenseDetails", "longName": "091204 - Disclosure - Equity Incentive Plans and Warrants, Share-Based Compensation Expense (Details)", "shortName": "Equity Incentive Plans and Warrants, Share-Based Compensation Expense (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "43", "firstAnchor": { "contextRef": "c20240401to20240630", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "U002", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["div", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "div", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ef20029680_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c20240401to20240630", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "U002", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["div", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "div", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ef20029680_10q.htm", "first": true, "unique": true } }, "R44": { "role": "http://femasys.com/role/EquityIncentivePlansAndWarrantsEmployeeStockPurchasePlanDetails", "longName": "091206 - Disclosure - Equity Incentive Plans and Warrants, Employee Stock Purchase Plan (Details)", "shortName": "Equity Incentive Plans and Warrants, Employee Stock Purchase Plan (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "44", "firstAnchor": { "contextRef": "c20240401to20240630", "name": "us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan", "unitRef": "U002", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["td", "tr", "table", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ef20029680_10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "c20240101to20240630_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_EmployeeStockPurchasePlanMember", "name": "us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans", "unitRef": "U001", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["span", "div", "ix:continuation", "div", "div", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ef20029680_10q.htm", "unique": true } }, "R45": { "role": "http://femasys.com/role/EquityIncentivePlansAndWarrantsApril2023FinancingDetails", "longName": "091208 - Disclosure - Equity Incentive Plans and

Warrants, April 2023 Financing (Details)", "shortName": "Equity Incentive Plans and Warrants, April 2023 Financing (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "45", "firstAnchor": { "contextRef": "c20230420to20230420", "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues", "unitRef": "U001", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["span", "div", "ix:continuation", "div", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ef20029680_10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "c20230420to20230420", "name": "femy:PaymentsOfEquityIssuanceCosts", "unitRef": "U002", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["span", "div", "ix:continuation", "div", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ef20029680_10q.htm", "unique": true } }, "R46": { "role": "http://femasys.com/role/RelatedpartyTransactionsDetails", "longName": "091300 - Disclosure - Related-Party Transactions (Details)", "shortName": "Related-Party Transactions (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "46", "firstAnchor": { "contextRef": "c20231101to20231130", "name": "us-gaap:RelatedPartyTransactionAmountsOfTransaction", "unitRef": "U002", "xsiNil": "false", "lang": null, "decimals": "-6", "ancestors": ["div", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ef20029680_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c20231101to20231130", "name": "us-gaap:RelatedPartyTransactionAmountsOfTransaction", "unitRef": "U002", "xsiNil": "false", "lang": null, "decimals": "-6", "ancestors": ["div", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ef20029680_10q.htm", "first": true, "unique": true } }, "R47": { "role": "http://femasys.com/role/NetLossPerShareAttributableToCommonStockholdersDetails", "longName": "091400 - Disclosure - Net Loss per Share Attributable to Common Stockholders (Details)", "shortName": "Net Loss per Share Attributable to Common Stockholders (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "47", "firstAnchor": { "contextRef": "c20240401to20240630", "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic", "unitRef": "U002", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["div", "td", "tr", "table", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ef20029680_10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "c20240401to20240630", "name": "us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements", "unitRef": "U001", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["div", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ef20029680_10q.htm", "unique": true } }, "R48": { "role": "http://femasys.com/role/IncomeTaxesDetails", "longName": "091500 - Disclosure - Income Taxes (Details)", "shortName": "Income Taxes (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "48", "firstAnchor": { "contextRef": "c20240401to20240630", "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations", "unitRef": "U007", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": ["us-gaap:EffectiveIncomeTaxRateContinuingOperations", "us-gaap:EffectiveIncomeTaxRateContinuingOperations", "us-gaap:EffectiveIncomeTaxRateContinuingOperations", "div", "ix:continuation", "div", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ef20029680_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c20240401to20240630", "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations", "unitRef": "U007", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": ["us-gaap:EffectiveIncomeTaxRateContinuingOperations", "us-gaap:EffectiveIncomeTaxRateContinuingOperations", "us-gaap:EffectiveIncomeTaxRateContinuingOperations", "div", "ix:continuation", "div", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ef20029680_10q.htm", "first": true, "unique": true } } }, "tag": { "femy_AFCOCreditCorporationMember": { "xbrltype": "domainItemType", "nsuri": "http://femasys.com/20240630", "localname": "AFCOCreditCorporationMember", "presentation": ["http://femasys.com/role/NotesPayableDetails"], "lang": { "en-us": { "role": { "documentation": "AFCO Credit Corporation, doing business as AFCO Insurance Premium Finance, provides premium financing services. The Company offers loans for businesses, finance property, and casualty insurance premiums. Afco Insurance Premium Finance serves clients worldwide.", "label": "AFCO Credit Corporation [Member]", "terseLabel": "AFCO Credit Corporation [Member]" } } }, "auth_ref": [] }, "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "presentation": ["http://femasys.com/role/AccruedExpenses"], "lang": { "en-us": { "role": { "terseLabel": "Accrued Expenses", "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]", "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period." } } }, "auth_ref": ["r44", "r47", "r52", "r724"] }, "us-gaap_AccountsPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableCurrent", "crdr": "credit", "presentation": ["http://femasys.com/role/CondensedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Accounts payable", "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": ["r44", "r645"] }, "us-gaap_AccountsReceivableNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsReceivableNetCurrent", "crdr": "debit", "presentation": ["http://femasys.com/role/CondensedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Accounts receivable, net", "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current." } } }, "auth_ref": ["r705"] }, "femy_AccruedClinicalTrialCost": { "xbrltype": "monetaryItemType", "nsuri": "http://femasys.com/20240630", "localname": "AccruedClinicalTrialCost", "crdr": "credit", "presentation": ["http://femasys.com/role/AccruedExpensesDetails"], "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to clinical trial cost.", "label": "Accrued Clinical Trial Cost", "terseLabel": "Clinical trail costs" } } }, "auth_ref": [] }, "us-gaap_AccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccruedLiabilitiesCurrent", "crdr": "credit", "presentation": ["http://femasys.com/role/AccruedExpensesDetails", "http://femasys.com/role/CondensedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Accrued expenses", "totalLabel": "Accrued expenses", "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": ["r47"] }, "us-gaap_AccruedProfessionalFeesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccruedProfessionalFeesCurrent", "crdr": "credit", "presentation": ["http://femasys.com/role/AccruedExpensesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Director fees", "label": "Accrued Professional Fees, Current", "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": ["r47"] }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "crdr": "credit", "presentation": ["http://femasys.com/role/CondensedBalanceSheets"], "lang": { "en-us": { "role": { "negatedLabel": "Less accumulated depreciation", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services." } } }, "auth_ref": ["r24", "r121", "r469"] }, "femy_AcquisitionOfPatentsIncludedInAccountsPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://femasys.com/20240630", "localname": "AcquisitionOfPatentsIncludedInAccountsPayable", "crdr": "debit", "presentation": ["http://femasys.com/role/CondensedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "documentation": "Value of acquisition of patents included in accounts payable as a noncash or partial noncash transaction..", "label": "Acquisition of Patents Included in Accounts Payable", "terseLabel": "Acquisition of patents included in accounts payable" } } }, "auth_ref": [] }, "us-gaap_AdditionalPaidInCapital": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapital", "crdr": "credit", "presentation": ["http://femasys.com/role/CondensedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Additional paid-in-capital", "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock." } } }, "auth_ref": ["r57", "r645", "r776"] }, "us-gaap_AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapitalMember", "presentation": ["http://femasys.com/role/CondensedStatementsOfStockholdersEquity"], "lang": { "en-us": { "role": { "label": "Additional Paid-in Capital [Member]", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": ["r505", "r693", "r694", "r695", "r696", "r725", "r777"] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "crdr": "credit", "presentation": ["http://femasys.com/role/CondensedStatementsOfStockholdersEquity"], "lang": { "en-us": { "role": { "label": "Share-based compensation expense", "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement." } } }, "auth_ref": ["r36", "r37", "r305"] }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": ["http://femasys.com/role/CondensedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Adjustments to reconcile net loss to net cash used in operating activities:" } } }, "auth_ref": [] }, "us-gaap_AllocatedShareBasedCompensationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AllocatedShareBasedCompensationExpense", "crdr": "debit", "presentation": ["http://femasys.com/role/EquityIncentivePlansAndWarrantsSharebasedCompensationExpenseDetails"], "lang": { "en-us": { "role": { "terseLabel": "Share-based compensation expense", "label": "Share-Based Payment Arrangement, Expense", "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized." } } }, "auth_ref": ["r334", "r336"] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentFlag", "presentation": ["http://femasys.com/role/DocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "us-gaap_AmortizationOfFinancingCostsAndDiscounts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AmortizationOfFinancingCostsAndDiscounts", "crdr": "debit", "presentation": ["http://femasys.com/role/CondensedStatementsOfCashFlows", "http://femasys.com/role/ConvertibleNotesWithWarrantsNovember2023FinancingConvertibleNotesPayableDetails"], "lang": { "en-us": { "role": { "label": "Amortization of debt issuance costs and discount", "terseLabel": "Amortization of debt discount and issuance costs", "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs." } } }, "auth_ref": ["r258", "r621", "r622", "r689", "r734"] }, "us-gaap_AmortizationOfIntangibleAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AmortizationOfIntangibleAssets", "crdr": "debit", "presentation": ["http://femasys.com/role/CondensedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "terseLabel": "Amortization", "label": "Amortization of Intangible Assets", "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method." } } }, "auth_ref": ["r4", "r208", "r209", "r617"] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Assets", "crdr": "debit", "presentation": ["http://femasys.com/role/CondensedBalanceSheets"], "lang": { "en-us": { "role": { "totalLabel": "Total assets", "label": "Assets", "documentation": "Amount of asset recognized for present right to economic benefit." } } }, "auth_ref": ["r95", "r106", "r123", "r146", "r186", "r190", "r197", "r198", "r204", "r227", "r228", "r229", "r230", "r231", "r232", "r233", "r234", "r235", "r363", "r365", "r399", "r463", "r542",

```
"r614", "r615", "r645", "r670", "r718", "r719", "r736" ] }, "us-gaap_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "AssetsAbstract", "presentation": [ "http://femasys.com/role/CondensedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Assets",
"label": "Assets [Abstract]" } } } }, "auth_ref": [] }, "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "AssetsCurrent", "crdr": "debit", "presentation": [ "http://femasys.com/role/CondensedBalanceSheets" ], "lang": { "en-us": { "role": {
"totalLabel": "Total current assets", "label": "Assets, Current", "documentation": "Amount of asset recognized for present right to economic benefit,
classified as current." } } }, "auth_ref": [ "r117", "r130", "r146", "r204", "r227", "r228", "r229", "r230", "r231", "r232", "r233", "r234", "r235", "r363",
"r365", "r399", "r645", "r718", "r719", "r736" ] }, "us-gaap_AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "AssetsCurrentAbstract", "presentation": [ "http://femasys.com/role/CondensedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Current
assets:" } } }, "auth_ref": [] }, "us-gaap_AssetsFairValueDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "AssetsFairValueDisclosureAbstract", "presentation": [ "http://femasys.com/role/CashAndCashEquivalentsDetails" ], "lang": { "en-us": { "role": {
"verboseLabel": "Assets, Fair Value Disclosure [Abstract]", "label": "Assets, Fair Value Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-
gaap_AssetsNoncurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsNoncurrentAbstract",
"presentation": [ "http://femasys.com/role/CondensedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Long-term assets:" } } }, "auth_ref": [] },
"us-gaap_AssetsNoncurrentOtherThanNoncurrentInvestmentsAndPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "AssetsNoncurrentOtherThanNoncurrentInvestmentsAndPropertyPlantAndEquipment", "crdr": "debit", "presentation": [
"http://femasys.com/role/CondensedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total long-term assets", "label": "Assets, Noncurrent, Other
than Noncurrent Investments and Property, Plant and Equipment", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets,
excluding property, plant, and equipment and other property and investments, that are expected to be realized in cash, sold or consumed after one year or
beyond the normal operating cycle, if longer. Alternate captions include Total Deferred Charges and Other Assets." } } }, "auth_ref": [] },
"femy_AuthorizedOfferingAmountOfSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://femasys.com/20240630", "localname":
"AuthorizedOfferingAmountOfSecurities", "crdr": "credit", "presentation": [ "http://femasys.com/role/StockholdersEquityDetails" ], "lang": { "en-us": {
"role": { "documentation": "The authorized offering amount of securities.", "label": "Authorized Offering Amount of Securities", "terseLabel": "Authorized
offering amount of securities" } } }, "auth_ref": [] }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "BasisOfAccountingPolicyPolicyTextBlock", "presentation": [
"http://femasys.com/role/OrganizationNatureOfBusinessAndLiquidityPolicies" ], "lang": { "en-us": { "role": { "label": "Basis of Presentation",
"documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US
Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)." } } }, "auth_ref": [] }, "us-gaap_CashAndCashEquivalentsAbstract":
{ "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsAbstract", "lang": { "en-us": { "role": {
"label": "Cash and Cash Equivalents [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "presentation": [
"http://femasys.com/role/CondensedBalanceSheets", "http://femasys.com/role/OrganizationNatureOfBusinessAndLiquidityDetails" ], "lang": { "en-us": { "role": {
"label": "Cash and cash equivalents", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes
other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily
convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.
Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": [ "r15", "r119", "r609" ] }, "us-
gaap_CashAndCashEquivalentsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"CashAndCashEquivalentsDisclosureTextBlock", "presentation": [ "http://femasys.com/role/CashAndCashEquivalents" ], "lang": { "en-us": { "role": {
"terseLabel": "Cash and Cash Equivalents", "label": "Cash and Cash Equivalents Disclosure [Text Block]", "documentation": "The entire disclosure for cash and
cash equivalent footnotes, which may include the types of deposits and money market instruments, applicable carrying amounts, restricted amounts and
compensating balance arrangements. Cash and equivalents include: (1) currency on hand (2) demand deposits with banks or financial institutions (3) other kinds
of accounts that have the general characteristics of demand deposits (4) short-term, highly liquid investments that are both readily convertible to known
amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Generally, only
investments maturing within three months from the date of acquisition qualify." } } }, "auth_ref": [ "r119", "r465" ] }, "us-
gaap_CashAndCashEquivalentsFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"CashAndCashEquivalentsFairValueDisclosure", "crdr": "debit", "presentation": [ "http://femasys.com/role/CashAndCashEquivalentsDetails" ], "lang": { "en-us":
{ "role": { "verboseLabel": "Cash and cash equivalent", "label": "Cash and Cash Equivalents, Fair Value Disclosure", "documentation": "Fair value portion of
currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of
demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity
that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r726", "r727" ] }, "us-
gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "presentation": [ "http://femasys.com/role/CondensedStatementsOfCashFlows"
], "lang": { "en-us": { "role": { "periodEndLabel": "End of period", "periodStartLabel": "Beginning of period", "label": "Cash, Cash Equivalents, Restricted
Cash, and Restricted Cash Equivalents", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or
usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or
financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term,
highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of
changes in value because of changes in interest rates." } } }, "auth_ref": [ "r15", "r75", "r143" ] }, "us-
gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": { "xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname":
"CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "crdr": "debit", "presentation": [
"http://femasys.com/role/CondensedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net change in cash and cash equivalents", "label":
"Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect", "documentation":
"Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange
rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general
characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible
to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } },
"auth_ref": [ "r0", "r75" ] }, "us-
gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectAbstract": { "xbrltype": "stringItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname":
"CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectAbstract", "presentation": [
"http://femasys.com/role/CondensedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash and cash equivalents:" } } }, "auth_ref": [] },
"femy_CashPaidForAbstract": { "xbrltype": "stringItemType", "nsuri": "http://femasys.com/20240630", "localname": "CashPaidForAbstract", "presentation": [
"http://femasys.com/role/CondensedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash Paid For [Abstract]", "terseLabel": "Cash paid for:"
} } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CityAreaCode",
"presentation": [ "http://femasys.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area
code of city" } } }, "auth_ref": [] }, "us-gaap_ClassOfStockDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ClassOfStockDomain", "presentation": [ "http://femasys.com/role/ConvertibleNotesWithWarrantsNovember2023FinancingSummaryDetails",
"http://femasys.com/role/ConvertibleNotesWithWarrantsNovember2023FinancingWarrantsDetails" ], "lang": { "en-us": { "role": { "label": "Class of Stock
[Domain]", "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock,
redeemable preferred stock, nonredeemable preferred stock, and convertible stock." } } }, "auth_ref": [ "r114", "r125", "r126", "r127", "r146", "r167",
"r172", "r179", "r181", "r188", "r189", "r204", "r227", "r229", "r230", "r231", "r234", "r235", "r267", "r268", "r271", "r274", "r281", "r399", "r496",
"r497", "r498", "r499", "r505", "r506", "r507", "r508", "r509", "r510", "r511", "r512", "r513", "r514", "r515", "r516", "r530", "r551", "r571", "r587",
"r588", "r589", "r590", "r591", "r680", "r690", "r697" ] }, "us-gaap_ClassOfStockLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "ClassOfStockLineItems", "presentation": [ "http://femasys.com/role/StockholdersEquityDetails" ], "lang": { "en-us": { "role": {
"label": "Class of Stock [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose
reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r125", "r126", "r127", "r188", "r267",
"r268", "r269", "r271", "r274", "r279", "r281", "r496", "r497", "r498", "r499", "r623", "r680", "r690" ] }, "us-gaap_ClassOfWarrantOrRightAxis": { "xbrltype":
"stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightAxis", "presentation": [
"http://femasys.com/role/EquityIncentivePlansAndWarrantsApril2023FinancingDetails",
"http://femasys.com/role/NetLossPerShareAttributableToCommonStockholdersDetails", "http://femasys.com/role/StockholdersEquityDetails" ], "lang": { "en-us": {
"role": { "label": "Class of Warrant or Right [Axis]", "documentation": "Information by type of warrant or right issued." } } }, "auth_ref": [ "r34" ] }, "us-
gaap_ClassOfWarrantOrRightDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightDomain",
"presentation": [ "http://femasys.com/role/EquityIncentivePlansAndWarrantsApril2023FinancingDetails",
"http://femasys.com/role/NetLossPerShareAttributableToCommonStockholdersDetails", "http://femasys.com/role/StockholdersEquityDetails" ], "lang": { "en-us": {
"role": { "label": "Class of Warrant or Right [Domain]", "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights
represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain
time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call
options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the
lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months." } } }, "auth_ref": [] }, "us-
gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "presentation": [
"http://femasys.com/role/ConvertibleNotesWithWarrantsNovember2023FinancingSummaryDetails",
"http://femasys.com/role/EquityIncentivePlansAndWarrantsApril2023FinancingDetails" ], "lang": { "en-us": { "role": { "label": "Warrants exercise price (in
dollars per share)", "verboseLabel": "Warrants exercise price (In dollars per share)", "documentation": "Exercise price per share or per unit of warrants or
rights outstanding." } } }, "auth_ref": [ "r282" ] }, "us-gaap_ClassOfWarrantOrRightLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-
```

gaap/2024", "localname": "ClassOfWarrantOrRightLineItems", "presentation": [
"http://femasys.com/role/EquityIncentivePlansAndWarrantsApril2023FinancingDetails",
"http://femasys.com/role/NetLossPerShareAttributableToCommonStockholdersDetails"], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] } }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "presentation": [
"http://femasys.com/role/ConvertibleNotesWithWarrantsNovember2023FinancingSummaryDetails",
"http://femasys.com/role/EquityIncentivePlansAndWarrantsApril2023FinancingDetails", "http://femasys.com/role/StockholdersEquityDetails"], "lang": { "en-us": { "role": { "label": "Warrants issued to purchase common stock (in shares)", "verboseLabel": "Warrants purchase shares of common stock (in shares)", "terseLabel": "Warrants issued to purchase common stock (in shares)", "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares." } } }, "auth_ref": ["r282"] }, "us-gaap_ClassOfWarrantOrRightOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightOutstanding", "presentation": ["http://femasys.com/role/EquityIncentivePlansAndWarrantsApril2023FinancingDetails",
"http://femasys.com/role/StockholdersEquityDetails"], "lang": { "en-us": { "role": { "label": "Warrants outstanding (in shares)", "documentation": "Number of warrants or rights outstanding." } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightTable", "presentation": ["http://femasys.com/role/EquityIncentivePlansAndWarrantsApril2023FinancingDetails",
"http://femasys.com/role/NetLossPerShareAttributableToCommonStockholdersDetails"], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right [Table]", "documentation": "Disclosure of information about warrant or right issued that give holder right to purchase security from issuer at specific price within certain time frame." } } }, "auth_ref": ["r34"] }, "femy_ClinicalHoldbackAbstract": { "xbrltype": "stringItemType", "nsuri": "http://femasys.com/20240630", "localname": "ClinicalHoldbackAbstract", "lang": { "en-us": { "role": { "label": "Clinical Holdback [Abstract]" } } }, "auth_ref": [] }, "femy_ClinicalHoldbackCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://femasys.com/20240630", "localname": "ClinicalHoldbackCurrent", "crdr": "credit", "presentation": ["http://femasys.com/role/ClinicalHoldbackDetails",
"http://femasys.com/role/CondensedBalanceSheets"], "lang": { "en-us": { "role": { "documentation": "Amount of clinical holdback expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Clinical Holdback Current", "verboseLabel": "Clinical holdback - current portion", "negatedLabel": "Less: clinical holdback - current portion" } } }, "auth_ref": [] }, "femy_ClinicalHoldbackLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://femasys.com/20240630", "localname": "ClinicalHoldbackLiability", "crdr": "credit", "presentation": [
"http://femasys.com/role/ClinicalHoldbackDetails"], "lang": { "en-us": { "role": { "documentation": "Amount of clinical holdback liability.", "label": "Clinical Holdback Liability", "periodStartLabel": "Balance", "periodEndLabel": "Balance" } } }, "auth_ref": [] },
"femy_ClinicalHoldbackLiabilityRollForward": { "xbrltype": "stringItemType", "nsuri": "http://femasys.com/20240630", "localname": "ClinicalHoldbackLiabilityRollForward", "presentation": ["http://femasys.com/role/ClinicalHoldbackDetails"], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Clinical Holdback Liability [Roll Forward]", "terseLabel": "Clinical Holdback Liability [Roll Forward]" } } }, "auth_ref": [] }, "femy_ClinicalHoldbackNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://femasys.com/20240630", "localname": "ClinicalHoldbackNoncurrent", "crdr": "credit", "presentation": [
"http://femasys.com/role/ClinicalHoldbackDetails", "http://femasys.com/role/CondensedBalanceSheets"], "lang": { "en-us": { "role": { "documentation": "Amount of clinical holdback, due after one year or beyond the normal operating cycle, if longer.", "label": "Clinical Holdback, Noncurrent", "verboseLabel": "Clinical holdback - long-term portion" } } }, "auth_ref": [] }, "femy_ClinicalHoldbackPaid": { "xbrltype": "monetaryItemType", "nsuri": "http://femasys.com/20240630", "localname": "ClinicalHoldbackPaid", "crdr": "credit", "presentation": ["http://femasys.com/role/ClinicalHoldbackDetails"], "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow reducing clinical holdback liability.", "label": "Clinical Holdback Paid", "negatedLabel": "Clinical holdback paid" } } }, "auth_ref": [] }, "femy_ClinicalHoldbackRetained": { "xbrltype": "monetaryItemType", "nsuri": "http://femasys.com/20240630", "localname": "ClinicalHoldbackRetained", "crdr": "debit", "presentation": ["http://femasys.com/role/ClinicalHoldbackDetails"], "lang": { "en-us": { "role": { "documentation": "Amount of clinical holdback retained during the period.", "label": "Clinical Holdback Retained", "terseLabel": "Clinical holdback retained" } } }, "auth_ref": [] }, "femy_ClinicalHoldbackTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://femasys.com/20240630", "localname": "ClinicalHoldbackTextBlock", "presentation": ["http://femasys.com/role/ClinicalHoldback"], "lang": { "en-us": { "role": { "documentation": "The entire disclosure of clinical holdback.", "label": "Clinical Holdback [Text Block]", "terseLabel": "Clinical Holdback" } } }, "auth_ref": [] }, "femy_CommissionCostsRelatingToCertainProceedsFromIssuanceOfCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://femasys.com/20240630", "localname": "CommissionCostsRelatingToCertainProceedsFromIssuanceOfCommonStock", "crdr": "debit", "presentation": [
"http://femasys.com/role/CondensedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "documentation": "The amount of commission costs relating to certain proceeds from issuance of common stock incurred as a noncash or partial noncash transaction.", "label": "Commission Costs Relating to Certain Proceeds From Issuance of Common Stock", "terseLabel": "Commissions costs relating to certain proceeds from issuance of common stock" } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingencies": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingencies", "crdr": "credit", "presentation": ["http://femasys.com/role/CondensedBalanceSheets"], "lang": { "en-us": { "role": { "verboseLabel": "Commitments and contingencies", "label": "Commitments and Contingencies", "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur." } } }, "auth_ref": ["r53", "r98", "r464", "r529"] }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingenciesDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Commitments and Contingencies [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "presentation": [
"http://femasys.com/role/CommitmentsAndContingencies"], "lang": { "en-us": { "role": { "terseLabel": "Commitments and Contingencies", "label": "Commitments and Contingencies Disclosure [Text Block]", "documentation": "The entire disclosure for commitments and contingencies." } } }, "auth_ref": ["r82", "r219", "r220", "r594", "r708", "r713"] }, "femy_CommonStockAuthorizedValueToBeIssuedBySalesAgent": { "xbrltype": "monetaryItemType", "nsuri": "http://femasys.com/20240630", "localname": "CommonStockAuthorizedValueToBeIssuedBySalesAgent", "crdr": "credit", "presentation": [
"http://femasys.com/role/StockholdersEquityDetails"], "lang": { "en-us": { "role": { "documentation": "Amount of common stock authorized value to be issued by Sales Agent to sell maximum shares at current market prices until all shares all sold.", "label": "Common Stock, Authorized Value to be Issued by Sales Agent", "terseLabel": "Common stock authorized value to be issued by Sales Agent" } } }, "auth_ref": [] }, "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockCapitalSharesReservedForFutureIssuance", "presentation": [
"http://femasys.com/role/EquityIncentivePlansAndWarrantsEmployeeStockPurchasePlanDetails",
"http://femasys.com/role/EquityIncentivePlansAndWarrantsStockOptionPlanActivityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Common stock reserved for issuance (in shares)", "label": "Common Stock, Capital Shares Reserved for Future Issuance", "documentation": "Aggregate number of common shares reserved for future issuance." } } }, "auth_ref": ["r56"] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockMember", "presentation": ["http://femasys.com/role/CondensedStatementsOfStockholdersEquity",
"http://femasys.com/role/ConvertibleNotesWithWarrantsNovember2023FinancingSummaryDetails", "http://femasys.com/role/StockholdersEquityDetails"], "lang": { "en-us": { "role": { "label": "Common Stock [Member]", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": ["r660", "r661", "r662", "r664", "r665", "r666", "r667", "r693", "r694", "r696", "r725", "r775", "r777"] }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockParOrStatedValuePerShare", "presentation": [
"http://femasys.com/role/CondensedBalanceSheetsParenthetical"], "lang": { "en-us": { "role": { "label": "Common stock, par value (in dollars per share)", "documentation": "Face amount or stated value per share of common stock." } } }, "auth_ref": ["r56"] }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesAuthorized", "presentation": [
"http://femasys.com/role/CondensedBalanceSheetsParenthetical"], "lang": { "en-us": { "role": { "label": "Common stock, authorized (in shares)", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": ["r56", "r530"] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesIssued", "presentation": ["http://femasys.com/role/CondensedBalanceSheetsParenthetical", "http://femasys.com/role/CondensedStatementsOfStockholdersEquity"], "lang": { "en-us": { "role": { "label": "Common stock, issued (in shares)", "periodEndLabel": "Balance (in shares)", "periodStartLabel": "Balance (in shares)", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": ["r56"] }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesOutstanding", "presentation": ["http://femasys.com/role/CondensedBalanceSheetsParenthetical", "http://femasys.com/role/StockholdersEquityDetails"], "lang": { "en-us": { "role": { "label": "Common stock, outstanding (in shares)", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth_ref": ["r7", "r56", "r530", "r548", "r777", "r778"] }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockValue", "crdr": "credit", "presentation": [
"http://femasys.com/role/CondensedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Common stock, $.001 par, 200,000,000 authorized, 22,350,022 shares issued and 22,232,799 outstanding as of June 30, 2024; and 21,774,604 shares issued and 21,657,381 outstanding as of December 31, 2023", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": ["r56", "r466", "r645"] }, "femy_CommonWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://femasys.com/20240630", "localname": "CommonWarrantsMember", "presentation": [
"http://femasys.com/role/EquityIncentivePlansAndWarrantsApril2023FinancingDetails", "http://femasys.com/role/StockholdersEquityDetails"], "lang": { "en-us": { "role": { "documentation": "A common warrant represents the right to purchase a company's stock at a specific price and at a specific date.", "label": "Common Warrants [Member]", "terseLabel": "Common Warrants [Member]" } } }, "auth_ref": [] },
"femy_ConsecutiveTradingDaysCommonStockExceedsTheConversionPrice": { "xbrltype": "durationItemType", "nsuri": "http://femasys.com/20240630", "localname": "ConsecutiveTradingDaysCommonStockExceedsTheConversionPrice", "presentation": [

```
"http://femasys.com/role/ConvertibleNotesWithWarrantsNovember2023FinancingSummaryDetails",
"http://femasys.com/role/ConvertibleNotesWithWarrantsNovember2023FinancingWarrantsDetails" ], "lang": { "en-us": { "role": { "documentation": "The consecutive trading days, in which common stock exceeds the conversion price, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Consecutive Trading Days, Common Stock Exceeds the Conversion Price", "terseLabel": "Consecutive trading days" } } }, "auth_ref": [] }, "us-gaap_ConstructionInProgressGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConstructionInProgressGross", "crdr": "debit", "presentation": [ "http://femasys.com/role/CondensedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Construction in progress", "documentation": "Amount of structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service." } } }, "auth_ref": [ "r81" ] }, "us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod", "crdr": "credit", "presentation": [
"http://femasys.com/role/RevenueRecognitionDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue recognized from performance obligations in prior periods", "label": "Contract with Customer, Performance Obligation Satisfied in Previous Period", "documentation": "Amount of revenue recognized from performance obligation satisfied or partially satisfied in previous reporting periods. Includes, but is not limited to, change in transaction price." } } }, "auth_ref": [ "r290" ] }, "us-gaap_ConvertibleDebtFairValueDisclosures": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConvertibleDebtFairValueDisclosures", "crdr": "credit", "presentation": [
"http://femasys.com/role/ConvertibleNotesWithWarrantsNovember2023FinancingConvertibleNotesPayableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Convertible note, fair value", "label": "Convertible Debt, Fair Value Disclosures", "documentation": "Fair value portion of borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock." } } }, "auth_ref": [ "r727", "r728", "r729", "r730", "r731" ] }, "us-gaap_ConvertibleDebtMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConvertibleDebtMember", "presentation": [
"http://femasys.com/role/ConvertibleNotesWithWarrantsNovember2023FinancingConvertibleNotesPayableDetails",
"http://femasys.com/role/ConvertibleNotesWithWarrantsNovember2023FinancingSummaryDetails" ], "lang": { "en-us": { "role": { "label": "Convertible Notes [Member]", "documentation": "Borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock." } } }, "auth_ref": [ "r84", "r237", "r238", "r248", "r249", "r250", "r254", "r255", "r256", "r257", "r258", "r618", "r619", "r620", "r621", "r622" ] }, "us-gaap_ConvertibleLongTermNotesPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConvertibleLongTermNotesPayable", "crdr": "credit", "presentation": [ "http://femasys.com/role/CondensedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Convertible notes payable, net (including related parties)", "documentation": "Carrying value as of the balance sheet date of long-term debt (with maturities initially due after one year or beyond the operating cycle if longer) identified as Convertible Notes Payable, excluding current portion. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder." } } }, "auth_ref": [ "r11" ] }, "femy_ConvertibleNotesWithWarrantsNovember2023FinancingAbstract": { "xbrltype": "stringItemType", "nsuri": "http://femasys.com/20240630", "localname": "ConvertibleNotesWithWarrantsNovember2023FinancingAbstract", "lang": { "en-us": { "role": { "label": "Convertible Notes with Warrants (November 2023 Financing) [Abstract]" } } }, "auth_ref": [] },
"femy_ConvertibleNotesWithWarrantsNovember2023FinancingTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://femasys.com/20240630", "localname": "ConvertibleNotesWithWarrantsNovember2023FinancingTextBlock", "presentation": [ "http://femasys.com/role/ConvertibleNotesWithWarrantsNovember2023Financing" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for information about convertible notes with warrants financing.", "label": "Convertible Notes with Warrants November 2023 Financing [Text Block]", "terseLabel": "Convertible Notes with Warrants (November 2023 Financing)" } } }, "auth_ref": [] }, "us-gaap_CostOfGoodsAndServicesSold": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CostOfGoodsAndServicesSold", "crdr": "debit", "presentation": [ "http://femasys.com/role/CondensedStatementsOfComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Cost of sales (excluding depreciation expense)", "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities." } } }, "auth_ref": [ "r66", "r67", "r427" ] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://femasys.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] },
"femy_DailyDollarTradingVolumeOfCommonStockExceedsPerDay": { "xbrltype": "monetaryItemType", "nsuri": "http://femasys.com/20240630", "localname": "DailyDollarTradingVolumeOfCommonStockExceedsPerDay", "crdr": "debit", "presentation": [
"http://femasys.com/role/ConvertibleNotesWithWarrantsNovember2023FinancingSummaryDetails",
"http://femasys.com/role/ConvertibleNotesWithWarrantsNovember2023FinancingWarrantsDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of daily dollar trading volume of the common stock exceeds per day during the same period and certain equity conditions.", "label": "Daily Dollar Trading Volume of Common Stock Exceeds per Day", "terseLabel": "Daily dollar trading volume of common stock exceeds per day" } } }, "auth_ref": [] }, "us-gaap_DebtConversionConvertedInstrumentExpirationOrDueDateDayMonthAndYear": { "xbrltype": "dateItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtConversionConvertedInstrumentExpirationOrDueDateDayMonthAndYear", "presentation": [
"http://femasys.com/role/ConvertibleNotesWithWarrantsNovember2023FinancingSummaryDetails" ], "lang": { "en-us": { "role": { "label": "Maturity date", "documentation": "Expiration, mandatory redemption, or due date, in YYYY-MM-DD format, of the financial instrument issued in exchange for the original debt being converted in a noncash or part noncash transaction." } } }, "auth_ref": [ "r17", "r18" ] }, "us-gaap_DebtDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Notes Payable [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DebtDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtDisclosureTextBlock", "presentation": [ "http://femasys.com/role/NotesPayable" ], "lang": { "en-us": { "role": { "terseLabel": "Notes Payable", "label": "Debt Disclosure [Text Block]", "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants." } } }, "auth_ref": [ "r83", "r144", "r212", "r213", "r214", "r215", "r216", "r225", "r226", "r236", "r242", "r243", "r244", "r245", "r246", "r247", "r252", "r259", "r260", "r262", "r407" ] }, "us-gaap_DebtInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentAxis", "presentation": [ "http://femasys.com/role/ConvertibleNotesWithWarrantsNovember2023FinancingConvertibleNotesPayableDetails",
"http://femasys.com/role/ConvertibleNotesWithWarrantsNovember2023FinancingSummaryDetails",
"http://femasys.com/role/ConvertibleNotesWithWarrantsNovember2023FinancingWarrantsDetails", "http://femasys.com/role/NotesPayableDetails" ], "lang": { "en-us": { "role": { "label": "Debt Instrument [Axis]", "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities." } } }, "auth_ref": [ "r11", "r46", "r47", "r96", "r97", "r148", "r237", "r238", "r239", "r240", "r241", "r243", "r248", "r249", "r250", "r251", "r253", "r254", "r255", "r256", "r257", "r258", "r618", "r619", "r620", "r621", "r622", "r644", "r691", "r709", "r710", "r711", "r733", "r735" ] },
"us-gaap_DebtInstrumentCarryingAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentCarryingAmount", "crdr": "credit", "presentation": [
"http://femasys.com/role/ConvertibleNotesWithWarrantsNovember2023FinancingConvertibleNotesPayableDetails",
"http://femasys.com/role/ConvertibleNotesWithWarrantsNovember2023FinancingSummaryDetails" ], "lang": { "en-us": { "role": { "label": "Notes principal balance", "verboseLabel": "Aggregate principal amount", "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt." } } }, "auth_ref": [ "r11", "r97", "r263" ] }, "us-gaap_DebtInstrumentConvertibleConversionPrice1": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentConvertibleConversionPrice1", "presentation": [
"http://femasys.com/role/ConvertibleNotesWithWarrantsNovember2023FinancingSummaryDetails" ], "lang": { "en-us": { "role": { "label": "Conversion price (in dollars per share)", "documentation": "The price per share of the conversion feature embedded in the debt instrument." } } }, "auth_ref": [ "r85", "r239" ] },
"femy_DebtInstrumentConvertibleConversionPriceOfCommonStockExceeds": { "xbrltype": "perShareItemType", "nsuri": "http://femasys.com/20240630", "localname": "DebtInstrumentConvertibleConversionPriceOfCommonStockExceeds", "presentation": [
"http://femasys.com/role/ConvertibleNotesWithWarrantsNovember2023FinancingSummaryDetails" ], "lang": { "en-us": { "role": { "documentation": "The closing price per share of the common stock exceeds of the conversion feature embedded in the debt instrument.", "label": "Debt Instrument, Convertible, Conversion Price of Common Stock Exceeds", "terseLabel": "Conversion price of common stock exceeds (in dollars per share)" } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentFrequencyOfPeriodicPayment": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentFrequencyOfPeriodicPayment", "presentation": [ "http://femasys.com/role/NotesPayableDetails" ], "lang": { "en-us": { "role": { "label": "Frequency of installment payments", "documentation": "Description of the frequency of periodic payments (monthly, quarterly, annual)." } } }, "auth_ref": [ "r11", "r42" ] }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentInterestRateStatedPercentage", "presentation": [ "http://femasys.com/role/ConvertibleNotesWithWarrantsNovember2023FinancingSummaryDetails", "http://femasys.com/role/NotesPayableDetails" ], "lang": { "en-us": { "role": { "label": "Interest rate", "verboseLabel": "Convertible note accrue interest rate", "documentation": "Contractual interest rate for funds borrowed, under the debt agreement." } } }, "auth_ref": [ "r49", "r238" ] }, "us-gaap_DebtInstrumentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentLineItems", "presentation": [ "http://femasys.com/role/ConvertibleNotesWithWarrantsNovember2023FinancingConvertibleNotesPayableDetails",
"http://femasys.com/role/ConvertibleNotesWithWarrantsNovember2023FinancingSummaryDetails",
"http://femasys.com/role/ConvertibleNotesWithWarrantsNovember2023FinancingWarrantsDetails", "http://femasys.com/role/NotesPayableDetails" ], "lang": { "en-us": { "role": { "label": "Debt Instrument [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r148", "r237", "r238", "r239", "r240", "r241", "r243", "r248", "r249", "r250", "r251", "r253", "r254", "r255", "r256", "r257", "r258", "r261", "r618", "r619", "r620", "r621", "r622", "r644", "r691", "r733", "r735" ] }, "us-gaap_DebtInstrumentMaturityDate": { "xbrltype": "dateItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentMaturityDate", "presentation": [ "http://femasys.com/role/NotesPayableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Maturity date of loan", "label": "Debt Instrument, Maturity Date", "documentation": "Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format." } } }, "auth_ref": [ "r124", "r618", "r729", "r730" ] }, "us-gaap_DebtInstrumentNameDomain": { "xbrltype": "domainItemType", "nsuri":
```

"http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentNameDomain", "presentation": [
"http://femasys.com/role/ConvertibleNotesWithWarrantsNovember2023FinancingConvertibleNotesPayableDetails",
"http://femasys.com/role/ConvertibleNotesWithWarrantsNovember2023FinancingSummaryDetails",
"http://femasys.com/role/ConvertibleNotesWithWarrantsNovember2023FinancingWarrantsDetails", "http://femasys.com/role/NotesPayableDetails"], "lang": { "en-us": { "role": { "label": "Debt Instrument, Name [Domain]", "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities." } } }, "auth_ref": ["r11", "r148", "r237", "r238", "r239", "r240", "r241", "r243", "r248", "r249", "r250", "r251", "r253", "r254", "r255", "r256", "r257", "r258", "r618", "r619", "r620", "r621", "r622", "r644", "r691", "r709", "r710", "r711", "r733", "r735"] }, "us-gaap_DebtInstrumentPeriodicPayment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentPeriodicPayment", "crdr": "debit", "presentation": ["http://femasys.com/role/NotesPayableDetails"], "lang": { "en-us": { "role": { "label": "Monthly principal and interest payments", "documentation": "Amount of the required periodic payments including both interest and principal payments." } } }, "auth_ref": ["r11", "r42"] }, "us-gaap_DebtInstrumentRedemptionPricePercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentRedemptionPricePercentage", "presentation": [
"http://femasys.com/role/ConvertibleNotesWithWarrantsNovember2023FinancingSummaryDetails"], "lang": { "en-us": { "role": { "label": "Notes redeem at premium, percentage", "documentation": "Percentage price of original principal amount of debt at which debt can be redeemed by the issuer." } } }, "auth_ref": ["r102"] }, "us-gaap_DebtInstrumentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentTable", "presentation": ["http://femasys.com/role/ConvertibleNotesWithWarrantsNovember2023FinancingConvertibleNotesPayableDetails",
"http://femasys.com/role/ConvertibleNotesWithWarrantsNovember2023FinancingSummaryDetails",
"http://femasys.com/role/ConvertibleNotesWithWarrantsNovember2023FinancingWarrantsDetails", "http://femasys.com/role/NotesPayableDetails"], "lang": { "en-us": { "role": { "label": "Schedule of Long-Term Debt Instruments [Table]", "documentation": "Disclosure of information about long-term debt instrument or arrangement." } } }, "auth_ref": ["r11", "r28", "r31", "r41", "r88", "r89", "r148", "r237", "r238", "r239", "r240", "r241", "r243", "r248", "r249", "r250", "r251", "r253", "r254", "r255", "r256", "r257", "r258", "r261", "r618", "r619", "r620", "r621", "r622", "r644", "r691", "r733", "r735"] }, "us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet", "crdr": "debit", "presentation": [
"http://femasys.com/role/ConvertibleNotesWithWarrantsNovember2023FinancingConvertibleNotesPayableDetails"], "lang": { "en-us": { "role": { "label": "Unamortized discount and debt issuance costs", "documentation": "Amount of unamortized debt discount (premium) and debt issuance costs." } } }, "auth_ref": ["r248", "r264", "r406", "r407", "r408", "r619", "r620", "r644"] }, "us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNetAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNetAbstract", "presentation": ["http://femasys.com/role/ConvertibleNotesWithWarrantsNovember2023FinancingConvertibleNotesPayableDetails"], "lang": { "en-us": { "role": { "label": "Convertible Notes Payable [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentsAbstract", "presentation": [
"http://femasys.com/role/ConvertibleNotesWithWarrantsNovember2023FinancingConvertibleNotesPayableDetails",
"http://femasys.com/role/ConvertibleNotesWithWarrantsNovember2023FinancingSummaryDetails", "http://femasys.com/role/NotesPayableDetails"], "lang": { "en-us": { "role": { "terseLabel": "Notes Payable [Abstract]", "label": "Convertible Notes [Abstract]" } } }, "auth_ref": [] },
"femy_DeferredOfferingCostsReclassifiedToAdditionalPaidInCapital": { "xbrltype": "monetaryItemType", "nsuri": "http://femasys.com/20240630", "localname": "DeferredOfferingCostsReclassifiedToAdditionalPaidInCapital", "crdr": "credit", "presentation": ["http://femasys.com/role/CondensedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "documentation": "The amount of offering costs from noncash transactions included in deferred offering costs reclassified to additional paid-in-capital.", "label": "Deferred Offering Costs Reclassified to Additional Paid-In-Capital", "terseLabel": "Deferred offering costs reclassified to additional paid-in-capital" } } }, "auth_ref": [] }, "us-gaap_Depreciation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Depreciation", "crdr": "debit", "presentation": ["http://femasys.com/role/CondensedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "terseLabel": "Depreciation", "label": "Depreciation", "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation." } } }, "auth_ref": ["r4", "r23"] }, "us-gaap_DepreciationAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DepreciationAndAmortization", "crdr": "debit", "presentation": ["http://femasys.com/role/CondensedStatementsOfComprehensiveLoss"], "lang": { "en-us": { "role": { "label": "Depreciation and amortization", "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production." } } }, "auth_ref": ["r4", "r23"] }, "us-gaap_DisaggregationOfRevenueAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisaggregationOfRevenueAbstract", "presentation": ["http://femasys.com/role/RevenueRecognitionDetails"], "lang": { "en-us": { "role": { "terseLabel": "Revenue Recognition [Abstract]", "label": "Disaggregation of Revenue [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DisaggregationOfRevenueLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisaggregationOfRevenueLineItems", "presentation": ["http://femasys.com/role/RevenueRecognitionDetails"], "lang": { "en-us": { "role": { "label": "Disaggregation of Revenue [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r294", "r624", "r625", "r626", "r627", "r628", "r629", "r630"] }, "us-gaap_DisaggregationOfRevenueTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisaggregationOfRevenueTable", "presentation": ["http://femasys.com/role/RevenueRecognitionDetails"], "lang": { "en-us": { "role": { "label": "Disaggregation of Revenue [Table]", "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor." } } }, "auth_ref": ["r294", "r624", "r625", "r626", "r627", "r628", "r629", "r630"] }, "us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock", "presentation": [
"http://femasys.com/role/EquityIncentivePlansAndWarrantsTables"], "lang": { "en-us": { "role": { "terseLabel": "Share-based Compensation Expense", "label": "Disclosure of Share-Based Compensation Arrangements by Share-Based Payment Award [Table Text Block]", "documentation": "Tabular disclosure of share-based payment arrangement." } } }, "auth_ref": ["r6", "r35"] }, "us-gaap_DividendsCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DividendsCommonStock", "crdr": "debit", "presentation": ["http://femasys.com/role/StockholdersEquityDetails"], "lang": { "en-us": { "role": { "label": "Dividends declared or paid", "documentation": "Amount of paid and unpaid common stock dividends declared with the form of settlement in cash, stock and payment-in-kind (PIK)." } } }, "auth_ref": ["r2", "r90"] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalPeriodFocus", "presentation": ["http://femasys.com/role/DocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] },
"dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalYearFocus", "presentation": ["http://femasys.com/role/DocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodEndDate", "presentation": ["http://femasys.com/role/DocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentQuarterlyReport", "presentation": ["http://femasys.com/role/DocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": ["r674"] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentTransitionReport", "presentation": ["http://femasys.com/role/DocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": ["r675"] },
"dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentType", "presentation": [
"http://femasys.com/role/DocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareAbstract", "lang": { "en-us": { "role": { "label": "Net Loss per Share Attributable to Common Stockholders [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareBasic", "presentation": ["http://femasys.com/role/CondensedStatementsOfComprehensiveLoss",
"http://femasys.com/role/NetLossPerShareAttributableToCommonStockholdersDetails"], "lang": { "en-us": { "role": { "label": "Net loss per share attributable to common stockholders, basic (in dollars per share)", "terseLabel": "Net loss per share attributable to common stockholders, basic (in dollars per share)", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": ["r136", "r154", "r155", "r156", "r157", "r158", "r159", "r164", "r167", "r179", "r180", "r181", "r185", "r359", "r362", "r375", "r376", "r460", "r474", "r611"] }, "us-gaap_EarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareDiluted", "presentation": ["http://femasys.com/role/CondensedStatementsOfComprehensiveLoss",
"http://femasys.com/role/NetLossPerShareAttributableToCommonStockholdersDetails"], "lang": { "en-us": { "role": { "label": "Net loss per share attributable to common stockholders, diluted (in dollars per share)", "terseLabel": "Net loss per share attributable to common stockholders, diluted (in dollars per share)", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": ["r136", "r154", "r155", "r156", "r157", "r158", "r159", "r167", "r179", "r180", "r181", "r185", "r359", "r362", "r375", "r376", "r460", "r474", "r611"] }, "us-gaap_EarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareTextBlock", "presentation": [
"http://femasys.com/role/NetLossPerShareAttributableToCommonStockholders"], "lang": { "en-us": { "role": { "label": "Net Loss per Share Attributable to Common Stockholders", "documentation": "The entire disclosure for earnings per share." } } }, "auth_ref": ["r163", "r182", "r183", "r184"] }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectiveIncomeTaxRateContinuingOperations", "presentation": ["http://femasys.com/role/IncomeTaxesDetails"], "lang": { "en-us": { "role": { "label":

"Effective tax rate", "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": ["r341", "r636"] }, "us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract", "presentation": ["http://femasys.com/role/IncomeTaxesDetails"], "lang": { "en-us": { "role": { "label": "Effective Income Tax Rate Reconciliation, Percent [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "crdr": "debit", "presentation": ["http://femasys.com/role/EquityIncentivePlansAndWarrantsSharebasedCompensationExpenseDetails"], "lang": { "en-us": { "role": { "terseLabel": "Share-based compensation expense expected to be recognized for employees and nonemployees", "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount", "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement." } } }, "auth_ref": ["r335"] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "presentation": ["http://femasys.com/role/EquityIncentivePlansAndWarrantsSharebasedCompensationExpenseDetails"], "lang": { "en-us": { "role": { "label": "Weighted-average period over which unrecognized compensation is expected to be recognized", "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r335"] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions", "crdr": "debit", "presentation": ["http://femasys.com/role/EquityIncentivePlansAndWarrantsSharebasedCompensationExpenseDetails"], "lang": { "en-us": { "role": { "label": "Unrecognized expenses", "documentation": "Amount of cost to be recognized for option under share-based payment arrangement." } } }, "auth_ref": ["r723"] }, "us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis", "presentation": ["http://femasys.com/role/EquityIncentivePlansAndWarrantsEmployeeStockPurchasePlanDetails", "http://femasys.com/role/EquityIncentivePlansAndWarrantsInducementGrantDetails", "http://femasys.com/role/EquityIncentivePlansAndWarrantsStockOptionPlanActivityDetails", "http://femasys.com/role/EquityIncentivePlansAndWarrantsTables"], "lang": { "en-us": { "role": { "label": "Employee Stock Ownership Plan (ESOP) Name [Axis]", "documentation": "Information by name of employee stock ownership plan." } } }, "auth_ref": ["r38"] }, "us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeStockOwnershipPlanESOPDisclosuresLineItems", "presentation": ["http://femasys.com/role/EquityIncentivePlansAndWarrantsEmployeeStockPurchasePlanDetails"], "lang": { "en-us": { "role": { "label": "Employee Stock Ownership Plan (ESOP) Disclosures [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeStockOwnershipPlanESOPPlanDomain", "presentation": ["http://femasys.com/role/EquityIncentivePlansAndWarrantsEmployeeStockPurchasePlanDetails", "http://femasys.com/role/EquityIncentivePlansAndWarrantsInducementGrantDetails", "http://femasys.com/role/EquityIncentivePlansAndWarrantsStockOptionPlanActivityDetails", "http://femasys.com/role/EquityIncentivePlansAndWarrantsTables"], "lang": { "en-us": { "role": { "label": "Employee Stock Ownership Plan (ESOP), Plan [Domain]", "documentation": "Entities identify multiple employee stock ownership plans by unique name." } } }, "auth_ref": ["r39"] }, "femy_EmployeeStockPurchasePlanAbstract": { "xbrltype": "stringItemType", "nsuri": "http://femasys.com/20240630", "localname": "EmployeeStockPurchasePlanAbstract", "presentation": ["http://femasys.com/role/EquityIncentivePlansAndWarrantsEmployeeStockPurchasePlanDetails"], "lang": { "en-us": { "role": { "label": "Employee Stock Purchase Plan [Abstract]", "terseLabel": "Employee Stock Purchase Plan [Abstract]" } } }, "auth_ref": [] }, "femy_EmployeeStockPurchasePlanMember": { "xbrltype": "domainItemType", "nsuri": "http://femasys.com/20240630", "localname": "EmployeeStockPurchasePlanMember", "presentation": ["http://femasys.com/role/EquityIncentivePlansAndWarrantsEmployeeStockPurchasePlanDetails"], "lang": { "en-us": { "role": { "documentation": "The Employee Stock Purchase Plan (the \"ESPP\") allows eligible full-time employees to purchase shares of common stock at 90 percent of the lower of the fair market value of a share of common stock on the first or last day of the quarter.", "label": "Employee Stock Purchase Plan [Member]", "terseLabel": "Employee Stock Purchase Plan [Member]" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine1", "presentation": ["http://femasys.com/role/DocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine2", "presentation": ["http://femasys.com/role/DocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCityOrTown", "presentation": ["http://femasys.com/role/DocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressPostalZipCode", "presentation": ["http://femasys.com/role/DocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressStateOrProvince", "presentation": ["http://femasys.com/role/DocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCentralIndexKey", "presentation": ["http://femasys.com/role/DocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": ["r672"] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCommonStockSharesOutstanding", "presentation": ["http://femasys.com/role/DocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCurrentReportingStatus", "presentation": ["http://femasys.com/role/DocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityEmergingGrowthCompany", "presentation": ["http://femasys.com/role/DocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": ["r672"] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityExTransitionPeriod", "presentation": ["http://femasys.com/role/DocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Ex Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": ["r679"] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFileNumber", "presentation": ["http://femasys.com/role/DocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFilerCategory", "presentation": ["http://femasys.com/role/DocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": ["r672"] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityIncorporationStateCountryCode", "presentation": ["http://femasys.com/role/DocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityInteractiveDataCurrent", "presentation": ["http://femasys.com/role/DocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": ["r678"] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityRegistrantName", "presentation": ["http://femasys.com/role/DocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": ["r672"] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityShellCompany", "presentation": ["http://femasys.com/role/DocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": ["r672"] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntitySmallBusiness", "presentation": ["http://femasys.com/role/DocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": ["r672"] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityTaxIdentificationNumber", "presentation": ["http://femasys.com/role/DocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The

```
Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r672" ] }, "us-gaap_EquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityAbstract", "lang": { "en-us": { "role": { "label": "Stockholders' Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityComponentDomain", "presentation": [ "http://femasys.com/role/CondensedStatementsOfStockholdersEquity", "http://femasys.com/role/ConvertibleNotesWithWarrantsNovember2023FinancingSummaryDetails", "http://femasys.com/role/StockholdersEquityDetails" ], "lang": { "en-us": { "role": { "label": "Equity Component [Domain]", "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": [ "r7", "r115", "r133", "r134", "r135", "r149", "r150", "r151", "r153", "r158", "r160", "r162", "r187", "r205", "r206", "r210", "r283", "r349", "r350", "r356", "r357", "r358", "r360", "r361", "r362", "r367", "r368", "r369", "r370", "r371", "r372", "r374", "r400", "r401", "r402", "r403", "r404", "r405", "r409", "r410", "r414", "r473", "r487", "r488", "r489", "r505", "r571" ] }, "femy_EquityDistributionAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://femasys.com/20240630", "localname": "EquityDistributionAgreementMember", "presentation": [ "http://femasys.com/role/StockholdersEquityDetails" ], "lang": { "en-us": { "role": { "documentation": "Equity distribution agreement is one under which a supplier or manufacturer of goods agrees that an independent third party will market and sell the goods.", "label": "Equity Distribution Agreement [Member]" } } }, "auth_ref": [] }, "femy_EquityIncentivePlansAndWarrantsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://femasys.com/20240630", "localname": "EquityIncentivePlansAndWarrantsAbstract", "lang": { "en-us": { "role": { "label": "Equity Incentive Plans and Warrants [Abstract]" } } }, "auth_ref": [] }, "femy_EquityWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://femasys.com/20240630", "localname": "EquityWarrantsMember", "presentation": [ "http://femasys.com/role/CondensedStatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "documentation": "Equity Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.", "label": "Equity Warrants [Member]", "terseLabel": "Warrants [Member]" } } }, "auth_ref": [] }, "femy_ExpirationOfWarrant": { "xbrltype": "monetaryItemType", "nsuri": "http://femasys.com/20240630", "localname": "ExpirationOfWarrant", "crdr": "credit", "presentation": [ "http://femasys.com/role/CondensedStatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "documentation": "The warrants expired during the period.", "label": "Expiration of Warrant" } } }, "auth_ref": [] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "presentation": [ "http://femasys.com/role/CashAndCashEquivalentsDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r378", "r379", "r392", "r637" ] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "presentation": [ "http://femasys.com/role/CashAndCashEquivalentsDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value, Recurring and Nonrecurring [Table]", "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis." } } }, "auth_ref": [ "r378", "r379", "r392", "r637" ] }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain", "presentation": [ "http://femasys.com/role/CashAndCashEquivalentsDetails" ], "lang": { "en-us": { "role": { "label": "Asset Class [Domain]", "documentation": "Class of asset." } } }, "auth_ref": [ "r383", "r384", "r385", "r386", "r387", "r388", "r393", "r638" ] }, "us-gaap_FairValueByAssetClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueByAssetClassAxis", "presentation": [ "http://femasys.com/role/CashAndCashEquivalentsDetails" ], "lang": { "en-us": { "role": { "label": "Asset Class [Axis]", "documentation": "Information by class of asset." } } }, "auth_ref": [ "r383", "r384", "r385", "r386", "r387", "r388", "r393", "r638" ] }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueByFairValueHierarchyLevelAxis", "presentation": [ "http://femasys.com/role/CashAndCashEquivalentsDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value Hierarchy and NAV [Axis]", "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient." } } }, "auth_ref": [ "r250", "r297", "r298", "r299", "r300", "r301", "r302", "r377", "r379", "r380", "r381", "r382", "r391", "r392", "r394", "r421", "r422", "r423", "r619", "r620", "r631", "r632", "r633", "r637", "r640" ] }, "us-gaap_FairValueDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueDisclosuresAbstract", "lang": { "en-us": { "role": { "label": "Fair Value [Abstract]" } } }, "auth_ref": [] }, "us-gaap_FairValueDisclosuresTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueDisclosuresTextBlock", "presentation": [ "http://femasys.com/role/FairValue" ], "lang": { "en-us": { "role": { "label": "Fair Value", "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information." } } }, "auth_ref": [ "r387", "r389", "r390", "r391", "r394", "r395", "r396", "r397", "r398", "r459", "r637", "r641" ] }, "us-gaap_FairValueInputsLevel1Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel1Member", "presentation": [ "http://femasys.com/role/CashAndCashEquivalentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Level 1 [Member]", "label": "Fair Value, Inputs, Level 1 [Member]", "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date." } } }, "auth_ref": [ "r250", "r297", "r302", "r379", "r392", "r421", "r631", "r632", "r633", "r637" ] }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementsFairValueHierarchyDomain", "presentation": [ "http://femasys.com/role/CashAndCashEquivalentsDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value Hierarchy and NAV [Domain]", "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value." } } }, "auth_ref": [ "r250", "r297", "r298", "r299", "r300", "r301", "r302", "r377", "r379", "r380", "r381", "r382", "r391", "r392", "r394", "r421", "r422", "r423", "r619", "r620", "r631", "r632", "r633", "r637", "r640" ] }, "femy_FemVueMember": { "xbrltype": "domainItemType", "nsuri": "http://femasys.com/20240630", "localname": "FemVueMember", "presentation": [ "http://femasys.com/role/RevenueRecognitionDetails" ], "lang": { "en-us": { "role": { "documentation": "Pressure management device evaluates the women's fallopian tubes after a FemBloc procedure and is part of the FemBloc validation study.", "label": "FemVue [Member]", "terseLabel": "FemVue [Member]" } } }, "auth_ref": [] }, "us-gaap_FinanceLeasePrincipalPayments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeasePrincipalPayments", "crdr": "credit", "presentation": [ "http://femasys.com/role/CondensedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Payments under lease obligations", "label": "Finance Lease, Principal Payments", "documentation": "Amount of cash outflow for principal payment on finance lease." } } }, "auth_ref": [ "r411", "r412" ] }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsNet", "crdr": "debit", "presentation": [ "http://femasys.com/role/CondensedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Intangible assets, net of accumulated amortization", "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r428", "r707" ] }, "femy_FollowUpPeriodForInterimAnalysisOfClinicalData": { "xbrltype": "durationItemType", "nsuri": "http://femasys.com/20240630", "localname": "FollowUpPeriodForInterimAnalysisOfClinicalData", "presentation": [ "http://femasys.com/role/OrganizationNatureOfBusinessAndLiquidityDetails" ], "lang": { "en-us": { "role": { "documentation": "Follow-up period for interim analysis of clinical data for permanent birth control", "label": "Follow-up Period for Interim Analysis of Clinical Data", "terseLabel": "Follow-up period for interim analysis of clinical data for permanent birth control" } } }, "auth_ref": [] }, "femy_FranchiseTaxes": { "xbrltype": "monetaryItemType", "nsuri": "http://femasys.com/20240630", "localname": "FranchiseTaxes", "crdr": "credit", "presentation": [ "http://femasys.com/role/AccruedExpensesDetails" ], "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to franchise taxes.", "label": "Franchise Taxes", "terseLabel": "Franchise taxes" } } }, "auth_ref": [] }, "us-gaap_FurnitureAndFixturesGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FurnitureAndFixturesGross", "crdr": "debit", "presentation": [ "http://femasys.com/role/CondensedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Furniture and fixtures", "documentation": "Amount before accumulated depreciation of equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases." } } }, "auth_ref": [ "r81" ] }, "us-gaap_GainLossOnDispositionOfAssets1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GainLossOnDispositionOfAssets1", "crdr": "credit", "presentation": [ "http://femasys.com/role/CondensedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Loss on disposal of assets", "label": "Gain (Loss) on Disposition of Assets", "documentation": "Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee." } } }, "auth_ref": [ "r689" ] }, "us-gaap_GeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GeneralAndAdministrativeExpense", "crdr": "debit", "presentation": [ "http://femasys.com/role/CondensedStatementsOfComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "General and administrative", "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line." } } }, "auth_ref": [ "r69", "r553" ] }, "us-gaap_GeneralAndAdministrativeExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GeneralAndAdministrativeExpenseMember", "presentation": [ "http://femasys.com/role/EquityIncentivePlansAndWarrantsSharebasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "label": "General and Administrative [Member]", "documentation": "Primary financial statement caption encompassing general and administrative expense." } } }, "auth_ref": [ "r69" ] }, "us-gaap_GranteeStatusAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GranteeStatusAxis", "presentation": [ "http://femasys.com/role/EquityIncentivePlansAndWarrantsStockOptionPlanActivityDetails" ], "lang": { "en-us": { "role": { "label": "Grantee Status [Axis]", "documentation": "Information by status of recipient to whom award is granted." } } }, "auth_ref": [ "r304", "r306", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r325", "r326", "r327", "r328", "r329", "r330", "r331",
```

```
"r332", "r333" ] }, "us-gaap_GranteeStatusDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"GranteeStatusDomain", "presentation": [ "http://femasys.com/role/EquityIncentivePlansAndWarrantsStockOptionPlanActivityDetails" ], "lang": { "en-us": {
"role": { "label": "Grantee Status [Domain]", "documentation": "Status of recipient to whom award is granted." } } }, "auth_ref": [ "r304", "r306", "r308",
"r309", "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r325", "r326", "r327",
"r328", "r329", "r330", "r331", "r332", "r333" ] }, "femy_IncentiveAndOtherCompensationCostsCurrent": { "xbrltype": "monetaryItemType", "nsuri":
"http://femasys.com/20240630", "localname": "IncentiveAndOtherCompensationCostsCurrent", "crdr": "credit", "presentation": [
"http://femasys.com/role/AccruedExpensesDetails" ], "lang": { "en-us": { "role": { "documentation": "The carrying values as of the balance sheet date of
obligations incurred through that date and payable for obligations related to incentive and other compensation costs.", "label": "Incentive and Other
Compensation Costs, Current", "terseLabel": "Incentive and other compensation costs" } } }, "auth_ref": [] }, "us-
gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "crdr": "credit",
"presentation": [ "http://femasys.com/role/CondensedStatementsOfComprehensiveLoss" ], "lang": { "en-us": { "role": { "totalLabel": "Loss before income taxes",
"label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "documentation": "Amount of income (loss) from continuing
operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to
noncontrolling interest." } } }, "auth_ref": [ "r65", "r100", "r105", "r461", "r471", "r613", "r614", "r699", "r701", "r702", "r703", "r704" ] }, "us-
gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementAbstract", "lang": { "en-
us": { "role": { "label": "Statements of Comprehensive Loss [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeStatementLocationAxis": { "xbrltype":
"stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementLocationAxis", "presentation": [
"http://femasys.com/role/EquityIncentivePlansAndWarrantsSharebasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "label": "Income Statement
Location [Axis]", "documentation": "Information by location in statement of income where disaggregated amount has been reported." } } }, "auth_ref": [ "r211",
"r217", "r218", "r384", "r388", "r393", "r484", "r486", "r556", "r606", "r639", "r746" ] }, "us-gaap_IncomeStatementLocationDomain": { "xbrltype":
"domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementLocationDomain", "presentation": [
"http://femasys.com/role/EquityIncentivePlansAndWarrantsSharebasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "label": "Income Statement
Location [Domain]", "documentation": "Location in statement of income where disaggregated amount has been reported." } } }, "auth_ref": [ "r217", "r218",
"r384", "r388", "r393", "r484", "r486", "r556", "r606", "r639", "r746" ] }, "us-gaap_IncomeTaxDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "IncomeTaxDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Income Taxes [Abstract]" } } },
"auth_ref": [] }, "us-gaap_IncomeTaxDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"IncomeTaxDisclosureTextBlock", "presentation": [ "http://femasys.com/role/IncomeTaxes" ], "lang": { "en-us": { "role": { "label": "Income Taxes [Text
Block]", "documentation": "The entire disclosure for income tax." } } }, "auth_ref": [ "r147", "r339", "r341", "r342", "r343", "r344", "r345", "r346", "r351",
"r353", "r354", "r355", "r501", "r636" ] }, "us-gaap_IncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "IncomeTaxExpenseBenefit", "crdr": "debit", "presentation": [ "http://femasys.com/role/CondensedStatementsOfComprehensiveLoss" ], "lang": { "en-
us": { "role": { "terseLabel": "Income tax benefit", "label": "Income Tax Expense (Benefit)", "documentation": "Amount of current income tax expense (benefit)
and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": [ "r107", "r112", "r161", "r162", "r186", "r195", "r198",
"r340", "r341", "r352", "r475", "r636" ] }, "us-gaap_IncomeTaxesPaidNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "IncomeTaxesPaidNet", "crdr": "credit", "presentation": [ "http://femasys.com/role/CondensedStatementsOfCashFlows" ], "lang": { "en-us": {
"role": { "label": "Taxes", "documentation": "Amount, after refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax." } } },
"auth_ref": [ "r16", "r142", "r347", "r348" ] }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "IncreaseDecreaseInAccountsPayable", "crdr": "debit", "presentation": [ "http://femasys.com/role/CondensedStatementsOfCashFlows" ],
"lang": { "en-us": { "role": { "terseLabel": "Accounts payable", "label": "Increase (Decrease) in Accounts Payable", "documentation": "The increase (decrease)
during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for
goods and services received that are used in an entity's business." } } }, "auth_ref": [ "r3" ] }, "us-gaap_IncreaseDecreaseInAccountsReceivable": {
"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccountsReceivable", "crdr": "credit",
"presentation": [ "http://femasys.com/role/CondensedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Accounts receivable", "label":
"Increase (Decrease) in Accounts Receivable", "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one
business cycle) from customers for the credit sale of goods and services." } } }, "auth_ref": [ "r3" ] }, "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccruedLiabilities", "crdr": "debit", "presentation":
[ "http://femasys.com/role/CondensedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued expenses", "label": "Increase (Decrease)
in Accrued Liabilities", "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid."
} } }, "auth_ref": [ "r3" ] }, "us-gaap_IncreaseDecreaseInInventories": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "IncreaseDecreaseInInventories", "crdr": "credit", "presentation": [ "http://femasys.com/role/CondensedStatementsOfCashFlows" ], "lang": { "en-
us": { "role": { "negatedLabel": "Inventory", "label": "Increase (Decrease) in Inventories", "documentation": "The increase (decrease) during the reporting
period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating
activities." } } }, "auth_ref": [ "r3" ] }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "xbrltype": "stringItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "presentation": [
"http://femasys.com/role/CondensedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Changes in operating assets and liabilities:" } } },
"auth_ref": [] }, "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"IncreaseDecreaseInOperatingLeaseLiability", "crdr": "debit", "presentation": [ "http://femasys.com/role/CondensedStatementsOfCashFlows" ], "lang": { "en-us":
{ "role": { "label": "Lease liabilities", "documentation": "Amount of increase (decrease) in obligation for operating lease." } } }, "auth_ref": [ "r681",
"r688" ] }, "us-gaap_IncreaseDecreaseInOtherOperatingAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"IncreaseDecreaseInOtherOperatingAssets", "crdr": "credit", "presentation": [ "http://femasys.com/role/CondensedStatementsOfCashFlows" ], "lang": { "en-us": {
"role": { "negatedLabel": "Prepaid and other assets", "label": "Increase (Decrease) in Other Operating Assets", "documentation": "Amount of increase
(decrease) in operating assets classified as other." } } }, "auth_ref": [ "r3" ] }, "us-gaap_IncreaseDecreaseInOtherOperatingLiabilities": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOtherOperatingLiabilities", "crdr": "debit", "presentation": [
"http://femasys.com/role/CondensedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Other liabilities", "documentation": "Amount of increase
(decrease) in operating liabilities classified as other." } } }, "auth_ref": [ "r3" ] }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "presentation": [
"http://femasys.com/role/CondensedStatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Stockholders' Equity
[Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref":
[] }, "us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "IncrementalCommonSharesAttributableToCallOptionsAndWarrants", "presentation": [
"http://femasys.com/role/NetLossPerShareAttributableToCommonStockholdersDetails" ], "lang": { "en-us": { "role": { "label": "Warrants to purchase common stock
(in shares)", "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of call options
and warrants using the treasury stock method." } } }, "auth_ref": [ "r168", "r169", "r170", "r181" ] },
"femy_IncrementalCommonSharesAttributableToDilutiveEffectOfPreFundedWarrantsCommonWarrantsAndPlacementAgentWarrants": { "xbrltype": "sharesItemType", "nsuri":
"http://femasys.com/20240630", "localname": "IncrementalCommonSharesAttributableToDilutiveEffectOfPreFundedWarrantsCommonWarrantsAndPlacementAgentWarrants",
"presentation": [ "http://femasys.com/role/NetLossPerShareAttributableToCommonStockholdersDetails" ], "lang": { "en-us": { "role": { "documentation":
"Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of pre-funded warrants, common warrants and
placement agent warrants using the treasury stock method.", "label": "Incremental Common Shares Attributable to Dilutive Effect of Pre-Funded Warrants, Common
Warrants and Placement Agent Warrants", "terseLabel": "Warrants to purchase common stock in connection financing (in shares)" } } }, "auth_ref": [] }, "us-
gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements", "presentation": [
"http://femasys.com/role/NetLossPerShareAttributableToCommonStockholdersDetails" ], "lang": { "en-us": { "role": { "label": "Options to purchase common stock
(in shares)", "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based
payment arrangements using the treasury stock method." } } }, "auth_ref": [ "r168", "r169", "r171", "r181", "r307" ] }, "femy_InducementGrantAbstract": {
"xbrltype": "stringItemType", "nsuri": "http://femasys.com/20240630", "localname": "InducementGrantAbstract", "presentation": [
"http://femasys.com/role/EquityIncentivePlansAndWarrantsInducementGrantDetails" ], "lang": { "en-us": { "role": { "label": "Inducement Grant [Abstract]" } }
}, "auth_ref": [] }, "femy_InducementGrantMember": { "xbrltype": "domainItemType", "nsuri": "http://femasys.com/20240630", "localname":
"InducementGrantMember", "presentation": [ "http://femasys.com/role/EquityIncentivePlansAndWarrantsInducementGrantDetails",
"http://femasys.com/role/EquityIncentivePlansAndWarrantsTables" ], "lang": { "en-us": { "role": { "documentation": "Inducement grants are a type of equity
award to newly hired personnel.", "label": "Inducement Grant [Member]", "terseLabel": "Inducement Grant [Member]" } } }, "auth_ref": [] },
"ecd_InsiderTradingArrLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTradingArrLineItems", "lang":
{ "en-us": { "role": { "label": "Insider Trading Arrangements [Line Items]" } } }, "auth_ref": [ "r676" ] }, "us-gaap_InterestExpenseDebt": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestExpenseDebt", "crdr": "debit", "presentation": [
"http://femasys.com/role/ConvertibleNotesWithWarrantsNovember2023FinancingConvertibleNotesPayableDetails", "http://femasys.com/role/NotesPayableDetails" ],
"lang": { "en-us": { "role": { "terseLabel": "Interest expense on loan", "verboseLabel": "Interest expense", "label": "Interest Expense, Debt",
"documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt." } } }, "auth_ref": [ "r71", "r256", "r265", "r621", "r622"
] }, "us-gaap_InterestExpenseDebtExcludingAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"InterestExpenseDebtExcludingAmortization", "crdr": "debit", "presentation": [
"http://femasys.com/role/ConvertibleNotesWithWarrantsNovember2023FinancingConvertibleNotesPayableDetails" ], "lang": { "en-us": { "role": { "label": "Coupon
interest expense", "documentation": "Represents the portion of interest incurred in the period on debt arrangements that was charged against earnings,
excluding amortization of debt discount (premium) and financing costs." } } }, "auth_ref": [ "r71", "r257", "r621", "r622" ] }, "us-
gaap_InterestExpenseNonoperating": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestExpenseNonoperating",
"crdr": "debit", "presentation": [ "http://femasys.com/role/CondensedStatementsOfComprehensiveLoss" ], "lang": { "en-us": { "role": { "negatedLabel":
"Interest expense", "label": "Interest Expense, Nonoperating", "documentation": "Amount of interest expense classified as nonoperating." } } }, "auth_ref": [
"r194", "r686" ] }, "us-gaap_InterestPaidNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestPaidNet",
```

```
"crdr": "credit", "presentation": [ "http://femasys.com/role/CondensedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Interest", "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount." } } }, "auth_ref": [ "r138", "r140", "r141" ] }, "us-gaap_InterestPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestPayableCurrent", "crdr": "credit", "presentation": [ "http://femasys.com/role/AccruedExpensesDetails",
"http://femasys.com/role/ConvertibleNotesWithWarrantsNovember2023FinancingConvertibleNotesPayableDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Accrued and unpaid interest", "terseLabel": "Accrued interest", "label": "Interest Payable, Current", "documentation": "Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r47" ] }, "us-gaap_InventoryDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Inventories [Abstract]" } } }, "auth_ref": [] }, "us-gaap_InventoryDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryDisclosureTextBlock", "presentation": [
"http://femasys.com/role/Inventories" ], "lang": { "en-us": { "role": { "label": "Inventories", "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory." } } }, "auth_ref": [ "r207" ] }, "us-gaap_InventoryFinishedGoods": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryFinishedGoods", "crdr": "debit", "presentation": [ "http://femasys.com/role/InventoriesDetails" ], "lang": { "en-us": { "role": { "label": "Finished goods", "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer." } } }, "auth_ref": [ "r682" ] }, "us-gaap_InventoryLIFOReservePeriodCharge": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryLIFOReservePeriodCharge", "crdr": "debit", "presentation": [
"http://femasys.com/role/CondensedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Inventory reserve write-off", "documentation": "The change in the inventory reserve representing the cumulative difference in cost between the first in, first out and the last in, first out inventory valuation methods, which change has been reflected in the statement of income during the period." } } }, "auth_ref": [ "r80" ] }, "us-gaap_InventoryNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryNet", "crdr": "debit", "presentation": [
"http://femasys.com/role/CondensedBalanceSheets", "http://femasys.com/role/InventoriesDetails" ], "lang": { "en-us": { "role": { "label": "Inventory, net", "totalLabel": "Inventory, net", "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer." } } }, "auth_ref": [ "r128", "r610", "r645" ] }, "us-gaap_InventoryRawMaterials": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryRawMaterials", "crdr": "debit", "presentation": [ "http://femasys.com/role/InventoriesDetails" ], "lang": { "en-us": { "role": { "label": "Materials", "documentation": "Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer." } } }, "auth_ref": [ "r684" ] }, "us-gaap_InventoryWorkInProcess": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryWorkInProcess", "crdr": "debit", "presentation": [
"http://femasys.com/role/InventoriesDetails" ], "lang": { "en-us": { "role": { "label": "Work in progress", "documentation": "Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer." } } }, "auth_ref": [ "r683" ] }, "us-gaap_InvestmentIncomeInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentIncomeInterest", "crdr": "credit", "presentation": [ "http://femasys.com/role/CondensedStatementsOfComprehensiveLoss" ], "lang": { "en-us": { "role": { "terseLabel": "Interest income", "label": "Investment Income, Interest", "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities." } } }, "auth_ref": [ "r186", "r193", "r198", "r614", "r685" ] },
"femy_JulyPromissoryNoteMember": { "xbrltype": "domainItemType", "nsuri": "http://femasys.com/20240630", "localname": "JulyPromissoryNoteMember", "presentation": [ "http://femasys.com/role/NotesPayableDetails" ], "lang": { "en-us": { "role": { "documentation": "Borrowing supported by a written promise to pay an obligation in July of 2023.", "label": "July Promissory Note [Member]", "terseLabel": "July Promissory Note [Member]" } } }, "auth_ref": [] },
"femy_JunePromissoryNoteMember": { "xbrltype": "domainItemType", "nsuri": "http://femasys.com/20240630", "localname": "JunePromissoryNoteMember", "presentation": [ "http://femasys.com/role/NotesPayableDetails" ], "lang": { "en-us": { "role": { "documentation": "Borrowing supported by a written promise to pay an obligation in June of 2022.", "label": "June Promissory Note [Member]" } } }, "auth_ref": [] }, "us-gaap_LeaseholdImprovementsGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeaseholdImprovementsGross", "crdr": "debit", "presentation": [
"http://femasys.com/role/CondensedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Leasehold improvements", "documentation": "Amount before accumulated depreciation of additions or improvements to assets held under a lease arrangement." } } }, "auth_ref": [ "r81" ] }, "us-gaap_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Liabilities", "crdr": "credit", "presentation": [
"http://femasys.com/role/CondensedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities", "label": "Liabilities", "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others." } } }, "auth_ref": [ "r11", "r46", "r47", "r48", "r51", "r52", "r53", "r54", "r146", "r204", "r227", "r228", "r229", "r230", "r231", "r232", "r233", "r234", "r235", "r364", "r365", "r366", "r399", "r528", "r612", "r670", "r718", "r736", "r737" ] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "presentation": [
"http://femasys.com/role/CondensedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities and stockholders' equity", "label": "Liabilities and Equity", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": [ "r61", "r99", "r468", "r645", "r692", "r706", "r732" ] }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquityAbstract", "presentation": [
"http://femasys.com/role/CondensedBalanceSheets" ], "lang": { "en-us": { "role": { "verboseLabel": "Liabilities and Stockholders' Equity", "label": "Liabilities and Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrent", "crdr": "credit", "presentation": [ "http://femasys.com/role/CondensedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total current liabilities", "label": "Liabilities, Current", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } }, "auth_ref": [ "r48", "r118", "r146", "r204", "r227", "r228", "r229", "r230", "r231", "r232", "r233", "r234", "r235", "r364", "r365", "r366", "r399", "r645", "r718", "r736", "r737" ] }, "us-gaap_LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrentAbstract", "presentation": [ "http://femasys.com/role/CondensedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Current liabilities:" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesNoncurrent", "crdr": "credit", "presentation": [ "http://femasys.com/role/CondensedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total long-term liabilities", "label": "Liabilities, Noncurrent", "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer." } } }, "auth_ref": [ "r11", "r51", "r52", "r53", "r54", "r146", "r204", "r227", "r228", "r229", "r230", "r231", "r232", "r233", "r234", "r235", "r364", "r365", "r366", "r399", "r718", "r736", "r737" ] }, "us-gaap_LiabilitiesNoncurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesNoncurrentAbstract", "presentation": [ "http://femasys.com/role/CondensedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Long-term liabilities:" } } }, "auth_ref": [] }, "us-gaap_LineOfCreditFacilityAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCreditFacilityAxis", "presentation": [ "http://femasys.com/role/NotesPayableDetails" ], "lang": { "en-us": { "role": { "label": "Lender Name [Axis]", "documentation": "Information by name of lender, which may be a single entity (for example, but not limited to, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit." } } }, "auth_ref": [ "r45", "r50", "r691", "r716", "r717" ] }, "us-gaap_LineOfCreditFacilityLenderDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCreditFacilityLenderDomain", "presentation": [ "http://femasys.com/role/NotesPayableDetails" ], "lang": { "en-us": { "role": { "label": "Line of Credit Facility, Lender [Domain]", "documentation": "Identification of the lender, which may be a single entity (for example, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit, including a letter of credit facility." } } }, "auth_ref": [ "r45", "r50", "r691", "r716" ] }, "femy_LiquidityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://femasys.com/20240630", "localname": "LiquidityAbstract", "presentation": [
"http://femasys.com/role/OrganizationNatureOfBusinessAndLiquidityDetails" ], "lang": { "en-us": { "role": { "label": "Liquidity [Abstract]", "terseLabel": "Liquidity [Abstract]" } } }, "auth_ref": [] }, "femy_LiquidityPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://femasys.com/20240630", "localname": "LiquidityPolicyTextBlock", "presentation": [ "http://femasys.com/role/OrganizationNatureOfBusinessAndLiquidityPolicies" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the liquidity.", "label": "Liquidity [Policy Text Block]", "terseLabel": "Liquidity" } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LocalPhoneNumber", "presentation": [ "http://femasys.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "us-gaap_LongtermDebtTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongtermDebtTypeAxis", "presentation": [
"http://femasys.com/role/ConvertibleNotesWithWarrantsNovember2023FinancingConvertibleNotesPayableDetails",
"http://femasys.com/role/ConvertibleNotesWithWarrantsNovember2023FinancingSummaryDetails" ], "lang": { "en-us": { "role": { "label": "Long-Term Debt, Type [Axis]", "documentation": "Information by type of long-term debt." } } }, "auth_ref": [ "r11", "r709", "r710", "r711" ] }, "us-gaap_LongtermDebtTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongtermDebtTypeDomain", "presentation": [
"http://femasys.com/role/ConvertibleNotesWithWarrantsNovember2023FinancingConvertibleNotesPayableDetails",
"http://femasys.com/role/ConvertibleNotesWithWarrantsNovember2023FinancingSummaryDetails" ], "lang": { "en-us": { "role": { "label": "Long-Term Debt, Type [Domain]", "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer." } } }, "auth_ref": [ "r11", "r25", "r709", "r710", "r711" ] }, "us-gaap_MachineryAndEquipmentGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MachineryAndEquipmentGross", "crdr": "debit", "presentation": [
"http://femasys.com/role/CondensedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Machinery and equipment", "documentation": "Amount before accumulated depreciation of tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment." } } }, "auth_ref": [ "r81" ] }, "srt_MaximumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MaximumMember", "presentation": [ "http://femasys.com/role/RevenueRecognitionDetails", "http://femasys.com/role/StockholdersEquityDetails" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]" } } }, "auth_ref": [ "r221", "r222", "r223", "r224", "r303", "r337", "r382", "r426", "r483", "r485", "r492", "r520", "r521", "r578", "r580", "r582", "r583", "r585", "r604", "r605", "r616", "r623", "r634", "r640", "r641", "r642", "r643", "r655", "r720", "r738", "r739", "r740", "r741", "r742", "r743" ] }, "srt_MinimumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MinimumMember", "presentation": [ "http://femasys.com/role/RevenueRecognitionDetails" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]" } } },
```

```
"auth_ref": [ "r221", "r222", "r223", "r224", "r303", "r337", "r382", "r426", "r483", "r485", "r492", "r520", "r521", "r578", "r580", "r582", "r583", "r585", "r604", "r605", "r616", "r623", "r634", "r640", "r641", "r642", "r655", "r720", "r738", "r739", "r740", "r741", "r742", "r743" ] }, "us-gaap_MoneyMarketFundsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MoneyMarketFundsMember", "presentation": [ "http://femasys.com/role/CashAndCashEquivalentsDetails" ], "lang": { "en-us": { "role": { "label": "Money Market Funds [Member]", "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities." } } }, "auth_ref": [ "r722" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "presentation": [ "http://femasys.com/role/CondensedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash provided by financing activities", "label": "Net Cash Provided by (Used in) Financing Activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } }, "auth_ref": [ "r139" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": [ "http://femasys.com/role/CondensedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash flows from financing activities:" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "presentation": [ "http://femasys.com/role/CondensedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash used in investing activities", "label": "Net Cash Provided by (Used in) Investing Activities", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, "auth_ref": [ "r139" ] }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "presentation": [ "http://femasys.com/role/CondensedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash flows from investing activities:" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivities", "presentation": [ "http://femasys.com/role/CondensedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash used in operating activities", "label": "Net Cash Provided by (Used in) Operating Activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": [ "r75", "r76", "r77" ] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://femasys.com/role/CondensedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash flows from operating activities:" } } }, "auth_ref": [] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLoss", "crdr": "credit", "presentation": [ "http://femasys.com/role/CondensedStatementsOfCashFlows", "http://femasys.com/role/CondensedStatementsOfComprehensiveLoss", "http://femasys.com/role/CondensedStatementsOfStockholdersEquity", "http://femasys.com/role/OrganizationNatureOfBusinessAndLiquidityDetails" ], "lang": { "en-us": { "role": { "label": "Net loss", "totalLabel": "Net loss", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": [ "r68", "r77", "r101", "r116", "r131", "r132", "r135", "r146", "r152", "r154", "r155", "r156", "r157", "r158", "r161", "r162", "r177", "r204", "r227", "r228", "r229", "r230", "r231", "r232", "r233", "r234", "r235", "r359", "r362", "r376", "r399", "r472", "r550", "r569", "r570", "r668", "r718" ] }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLossAvailableToCommonStockholdersBasic", "crdr": "credit", "presentation": [ "http://femasys.com/role/CondensedStatementsOfComprehensiveLoss", "http://femasys.com/role/NetLossPerShareAttributableToCommonStockholdersDetails" ], "lang": { "en-us": { "role": { "label": "Net loss attributable to common stockholders, basic", "terseLabel": "Net loss attributable to common stockholders, basic", "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders." } } }, "auth_ref": [ "r137", "r154", "r155", "r156", "r157", "r164", "r165", "r178", "r181", "r362" ] }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLossAvailableToCommonStockholdersBasicAbstract", "presentation": [ "http://femasys.com/role/NetLossPerShareAttributableToCommonStockholdersDetails" ], "lang": { "en-us": { "role": { "label": "Net Income (Loss) Available to Common Stockholders, Basic [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLossAvailableToCommonStockholdersDiluted", "crdr": "credit", "presentation": [ "http://femasys.com/role/CondensedStatementsOfComprehensiveLoss", "http://femasys.com/role/NetLossPerShareAttributableToCommonStockholdersDetails" ], "lang": { "en-us": { "role": { "label": "Net loss attributable to common stockholders, diluted", "terseLabel": "Net loss attributable to common stockholders, diluted", "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders." } } }, "auth_ref": [ "r137", "r166", "r173", "r174", "r175", "r176", "r178", "r181" ] }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "presentation": [ "http://femasys.com/role/OrganizationNatureOfBusinessAndLiquidityPolicies" ], "lang": { "en-us": { "role": { "label": "Recently Issued Accounting Pronouncements Adopted and Not Yet Adopted", "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact." } } }, "auth_ref": [] }, "ecd_NonRule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrAdoptedFlag", "presentation": [ "http://femasys.com/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted", "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]" } } }, "auth_ref": [ "r677" ] }, "ecd_NonRule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrTrmntdFlag", "presentation": [ "http://femasys.com/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated", "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]" } } }, "auth_ref": [ "r677" ] }, "us-gaap_NonUsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NonUsMember", "presentation": [ "http://femasys.com/role/RevenueRecognitionDetails" ], "lang": { "en-us": { "role": { "label": "International [Member]", "documentation": "Countries excluding the United States of America (US)." } } }, "auth_ref": [ "r779", "r780", "r781", "r782" ] }, "us-gaap_NoncashInvestingAndFinancingItemsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NoncashInvestingAndFinancingItemsAbstract", "presentation": [ "http://femasys.com/role/CondensedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Non-cash investing and financing activities:" } } }, "auth_ref": [] }, "us-gaap_NonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NonoperatingIncomeExpense", "crdr": "credit", "presentation": [ "http://femasys.com/role/CondensedStatementsOfComprehensiveLoss" ], "lang": { "en-us": { "role": { "totalLabel": "Total other income (expense), net", "label": "Nonoperating Income (Expense)", "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)." } } }, "auth_ref": [ "r70" ] }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NonoperatingIncomeExpenseAbstract", "presentation": [ "http://femasys.com/role/CondensedStatementsOfComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Other income (expense):" } } }, "auth_ref": [] }, "us-gaap_NotesPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NotesPayableCurrent", "crdr": "credit", "presentation": [ "http://femasys.com/role/NotesPayableDetails" ], "lang": { "en-us": { "role": { "label": "Note payable", "documentation": "Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer." } } }, "auth_ref": [ "r46", "r47" ] }, "femy_November2023FinancingMember": { "xbrltype": "domainItemType", "nsuri": "http://femasys.com/20240630", "localname": "November2023FinancingMember", "presentation": [ "http://femasys.com/role/ConvertibleNotesWithWarrantsNovember2023FinancingConvertibleNotesPayableDetails", "http://femasys.com/role/ConvertibleNotesWithWarrantsNovember2023FinancingSummaryDetails", "http://femasys.com/role/ConvertibleNotesWithWarrantsNovember2023FinancingWarrantsDetails" ], "lang": { "en-us": { "role": { "documentation": "The November 2023 financing.", "label": "November 2023 Financing [Member]", "terseLabel": "November 2023 Financing [Member]" } } }, "auth_ref": [] }, "us-gaap_NumberOfOperatingSegments": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NumberOfOperatingSegments", "presentation": [ "http://femasys.com/role/OrganizationNatureOfBusinessAndLiquidityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of operating segments", "label": "Number of Operating Segments", "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues." } } }, "auth_ref": [ "r615", "r700" ] }, "femy_NumberOfProductsReceivedEUMDRAndCEMarkCertifications": { "xbrltype": "integerItemType", "nsuri": "http://femasys.com/20240630", "localname": "NumberOfProductsReceivedEUMDRAndCEMarkCertifications", "presentation": [ "http://femasys.com/role/OrganizationNatureOfBusinessAndLiquidityDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of products received European Union Medical Device Regulation (EU MDR) certificates and CE Mark certifications during the period.", "label": "Number of Products Received EU MDR and CE Mark Certifications", "terseLabel": "Number of products received EU MDR and CE Mark certifications" } } }, "auth_ref": [] }, "femy_NumberOfWarrantsExercised": { "xbrltype": "sharesItemType", "nsuri": "http://femasys.com/20240630", "localname": "NumberOfWarrantsExercised", "presentation": [ "http://femasys.com/role/EquityIncentivePlansAndWarrantsApril2023FinancingDetails", "http://femasys.com/role/StockholdersEquityDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of warrants exercised during the period.", "label": "Number of Warrants Exercised", "terseLabel": "Warrants exercised (in shares)" } } }, "auth_ref": [] }, "femy_NumberOfWomenEnrolledForClinicalReadout": { "xbrltype": "integerItemType", "nsuri": "http://femasys.com/20240630", "localname": "NumberOfWomenEnrolledForClinicalReadout", "presentation": [ "http://femasys.com/role/OrganizationNatureOfBusinessAndLiquidityDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of additional women enrolled for a clinical readout.", "label": "Number of Women Enrolled for Clinical Readout", "terseLabel": "Number of women enrolled for a clinical readout" } } }, "auth_ref": [] }, "femy_NumberOfWomenNeedToUseForInterimAnalysisOfClinicalData": { "xbrltype": "integerItemType", "nsuri": "http://femasys.com/20240630", "localname": "NumberOfWomenNeedToUseForInterimAnalysisOfClinicalData", "presentation": [ "http://femasys.com/role/OrganizationNatureOfBusinessAndLiquidityDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of women need to use for interim analysis of clinical data for permanent birth control", "label": "Number of Women Need to Use for Interim Analysis of Clinical Data", "terseLabel": "Number of women need to use for interim analysis of clinical data for permanent birth control" } } }, "auth_ref": [] }, "femy_NumberOfWomenUsedFemBlocForPermanentBirthControl": { "xbrltype": "integerItemType", "nsuri": "http://femasys.com/20240630", "localname":
```

```
"NumberOfWomenUsedFemBlocForPermanentBirthControl", "presentation": [ "http://femasys.com/role/OrganizationNatureOfBusinessAndLiquidityDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of women used FemBloc for permanent birth control", "label": "Number of Women Used FemBloc for Permanent Birth Control", "terseLabel": "Number of women used FemBloc for permanent birth control" } } }, "auth_ref": [] },
"femy_NumberOfYearWhereWomenSUsedForPermanentBirthControl": { "xbrltype": "durationItemType", "nsuri": "http://femasys.com/20240630", "localname": "NumberOfYearWhereWomenSUsedForPermanentBirthControl", "presentation": [ "http://femasys.com/role/OrganizationNatureOfBusinessAndLiquidityDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of year where women's used for permanent birth control.", "label": "Number of Year Where Women's Used for Permanent Birth Control", "terseLabel": "Number of year where women's used for permanent birth control." } } }, "auth_ref": [] },
"femy_OperatingAndFinanceLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://femasys.com/20240630", "localname": "OperatingAndFinanceLeaseLiabilityCurrent", "crdr": "credit", "presentation": [ "http://femasys.com/role/CondensedBalanceSheets" ], "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating and finance lease, classified as current.", "label": "Operating and Finance Lease, Liability, Current", "terseLabel": "Lease liabilities - current portion" } } }, "auth_ref": [] },
"femy_OperatingAndFinanceLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://femasys.com/20240630", "localname": "OperatingAndFinanceLeaseLiabilityNoncurrent", "crdr": "credit", "presentation": [ "http://femasys.com/role/CondensedBalanceSheets" ], "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating and finance lease, classified as noncurrent.", "label": "Operating and Finance Lease, Liability, Noncurrent", "verboseLabel": "Lease liabilities - long-term portion" } } }, "auth_ref": [] }, "us-gaap_OperatingExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingExpenses", "crdr": "debit", "presentation": [ "http://femasys.com/role/CondensedStatementsOfComprehensiveLoss" ], "lang": { "en-us": { "role": { "totalLabel": "Total operating expenses", "label": "Operating Expenses", "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense." } } }, "auth_ref": [] }, "us-gaap_OperatingExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingExpensesAbstract", "presentation": [ "http://femasys.com/role/CondensedStatementsOfComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Operating expenses:" } } }, "auth_ref": [] }, "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingIncomeLoss", "crdr": "credit", "presentation": [ "http://femasys.com/role/CondensedStatementsOfComprehensiveLoss" ], "lang": { "en-us": { "role": { "totalLabel": "Loss from operations", "label": "Operating Income (Loss)", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } }, "auth_ref": [ "r105", "r613", "r699", "r701", "r702", "r703", "r704" ] }, "femy_OperatingLeaseAndFinanceLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://femasys.com/20240630", "localname": "OperatingLeaseAndFinanceLeaseRightOfUseAsset", "crdr": "debit", "presentation": [ "http://femasys.com/role/CondensedBalanceSheets" ], "lang": { "en-us": { "role": { "documentation": "Amount of right-of-use asset from operating and finance lease.", "label": "Operating Lease and Finance Lease, Right-of-Use Asset", "terseLabel": "Lease right-of-use assets, net" } } }, "auth_ref": [] }, "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense", "crdr": "debit", "presentation": [ "http://femasys.com/role/CondensedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Amortization of right-of-use assets", "documentation": "Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease." } } }, "auth_ref": [ "r689" ] }, "femy_OrganizationAndNatureOfBusinessAbstract": { "xbrltype": "stringItemType", "nsuri": "http://femasys.com/20240630", "localname": "OrganizationAndNatureOfBusinessAbstract", "presentation": [ "http://femasys.com/role/OrganizationNatureOfBusinessAndLiquidityDetails" ], "lang": { "en-us": { "role": { "label": "Organization and Nature of Business [Abstract]", "terseLabel": "Organization and Nature of Business [Abstract]" } } }, "auth_ref": [] }, "femy_OrganizationAndNatureOfBusinessPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://femasys.com/20240630", "localname": "OrganizationAndNatureOfBusinessPolicyTextBlock", "presentation": [ "http://femasys.com/role/OrganizationNatureOfBusinessAndLiquidityPolicies" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the organization and nature of business.", "label": "Organization and Nature of Business [Policy Text Block]", "terseLabel": "Organization and Nature of Business" } } }, "auth_ref": [] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "lang": { "en-us": { "role": { "label": "Organization, Nature of Business, and Liquidity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "presentation": [ "http://femasys.com/role/OrganizationNatureOfBusinessAndLiquidity" ], "lang": { "en-us": { "role": { "terseLabel": "Organization, Nature of Business, and Liquidity", "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]", "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure." } } }, "auth_ref": [ "r43", "r94", "r493", "r494" ] }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAccruedLiabilitiesCurrent", "crdr": "credit", "presentation": [ "http://femasys.com/role/AccruedExpensesDetails" ], "lang": { "en-us": { "role": { "label": "Other", "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r47" ] }, "us-gaap_OtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAssetsCurrent", "crdr": "debit", "presentation": [ "http://femasys.com/role/CondensedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Prepaid and other current assets", "documentation": "Amount of current assets classified as other." } } }, "auth_ref": [ "r129", "r645" ] }, "us-gaap_OtherAssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAssetsNoncurrent", "crdr": "debit", "presentation": [ "http://femasys.com/role/CondensedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Other long-term assets", "documentation": "Amount of noncurrent assets classified as other." } } }, "auth_ref": [ "r122" ] }, "us-gaap_ParentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ParentMember", "presentation": [ "http://femasys.com/role/StockholdersEquityDetails" ], "lang": { "en-us": { "role": { "label": "Parent [Member]", "documentation": "Portion of equity, or net assets, in the consolidated entity attributable, directly or indirectly, to the parent. Excludes noncontrolling interests." } } }, "auth_ref": [] }, "us-gaap_PayablesAndAccrualsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PayablesAndAccrualsAbstract", "lang": { "en-us": { "role": { "label": "Accrued Expenses [Abstract]" } } }, "auth_ref": [] }, "us-gaap_PaymentsForRepurchaseOfCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsForRepurchaseOfCommonStock", "crdr": "credit", "presentation": [ "http://femasys.com/role/CondensedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Issuance costs for at-the-market sales of common stock", "label": "Payments for Repurchase of Common Stock", "documentation": "The cash outflow to reacquire common stock during the period." } } }, "auth_ref": [ "r73" ] }, "us-gaap_PaymentsOfDebtIssuanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsOfDebtIssuanceCosts", "crdr": "credit", "presentation": [ "http://femasys.com/role/ConvertibleNotesWithWarrantsNovember2023FinancingSummaryDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Transaction costs", "label": "Payments of Debt Issuance Costs", "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt." } } }, "auth_ref": [ "r14" ] }, "femy_PaymentsOfEquityIssuanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://femasys.com/20240630", "localname": "PaymentsOfEquityIssuanceCosts", "crdr": "credit", "presentation": [ "http://femasys.com/role/CondensedStatementsOfCashFlows", "http://femasys.com/role/EquityIncentivePlansAndWarrantsApril2023FinancingDetails" ], "lang": { "en-us": { "role": { "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.", "label": "Payments of Equity Issuance Costs", "negatedLabel": "Equity issuance costs for April 2023 Financing", "terseLabel": "Transaction costs" } } }, "auth_ref": [] }, "us-gaap_PaymentsToAcquireIntangibleAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquireIntangibleAssets", "crdr": "credit", "presentation": [ "http://femasys.com/role/CondensedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Acquisition of patents", "label": "Payments to Acquire Intangible Assets", "documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill." } } }, "auth_ref": [ "r72" ] }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "crdr": "credit", "presentation": [ "http://femasys.com/role/CondensedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Purchases of property and equipment", "label": "Payments to Acquire Property, Plant, and Equipment", "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets." } } }, "auth_ref": [ "r72" ] },
"femy_PercentageOfRestockingFee": { "xbrltype": "percentItemType", "nsuri": "http://femasys.com/20240630", "localname": "PercentageOfRestockingFee", "presentation": [ "http://femasys.com/role/RevenueRecognitionDetails" ], "lang": { "en-us": { "role": { "documentation": "The percentage of restocking fee on items to be returned.", "label": "Percentage of Restocking Fee", "terseLabel": "Percentage of restocking fee" } } }, "auth_ref": [] },
"femy_PercentageOfWarrantClosingPriceOfCommonStockExceedsPercentage": { "xbrltype": "percentItemType", "nsuri": "http://femasys.com/20240630", "localname": "PercentageOfWarrantClosingPriceOfCommonStockExceedsPercentage", "presentation": [ "http://femasys.com/role/ConvertibleNotesWithWarrantsNovember2023FinancingWarrantsDetails" ], "lang": { "en-us": { "role": { "documentation": "Percentage of warrant has the right to call the exercise, if the closing price of the common stock exceeds.", "label": "Percentage of Warrant Closing Price of Common Stock Exceeds, Percentage", "terseLabel": "Percentage of warrant closing price of common stock exceeds" } } }, "auth_ref": [] },
"femy_PeriodForAnalysisOfClinicalData": { "xbrltype": "durationItemType", "nsuri": "http://femasys.com/20240630", "localname": "PeriodForAnalysisOfClinicalData", "presentation": [ "http://femasys.com/role/OrganizationNatureOfBusinessAndLiquidityDetails" ], "lang": { "en-us": { "role": { "documentation": "Period for analysis of clinical data for permanent birth control.", "label": "Period for analysis of clinical data", "terseLabel": "Period for analysis of clinical data for permanent birth control" } } }, "auth_ref": [] }, "femy_PeriodOfConversionPrice": { "xbrltype": "durationItemType", "nsuri": "http://femasys.com/20240630", "localname": "PeriodOfConversionPrice", "presentation": [ "http://femasys.com/role/ConvertibleNotesWithWarrantsNovember2023FinancingSummaryDetails" ], "lang": { "en-us": { "role": { "documentation": "Period of conversion price for a period after closing, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Period of Conversion Price", "terseLabel": "Conversion price, period" } } }, "auth_ref": [] },
"femy_PlacementAgentFeesExpensesAndOfferingExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://femasys.com/20240630", "localname": "PlacementAgentFeesExpensesAndOfferingExpenses", "crdr": "debit", "presentation": [ "http://femasys.com/role/StockholdersEquityDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of placement agent fees expense and offering expenses related to common stock and warrants.", "label": "Placement Agent Fees Expenses and Offering Expenses", "terseLabel": "Placement agent fees expenses and offering expenses" } } }, "auth_ref": [] },
"femy_PlacementAgentWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://femasys.com/20240630", "localname": "PlacementAgentWarrantsMember", "presentation": [ "http://femasys.com/role/EquityIncentivePlansAndWarrantsApril2023FinancingDetails", "http://femasys.com/role/StockholdersEquityDetails" ], "lang": { "en-us": { "role": { "documentation": "The member stands common stock issued to the placement agent as compensation for services (\"placement agent warrants\").", "label": "Placement Agent Warrants [Member]", "terseLabel": "Placement Agent Warrants [Member]" } } }, "auth_ref": [] },
"femy_PreFundedWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://femasys.com/20240630", "localname": "PreFundedWarrantsMember",
```

```
"presentation": [ "http://femasys.com/role/EquityIncentivePlansAndWarrantsApril2023FinancingDetails", "http://femasys.com/role/StockholdersEquityDetails" ], "lang": { "en-us": { "role": { "documentation": "A pre-funded warrant that allows the warrant holder to purchase a specified number of a company's securities at a nominal exercise price.", "label": "Pre Funded Warrants [Member]", "terseLabel": "Pre-funded Warrants [Member]" } } }, "auth_ref": [] }, "femy_PrimaryGeographicalMarketsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://femasys.com/20240630", "localname": "PrimaryGeographicalMarketsAbstract", "presentation": [ "http://femasys.com/role/RevenueRecognitionDetails" ], "lang": { "en-us": { "role": { "label": "Primary Geographical Markets [Abstract]", "terseLabel": "Primary Geographical Markets [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ProceedsFromConvertibleDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromConvertibleDebt", "crdr": "debit", "presentation": [ "http://femasys.com/role/ConvertibleNotesWithWarrantsNovember2023FinancingSummaryDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from convertible notes", "label": "Proceeds from Convertible Debt", "documentation": "The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder." } } }, "auth_ref": [ "r13" ] }, "femy_ProceedsFromExerciseOfCommonStockWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://femasys.com/20240630", "localname": "ProceedsFromExerciseOfCommonStockWarrants", "crdr": "debit", "presentation": [ "http://femasys.com/role/EquityIncentivePlansAndWarrantsApril2023FinancingDetails", "http://femasys.com/role/StockholdersEquityDetails" ], "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the amount received from holders exercising their common stock warrants.", "label": "Proceeds from Exercise of Common Stock Warrants", "verboseLabel": "Cash proceeds from warrants exercised" } } }, "auth_ref": [] }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceOfCommonStock", "crdr": "debit", "presentation": [ "http://femasys.com/role/CondensedStatementsOfCashFlows", "http://femasys.com/role/StockholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from at-the-market sales of common stock", "verboseLabel": "Proceeds from Issuance of Common Stock", "label": "Proceeds from Issuance of Common Stock", "documentation": "The cash inflow from the additional capital contribution to the entity." } } }, "auth_ref": [ "r1" ] }, "us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions", "crdr": "debit", "presentation": [ "http://femasys.com/role/CondensedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Proceeds from common stock issued through ESPP and exercised options", "documentation": "Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised." } } }, "auth_ref": [ "r1", "r10" ] }, "us-gaap_ProceedsFromIssuanceOfWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceOfWarrants", "crdr": "debit", "presentation": [ "http://femasys.com/role/CondensedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Proceeds from the issuance of common stock and warrants in April 2023 Financing", "documentation": "The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt)." } } }, "auth_ref": [ "r1" ] }, "us-gaap_ProceedsFromIssuanceOrSaleOfEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceOrSaleOfEquity", "crdr": "debit", "presentation": [ "http://femasys.com/role/EquityIncentivePlansAndWarrantsApril2023FinancingDetails", "http://femasys.com/role/StockholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Gross proceeds from offering", "label": "Proceeds from Issuance or Sale of Equity", "documentation": "The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity." } } }, "auth_ref": [ "r1", "r496" ] }, "us-gaap_ProceedsFromNotesPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromNotesPayable", "crdr": "debit", "presentation": [ "http://femasys.com/role/NotesPayableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds to pay insurance premiums", "label": "Proceeds from Notes Payable", "documentation": "The cash inflow from a borrowing supported by a written promise to pay an obligation." } } }, "auth_ref": [ "r13" ] }, "us-gaap_ProceedsFromWarrantExercises": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromWarrantExercises", "crdr": "debit", "presentation": [ "http://femasys.com/role/CondensedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Proceeds from exercise of pre-funded warrants", "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants." } } }, "auth_ref": [ "r687" ] }, "srt_ProductOrServiceAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ProductOrServiceAxis", "presentation": [ "http://femasys.com/role/RevenueRecognitionDetails" ], "lang": { "en-us": { "role": { "label": "Product and Service [Axis]" } } }, "auth_ref": [ "r199", "r427", "r476", "r477", "r478", "r479", "r480", "r481", "r482", "r607", "r624", "r654", "r655", "r656", "r658", "r659", "r714", "r715", "r721", "r745", "r747", "r748", "r749", "r750", "r751", "r752", "r753", "r754", "r755", "r756", "r757", "r758", "r759", "r760", "r761", "r762", "r763", "r764", "r765", "r766", "r767", "r768", "r769", "r770", "r771", "r772", "r773", "r774" ] }, "srt_ProductsAndServicesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ProductsAndServicesDomain", "presentation": [ "http://femasys.com/role/RevenueRecognitionDetails" ], "lang": { "en-us": { "role": { "label": "Product and Service [Domain]" } } }, "auth_ref": [ "r199", "r427", "r476", "r477", "r478", "r479", "r480", "r481", "r482", "r607", "r624", "r654", "r655", "r656", "r658", "r659", "r714", "r715", "r721", "r745", "r747", "r748", "r749", "r750", "r751", "r752", "r753", "r754", "r755", "r756", "r757", "r758", "r759", "r760", "r761", "r762", "r763", "r764", "r765", "r766", "r767", "r768", "r769", "r770", "r771", "r772", "r773", "r774" ] }, "femy_PropertyAndEquipmentCostsIncludedInAccountsPayableAndAccruedExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://femasys.com/20240630", "localname": "PropertyAndEquipmentCostsIncludedInAccountsPayableAndAccruedExpense", "crdr": "debit", "presentation": [ "http://femasys.com/role/CondensedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "Value of property and equipment costs included in accounts payable and accrued expense as a noncash or partial noncash transaction.", "label": "Property and Equipment Costs, Included in Accounts Payable and Accrued Expense", "terseLabel": "Property and equipment costs included in accounts payable and accrued expense" } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentGross", "crdr": "debit", "presentation": [ "http://femasys.com/role/CondensedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Property and equipment, gross", "label": "Property, Plant and Equipment, Gross", "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r81", "r120", "r470" ] }, "us-gaap_PropertyPlantAndEquipmentNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentNet", "crdr": "debit", "presentation": [ "http://femasys.com/role/CondensedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Net property and equipment", "label": "Property, Plant and Equipment, Net", "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r5", "r413", "r462", "r470", "r645" ] }, "us-gaap_PropertyPlantAndEquipmentNetAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentNetAbstract", "presentation": [ "http://femasys.com/role/CondensedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Property and equipment, at cost:" } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentOther": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentOther", "crdr": "debit", "presentation": [ "http://femasys.com/role/CondensedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Office equipment", "label": "Property, Plant and Equipment, Other, Gross", "documentation": "Amount before accumulated depreciation, depletion and amortization of other physical assets used in the normal conduct of business to produce goods and services and not intended for resale." } } }, "auth_ref": [ "r5" ] }, "srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeAxis", "presentation": [ "http://femasys.com/role/RevenueRecognitionDetails", "http://femasys.com/role/StockholdersEquityDetails" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]" } } }, "auth_ref": [ "r221", "r222", "r223", "r224", "r296", "r303", "r330", "r331", "r332", "r337", "r382", "r424", "r425", "r426", "r483", "r485", "r492", "r520", "r521", "r578", "r580", "r582", "r583", "r585", "r604", "r605", "r616", "r623", "r634", "r640", "r641", "r642", "r643", "r655", "r662", "r712", "r720", "r729", "r739", "r740", "r741", "r742", "r743" ] }, "srt_RangeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeMember", "presentation": [ "http://femasys.com/role/RevenueRecognitionDetails", "http://femasys.com/role/StockholdersEquityDetails" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Domain]" } } }, "auth_ref": [ "r221", "r222", "r223", "r224", "r296", "r303", "r330", "r331", "r332", "r337", "r382", "r424", "r425", "r426", "r483", "r485", "r492", "r520", "r521", "r578", "r580", "r582", "r583", "r585", "r604", "r605", "r616", "r623", "r634", "r640", "r641", "r642", "r643", "r655", "r662", "r712", "r720", "r729", "r739", "r740", "r741", "r742", "r743" ] }, "us-gaap_RelatedPartyTransactionAmountsOfTransaction": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionAmountsOfTransaction", "crdr": "debit", "presentation": [ "http://femasys.com/role/RelatedpartyTransactionsDetails" ], "lang": { "en-us": { "role": { "label": "Related-party transaction", "documentation": "Amount of transactions with related party during the financial reporting period." } } }, "auth_ref": [ "r40", "r418" ] }, "us-gaap_RelatedPartyTransactionsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionsAbstract", "lang": { "en-us": { "role": { "label": "Related-Party Transactions [Abstract]" } } }, "auth_ref": [] }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionsDisclosureTextBlock", "presentation": [ "http://femasys.com/role/RelatedpartyTransactions" ], "lang": { "en-us": { "role": { "label": "Related-Party Transactions", "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates." } } }, "auth_ref": [ "r415", "r416", "r417", "r419", "r420", "r502", "r503", "r504", "r554", "r555", "r556", "r575", "r577" ] }, "us-gaap_RepaymentsOfNotesPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RepaymentsOfNotesPayable", "crdr": "credit", "presentation": [ "http://femasys.com/role/CondensedStatementsOfCashFlows", "http://femasys.com/role/NotesPayableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Down payments", "negatedLabel": "Repayment of note payable", "label": "Repayments of Notes Payable", "documentation": "The cash outflow for a borrowing supported by a written promise to pay an obligation." } } }, "auth_ref": [ "r74" ] }, "us-gaap_ResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpense", "crdr": "debit", "presentation": [ "http://femasys.com/role/CondensedStatementsOfComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Research and development", "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity." } } }, "auth_ref": [ "r338", "r606", "r614", "r744" ] }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpenseMember", "presentation": [ "http://femasys.com/role/EquityIncentivePlansAndWarrantsSharebasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "label": "Research and Development [Member]", "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included." } } }, "auth_ref": [] }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "presentation": [ "http://femasys.com/role/CondensedBalanceSheets", "http://femasys.com/role/OrganizationNatureOfBusinessAndLiquidityDetails" ], "lang": { "en-us": { "role": { "label": "Accumulated deficit", "documentation":
```

"Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": ["r58", "r90", "r467", "r490", "r491", "r500", "r531", "r645"] }, "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsMember", "presentation": ["http://femasys.com/role/CondensedStatementsOfStockholdersEquity"], "lang": { "en-us": { "role": { "label": "Accumulated Deficit [Member]", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": ["r115", "r149", "r150", "r151", "r153", "r158", "r160", "r162", "r205", "r206", "r210", "r349", "r350", "r356", "r357", "r358", "r360", "r361", "r362", "r367", "r369", "r370", "r372", "r374", "r409", "r410", "r487", "r489", "r505", "r777"] }, "us-gaap_RevenueFromContractWithCustomerAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromContractWithCustomerAbstract", "lang": { "en-us": { "role": { "label": "Revenue Recognition [Abstract]" } } }, "auth_ref": [] }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "crdr": "credit", "presentation": ["http://femasys.com/role/CondensedStatementsOfComprehensiveLoss", "http://femasys.com/role/RevenueRecognitionDetails"], "lang": { "en-us": { "role": { "label": "Sales", "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise." } } }, "auth_ref": ["r103", "r104", "r186", "r191", "r192", "r196", "r198", "r199", "r200", "r202", "r293", "r294", "r427"] }, "us-gaap_RevenueFromContractWithCustomerTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromContractWithCustomerTextBlock", "presentation": ["http://femasys.com/role/RevenueRecognition"], "lang": { "en-us": { "role": { "terseLabel": "Revenue Recognition", "label": "Revenue from Contract with Customer [Text Block]", "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts." } } }, "auth_ref": ["r113", "r284", "r285", "r286", "r287", "r288", "r289", "r291", "r292", "r295"] }, "us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromExternalCustomersByGeographicAreasTableTextBlock", "presentation": ["http://femasys.com/role/RevenueRecognitionTables"], "lang": { "en-us": { "role": { "label": "Sales by Geographic Region", "documentation": "Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue." } } }, "auth_ref": ["r78"] }, "femy_RevenueRecognitionPaymentTermOfPeriod": { "xbrltype": "durationItemType", "nsuri": "http://femasys.com/20240630", "localname": "RevenueRecognitionPaymentTermOfPeriod", "presentation": ["http://femasys.com/role/RevenueRecognitionDetails"], "lang": { "en-us": { "role": { "documentation": "Revenue recognition payment period term, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.", "label": "Revenue Recognition, Payment Term of Period", "terseLabel": "Revenue recognition payment period term" } } }, "auth_ref": [] }, "ecd_Rule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrAdoptedFlag", "presentation": ["http://femasys.com/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "terseLabel": "Rule 10b5-1 Arrangement Adopted", "label": "Rule 10b5-1 Arrangement Adopted [Flag]" } } }, "auth_ref": ["r677"] }, "ecd_Rule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrTrmntdFlag", "presentation": ["http://femasys.com/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "terseLabel": "Rule 10b5-1 Arrangement Terminated", "label": "Rule 10b5-1 Arrangement Terminated [Flag]" } } }, "auth_ref": ["r677"] }, "us-gaap_SalariesWagesAndOfficersCompensationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SalariesWagesAndOfficersCompensationAbstract", "presentation": ["http://femasys.com/role/EquityIncentivePlansAndWarrantsSharebasedCompensationExpenseDetails"], "lang": { "en-us": { "role": { "terseLabel": "Share-Based Compensation Expense [Abstract]", "label": "Salary and Wage, Excluding Cost of Good and Service Sold [Abstract]" } } }, "auth_ref": [] }, "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SaleOfStockConsiderationReceivedOnTransaction", "crdr": "debit", "presentation": ["http://femasys.com/role/EquityIncentivePlansAndWarrantsApril2023FinancingDetails"], "lang": { "en-us": { "role": { "terseLabel": "Net proceeds from issuance of common stock and warrants", "label": "Sale of Stock, Consideration Received on Transaction", "documentation": "Cash received on stock transaction after deduction of issuance costs." } } }, "auth_ref": [] }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SaleOfStockNameOfTransactionDomain", "presentation": ["http://femasys.com/role/StockholdersEquityDetails"], "lang": { "en-us": { "role": { "label": "Sale of Stock [Domain]", "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement." } } }, "auth_ref": [] }, "us-gaap_SaleOfStockPricePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SaleOfStockPricePerShare", "presentation": ["http://femasys.com/role/StockholdersEquityDetails"], "lang": { "en-us": { "role": { "label": "Purchase price (in dollars per share)", "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock", "presentation": ["http://femasys.com/role/AccruedExpensesTables"], "lang": { "en-us": { "role": { "terseLabel": "Accrued Expenses", "label": "Schedule of Accrued Liabilities [Table Text Block]", "documentation": "Tabular disclosure of the components of accrued liabilities." } } }, "auth_ref": [] }, "femy_ScheduleOfClinicalHoldbackLiabilityAccountTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://femasys.com/20240630", "localname": "ScheduleOfClinicalHoldbackLiabilityAccountTableTextBlock", "presentation": ["http://femasys.com/role/ClinicalHoldbackTables"], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of clinical holdback liability account.", "label": "Schedule Of Clinical Holdback Liability Account [Table Text Block]", "terseLabel": "Clinical Holdback Liability" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "presentation": ["http://femasys.com/role/NetLossPerShareAttributableToCommonStockholdersTables"], "lang": { "en-us": { "role": { "label": "Computation of Basic and Diluted Net Loss Per Share", "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations." } } }, "auth_ref": ["r698"] }, "us-gaap_ScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable", "presentation": ["http://femasys.com/role/EquityIncentivePlansAndWarrantsEmployeeStockPurchasePlanDetails"], "lang": { "en-us": { "role": { "label": "Schedule of Employee Stock Ownership Plan (ESOP) Disclosures [Table]", "documentation": "Disclosure of information about employee stock ownership plan (ESOP) by plan." } } }, "auth_ref": ["r38"] }, "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfInventoryCurrentTableTextBlock", "presentation": ["http://femasys.com/role/InventoriesTables"], "lang": { "en-us": { "role": { "label": "Inventory Stated at Cost, Net of Reserve", "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process." } } }, "auth_ref": ["r12", "r62", "r63", "r64"] }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "presentation": ["http://femasys.com/role/EquityIncentivePlansAndWarrantsInducementGrantDetails", "http://femasys.com/role/EquityIncentivePlansAndWarrantsSharebasedCompensationExpenseDetails", "http://femasys.com/role/EquityIncentivePlansAndWarrantsStockOptionPlanActivityDetails", "http://femasys.com/role/EquityIncentivePlansAndWarrantsTables"], "lang": { "en-us": { "role": { "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]", "documentation": "Disclosure of information about share-based payment arrangement." } } }, "auth_ref": ["r304", "r306", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r325", "r326", "r327", "r328", "r329", "r330", "r331", "r332", "r333"] }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "presentation": ["http://femasys.com/role/EquityIncentivePlansAndWarrantsTables"], "lang": { "en-us": { "role": { "label": "Stock Option Plan Activity", "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value." } } }, "auth_ref": ["r8", "r9", "r92"] }, "us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock", "presentation": ["http://femasys.com/role/EquityIncentivePlansAndWarrantsTables"], "lang": { "en-us": { "role": { "label": "Estimated Using Assumptions", "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of employee stock purchase plans, including, but not limited to: (a) expected term, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions." } } }, "auth_ref": ["r93"] }, "femy_ScheduleOfShareBasedPaymentAwardFairValueWarrantLiabilityValuationAssumptionsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://femasys.com/20240630", "localname": "ScheduleOfShareBasedPaymentAwardFairValueWarrantLiabilityValuationAssumptionsTableTextBlock", "presentation": ["http://femasys.com/role/EquityIncentivePlansAndWarrantsTables"], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of warrants, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.", "label": "Schedule of Share Based Payment Award, Fair Value Warrant Liability, Valuation Assumptions [Table Text Block]", "terseLabel": "Warrants Valuation Assumptions" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfStockByClassTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfStockByClassTable", "presentation": ["http://femasys.com/role/StockholdersEquityDetails"], "lang": { "en-us": { "role": { "label": "Schedule of Stock by Class [Table]", "documentation": "Disclosure of information about stock by class. Includes, but is not limited to, common, convertible, and preferred stocks." } } }, "auth_ref": ["r26", "r27", "r28", "r29", "r30", "r31", "r86", "r88", "r89", "r90", "r125", "r126", "r127", "r188", "r267", "r268", "r269", "r271", "r274", "r279", "r281", "r496", "r497", "r498", "r499", "r623", "r680", "r690"] }, "us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfWeightedAverageNumberOfSharesTableTextBlock", "presentation": ["http://femasys.com/role/NetLossPerShareAttributableToCommonStockholdersTables"], "lang": { "en-us": { "role": { "label": "Computations of Diluted Weighted Average Shares Outstanding", "documentation": "Tabular disclosure of the weighted average number of shares used in calculating basic net earnings per share (or unit) and diluted earnings per share (or unit)." } } }, "auth_ref": ["r19"] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12bTitle", "presentation": ["http://femasys.com/role/DocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": ["r671"] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityExchangeName", "presentation": ["http://femasys.com/role/DocumentAndEntityInformation"], "lang": {

```
"en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r673" ] }, "srt_SegmentGeographicalDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "SegmentGeographicalDomain", "presentation": [ "http://femasys.com/role/RevenueRecognitionDetails" ], "lang": { "en-us": { "role": { "label": "Geographical [Domain]" } } }, "auth_ref": [ "r200", "r201", "r429", "r430", "r431", "r432", "r433", "r434", "r435", "r436", "r437", "r438", "r439", "r440", "r441", "r442", "r443", "r444", "r445", "r446", "r447", "r448", "r449", "r450", "r451", "r452", "r453", "r454", "r455", "r456", "r457", "r458", "r517", "r518", "r519", "r579", "r581", "r584", "r586", "r593", "r595", "r596", "r597", "r598", "r599", "r600", "r601", "r602", "r603", "r608", "r625", "r646", "r647", "r648", "r649", "r650", "r651", "r652", "r653", "r657", "r662", "r721", "r745", "r747", "r748", "r750", "r751", "r752", "r753", "r754", "r755", "r756", "r757", "r758", "r759", "r760", "r761", "r762", "r763", "r764", "r765", "r766", "r767", "r768", "r769", "r770", "r771", "r772", "r773", "r774" ] }, "us-gaap_SellingAndMarketingExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SellingAndMarketingExpense", "crdr": "debit", "presentation": [ "http://femasys.com/role/CondensedStatementsOfComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Sales and marketing", "documentation": "The aggregate total amount of expenses directly related to the marketing or selling of products or services." } } }, "auth_ref": [] }, "us-gaap_SellingAndMarketingExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SellingAndMarketingExpenseMember", "presentation": [ "http://femasys.com/role/EquityIncentivePlansAndWarrantsSharebasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "label": "Sales and Marketing [Member]", "documentation": "Primary financial statement caption encompassing selling and marketing expense." } } }, "auth_ref": [ "r69" ] }, "femy_SeriesAWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://femasys.com/20240630", "localname": "SeriesAWarrantsMember", "presentation": [ "http://femasys.com/role/ConvertibleNotesWithWarrantsNovember2023FinancingSummaryDetails", "http://femasys.com/role/ConvertibleNotesWithWarrantsNovember2023FinancingWarrantsDetails" ], "lang": { "en-us": { "role": { "documentation": "A classification of Information by type of warrant or right issued, for example Series A Warrants.", "label": "Series A Warrants [Member]", "terseLabel": "Series A Warrants [Member]" } } }, "auth_ref": [] }, "femy_SeriesBWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://femasys.com/20240630", "localname": "SeriesBWarrantsMember", "presentation": [ "http://femasys.com/role/ConvertibleNotesWithWarrantsNovember2023FinancingSummaryDetails", "http://femasys.com/role/ConvertibleNotesWithWarrantsNovember2023FinancingWarrantsDetails" ], "lang": { "en-us": { "role": { "documentation": "A classification of Information by type of warrant or right issued, for example Series B Warrants.", "label": "Series B Warrants [Member]", "terseLabel": "Series B Warrants [Member]" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensation", "crdr": "debit", "presentation": [ "http://femasys.com/role/CondensedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based compensation expense", "label": "Share-Based Payment Arrangement, Noncash Expense", "documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth_ref": [ "r3" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "presentation": [ "http://femasys.com/role/EquityIncentivePlansAndWarrantsInducementGrantDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Vesting period", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period", "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition." } } }, "auth_ref": [ "r635" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract", "presentation": [ "http://femasys.com/role/EquityIncentivePlansAndWarrantsApril2023FinancingDetails", "http://femasys.com/role/EquityIncentivePlansAndWarrantsInducementGrantDetails", "http://femasys.com/role/EquityIncentivePlansAndWarrantsStockOptionPlanActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Estimated Fair Value Assumptions [Abstract]", "label": "Estimated Fair Value Assumptions [Abstract]" } } }, "auth_ref": [] }, "femy_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsBlackScholesValue": { "xbrltype": "perShareItemType", "nsuri": "http://femasys.com/20240630", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsBlackScholesValue", "presentation": [ "http://femasys.com/role/EquityIncentivePlansAndWarrantsApril2023FinancingDetails" ], "lang": { "en-us": { "role": { "documentation": "Price of a single share of a number of saleable stocks of a company under Black-Scholes assumptions.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Black-Scholes Value", "terseLabel": "Black-Scholes value (in dollars per share)" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice", "presentation": [ "http://femasys.com/role/EquityIncentivePlansAndWarrantsApril2023FinancingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Exercise price (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Exercise Price", "documentation": "Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "presentation": [ "http://femasys.com/role/EquityIncentivePlansAndWarrantsApril2023FinancingDetails", "http://femasys.com/role/EquityIncentivePlansAndWarrantsInducementGrantDetails", "http://femasys.com/role/EquityIncentivePlansAndWarrantsStockOptionPlanActivityDetails" ], "lang": { "en-us": { "role": { "label": "Dividend yield", "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term." } } }, "auth_ref": [ "r331" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "presentation": [ "http://femasys.com/role/EquityIncentivePlansAndWarrantsApril2023FinancingDetails", "http://femasys.com/role/EquityIncentivePlansAndWarrantsInducementGrantDetails", "http://femasys.com/role/EquityIncentivePlansAndWarrantsStockOptionPlanActivityDetails" ], "lang": { "en-us": { "role": { "label": "Expected volatility", "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period." } } }, "auth_ref": [ "r330" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "presentation": [ "http://femasys.com/role/EquityIncentivePlansAndWarrantsApril2023FinancingDetails", "http://femasys.com/role/EquityIncentivePlansAndWarrantsInducementGrantDetails", "http://femasys.com/role/EquityIncentivePlansAndWarrantsStockOptionPlanActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Risk free interest rate", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate", "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares." } } }, "auth_ref": [ "r332" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "presentation": [ "http://femasys.com/role/EquityIncentivePlansAndWarrantsInducementGrantDetails", "http://femasys.com/role/EquityIncentivePlansAndWarrantsSharebasedCompensationExpenseDetails", "http://femasys.com/role/EquityIncentivePlansAndWarrantsStockOptionPlanActivityDetails", "http://femasys.com/role/EquityIncentivePlansAndWarrantsTables" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r304", "r306", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r325", "r326", "r327", "r328", "r329", "r330", "r331", "r332", "r333" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "presentation": [ "http://femasys.com/role/EquityIncentivePlansAndWarrantsStockOptionPlanActivityDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Forfeited (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period", "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan." } } }, "auth_ref": [ "r317" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "presentation": [ "http://femasys.com/role/EquityIncentivePlansAndWarrantsInducementGrantDetails", "http://femasys.com/role/EquityIncentivePlansAndWarrantsStockOptionPlanActivityDetails" ], "lang": { "en-us": { "role": { "label": "Granted (in shares)", "documentation": "Gross number of share options (or share units) granted during the period." } } }, "auth_ref": [ "r315" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "presentation": [ "http://femasys.com/role/EquityIncentivePlansAndWarrantsInducementGrantDetails", "http://femasys.com/role/EquityIncentivePlansAndWarrantsStockOptionPlanActivityDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Weighted-average fair values of options granted (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value", "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology." } } }, "auth_ref": [ "r325" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "presentation": [ "http://femasys.com/role/EquityIncentivePlansAndWarrantsInducementGrantDetails", "http://femasys.com/role/EquityIncentivePlansAndWarrantsStockOptionPlanActivityDetails" ], "lang": { "en-us": { "role": { "periodEndLabel": "Ending balance (in shares)", "periodStartLabel": "Beginning balance (in shares)", "terseLabel": "Shares outstanding (in shares)", "label": "Share-Based Compensation
```

```
Arrangement by Share-Based Payment Award, Options, Outstanding, Number", "documentation": "Number of options outstanding, including both vested and non-vested options." } } }, "auth_ref": [ "r311", "r312" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward", "presentation": [
"http://femasys.com/role/EquityIncentivePlansAndWarrantsStockOptionPlanActivityDetails" ], "lang": { "en-us": { "role": { "label": "Number of Options [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] },
"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
"presentation": [ "http://femasys.com/role/EquityIncentivePlansAndWarrantsInducementGrantDetails",
"http://femasys.com/role/EquityIncentivePlansAndWarrantsStockOptionPlanActivityDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Beginning balance (in dollars per share)", "periodEndLabel": "Ending balance (in dollars per share)", "label": "Weighted average exercise price (in dollars per share)",
"documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan." } } }, "auth_ref": [
"r311", "r312" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward", "presentation": [
"http://femasys.com/role/EquityIncentivePlansAndWarrantsStockOptionPlanActivityDetails" ], "lang": { "en-us": { "role": { "label": "Weighted Average Exercise Price [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract": {
"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract", "presentation": [
"http://femasys.com/role/EquityIncentivePlansAndWarrantsStockOptionPlanActivityDetails" ], "lang": { "en-us": { "role": { "label": "Options vested and exercisable [Abstract]" } } }, "auth_ref": [] }, "us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
"presentation": [ "http://femasys.com/role/EquityIncentivePlansAndWarrantsInducementGrantDetails",
"http://femasys.com/role/EquityIncentivePlansAndWarrantsStockOptionPlanActivityDetails" ], "lang": { "en-us": { "role": { "label": "Options vested and exercisable, Number of option vested (in shares)", "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r327" ] }, "us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": { "xbrltype":
"perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice", "presentation": [
"http://femasys.com/role/EquityIncentivePlansAndWarrantsInducementGrantDetails",
"http://femasys.com/role/EquityIncentivePlansAndWarrantsStockOptionPlanActivityDetails" ], "lang": { "en-us": { "role": { "label": "Options vested and exercisable, Exercise price (in dollars per share)", "verboseLabel": "Options vested and exercisable, Weighted average exercise price (in dollars per shares)", "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r327" ] }, "us-
gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "presentation": [
"http://femasys.com/role/EquityIncentivePlansAndWarrantsStockOptionPlanActivityDetails" ], "lang": { "en-us": { "role": { "label": "Forfeited (in dollars per share)", "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated." } } }, "auth_ref": [ "r317" ] }, "us-
gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
"presentation": [ "http://femasys.com/role/EquityIncentivePlansAndWarrantsStockOptionPlanActivityDetails" ], "lang": { "en-us": { "role": { "label": "Granted (in dollars per share)", "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options." } } },
"auth_ref": [ "r315" ] }, "femy_ShareBasedCompensationExpenseToBeRecognizedUponAchievingCertainPerformanceCondition": { "xbrltype": "monetaryItemType",
"nsuri": "http://femasys.com/20240630", "localname": "ShareBasedCompensationExpenseToBeRecognizedUponAchievingCertainPerformanceCondition", "crdr": "debit",
"presentation": [ "http://femasys.com/role/EquityIncentivePlansAndWarrantsSharebasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": {
"documentation": "Amount of expense for award under share-based payment arrangement to be recognized upon achieving certain performance condition.", "label":
"Share-based Compensation Expense to be Recognized upon Achieving Certain Performance Condition", "terseLabel": "Compensation expense to be recognized upon
achieving certain performance condition" } } }, "auth_ref": [] }, "us-gaap_ShareBasedPaymentArrangementEmployeeMember": { "xbrltype": "domainItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedPaymentArrangementEmployeeMember", "presentation": [
"http://femasys.com/role/EquityIncentivePlansAndWarrantsStockOptionPlanActivityDetails" ], "lang": { "en-us": { "role": { "label": "Employees [Member]",
"documentation": "Recipient, of award granted under share-based payment arrangement, over whom grantor exercises or has right to exercise sufficient control to establish employer-employee relationship based on law of pertinent jurisdiction. Includes, but is not limited to, nonemployee director treated as employee when acting as member of board of directors, if elected by grantor's shareholders or appointed to board position to be filled by shareholder election when existing term expires." } } }, "auth_ref": [ "r306", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r320",
"r321", "r322", "r323", "r324", "r325", "r326", "r327", "r328", "r329", "r330", "r331", "r332", "r333" ] }, "us-
gaap_ShareBasedPaymentArrangementNonemployeeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ShareBasedPaymentArrangementNonemployeeMember", "presentation": [ "http://femasys.com/role/EquityIncentivePlansAndWarrantsStockOptionPlanActivityDetails" ],
"lang": { "en-us": { "role": { "label": "Nonemployee [Member]", "documentation": "Recipient, of award granted under share-based payment arrangement, over whom grantor does not exercise nor has right to exercise sufficient control to establish employer-employee relationship based on law of pertinent jurisdiction. Excludes nonemployee director treated as employee when acting as member of board of directors, if elected by grantor's shareholders or appointed to board position to be filled by shareholder election when existing term expires." } } }, "auth_ref": [ "r304", "r308", "r309", "r310", "r311", "r312", "r313",
"r314", "r315", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r325", "r326", "r327", "r328", "r329", "r330", "r331", "r332", "r333"
] }, "us-gaap_SharePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharePrice", "presentation": [
"http://femasys.com/role/EquityIncentivePlansAndWarrantsApril2023FinancingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stock price (in dollars per share)", "label": "Share Price", "documentation": "Price of a single share of a number of saleable stocks of a company." } } }, "auth_ref": [] }, "us-
gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "xbrltype": "durationItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "presentation": [
"http://femasys.com/role/EquityIncentivePlansAndWarrantsApril2023FinancingDetails",
"http://femasys.com/role/EquityIncentivePlansAndWarrantsInducementGrantDetails",
"http://femasys.com/role/EquityIncentivePlansAndWarrantsStockOptionPlanActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Expected term (in years)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term", "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r329" ] }, "us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "ShareholdersEquityAndShareBasedPaymentsTextBlock", "presentation": [
"http://femasys.com/role/EquityIncentivePlansAndWarrants" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Incentive Plans and Warrants", "label":
"Shareholders' Equity and Share-Based Payments [Text Block]", "documentation": "The entire disclosure for shareholders' equity and share-based payment arrangement. Includes, but is not limited to, disclosure of policy and terms of share-based payment arrangement, deferred compensation arrangement, and employee stock purchase plan (ESPP)." } } }, "auth_ref": [ "r87", "r91" ] }, "us-gaap_StatementClassOfStockAxis": { "xbrltype": "stringItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "StatementClassOfStockAxis", "presentation": [
"http://femasys.com/role/ConvertibleNotesWithWarrantsNovember2023FinancingSummaryDetails",
"http://femasys.com/role/ConvertibleNotesWithWarrantsNovember2023FinancingWarrantsDetails" ], "lang": { "en-us": { "role": { "label": "Class of Stock [Axis]",
"documentation": "Information by the different classes of stock of the entity." } } }, "auth_ref": [ "r114", "r125", "r126", "r127", "r146", "r167", "r172",
"r179", "r181", "r188", "r189", "r204", "r227", "r229", "r230", "r231", "r234", "r235", "r267", "r268", "r271", "r274", "r281", "r399", "r496", "r497",
"r498", "r499", "r505", "r506", "r507", "r508", "r509", "r510", "r511", "r512", "r513", "r514", "r515", "r516", "r530", "r551", "r571", "r587", "r588",
"r589", "r590", "r591", "r680", "r690", "r697" ] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "StatementEquityComponentsAxis", "presentation": [ "http://femasys.com/role/CondensedStatementsOfStockholdersEquity",
"http://femasys.com/role/ConvertibleNotesWithWarrantsNovember2023FinancingSummaryDetails", "http://femasys.com/role/StockholdersEquityDetails" ], "lang": {
"en-us": { "role": { "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": [ "r7", "r56", "r59",
"r60", "r115", "r133", "r134", "r135", "r149", "r150", "r151", "r153", "r158", "r160", "r162", "r187", "r205", "r206", "r210", "r283", "r349", "r350", "r356",
"r357", "r358", "r360", "r361", "r362", "r367", "r368", "r369", "r370", "r371", "r372", "r374", "r400", "r401", "r402", "r403", "r404", "r405", "r409",
"r410", "r414", "r473", "r487", "r488", "r489", "r505", "r571" ] }, "srt_StatementGeographicalAxis": { "xbrltype": "stringItemType", "nsuri":
"http://fasb.org/srt/2024", "localname": "StatementGeographicalAxis", "presentation": [ "http://femasys.com/role/RevenueRecognitionDetails" ], "lang": { "en-
us": { "role": { "label": "Geographical [Axis]" } } }, "auth_ref": [ "r200", "r201", "r429", "r430", "r431", "r432", "r433", "r434", "r435", "r436", "r437",
"r438", "r439", "r440", "r441", "r442", "r443", "r444", "r445", "r446", "r447", "r448", "r449", "r450", "r451", "r452", "r453", "r454", "r455", "r456",
"r457", "r458", "r517", "r518", "r519", "r579", "r581", "r584", "r586", "r593", "r595", "r596", "r597", "r598", "r599", "r600", "r601", "r602", "r603",
"r608", "r625", "r646", "r647", "r648", "r649", "r650", "r651", "r652", "r653", "r657", "r662", "r721", "r745", "r747", "r748", "r750", "r751", "r752",
"r753", "r754", "r755", "r756", "r757", "r758", "r759", "r760", "r761", "r762", "r763", "r764", "r765", "r766", "r767", "r768", "r769", "r770", "r771",
"r772", "r773", "r774" ] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"StatementLineItems", "presentation": [ "http://femasys.com/role/CondensedStatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "label":
"Statement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable
```

```
information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r149", "r150", "r151", "r187", "r410", "r427", "r495", "r516", "r522", "r523", "r524", "r525", "r526", "r527", "r530", "r533", "r534", "r535", "r536", "r537", "r538", "r539", "r540", "r541", "r543", "r544", "r545", "r546", "r547", "r549", "r552", "r553", "r557", "r558", "r559", "r560", "r561", "r562", "r563", "r564", "r565", "r566", "r567", "r568", "r571", "r663" ] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "label": "Statements of Cash Flows [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "label": "Balance Sheets [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfStockholdersEquityAbstract", "lang": { "en-us": { "role": { "label": "Statements of Stockholders' Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementTable", "presentation": [ "http://femasys.com/role/CondensedStatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Statement [Table]", "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity." } } }, "auth_ref": [ "r149", "r150", "r151", "r187", "r203", "r410", "r427", "r495", "r516", "r522", "r523", "r524", "r525", "r526", "r527", "r530", "r533", "r534", "r535", "r536", "r537", "r538", "r539", "r540", "r541", "r543", "r544", "r545", "r546", "r547", "r549", "r552", "r553", "r557", "r558", "r559", "r560", "r561", "r562", "r563", "r564", "r565", "r566", "r567", "r568", "r571", "r663" ] }, "femy_StockBasedCompensationExpenseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://femasys.com/20240630", "localname": "StockBasedCompensationExpenseAbstract", "presentation": [ "http://femasys.com/role/EquityIncentivePlansAndWarrantsSharebasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "label": "Stock-based Compensation Expense [Abstract]", "terseLabel": "Share-based Compensation Expense [Abstract]" } } }, "auth_ref": [] }, "femy_StockIssuedDuringPeriodSharesAtTheMarketOfferingNetOfIssuanceCosts": { "xbrltype": "sharesItemType", "nsuri": "http://femasys.com/20240630", "localname": "StockIssuedDuringPeriodSharesAtTheMarketOfferingNetOfIssuanceCosts", "presentation": [ "http://femasys.com/role/CondensedStatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "documentation": "Number of new stock issued in connection with the at-the-market program during the period.", "label": "Stock Issued During Period, Shares, At-The-Market Offering, Net of issuance Costs", "terseLabel": "Issuance of common stock in connection with at-the-market offering, net of issuance costs (in shares)" } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans", "presentation": [ "http://femasys.com/role/CondensedStatementsOfStockholdersEquity", "http://femasys.com/role/EquityIncentivePlansAndWarrantsEmployeeStockPurchasePlanDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Issuance of common stock in connection with ESPP (in shares)", "label": "Stock issued (in shares)", "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan." } } }, "auth_ref": [ "r7", "r55", "r56", "r90" ] }, "femy_StockIssuedDuringPeriodSharesExerciseOfPreFundedWarrants": { "xbrltype": "sharesItemType", "nsuri": "http://femasys.com/20240630", "localname": "StockIssuedDuringPeriodSharesExerciseOfPreFundedWarrants", "presentation": [ "http://femasys.com/role/CondensedStatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "documentation": "Number of pre-funded warrants exercise.", "label": "Stock Issued During Period, Shares, Exercise of Pre-funded Warrants", "terseLabel": "Exercise of pre-funded warrants (in shares)" } } }, "auth_ref": [] }, "femy_StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndWarrants": { "xbrltype": "sharesItemType", "nsuri": "http://femasys.com/20240630", "localname": "StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndWarrants", "presentation": [ "http://femasys.com/role/CondensedStatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "documentation": "Number of common stock and warrants, in connection with \"April 2023 Financing\" during the period.", "label": "Stock Issued During Period, Shares, Issuance of Common Stock and Warrants", "terseLabel": "Issuance of common stock and warrants in connection with April 2023 Financing, net of issuance costs (in shares)" } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesNewIssues", "presentation": [ "http://femasys.com/role/EquityIncentivePlansAndWarrantsApril2023FinancingDetails", "http://femasys.com/role/StockholdersEquityDetails" ], "lang": { "en-us": { "role": { "label": "Common stock sold (in shares)", "verboseLabel": "Issuance and sale of common stock (in shares)", "documentation": "Number of new stock issued during the period." } } }, "auth_ref": [ "r7", "r55", "r56", "r90", "r496", "r571", "r588" ] }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "presentation": [ "http://femasys.com/role/EquityIncentivePlansAndWarrantsStockOptionPlanActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Options exercised (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period", "documentation": "Number of share options (or share units) exercised during the current period." } } }, "auth_ref": [ "r7", "r55", "r56", "r90", "r316" ] }, "femy_StockIssuedDuringPeriodValueAtTheMarketOfferingNetOfIssuanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://femasys.com/20240630", "localname": "StockIssuedDuringPeriodValueAtTheMarketOfferingNetOfIssuanceCosts", "crdr": "credit", "presentation": [ "http://femasys.com/role/CondensedStatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of new stock issued in connection with at-the-market program during the period.", "label": "Stock Issued During Period, Value, At-The-Market Offering, Net of Issuance Costs", "terseLabel": "Issuance of common stock in connection with at-the-market offering, net of issuance costs" } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan", "crdr": "credit", "presentation": [ "http://femasys.com/role/CondensedStatementsOfStockholdersEquity", "http://femasys.com/role/EquityIncentivePlansAndWarrantsEmployeeStockPurchasePlanDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Issuance of common stock in connection with ESPP", "label": "Stock issued, fair value", "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan." } } }, "auth_ref": [ "r7", "r55", "r56", "r90" ] }, "femy_StockIssuedDuringPeriodValueExerciseOfPreFundedWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://femasys.com/20240630", "localname": "StockIssuedDuringPeriodValueExerciseOfPreFundedWarrants", "crdr": "credit", "presentation": [ "http://femasys.com/role/CondensedStatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "documentation": "Aggregate value of issuance of common stock from exercise of pre-funded warrants issued during the period.", "label": "Stock Issued During Period, Value, Exercise of Pre-funded Warrants", "terseLabel": "Exercise of pre-funded warrants" } } }, "auth_ref": [] }, "femy_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://femasys.com/20240630", "localname": "StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrants", "crdr": "credit", "presentation": [ "http://femasys.com/role/CondensedStatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "documentation": "Equity impact of the value in issuance of common stock and warrants, in connection with \"April 2023 Financing\", net of issuance costs.", "label": "Stock Issued During Period, Value, Issuance of Common Stock and Warrants", "terseLabel": "Issuance of common stock and warrants in connection with April 2023 Financing, net of issuance costs" } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueNewIssues", "crdr": "credit", "presentation": [ "http://femasys.com/role/EquityIncentivePlansAndWarrantsApril2023FinancingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock value", "label": "Stock Issued During Period, Value, New Issues", "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering." } } }, "auth_ref": [ "r7", "r55", "r56", "r90", "r505", "r571", "r588", "r669" ] }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquity", "crdr": "credit", "presentation": [ "http://femasys.com/role/CondensedBalanceSheets", "http://femasys.com/role/CondensedStatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "totalLabel": "Total stockholders' equity", "periodStartLabel": "Balance", "periodEndLabel": "Balance", "label": "Equity, Attributable to Parent", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": [ "r56", "r59", "r60", "r79", "r532", "r548", "r572", "r573", "r645", "r670", "r692", "r706", "r732", "r777" ] }, "us-gaap_StockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityAbstract", "presentation": [ "http://femasys.com/role/CondensedBalanceSheets", "http://femasys.com/role/CondensedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Stockholders' equity:" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityNoteAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityNoteAbstract", "presentation": [ "http://femasys.com/role/StockholdersEquityDetails" ], "lang": { "en-us": { "role": { "label": "Stockholders Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityNoteDisclosureTextBlock", "presentation": [ "http://femasys.com/role/StockholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Stockholders' Equity", "label": "Equity [Text Block]", "documentation": "The entire disclosure for equity." } } }, "auth_ref": [ "r87", "r145", "r266", "r268", "r270", "r271", "r272", "r273", "r274", "r275", "r276", "r277", "r278", "r280", "r283", "r373", "r574", "r576", "r592" ] }, "us-gaap_SubsidiarySaleOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsidiarySaleOfStockAxis", "presentation": [ "http://femasys.com/role/StockholdersEquityDetails" ], "lang": { "en-us": { "role": { "label": "Sale of Stock [Axis]", "documentation": "Information by type of sale of the entity's stock." } } }, "auth_ref": [] }, "us-gaap_SupplementalCashFlowInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SupplementalCashFlowInformationAbstract", "presentation": [ "http://femasys.com/role/CondensedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Supplemental cash flow information" } } }, "auth_ref": [] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "TradingSymbol", "presentation": [ "http://femasys.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "us-gaap_TreasuryStockCommonMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TreasuryStockCommonMember", "presentation": [ "http://femasys.com/role/CondensedStatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Treasury Common Stock [Member]", "documentation": "Previously issued common shares repurchased by the issuing entity and held in treasury." } } }, "auth_ref": [ "r32" ] }, "us-gaap_TreasuryStockCommonShares": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TreasuryStockCommonShares", "presentation": [ "http://femasys.com/role/CondensedBalanceSheetsParenthetical", "http://femasys.com/role/CondensedStatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Treasury stock, common shares (in shares)", "periodEndLabel": "Treasury stock, common shares (in shares)", "periodStartLabel": "Treasury stock, common shares (in shares)", "documentation": "Number of previously issued common shares repurchased by the issuing entity and held in treasury." } } }, "auth_ref": [ "r32" ] }, "us-gaap_TreasuryStockCommonValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TreasuryStockCommonValue", "crdr": "debit", "presentation": [ "http://femasys.com/role/CondensedBalanceSheets", "http://femasys.com/role/CondensedStatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "negatedLabel": "Treasury stock, 117,223 common shares", "negatedPeriodStartLabel": "Treasury stock, common value", "negatedPeriodEndLabel": "Treasury stock, common value", "label": "Treasury Stock, Common, Value", "documentation": "Amount allocated to previously issued common shares repurchased by the issuing entity and held in treasury." } } }, "auth_ref": [ "r32", "r33", "r59" ] }, "femy_Two021StockOptionPlanMember": { "xbrltype": "domainItemType", "nsuri": "http://femasys.com/20240630", "localname": "Two021StockOptionPlanMember", "presentation": [ "http://femasys.com/role/EquityIncentivePlansAndWarrantsStockOptionPlanActivityDetails",
```

```
"http://femasys.com/role/EquityIncentivePlansAndWarrantsTables" ], "lang": { "en-us": { "role": { "documentation": "Name of the stock-based compensation arrangement option plan.", "label": "2021 Stock Option Plan [Member]", "terseLabel": "2021 Stock Option Plan [Member]" } } }, "auth_ref": [] }, "country_US": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2024", "localname": "US", "presentation": [
"http://femasys.com/role/RevenueRecognitionDetails" ], "lang": { "en-us": { "role": { "label": "U.S. [Member]" } } }, "auth_ref": [] }, "us-gaap_UseOfEstimates": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UseOfEstimates", "presentation": [
"http://femasys.com/role/OrganizationNatureOfBusinessAndLiquidityPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Use of Estimates", "label": "Use of Estimates, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles." } } }, "auth_ref": [ "r20", "r21", "r22", "r108", "r109", "r110", "r111" ] }, "femy_WarrantsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://femasys.com/20240630", "localname": "WarrantsAbstract", "presentation": [
"http://femasys.com/role/EquityIncentivePlansAndWarrantsApril2023FinancingDetails" ], "lang": { "en-us": { "role": { "label": "Warrants [Abstract]", "terseLabel": "Warrants [Abstract]" } } }, "auth_ref": [] }, "us-gaap_WarrantsAndRightsOutstanding": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WarrantsAndRightsOutstanding", "crdr": "credit", "presentation": [
"http://femasys.com/role/CondensedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Warrants", "documentation": "Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price." } } }, "auth_ref": [ "r728", "r729", "r730" ] }, "us-gaap_WarrantsAndRightsOutstandingTerm": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WarrantsAndRightsOutstandingTerm", "presentation": [ "http://femasys.com/role/ConvertibleNotesWithWarrantsNovember2023FinancingWarrantsDetails",
"http://femasys.com/role/EquityIncentivePlansAndWarrantsApril2023FinancingDetails" ], "lang": { "en-us": { "role": { "label": "Warrants term", "terseLabel": "Warrants term", "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r728", "r729", "r730" ] }, "femy_WarrantsSevenMember": { "xbrltype": "domainItemType", "nsuri": "http://femasys.com/20240630", "localname": "WarrantsSevenMember", "presentation": [
"http://femasys.com/role/NetLossPerShareAttributableToCommonStockholdersDetails" ], "lang": { "en-us": { "role": { "documentation": "Warrants and rights represent derivative securities that give the holder the right to purchase securities.", "label": "Warrants Seven [Member]", "terseLabel": "November 2023 Financing [Member]" } } }, "auth_ref": [] }, "femy_WarrantsSixMember": { "xbrltype": "domainItemType", "nsuri": "http://femasys.com/20240630", "localname": "WarrantsSixMember", "presentation": [ "http://femasys.com/role/NetLossPerShareAttributableToCommonStockholdersDetails" ], "lang": { "en-us": { "role": { "documentation": "Warrants and rights represent derivative securities that give the holder the right to purchase securities.", "label": "Warrants Six [Member]", "terseLabel": "April 2023 Financing [Member]" } } }, "auth_ref": [] }, "femy_WarrantsTransactionsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://femasys.com/20240630", "localname": "WarrantsTransactionsAbstract", "presentation": [
"http://femasys.com/role/ConvertibleNotesWithWarrantsNovember2023FinancingWarrantsDetails" ], "lang": { "en-us": { "role": { "label": "Warrants Transactions [Abstract]", "terseLabel": "Warrants [Abstract]" } } }, "auth_ref": [] }, "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustment", "presentation": [
"http://femasys.com/role/NetLossPerShareAttributableToCommonStockholdersDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total potential shares (in shares)", "label": "Weighted Average Number of Shares Outstanding, Diluted, Adjustment", "documentation": "The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation." } } }, "auth_ref": [ "r698" ] }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "presentation": [ "http://femasys.com/role/CondensedStatementsOfComprehensiveLoss",
"http://femasys.com/role/NetLossPerShareAttributableToCommonStockholdersDetails" ], "lang": { "en-us": { "role": { "label": "Weighted-average shares used in computing net loss per share attributable to common stockholders, diluted (in shares)", "terseLabel": "Weighted average number of shares used in computing net loss per share attributable to common stockholders, diluted (in shares)", "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period." } } }, "auth_ref": [ "r166", "r181" ] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "presentation": [ "http://femasys.com/role/CondensedStatementsOfComprehensiveLoss",
"http://femasys.com/role/NetLossPerShareAttributableToCommonStockholdersDetails" ], "lang": { "en-us": { "role": { "label": "Weighted-average shares used in computing net loss per share attributable to common stockholders, basic (in shares)", "terseLabel": "Weighted average number of shares used in computing net loss per share attributable to common stockholders, basic (in shares)", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period." } } }, "auth_ref": [ "r164", "r181" ] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract", "presentation": [
"http://femasys.com/role/NetLossPerShareAttributableToCommonStockholdersDetails" ], "lang": { "en-us": { "role": { "label": "Weighted Average Number of Shares Outstanding [Abstract]" } } }, "auth_ref": [] } } } }, "std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477401/830-230-45-1" }, "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "SubTopic": "405", "Topic": "942", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477787/942-405-45-2" }, "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480429/718-10-50-1" }, "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2A", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2A" }, "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147483489/210-10-50-1" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Subparagraph": "(e)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4" }, "r16": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2" }, "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-3" }, "r18": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482913/230-10-50-5" }, "r19": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4" }, "r21": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-8" }, "r22": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482861/275-10-50-9" }, "r23": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r24": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-5" }, "r26": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481142/505-10-45-2" }, "r27": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-10" }, "r28": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481112/505-10-50-3" }, "r29": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-
```

10-50-4" }, "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-5" }, "r31": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-8" }, "r32": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "30", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481549/505-30-45-1" }, "r33": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "30", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481520/505-30-50-4" }, "r34": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-1" }, "r35": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r36": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-12" }, "r37": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-13" }, "r38": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "40", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480489/718-40-50-1" }, "r39": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "40", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480489/718-40-50-1" }, "r40": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "850", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3" }, "r41": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "470", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3" }, "r42": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "470", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3" }, "r43": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/205/tableOfContent" }, "r44": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r45": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r46": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r47": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r48": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r49": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r50": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r51": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r52": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r53": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r54": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r55": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r56": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r57": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r58": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r59": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r60": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(31))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r61": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(32))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r62": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r63": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r64": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r65": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r66": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r67": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(2)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r68": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r69": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r70": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r71": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r72": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13" }, "r73": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r74": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r75": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r76": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r77": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r78": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r79": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 4.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2" }, "r80": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "330", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.L)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480581/330-10-S99-1" }, "r81": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r82": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "440", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/440/tableOfContent" }, "r83": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/470/tableOfContent" }, "r84": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481284/470-20-25-10" }, "r85": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "

(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-5" }, "r86": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "480", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1" }, "r87": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/505/tableOfContent" }, "r88": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6" }, "r89": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-7" }, "r90": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r91": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/718/tableOfContent" }, "r92": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r93": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(f)(2)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r94": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/810/tableOfContent" }, "r95": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r96": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r97": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r98": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r99": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r100": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r101": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r102": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "470", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3" }, "r103": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r104": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r105": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r106": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r107": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2" }, "r108": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r109": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r110": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-11" }, "r111": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12" }, "r112": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h))", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r113": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Topic": "606", "Publisher": "FASB", "URI": "https://asc.fasb.org/606/tableOfContent" }, "r114": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "a", "Publisher": "SEC" }, "r115": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r116": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7" }, "r117": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r118": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5" }, "r119": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r120": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r121": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r122": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r123": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r124": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r125": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r126": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r127": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r128": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r129": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r130": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r131": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r132": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B" }, "r133": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4" }, "r134": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5" }, "r135": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6" }, "r136": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r137": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SAB Topic 6.B)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-5" }, "r138": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17" }, "r139": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r140": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r141": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI":

"https://asc.fasb.org/1943274/2147482913/230-10-50-2" }, "r142": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2A" }, "r143": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8" }, "r144": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r145": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(e)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r146": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r147": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r148": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3" }, "r149": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r150": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r151": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r152": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r153": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r154": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r155": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r156": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3" }, "r157": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4" }, "r158": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r159": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r160": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r161": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8" }, "r162": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9" }, "r163": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/260/tableOfContent" }, "r164": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10" }, "r165": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-11" }, "r166": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16" }, "r167": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2" }, "r168": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-22" }, "r169": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-23" }, "r170": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "26", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-26" }, "r171": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-28A" }, "r172": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-3" }, "r173": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "40", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-40" }, "r174": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "40", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-40" }, "r175": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "40", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-40" }, "r176": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "40", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-40" }, "r177": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r178": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r179": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r180": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7" }, "r181": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r182": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r183": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2" }, "r184": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-3" }, "r185": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15" }, "r186": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r187": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1" }, "r188": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1" }, "r189": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-3" }, "r190": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r191": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r192": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r193": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r194": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r195": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r196": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r197": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI":

"https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r198": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r199": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40" }, "r200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "42", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42" }, "r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13" }, "r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5" }, "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "330", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/330/tableOfContent" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-2" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r210": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1" }, "r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3" }, "r212": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r244": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C" }, "r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C" }, "r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C" }, "r248": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r249": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r251": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph":

"1E", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r253": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r255": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r256": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r257": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r259": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r260": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r261": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r262": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r263": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-4" }, "r264": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-4" }, "r265": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-6" }, "r266": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r267": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r268": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r269": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r270": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r271": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r272": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r273": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r274": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r275": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r276": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16" }, "r277": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r278": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r279": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r281": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r282": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3" }, "r283": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r284": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-10" }, "r285": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r286": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r287": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r288": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r289": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r290": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12A" }, "r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-13" }, "r292": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-15" }, "r293": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-4" }, "r294": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5" }, "r295": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-9" }, "r296": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r297": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r298": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r299": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(A)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r300": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(B)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r301": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(C)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r302": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r303": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5" }, "r304": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1D", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D" }, "r305": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification",

```
"Section": "35", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2" }, "r306": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph":
"3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3" }, "r307": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480454/718-10-45-1" }, "r308": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r309": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r310": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r311": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r312": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r313": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r314": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r315": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r316": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r317": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r318": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r319": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r320": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r321": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r322": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r323": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r324": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r325": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r326": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r327": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r328": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r329": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r330": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r331": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r332": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r333": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r334": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r335": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(i)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r336": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.F)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r337": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "720", "SubTopic": "20",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483359/720-20-
50-1" }, "r338": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification",
"Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1" }, "r339": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI":
"https://asc.fasb.org/740/tableOfContent" }, "r340": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10" },
"r341": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section":
"50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12" }, "r342": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph":
"12B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12B" }, "r343": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12C", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482685/740-10-50-12C" }, "r344": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-
50-14" }, "r345": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification",
"Section": "50", "Paragraph": "17", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17" }, "r346": {
"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-21" }, "r347": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph":
"22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-22" }, "r348": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482685/740-10-50-23" }, "r349": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r350": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r351": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.5.Q1)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479360/740-10-S99-1" }, "r352": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.7)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479360/740-10-S99-1" }, "r353": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 11.C)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479360/740-10-S99-2" }, "r354": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "270",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477891/740-270-
50-1" }, "r355": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "30", "Name": "Accounting Standards Codification",
"Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2" }, "r356": {
"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65",
"Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r357": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph":
"2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r358": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph":
"2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r359": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph":
"2", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r360": { "role":
```

```
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r361": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r362": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r363": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r364": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r365": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r366": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r367": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r368": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r369": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r370": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r371": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r372": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r373": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6" }, "r374": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r375": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r376": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r377": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "54B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B" }, "r378": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r379": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r380": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r381": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r382": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r383": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r384": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r385": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r386": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r387": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r388": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r389": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r390": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r391": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E" }, "r392": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r393": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r394": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r395": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r396": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r397": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r398": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r399": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r400": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17" }, "r401": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r402": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r403": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r404": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r405": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1" }, "r406": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-1A" }, "r407": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2" }, "r408": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1" }, "r409": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8" }, "r410": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "12A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A" }, "r411": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5" }, "r412": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r413": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(a)", "Publisher": "FASB", "URI":
```

"https://asc.fasb.org/1943274/2147478964/842-20-50-7A" }, "r414": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r415": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/850/tableOfContent" }, "r416": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r417": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r418": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r419": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r420": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-6" }, "r421": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r422": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r423": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r424": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r425": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7" }, "r426": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "910", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6" }, "r427": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "924", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 11.L)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1" }, "r428": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483154/926-20-50-5" }, "r429": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478934/932-220-50-1" }, "r430": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18" }, "r431": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18" }, "r432": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18" }, "r433": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-19" }, "r434": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r435": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r436": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r437": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r438": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r439": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r440": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r441": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r442": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r443": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r444": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r445": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r446": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r447": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r448": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r449": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r450": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r451": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r452": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-6" }, "r453": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-7" }, "r454": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8" }, "r455": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8" }, "r456": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8" }, "r457": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "280", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478657/932-280-50-1" }, "r458": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478988/932-323-50-1" }, "r459": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "940", "SubTopic": "820", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478119/940-820-50-1" }, "r460": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r461": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-05(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1" }, "r462": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1" }, "r463": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r464": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r465": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r466": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r467": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" },

```
"r468": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" },
"r469": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" },
"r470": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r471": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r472": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r473": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r474": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r475": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r476": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r477": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r478": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r479": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r480": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r481": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r482": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4E" }, "r483": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r484": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r485": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r486": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9" }, "r487": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r488": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r489": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r490": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r491": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r492": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.W.O2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1" }, "r493": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-1" }, "r494": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-2" }, "r495": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r496": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r497": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r498": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r499": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r500": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11" }, "r501": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13" }, "r502": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-2" }, "r503": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-5" }, "r504": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-6" }, "r505": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r506": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-2" }, "r507": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "27", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-27" }, "r508": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r509": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r510": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r511": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r512": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r513": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r514": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r515": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r516": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4" }, "r517": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r518": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-2" }, "r519": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r520": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r521": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r522": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210",
```

"Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r523": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r524": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r525": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r526": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r527": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r528": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r529": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r530": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(16)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r531": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r532": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r533": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r534": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r535": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r536": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r537": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r538": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r539": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r540": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r541": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r542": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r543": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r544": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r545": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r546": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r547": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r548": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r549": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3" }, "r550": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7" }, "r551": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478297/946-220-50-3" }, "r552": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r553": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r554": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r555": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r556": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r557": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r558": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r559": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r560": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r561": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r562": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r563": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r564": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r565": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r566": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r567": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r568": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r569": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r570": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(1)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r571": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r572": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r573": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r574": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r575": { "role":

```
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r576": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r577": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r578": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r579": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r580": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r581": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r582": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r583": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r584": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r585": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r586": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r587": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-1" }, "r588": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r589": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r590": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r591": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r592": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6" }, "r593": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "948", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-29(Column A)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1" }, "r594": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "440", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1" }, "r595": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r596": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r597": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r598": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r599": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r600": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r601": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r602": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r603": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column I))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r604": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "976", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1" }, "r605": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "978", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1" }, "r606": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "985", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2" }, "r607": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(a)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H" }, "r608": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(b)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H" }, "r609": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r610": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r611": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52" }, "r612": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r613": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31" }, "r614": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "48", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48" }, "r615": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "49", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49" }, "r616": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A" }, "r617": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482640/350-30-55-40" }, "r618": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r619": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B" }, "r620": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C" }, "r621": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69E" }, "r622": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69F", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69F" }, "r623": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r624": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r625": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r626": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r627": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r628": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91",
```

```
"Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r629": { "role":
"http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91",
"Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r630": { "role":
"http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91",
"Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r631": { "role":
"http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1",
"Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r632": { "role":
"http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1",
"Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r633": { "role":
"http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "17",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17" }, "r634": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic":
"715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480547/715-80-55-8" }, "r635": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r636": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "740", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "231", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482663/740-10-
55-231" }, "r637": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification",
"Section": "55", "Paragraph": "100", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100" }, "r638": { "role":
"http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph":
"101", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-101" }, "r639": { "role": "http://www.xbrl.org/2003/role/exampleRef",
"Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "102", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482078/820-10-55-102" }, "r640": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "103", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-
55-103" }, "r641": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification",
"Section": "55", "Paragraph": "107", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r642": { "role":
"http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph":
"107", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r643": { "role":
"http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph":
"107", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r644": { "role":
"http://www.xbrl.org/2003/role/exampleRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482949/835-30-55-8" }, "r645": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic":
"852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481372/852-10-55-10" }, "r646": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-
50-17" }, "r647": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification",
"Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-21" }, "r648": { "role":
"http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph":
"29", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-29" }, "r649": { "role": "http://www.xbrl.org/2003/role/exampleRef",
"Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477215/932-235-50-3" }, "r650": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235",
"Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-
55-2" }, "r651": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification",
"Section": "55", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-4" }, "r652": { "role":
"http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "5",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-5" }, "r653": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic":
"932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "6", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477916/932-235-55-6" }, "r654": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "30",
"Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479401/944-30-
55-2" }, "r655": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification",
"Section": "55", "Paragraph": "29F", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F" }, "r656": { "role":
"http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C",
"Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r657": { "role":
"http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C",
"Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r658": { "role":
"http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9E",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9E" }, "r659": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic":
"944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "18", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480078/944-80-55-18" }, "r660": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r661": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r662": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210",
"Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477439/946-210-
55-1" }, "r663": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification",
"Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1" }, "r664": {
"role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99",
"Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-
1" }, "r665": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section":
"S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-
320-S99-2" }, "r666": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification",
"Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r667": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320",
"Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r668": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic":
"830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479168/946-830-55-10" }, "r669": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830",
"Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-
55-11" }, "r670": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification",
"Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12" }, "r671": { "role":
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r672": {
"role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" },
"r673": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection":
"d1-1" }, "r674": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308",
"Subsection": "a" }, "r675": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240",
"Section": "13", "Subsection": "a-1" }, "r676": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K",
"Number": "229", "Section": "408", "Subsection": "a" }, "r677": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name":
"Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "1" }, "r678": { "role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r679": { "role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" }, "r680": { "role":
"http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45",
"Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3" }, "r681": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(1)",
"SubTopic": "20", "Topic": "842", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r682": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99",
"Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r683": {
"role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99",
"Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r684": {
"role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99",
"Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r685": {
"role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99",
"Paragraph": "2", "Subparagraph": "(SX 210.5-03(7)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r686": {
"role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99",
"Paragraph": "2", "Subparagraph": "(SX 210.5-03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r687": { "role";
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45",
"Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r688": { "role":
```

```
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45",
"Paragraph": "28", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r689": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45",
"Paragraph": "28", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r690": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99",
"Paragraph": "1", "Subparagraph": "(SX 210.4-08(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r691": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99",
"Paragraph": "1", "Subparagraph": "(SX 210.4-08(f))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r692": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99",
"Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r693": {
"role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45",
"Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r694": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45",
"Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r695": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45",
"Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r696": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r697": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45",
"Paragraph": "55", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-55" }, "r698": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r699": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r700": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-18" }, "r701": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r702": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r703": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r704": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r705": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45",
"Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-2" }, "r706": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r707": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r708": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "30", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI":
"https://asc.fasb.org/405-30/tableOfContent" }, "r709": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r710": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic":
"40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r711": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic":
"40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r712": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "410", "SubTopic":
"30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(c)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481931/410-30-50-10" }, "r713": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "Name":
"Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/450/tableOfContent" }, "r714": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r715": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99",
"Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r716": {
"role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r717": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r718": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99",
"Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r719":
{ "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99",
"Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r720":
{ "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r721": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5" }, "r722": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r723": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "2", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r724": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "720", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45",
"Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483384/720-30-45-1" }, "r725": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65",
"Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r726": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r727": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r728": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r729": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r730": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "2", "Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r731": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "2E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E" }, "r732": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r733": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45",
"Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2" }, "r734": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45",
"Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-3" }, "r735": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1" }, "r736": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r737": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r738": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r739": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r740": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r741": { "role":
```

```
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r742": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r743": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r744": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "912", "SubTopic": "730", "Name": "Accounting Standards Codification", "Section": "25",
"Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1" }, "r745": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "2B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B" }, "r746": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3" }, "r747": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "4B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B" }, "r748": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "4B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B" }, "r749": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "4C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C" }, "r750": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "4D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D" }, "r751": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "4G", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G" }, "r752": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r753": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r754": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r755": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r756": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r757": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "6", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r758": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "6", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r759": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "6", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r760": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "6", "Subparagraph": "(b)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r761": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "6", "Subparagraph": "(b)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r762": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "6", "Subparagraph": "(b)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r763": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r764": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "7A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r765": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "7A", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r766": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "7A", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r767": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "7A", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r768": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "7A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r769": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r770": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "7B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r771": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "7B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r772": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "7B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r773": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2" }, "r774": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2" }, "r775": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45",
"Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r776": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99",
"Paragraph": "1", "Subparagraph": "(SX 210.6-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r777": {
"role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99",
"Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r778": {
"role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99",
"Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r779": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99",
"Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-
S99-1" }, "r780": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification",
"Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r781": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic":
"320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(b))",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r782": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
"Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)
(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" } } } ZIP 68 0001140361-24-036299-xbrl.zip IDEA: XBRL
DOCUMENT begin 644 0001140361-24-036299-xbrl.zip M4$L#!!0 ( +!%"%D.X:NW5)3_Y9>>Z+&_? MO7W[_?OW/7-E+\NOWD+?1V^3M"A9*M1._7P_2;\^\KBYS5DQ>OS'U//?D7T:
M1%'TUMX=/5HD;0_J9L';__WM\X6X5C=L=[(_YO7R_H?-W@1OJYO#1Y,BPQ#0 MQP9;/3'\09&7HX=C5G#[H+ZH'X9XU.J/AQH$9O;T"-7_?CS_?/]XV?[\_:-O MRYRE19SE-ZS4ZVC>YN_ZGO>U?9MT?;
637#W<1&+8S*':O M&+N='F1]8VR@4DU,\_"-^L;8@R(;I&5^U_YP?7/\!X,\UV3ZT"_JN^.=*?/= M\NY6%>V3J6^_-;?-;^"NCYIC+O,'*2!ZJ^\.'TO9(HKV+ME;8_TI$M'^J+XQ
M_F!YFS_PI+XS]JCZ(:[;'S5WQF=0Q0],GHK'VQ3R@2:%''LP5C?WZZ&_L.*N MV!/9C7W(#Y!?/_@P;QN0V=G_R?,^7"LFS0?]L4S*OMK_\+;ZM[KVA]U=[W,B M5%HHZ979.^]CGC&9)_)*V0?LGT^9&-
RHM/1$KEBI'QP4&M0:CWI?SL_BI*\\_MB/>"/;A'(,;W/S_;_N_RY.JZ]'3GB+?KF6$T?[V[6_?F1I7,,V/:5?\>)-]^_MV3G,TE*_>/=2T]..)ZIOO^R4ZD?YUH[QK4;4M]48?_K ,WGG%>5=7_VRPYGX
M>I5K@I>[(NMG^3OOC[']\]X;?O?MG_=ZGC[(Y)N7Z-7Y=/'E.#'\^]=$2I7N M#%N327';9W?OO#1+E?[%A^3'._-6E50?Y;FA,6&7
M7S]>90>$4$',+SL:EM[%R0\E=V/6US)@W_[SX>U8EQ[NX;%E]/(X*03K_U.Q M_"B5G_1:-SHK_M\G-(Y]+!6&3(0^#+"*D._2$D3!G)V5NO7=&_V+ZUW)[G;V M_=1_,7-
_AR1YW^%C?:5H=%=QR4/I\R"4$'."N.!$_@8)@U$<$0)T=_?-IP5[_M]$7?S>1DGV+!<2Q_)+E/L(QQZ_/E*P10)_,@L)RA3W^',_?H*-6H^Y2S_M_DDJU8__5G>-WG_4<1@!BG&_L9*,A53X$?
%!%!*$F#]#;S3_(0B31@S]:H6_M;>\^*5Z>:&4BMS/V&RL'N>[I!+WI3ND.(JP]J7_$510R*@!C2O-)S/UXNGO0_M#^KN0=.]?XV_YN!'4OSK;X-4?L.V5\
<'!^>59Y#A4(8@PXW$L11!',:"WY$]6D7QDHQCFGD82Q[A5A/E(BP_H2(*_M.*59?Q!_MFE37?O=]HTD5R;LTZ6L@SP=*8_@R^B9@+'S((T%PC+DB3"!-T_PQJN$IY&JZ_M;PA_HYK,UK=G$#*#@E(N0_V__'-
!&=90&H:!CP3%(N0M/?-IO:3Z$P+MA-R__M6S8A_["+_"FZ>3LNX'(5*Z,3JF+_@S$AWA76.-!]]ZQ)\>XZ-\,P.LSND_#V_M?A0:VZK;1C7\9;=(;F[[=GK?3K1IOQ;9(+??K(GTKIX?.Z6M)%\_IRSB#;\E
MTGR/$Y5[MH^J56<_//GO<1R;_/'^\-)XZ[<6X8??M&&4EV;=K=#8]8'^;_B[_M^WNC;LK&HX&=]/$[P^_#E[P=FX>'IR7T:0WQ\S?5[WO@J0.K4^#0H5'K94L8W8E04D94<8ULT.]NBY;(M[CB:X9=_,S2:
MEJY2RZS3LE1J03[2&L%%J5LPRL"1-I2UDI_=W&K+U&A(1M0;C2E++\I,?!T*_M^-5.7CT'ZLITJ?HJ]LANDY+UMV+1'AW;ZA9P_MB>*X(["SNO$]C23GJF3:H)!'+$^UU55L!66V#VH3,
6;)>L62>+E8N;3)%E=_M_?+<_V>S29(8R2_:QO/)M_B--:*DV]KE6]PF>;8+_OH-,D-62@GJ#NU9*A[_M@GKYX-^M\2UY_9XVWIPBT@T[#3N/R,H6:LG:_=-,Y1:J_QPUBQGF5/L.VV:S
M0*+3&#L%CK,LF=,XNK%6LP@RQUZ=$FFSL)<3:1WFN5F<(_X?N^']P$[17R53_MK1<5+W/%BD%^9X=6C7(K%NS!<6T"&J(9T-_MW++TD#7[\MW"=5"FS>(3<0O7_M05_(+,;:6[@.FFP3
:!.]U_JJG4DF!6X)5[;$K](=/M\2^R\9IN\TO/@M1.Y_MKPN\G;]G\_AYG05U_/RZUMMMEFS/NL\CM]VZ;X_\GF?=G6;^6E;::6J;MKX3_M)\@=@J\9P5_JB/Q$'A3'UZM;WQ=*Z#((/7[OUW3S^G6=]G?
M[(Y=X'HAVHOEU_M0KGF>EG4-\\]=[']@QWZ_VZD-RIXQO)THZ1UQCPON3I?,>9$ZO("S"#+'.Y#5]_IY-T_M8ZTFC?"CF]M^=J>458//OJYA01A_MR."8)?G_L/Y_?;P[*
I5'O994:'Z;QH7[WYC^5=5'@]2G>-@\P>CCW_5"\5R_M<7WW67U3??OKT;V3]'90%O8&Z#;!/#@5]^*\?4X>)(U%7OW(I-[WXY'9W1Q%_MWI'>6M?_!?
F@PSK2N2DD6!$=^Y'<#&ZZ22A%7KX;=75GWWP=Z^\62J<'URE)_M-VN=FOW=PG4:W^C]DF=:>2K/\@N5?TM$M63'ZN9_!JJ[*];6Z5H7;'9]ZW9M_M)X^M/;EX]XZ_7U5VE;/;ZT2P2NK^?
M'%E7VPOSO[=4GW=[]?+"XRNT_\73G[_MYCA_@XZ]S+UX&\?YSUW9-<"+(Y[B7Z=9^GM'7<9=H**AP=68IBTDISFUD&TD_ME$W5_N;6_S<7"Y;$IAM!3EV)(]T^O>056"1=\1DY0;+-B[>Y@N0U*94O14[+
```

M=&UUG)O>DUZR#6JNTTM>F5(+_:F'FB)YY/BY4E:E/G C,/2Q-\&J=+3'YY5EP^S_#;+F8E?ZB9(#5'H MH;'4-/#(B)Z J3T]Y 5;'YKYE5$A-*0U&Q7"Y4I$.I*(%V*NS?;3T5/D() M[:-_/O&M@/"7(${CI[(*4-N(OGHV%#@%?'P*.E199:J&#UPQE'26G.6'T>>0T M@4[+C0Y[K83E9&277&&O55HN3V(Y*EQ M-H@[=>*@$ZTKB2Y@2.GUTM.2S[, MCYVF]IH)JQ.>WZ%
(D]FNE0H>%+QK&"0!LM1=.LV]V:..9XR1E MJ4C2JR'Y9>E5J?(;\[/+NUM5)R-+OZF\3'A?F>N3&ZJ;G<#L04)Y9)J>3YY+ M3YLV.U.VK'#SA2U+03IS!NS"I>5%61.UV].W9[%=$_0\A>ZG*CYN1KJ5EZ'V
M9=+<_"PVN6+UB%07;6M)_2GZ/7#T^UQ2.MA04JHTU06(ZE40R?/5O['U>ES] M&WMT&>ED5B807\7:;Z!2M62GWI,;7]M-32^BN'0*OCJ\Y^HDTV8NK5,UNJ\8
M+H3WSL;8$AMC!6F^ETQ*SMVR(9Z/)>L44N"$2 M@_-R6^7Z>S1"8?CYZ&?ZS?ZS?PT8,3_J^+ 2\2F;#\[H+U55,AJ8*S M/B6:!A_(A,^..&)!!U>YLE*_FXLU4DX>&M)81:5'!K8X[X0O6@&]9=79*L1P(N?
MK%&X,:&.2P\Z?+X-/4]H+%Y==6R' +,CP*8:#14KU]9:;9:=Y>?)U76EP'WI MLZK(U,&5_FO<;MMZ83TS73TX?S5=/3:+*X/^,6AX-00_2B45.&XF=@U+#?R9EWK,V;2,@QIN M@3HC*Y3\PNXL?QC.
MN+*LD<$&L+I;V)**[$;-?-V?,V&SQ-FU/%>%8KFX/M H MH;ZI?G9K5:P?MWH>.ZX^/C*L>T5RAO&MTN_9B;I>CZW_KTIS!.OKZ3F0-TEJ M0EGTS6]J>RA@IA&N4FYWHN:LHX$7I8%.G/!XC 8N5+^?
I%=ZAGYC^5=5ZL_; ML_Q/#6[KN'\>#<"M_#;)_LFTR0[W7P[W7RII\3RRWW'_=DG\V5?>67[;M_[S MR'V'_MNI 67$8,R]ILO \T[K%#; MO&'_Q("W7D5T1-)A(GDY'=*11O=
(8V6!V#Z&_O"D$.SF22'HS\@$4>?K4C! M>4\Q=Y6^EWI:^7FD.[%&2R!==^YCN];,G7MR$H!=:K*{6#GA+?CJY5:]2^E MALRTP(X=-VUIP<@6#Z"+1_3$!'*7CN[;<I2-ZFGZ?3D\WB3=W%Y M<'ET\8'G;T>M5^NYS'=='!W^?
GYR>7)TX1VGOQYYAV>__79R M<7%R=KKX2Z%^Z<[^/UAQG:1799:VO$][AWL>]F.IEO=7\Y(PX=&>GQV_IOW M03.'IC:+6:K>3-PL&>\K M/1/]?G'+3*&A7W;\'?
O]EDDY_+XH4W]/9'EMOOA_GH7#/6&TAE]V/EU\.?Z< M%.6EZ=S.<%@68QH?/Y3Y?N-*??M#*8?=K=^.B.F*K6LD6'_8 XT#[[WZLV7+ M]SOCK0TG]JDE__M *00J[]^=J]LL+QNKCT. ?
1X(*6.,*57<5X#Y),)^I (2 M^D^OOI[1_(:5O^PD>NJTUO:.9UF?LWX_*WGV8V?_O_X844S>3]%'@QA&@WG; MP)GAI5+.-(,5AK7-8/N<_?WW@_/+H_//__3.C[ZO_J?
=%39EOR:>CX8I\^JG3.!A4%08@04RIB_M8825CWA,H2\D8"P.%0!X/BIZ)W7KNS?Z%]>F"[N2W>W>*9;OJG1G_V^#5'G(M[WGFI\\&G4G+K8}520F,'X*J'@OOI_ MRJSY;>*MB >A%3N]<4(8;WZQ)DW(0%
(8IX07)OHZTH%Q)[O[&(>/K$/A6#][M:A]M\(<(L(P9)41RAHTBOQ'AD$,!M"H'5#"#&J>Y:1?[.(*/P^H*IF\A(*V_ MI>5A:FU\:2#ML]M"/S/\] CZ\>^LAX MA-
H*W&E!IYF!B/B/O&W"4H4C8W1LQ,T9A?CV =R?EU2>(/]S=64/QJ;EJ;[3 M8 %"?8&US@J9#W D5 @0YTK_ Q"6^H&=I&)OU8)@):LI!=E+ M(\"5T=J\-+.S__/1#
[W>GEE^>XN]>X+P6.%=W"IA',22U(O*0OO\-HJNV!6 8M58++Z+0G/ ^S M05KF=X>9'#.2M(V-:*Q\GP,LN!\2(0@(*8[#4%(Z SQ-:;"%>=MMGGTS?3+6 MT2?59]^9<;>N%KO 7@!;%L<:
FW3NG3AM2&T<ZSC^57+$W^8[_"_/GI/&5D?,":[0;3':9:!,H.I,Q54=3_?$Y2!9J["#$4 M3&CLTO8CQDAJ%=S'BLD@C#$.")T!QE!$?.]OV76J5;9%J-Y.0EIO:>L
MX^E^PJ:9C*@4D4*8T@!CJNT#!CEB9DCGPZ2S\O!HD&)*T?379MG1)URPFZ M0R*\)J1# ?$LO\R^IPUJ HA$"(N(B)AH:OIFE+8 M9B5S*QW/\B]:!]22L*EN:MV!DU P*@* 10A@Q3X$2*8*D8
F*%OOQY,=JNB M@S$#91W4WDG]L;6CBQ/8ETQK_W +[F=,!LDHT$8150!0;&B/*244*8!+")* M:1MB%F3U6_=*NBJ=M)3SXE1\&YS3=C)+>M[ZH<2 Y,.35 6ZHPJ7JMZIXG$ M,U3RIGOZO9=GWXM;EOZR
U:NTSWG7<\=Q,N+OK%.+D$._OP@3!G1=Y K-@%, M*J0L8GY. (:;*(H8#X+)2+0(/ 9AB*68")TBDEZLW#@L\DS>I_N<]2Z=T/!F.@ MM;H !!3A2DA,.6:BE'=06-8^T03U#7XCO[Z((3'7HQ<7M"S[FQL5[
M1_!__3&$@+XO]"SWU:TAF7ISK6<W;K0'JAM6+-4CF\%">%[JMG(JPT.L:>N#9U* 7 C$'I]5E1>KF-QGF] M,%E_>$:$WGAP-:#C>^6VH0MMW>1)F>AUS*T@4[E>A=M!7@S,UF:9>?H)Z\(% M\&?
^QMA&)DSF0)3OV@(TG@O8V9P=Q8=]/I/4,,6F#^]([_EX[OWWA^AP^BU+ M]FO-H/U<)F7?;H6636AC$7ELC4CTI6>!J3OE\GXKIU%F=HM0%X,RY$ MBY1>*0#,P^LSK,C\4SV?)[&6'7<
G_P]WP>:JG/O&^L/IF,-5L=**\6:5:]1#3@7%F^: MO@L9X8@2)A!E6.I002##@" L,8H5Y[.$K1W]]L]-6H8UL,JE5HW&#"$3,+.; M_-B]3J14Z;O*A44H@4H
%>FIC$,5@@@S'L=2!'$4=F'IM/"4'6O6$YHE"TZY916.9^.>9)*L_.0/'ZG-7LEOIIS?E\U7"L;3F$T MR/P^?NYG\,:[9H4-1Y8>Z_=KU=^HI/\>)$4AU7HH5_4#NLV13HI,\$45@%YK
MI@V%]F@H*;2V:FZ; '1/ZKM:)M';W,EE!7' 'KVY$?A_:S;TR:*5PRTJ"FN M,Q/$5T>"CZ:FO&;EY!B^L_'>VM!JVT@]EC<]:_[\#*NQVJ<['.2Y_G5UGL&P?\G*0=$\@85" M G 4F9!5'# 4HBB@,
(RHI%$8S;1/]T]S-'ER+WK*"3!2V2_45::\WT^\"HK^ MTO,*EA::/_(D?M\XL&6)W#O-YFIKNBG\?IQ?YC>>I@R#>X9ND+#5- MJ+Y>Z3O+#?CT[SRE@>C..S%0HM?#;"]]8B7S3)3])-7?
M]$TR\X'^DGLDSH6 M==^O FTN=B\7(?$1;=>'''F8A\:I?(\I5Q9LGZ;(Q7C/,SK:^Q5'A/:?#;I!?2RF'7(M#=*T7C4'PG=;;FAB8%YQHPE3OR@?@H:>ZAL]R+OJ?NII0#@)0?^5=Y=GW\GIX
M>T]#KK+=0V315U.ZA&G[&K+ MLP_T>OADDE:1S'@X?\:V 0V9015!EK%\G %$ZYSQ4@#<:XOVG9(_]X<=!D:2J:*I"/HH%CX$2""F,411AA100F(=< M1%HO7]UA]!60QE$[VCTU-\.?
_6I_=5C]J$DZ*A!$.9@1R(?V@- /[,WDU)R-)5&6CY):3 NCUM7!_N;\;P!ISX+ M0*HMHQCR80,!<8@8#%$E,V0%6IA,ILW;\@"VEIQK27ZB"-_UDML%;;JS-CC M2LB;O5IUUPU";&%
(&E&B2HXRW$EGHTQW/9(6RUVP>,[UX(M$BI?AEY^3T6.MD_MVJY35CMK)I5(!S>[,BMWZX=W]B'L001[]/[8S' \^UZ5[\NLOWC4]ZD5\ON1
MF=.'^A<'@RNM@7JT2E&Q]P3UMA[V&S^L/F,VJ:F$4#UJMQJ45:7K*Z.D6O[TWFKK.T;M MW^HKN]Q:7];^SNV+<%3FU#+NUO*LF<+J/U8K8NV/:_7#F87/BAW9 MR\0/CU-.,>?
XMS_L[GXY/S/ZG1EA%2%GJHF6?]:?_PS__.<_[^XVY__%T7C_MMM3JZJ*MY"7M6UH?F(69Rx./GX_.C@_/3B^/3B\OM%BJBI^D@%==9KF?CPUNV M_],6(///JJ8V(A\F=+9P#RRT&39+T\%>^&CX\\/A2D-
7OEE$D[9DN(Q#U^1" M_<%[$7TJ1F>L ^L[$?/L59ASYB>W+A[SBDT NK]WGX5N#A[8V7_^V9$E+:!G M8/+9H?&+L]1<@7?/8:_EO&=)L[[\#!8:&ZLNH\DN5T"[K".3X_0/%Z/_UJW* M+RPOO9,]
[WAD#IZDE>:J==&5'^=XG$Y;%!(CA:"/M7J+0OT7(7..=3;YWG!5524ZU!7>?&QOKCB"Y'Y:/!:<> M9JDTASX.4#612 M*OGF!?CFI3@BV!#YN%R^Z;)@:A+[S6VNKDW9A6_JW7/> MO?@Q+#?
VJ&>>'<7_7.K6E.7"B^3',)2CV@F89M0.\&:W91IU,FVS99IU\U]K M4T;EQ=&_!TEY]S!7-9^MSVAZU6\VEKM>BF]")_DZ)OE>4K"QXOJXGWU_3*#I M1S5[S(C5-H/!9EOR=G>3.
<[O1,G&D/%I5JJBS*8=#DVRM@^94(@VS\$K%09@ M%C=8%Z3!B_D)H?,3SO+6Y_@)?V,INZK8\%-2B(-;/]L3^%]JZ.D'O>M6QEU MD++^79%8*7>/"08PJI@aL_Q653E6RG?/Q(8QY:8WS!=$# MK1
]MAX7_FYB%Q,MHI-O2O.B_MJWWYX-##1(]#-33+#P#G@V M*.O#>]YY4GQ].IY_*>Z%F^(I?3$>GZ4BCM,0GH4$6B:7>=8O-*]^R3.AEK&- M:!NTW&^;E -;J-6)\+6!P.
(!&,L)H5KP]6M9J.5'B9SL>6&BYU]>\5K7'H WS9=4WGI':$N"^N*[ ]>J:IRSQU&B3=G M2+)<,X;YXM?75LL3'1?OK]A"7Z5_[Z6) ??T/C_6!>NK(HN/_KVSW[SLV>O&
MD55OIS:2KQC=^/?"INVJA<>V2HZ7IO\N8^?*_5A='OP]+WU2,3,^W]]OL_1" MF8IIU7?/7-!)TY>ISA9I3/HI5G@MR15%RQ6Y=VG9&???/.JKTV? MJ9,0KU-"S!)BOMT2POI7&NZ5G?
T6CXN3"J]1+LSB/MU4J7#TXSKAB5F,_/SD M1,#\3F@AZ82.R)Z/7A02P?-IX^+DU]./RJ_/CRYV!N_OV841/XB5%1_>$8= M045R83R<&>.?VU9,HZS3$_9SD3:B2>G>.]52Z*ZH6/)'-[=-KOEVFBEDG]
MD&FP4=\$MF:%'._ZPVD_VM.%-%>VD0SD\60?$ZE"%[^,99@9"H52/OZ_54Q M::IDM>R*C0_&DM^(V:=S9DSOT5;3;5(B)V)JG7;V+VU*#7N*1I/$Q(`.B1/@ M4R-Y,,G)9+ZO!?#DZ/#GX[])V>71YYYT>_
M'IQ_.CG]U3L^._^' KC[^>SLO\WWB\N#RZ/?JEP9DU"R:%[4!5#R\CHI3%". MR60;O _.J),BF6H I3:,?VOV[S?#$DM0&I7]GN=5M9]G7.@]:'=.[YQWT^XWO M=27P\MI293/&7;^NS'(C3+R8"7VM;KU*
[%4^7)L1-WWBN7JT0Z=Z#=G-\H3 MK%!%S[O+!OICZB55J>V[1WYKLI3!\45;9>5QRSH]ZPN\D$K-^3?G_R6G&= M#?IR\JKZ<:M$.7GUML 2J:2NNH.FG&:I)N^(MH83P[135TN3,W3Z=7GV?RV]
ML#F\;G1?IE_)53]1WT:71PLQ'%51)CI8W^Y"D M_]6X8PY_I.J*U05%S7>3U\\NS:C:?)%H:F>YI^?7E$TRX:$]+29*00A7US8? MH,F1_LAJUP18M_Y=2P--/<NXUGAW-EGZ'
M4'FJ6WK7PNUC(N+1S/*3/YC^WG;%FS5K;BV=/EU\.?ZL^=3*B.4D4VJ)89JZ M,%3@AR]L*T35TLZHK9:*5N%80IOIX@?MOV[BJA49#03%&E;LF"@5-3'U3=6P M189-BSK38Y_*;3QXGPU2#;@F1ES=L
NEI%XYBM\O,A$M MYF%C?AI?I\H[5*V.O\;^1O>$?TWTS\QOBS+/OJJQ''W?KS6*VM\T1O^ ME4F(-3#'#I=));+JC,"N5B7$5Y.]^%U->/WI9X9*\D/WZ]<-[T_G1FJABC4@ M[4,K^,"*3"_#8C,ZYVP]+A
6*24WS;PM#I_18P^#@[;*. \!R0,R6)],OP4&YT;LC%MER)?652CIE?G=4R-C,R+-DLEKE/]FRMS0>05!G(U UAU)9 M>CY7<.7!VX.G!UX.K]4D'!:\KD7DWF51]BZRF
MUDVIKA+AF3VT8DJA[4UKL[UQ.#:M#!ONU=LZ1F^V&'USV[=[.)4+P^PTJ2QV MB.T0VR&V0VR'V$^IP\,MO7H#T&)M[7DPM2YO2YM!>]PS['P0#G0=Z#K0?1+% M'.@^08_'Q+6)VZJ!-
TGK73WU[X'9>>N;3;NZ>*+NF"FS9(N>)C=\D!=6\;4* M]3 .HV<^?>QGHJIN?N?% P-=TV!M8J_J/:P1JG\W3N<[KU#J]^E9M7MM##7G6]XJ[HE0W5=0?M7C0)'FKA&FK9>2>=V-.;>B7#(5&D?4'-
@S/[%U6 M';,?*QV_+!(Y/)CA_9[: Q VS[^+VG."Q D2)TB<('E:D%3G JM@9RU53!;T M6@*4N4I-'CB'I Y)'9(Z)'5(.K-*7A]*L7HJD]^JS4;]B!CDN5&26T)#:@=W M=>*P.C%:Z> /'6&LGS'Q?
IJ4=0NC(S&EAK"^TX$=# APX:-L%]". M5\HC;K*BB MMO.JS)C#;(?9#K,=2O3\6L2,5FF>F?1/ VZ2"Q55(B,/[DC>1Y<8E[G) MOF8W.6N]W335/&1>QV*;'%7,*S6A:[VZ*6U2K?9;_SY^-
/!&X_=:OC^QOHSH'G//O/ SF1O3(_4 MAHF2XKI2ZG_<6L?+L%R*>1Z MRW+=G6)@6M+7>UZA\F^)L">/OB527[*_^Z92F>5#SU.[6:!R6QRH/G=J#C%9
M4T0/46FCO^PB5+4837BCT+0L%OR($S=.W#AQX\2-$5?SB!N-]JJ&TE'D?%&5 M^JP"ZT<)9JN=VVN-+/T[[!\#W9LXT0BN\;W(TE3U'?XZ_'7XZ_#7X>^C^'O\
MZ>"^B(KU_NMOYC2I;KSI7=%7KXQ.GMIL6'VK*5NUMPJ]2:^\03%TV5PK4WA% MF*(HPR2'WI5*5<[Z_;MFBJW&@[DR1.O=*&:+V@XWC\>.$UG<-W5N\NKP?V#NP=V#\99%DF-]694Z^??%7]Y-
IL]F9Q$^MCK8ZG5O7 ZP'6 ZP!WO@<O]L0"747H H]+V^UJ-'E11*+?*>+0UAU)9 M+N1)"ZC-%O-M##?LD0:)DAN;.!,DL:Y)D_K.K%1[PZ['78[[';8[;#[67Y M6V<]VX:'DJSZG#/KNKC-
D_O,M2;.)#,ECC/Q=6^EZ-I:! :Q4K$M9:,?+#(_ MFH\%2M?OCW6IK>IHAXK.H\>*SK>6E! VZ>%2]&/H=U]T?J*LO*TE/SV]#Q6E M7[&_2LM. \P[54X^NQ"[S-
0^1ABCY9J_A==7C]6U_RQ(ND3O=&SM&]T25N' M>Q2H8&YP5BCI14V!@JKV6J,OS[?9#5M+[7@9=KZFF;?JZX.TNIS MGA1?]8@&IN:WT?/+8;4)S82#F]NRJE%^[PTOK[/"G'$J1)YP9=JO1Z!T?XOA
M?,^V[*:V>MG7+=0UU<]U1[QC)LHL+X9UU4T_ZMLM[-O039X@W9W]WT;[LJ8] M0-\/F=G[E!1B8&NQV]<=I*Q_5R1V%8Y'RWPXMLSG]\M\-EKF9I5OU#?S=&O M1^?"3,.>]U$)-BC4,\Y:N/#=#(M^W=-
@K$D41-)@RIZ M7I'=6(K4>KXQ-O:=J2;/U9!Q15IJ$_#? VW&5-O<]F3$V&\L2ZN[K+8'1^SE4XRCN:6)&OH]8VQN6:\Q__;SBR07@YO"Y08WA0AC M8]HJ.:Q[]<@[#2K4 Z\35]MQ9R;/:<4YE8T\! -
AAR43#20F/D!306*VF+PX MSVYJ=JK1JGI]^2BH[GF_9;DRFUP] U45S*@JSYT>7]; 9IY7Z;IJ@S0S<9IIOC(R,QR,? M].UJFC%H__$&_>\?]XOOM99Y./@L4P^,0RXS/9876]89IJT+*T,)8JF+\-H
MXG% V(3Q73,M&./$ +<--S3CO5":]).1Y#CZ(:Y9J@GH4%L<20VMA9;6UPE/ M]*08S*ERJ]MD-/TJ/<*H-2M1#&/6\H95TK?FJIJ A\QER)6K)EM5C&:3PFOZ M;1! (Q7\\-=:@3"U1BL&-
F64#&KQNR=Q9\^,4=V69EAU.*7]W7CLI650F56L MTM>K8/ABP/43NIN#VTJ^FTSVWY)"5=U[&'4,5&J.T>\QTY>DNO%K9??#=1]8 M/:)AL&BJOC<&GJ0VF+1*W#F&CSVO6JE).!SNM7_7';,8ND+IU#
[(I^2FE23J MA]%*]-,UE%;I-2)YMJ&G5<&AT[*.A1WN,K>ESSY9M:A0<*?]3]V3'"\VJ_ M_Z ZV@&BB%A2O:@;@_1@J*#PU?C]Z&J&>71P]-OW&059C9X7*N>=:7^H$O!^>7WLF>=WQR
M>G!Z>'+PV3LY/3X[_^W@\N3LM(5@G__&,>!XX VSM-+RRS_L[AZDXCK+=W?K M^6%>(G_9&5E:%R-AH#O:?-J0P$\SNN<77=39/-RC%6[?!AA.W(@PI]W<#WB, M,9G++>U-S_KD#LSWG-
V^GYC(D\NCWPP]3?/3N.MW;K?VA =[>JUGN#/3IMP$ MH8V3R6Q?[BW[>X*;WW7CW2D<8(6 ,0:P1[$"6>1?,'VO1[DN_7,3[392,L?]D!]\;2 MN,:S5CG M6RXM:YZ@# 'TIO>SJ78:&#I-
QYWH1'>9Z4GB_:2$LKM "#Q&QTLD6K0M1#L5 M +$\$;B(M!N&<>W2/=CPNU3*2'VM71DYK/=-F95[[U8F^-;%EM8T>IKC%GO9 M[*2V;A3JV/LZ.\.KY-M*9Z;!GUO];8>'1T?'QW.S=RNZCK%W9-
UDAZP.SA7F M@iE_T-V?P82=;TER ^B/K$EM-BPP TN@U3EH9TG]G&O5=O;_M#)T];5FC>HS1 MFL?X(?GO+LW2GK[PZ9^FE[$8 .RAVKQB[?6>H]"'5YI^C>Q(]*)9GM]IT?P MK#10.Y7[3S?
PKXCZ0<0"S%6 ,8L8"QB/ 1$!E @P7^[8[2$]^'/C;A9&+?8# MI$WC09I4UW[W?;CC2262&]8O*K-93Z"RGZH]L%]VDA_ENW1PLRLS&_YJ'MW9 M!ZA'(.F%4?CA[?B@IK6D[I/J\UG*\?
X*Y>FV,C)"65B]*$2PBE28GW5<]+ M5?E"&DNGH*E;^+-FD!D2QOF(+DY561NJ#6P1F%$A.(8AE?IC$"&," YH%(&0 MA0"N4CF(8(\@TA%/6$OJ[5/@Z,]16175-FSX\8'&H?,IB # *>0@41U3B"$(("&D!
ML26Z$"+:"R#J"(B]&"H!2GM19WRIZV&L;H9D/#-(,LPM:M- M9/3006(KV?<\5NH?%.7SH\;=3O/:=YJW8&HA&O2/8?-GQ0IU MG?6E25:49]]F.KCNM@$W100MC(XYHK.3!IG]FF=%T5 XD40*Q#
[WM=J'*0K# M(& 1AA&77N0CVA+NN\R]>PA@#X.MC?9U3.N8=A5,*V*B&, D8BC&C$L&%.8Q M#K'T.2%!O$HK<>N9=E/MP<>5CK,X-EGD1Z:@,P"[AD%K!IJAA^!+GZ7E02J/ MAI1A=_2:GFH9!"
(R<8XAASAD,*9$@)*6$*%JEAH!I# E=B1KJE@[@.&GC M.$G0B+*80(9DC'T8LY **".!8!"'")5BNTMX*17YR@X'N1ZX0=UF?)8KZLI M.>4=$L-<(RT68P4&O\;"P!F',=^Q!C%@E/& M6(1@K,1*
(\!ZA$0]1+H2%]IIZ;SB /GG2O/#+"W*?%#186)KYER9,DDN=MX% MR6Y(D&R3A$_2+S4!3T4P1)Q)"K5Q P2&Q(\B!93)/>@#B:)XI1$, 0$]0+JR M%=I%'G,(X1#BI1&"BBAB"$JM3S&,XI!)H?P
"AYQR<*P90=SB9X0B#J4S _5 M1-0[TZH3*-*5/=A+)"^$#ZD7H1W@ .-"Q3ZE \]3XQ*E>[C]&+L-\:X< M2NZ6_'?,M'',1.-8 HA#B$6_,5!$2 $>DH!$@8]YN-(X1-P+2-## =AH9GHM
MOHI'#ZM]UCJ;QX08W SZS-1/E^HVU^MLR_C=0 M+Z!A#Y/M/0\\Y_* <6#DP.@5@Q$D08A8*"A3/O8Y9#"D%! D$!>2\)4Z4E'/ M8-+#$#HPF@V,7E*U7+
[^Z#^F0)ZJTNQOM60\Z!)@;Q@J;QKT=L5('D^Z&X<4 M!5% "6&1UJ2T%A@;T8 ![B'3%W^0R5CK&W1C&19@$/J&A M3RG&A,21!!0*[#.%$:)JI76P0 \ T//1%C+NFK22[OBV.CUOI3>++P?Z2R527
G&U[QI&ZN;NW=G M6J-EI5;1+)'80V$I2X6R7\]-U\[BW_4-0R _U X,2QP3&OLQP8KX7-NH80!4 MP!#&<="2;729AS;\4.NXQ!W:<'RU;7R%L8V)X$P2S5"^9)J;6.1C+J,HB%G+ M8:AEGN% H=^#<+-
+G6ZAF?BX=#]]2Y9>);P ,P]M6]+!X+C&"-#1MG2':MGQM_ MJCS1*,^J)'^4O"?'*7E/YN&^,V#00/E"4"PQC&5) :1 !@@,00[C2PYX8]]#V M)I]S7:NX=E5<&XLX$+%B<&B593=* >^?]Y3*YJKPE]G
-J=)S\4'+W/RK/S*J$ M$,#WV\JQ6[7- D0.25L&LC_AT79;[&ZG;C7(UJ@M=YJE8JI8"E 0$";]. 4 M$\88]R$7T'@O.(K:,PPLL18DH3V?=B6AGMM9=_S:?7X5,48A41$.&,!Q K%/,X8K$2OJGN$9&P
M)>7P,H^/^"'L8=SI**:-\>!TL?<.4EXAI$@5XY!RI+0NARF*PE 0 17P(94(M4KC:0R X"JAWY4$9=N?3\/+L^^CSGW@^=NNQ)@T^M6M??'E=FR9>^2O9,H<
ME3DJ>V[']LBFQEVTJ3ME22\T0QU3>V4V,'$>SQ_*G,KBGYZ]ADM5F5]J&F;1 MF1OZKJ^XSRC0NBV06 +!@D@P&5 >P4AATN*U7&*0I-^#-- V=%>B)+O(C@Y, MEL)%'3"B-P01 !- \WX8GAJ
M0A^S__RDKS!-+]5%L\H- [6>C,8MT_YPI+%>GUW['^U?2:?AEFU)!TH^>;#6/_TH\T]>,L3^:TQ_;+S\$1=VI3[FBGT]T'^-YEGT%#&ZYRV_NG6&BS93=* >^?]Y3*YJKPE]G-
2__RWJMF./F/GN#0#,I^ M_ZX,$IAEUQ3>'SY4+4-];6>?#"=_NN-M,SN:U5M]99>;2[LLUH-YQ_K?V5W1 MU(_7.?#IZM)MN3J^7;OK3&90WRK_GOO>NZY];!,R3I"K5:J7UXJ[G4.V]G M&--?
%9.F:&#;$C<&8DF0>=>Y09,_7AY_'QT=GOX=GIY=`IYT;94X\0^N3O; MU3><9,*-#PUTV7KT]2JP";?/O!B:U# _)"0\36JO!,4XD/.M+4P3OZ+>#BW]> M>'>GAWMC+_C#[NY!*JZS?'=W?
^%7ZJEJMJ.GU*"\G@-M,Q5*?F1]$^Y_<:V, M!)AX5L_,Z$&O?M*K'GWN3&@P&J1L(#54RC?/;\Q[*TL?.K?]@WX"HWB5OZ8 M[S6JV^\5,U2W*F(5<6E_NK, &E08-RUJ)CFGE?)78(ZW$>
(VK4H]UMU[X^R?' M?0;17F!Z8R^6.4L+HYR8AU/5/B/>=TTMJZWZHU]K#2;+[<&%$9IZ;2@9Q;)Q MOY[&T7V9%+=]F=>N])-4>7_PDIO;+"U_,/?(ADKZQ[M[']..&$_Z>=ZDDTB
MH(LR$U]-.765%S80E;[WS*9&>3?"MQEUI(:&\A1)S4$^FU1$STU!;#=[PKS?33%=>)^)KJHKB$<9\-N,^R+=_&^C;R*^9 MLC=ERBR1%(V#9G(C:R07FQ<6!X;9#:DU0(7#JP6(Y),2RE@^'@*K)D:T+<2X
MRCV3M>;L.:Q"([S^O3+QC+0]39ZX/A-#= M* L-?'?&G%T9[*[NG.9Z2>D9_5S?5N4<:+#<(YY+WG6HB?-+19N'4Z!'*>O4'AO-+LB M#"(5!1!S"C'T$8^9C(E0C
>$8[;2NKZ@!Q#MA=K4V%*&79/JLG[])!\HZ:D? MMV:3X1DA6$M#K4Y!4[?P9ST@8PBBX>2>QAD_B!'R820#(#&@/O<98]!GD@$> M4K;2<*4P#'J(++-"0]=)Q7'1=G(1B;G4_V<18@ '@04@=
7"D/&-2NUE(E< MIK3&&/=@M,0#+NLGEE?G33CL)ZGIK6>V$L3^%&]Q[WWH(+OA"/3SM3_1[T*W&;,SZ< M\3&5HW)(=W^MR6X:Y$'@0*8O" 5*!PD$+ I5I!#%>]+8KI23P'LH6B9Z^M4V MF+0?8I7@5! 2(0D
@1SR+E6/TB(ZW$Q]*/5UI2-R]Y&^M4V]-"DD7 M$K55J>(;VY<=5D76&@&QSKO0+X=ORXZDF!OF1FFS)S)F#TVNNVGWA1YW-L1\2+ ##2".H.4\:"U^RD -?
T8#1E>;QA3T"1A0R2B).4*P"*%;JCD>P1Y>;X7>#J]3@E@$ ^P3$D52A5P+[C!0 0!X MI=OF/:BY!]"V^CP;00JO97M\T6" +GH2W*Y81RR:CNZ*S19 U&H$A8+[& ,6 M4 AP# ..I-9#?*@MH9A2O-)M=-
"C%/1PV,63#EUD.0<8#C!>'# "*7TL()Q MB# !*I0,A)%2((*9Q'&XTCSN/1\%/3]X78#QDAK;"]>CW8"XQ0V#SDW#Q_7& M$K4B7J2$'P ?0.Y+[,_A)%",:,(411&DJU210IZ)( ]V,FL4>Z/8;G)L
MR"EEV!55%@)K^XQOP&V;(\Z%#R68:2**H(=PU ,AV#Z.?2VNHYETE.YK)L[> MZR_Z=89LN@&7*0;], 2MA'/;@AYU,WR20(CC%7 MA_G$0LH0HQ*2D*N-(+TUB8&UVM.-28BV8G/*%IOKPE&[C=&7-
T8;=A/J*-11 M:%D P*I&\W*+:/JCLMRV13.8Z?J8$UGJE],E+R?FM]'>>BK(&C,O,[.L97G/^]/8G(^M4U66_:E M8-.8U0N^L/PLORC-:8O_8?V!^J+RBVN6-X.!E4]B!@0)6"@PCZ,H)CS$F,2$
M<8BCV4[QH*;C LWLJ%CF.)#4=I)"A$(%,(]BAF7H8^4S7T8L!'PF)^R"X_#W M?+]MOVKJ@E6>S;F7GK>T-;8341P,RNLLUTPF&W-"J1\&/L6Q$#&.'&$%Z/2F(MH0K\(%!RMFI-8#$GU#+Z#ZF"#$(,1"1P&
(A0AGH\2D:_W M_.K ,Z_L&"";/VPTJM[0ZSP_MLMC;Q#+@>)$RX TN>$EU +HRX#.4 9_B*]1&>PS-/Q^%PV1!4$0 M$BVQ:1A3PCFVE95B'K= T!(EGCE/@'N!WY'4N E!->14]M#:< <$,0PC@A0A M&$?
*YRBF,00*$Q93&+;4F%KJU 2$]E!K5-)#N-,LY^W9FMM#Y^F+N^4Z98AW MRWVQAAWC!L%;:Z9)Y%1I;0-*13G#B(,H9"*22 H1,BGBELB[)6;EM"I(! >, MN^4P=+S34=X14C%MWA),
<8B)8A&'$=&6+@<\B@%H20JPQ),U1G9V,1]YUR9 MW3G#?)DK5@SRNZ';[7E:S+ U2YHUE5IMIAE7'9LS#TCK,!S@4-&0L1!Q!(R. MIZ _V]FOE?AC9ND],JE@L8"QMH\Q,ITGNH,H9K%2(2(K-?P
H#W86DKX 75, MU!Y5.X@.:%RO:E>DD]M,#:Y5 MNY6>>WK(A!2X M3^5J$6+"001R9FMAQ*!%EF*ST MQ)3C]?8A=G-S_KEJZS]8GK.T[()2TRDTZQ9DK<$4'A+"02K/S?L?\)O2*(Y, M,ET?HP@C&82"
2@D#V' 9,!G4]L73C@1^&$OP&V;6B^-3LZKY%AI3E9B00B8 M"![[(<4AC+C/54Q\DX729U3.MCNS,"O1D/8 ZF+N%N=D>E!:'TB9F%5B?>^6 M)5(W9;9]DY+U.R"_G:&R88;*XRAV3VM?-

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x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

[G!T:JMHOO%*AIS*Q*:+;1D>)O+([&L)FT5*8.$M+G+U^GM8*VFA\ M@HKFB+5GBG2U@H,ACC$IB;L<@=(R^M+Z%O8!F*HX.T J.XNCQ>%L$ 0^<^RQ MB...3N>_$KZ91YWC)S)PZGB\77WN6-;.\FC>,%L79X]')8V=U!LAY,>]E43 M9I:3JA$=>_I+A&BHLN-[>K=,BVB{$9&E$WY,CWNL,T2]@WW#),VC?6-,G4$* M[$CPN @S,
(ECP0TDU2T0;7(4@)$?#K9!C/T!X?%W SDB+!6ACY8N4-HFY\D# M!1PCD)[U$]G]F9//[+!FT@'3T*/B'=J/;,#:Y 3N)0>82]'9:[NYHOWF&_\[M'-
%!X!&BJQ[XG/L!ASG.B%@3X-407J=HB\,Pw@W3V*/ M^.7T/$AIW)EDY0G:LA'E'/@B=V>;Y?[2UZ<'01!/#%X;Z!QT+=+G19\'GMM@JL<.W-/(}$B!-DRP*7_F'B()[N[%[4RQ
DV] M3Q(\T#X\$)02+T_HU)N[()RA._8C\R/L9!H;8;96S>C96._IA[G':9-J8;:5OB6, ''$HR_D;+60]%I T;TP4K,E^&(2SR1YI!;^B1IW^T= MTQ!K]>%^M3G;)T&(J
7^!7T*(AS@A'-/=L2M!]9.KG>-NK-^BZ\B:+4"@ M6#-TY\QZ,J:1V2%Y?@YM HJN ^/G03T=>,^[+N, '" +V+7UF>MBJN7>V*.U MF3M!$PY.74(0#FZ_CL NKH6PM>[
M<%A6^V&Z)EUUNKQ+R*8]\XI>=$Z3E_YU% M_E6(/<[V[([^IWS0P>$BLHLO/[-L&TV=M:O@$<82O9<:FOD[LSFKJY'SNZ?5 MF; J6X*'0R\/JQI./A-
/GUY<72,LRCRE>5@M'N_CC!5CQ&%X$$U9\$1X5UD3 M&FZ]V_+>HI]%/T[*F['E#SQ_VY=]1IAUNGZ8IV6!ARPA.,V30W&E=D>R^\7K
M/2QC,^*E5;'M+V;M1N6)%GCY)V4V8<+G1;J]'H-)0_Z&S"K[A;"<3;$,EJ5@ M=%'9/RK[G1!>154G)9?6!+7J N)]J!Z^F+%D.Q{+IRXY!E9IV=KF" 7%R[^R8/L
M0+O/9BP/A J,F."J#\,W8S6IBA%2IK(QN8I"X*)!38%26Z?%9R-:HZHYXNUY MV%2!P0!;CBUH>C46B7R@D:Q/PXL]B5*^C'G&!(IC MM!\.=9/BYM#93YSXGW"0_{G#G)RE:;
[;,ZKT PU(?EQ[] 1[I?Q9!U;S'"M3 MM3D69I5QQVG?X-.^S=%=>2(?][)W5;96C-CJ>4CJ=,H813G?T*-_IS@D?.V* MS_=2\9C=UL;1 ;%@/4%_'L"._D{G(JM\Y8-,/KK=O M
*7*FZ6?"YH6EG:/<7C'6:"F&-20@VX/J-FNO'#/A9T@)@X)!#8$GG2,#6_P M8F7

F='GX8#U?.!/IMZPW7%EOT1&8GQ->3C-!.ZB23ML66Z?EJGH-Z#Z;PEZ_"8]TT\)MLV MZ#;Z]B6BX:M1PD[GI32L8'T:W]^$A8C6[[R*!V %#(/,N',\,%P#'(/H17F(D[C?
(-6GS%>"0'')6(!PA % Q"9 M<&8 83BZ2,]H#R#72#AF=CZQ8"@_!0.!H2!FAB_YC+@5C(LH<1>MQ[P1[G#^ M%L(CX8([';42F^M#]W06<8KSP<:@@JS9#Q22^?Z(-U# ?C]3/-
DMYNGL9H\% M/TM:@/*B%OV4+ .)/@8>5T;4^EX^D>](0FGA1,11]]2W;09;8D-F0HT<02NQ%F^FO%'6I53)>N6_[*&Q+;Z)8 MA8DNB0 /%4FP6.!(: <'%6.##8^?
*PRD:$U33DR. NT!Y+>/;VD(&4@[U2!B ML(M1#2+GZ?0@X2] %%0">+A??(P%!V0-8@H,=BFBLQ%R8,]QC=,E"!=#0@$T MNH3!HD,HK1V =-F;;V1X$LVL7"[*7+-X42;7=.\:
(BYS7/3@VX+W*)GE.X0 MO8ZW3F/*T&&X0MV8"V+Y,C<\,<'7N-B<[0(";U$FV%'0+-6F- .61>$.=\Z3:3?Q5\NH9^(;YIN]OR[[+SQC57V/0?G'EWGCJQO.E]S]UA M4%X+[Q?
T)^189C4L,P=$V:K#/@1T5R\ZVV,J)F:!XN{AK1N')18U^K\H\"Z)"H/.+?H-2VO M7E^:=1CM>88>"F5>43EF1LQTD('*R[47:Q*:8HB//@,*],)RS
M23$!5Q1W3S/UVW$=;1'W8%)%QI6J2V9Q@OZ?N^3UAOBG.,]I1CS29[G'6"JR MNL5B,G<#JDK7&"P=,X@*&%-0+F;HVP+M/W 5(UAE"XT%H^GI*5Q
M<1$MRXM0G&F!BJS6G9C,%]FNZ+0ZXTX5H.026?OD%G.G7IPNJII.!FR%$S/MJA M!^A$00.0F)<_X;+&J[G!UAIW,2?:@!-2N1=,=!2CH.(*YOC0I7SE :URNN/6
MW7\:'#+)R?;W001DGG1F[L$(4#A9A^X=>8CYA1OUJC">?/$HP8F*K#UF M$Y'YC!.@<&"]P M^AS-DV^YGEUU9XG\S'X2BO86'8?"9W"H10*C@LO*/'6X0]_1S-[JQ\RHS P2
M)!3,@TH]"I^1H!8)C 0NJQH)?PYI0UBUKS9PM, X0S[;H9<=QA2&NK6N=?@H MVL T.(&\&L0+!OBFN2(T;* =50@G^-0?0''_IWB]!EE14P$* "GBSB-TF6C:'GDT7GH73 M-
<'\E@IT3^KAA9U)2)HP+"Z}# +P@\RD1 *9;*7(,LQ:T$RC:'.X XF49C@= MZ]*X"X*2&P+#I&+BGK@\Z_0^/%[ANCIIS\1 G,NUUT:,"5B%JSQ5G)C:Z\%B MQ+A\@HP/:_-
'G?]S%Q>O]+EIG)8[1Y+TBC):-L4BG]:%J$Q+N*.(E*8634#C M9@S9;G%Z1S-5",8/P?=VF!A\=]9WY:K':F'Z79?+KAHQ!FS"=7BP+HEAP!9D M\N.QIHH4L
Q7F8K10\?]@881!<,@ WY:F4Z3*,\7CV4 DXTE(CIV'!G2.7&X MG59P!Q Q0?M.UY# WA[5'MFOD)8&0!3<_(QJOC2R7"&[D 9 T6YK"7RH=GY0K(DOJ M2=
<&!#M*A30,=V1YFGM*V6NC3M"SWX"M_IK3!,-90$0?Y%!2E^/C2E8N()"! MQ3=%G*R"(+FTF>#4A M.QY9XM9?U9ES\QFY=E4%QO/H:LTW4-P[6:
[PYR\H6\8Y*KMQ^[&5F'6XHWC(M@*WF$1R<-=4R#L3JRH)<"'1O63/GL@PR 92<^^L#2I]1!A?1Z!;[@*7Y?2O7 M5VANVBO7I>QYOJ.9^DIQ/ABS 90-;&247L,&+"(<-
C*6YC>OW(^1^0>SYYOM MO+6()S?;#:Y[^8'!_?JJ]LKT49%&]/.7I[A*$795IX7QTU>:WW,QG>^*W9F*\6CPR>P;L0"RGVK\S MPZ?R&4LPT>"#KXA=;?._^'*H"-T]HJ*T
33G+^6$U'"C3\9*<^^/S\IGG%E4 MDO4=0GZ=-6)_]@6QI-$Y6NZ*^!G=9Q%]L80XUGS8\OL-*]\@2FXLHWTHMC$C MG[%J34'P;9,1-3:;V]['$:YQ%EI9BCNV2TIYC40CT0U';
G[M!G.!9B<(/DF&7TITF1 #5L:O0P8>CLZ,8)!"P[C2MYUEH_DXI]F8TVP<2)@Y MS<:<9F-.LQ%&'/R<9F-.LS%?=9NONLU7W>:K;@,CSU?=YJMN\U4WKZZZA74%
MP=>K;@+OV73\>_+?/%I24XENL4%(ZX;+25V8I6G12;JJ(J@7NR(OHI0>U]RC M;"N0547.R"LF=]:705;#VA+W^[:L$MK)U97P?QYWF+^760^740
M3\;)^7608,Z[Y]2N\RO4G9Y[H%>H@\S6RA'H_&69[%95-EHR./ZKU(H:)=B M8N@(B@6&)XCP8T FX! DJ-$58?'8V1'-RR 1^FXTS8+,#B6.2G6JMPXOY##E# MX<&0@_.?
XOC8KT.[0&\3NY@9_9)&%7!0"Y&;#&WCW9:"!C'I!*]1 9I)C>;* MG7F-X.I>T6\J"?]X^]M+VF_QG.6X>H;G)"6Y]7SR^:1F:-'ZZH!@JT3_L?>6_1N-S+NEANT
MVB6HOM[fZ;6\[,L+I010-O?U991.DWW('0]F$WX '@I7T+H05?I4? ^4\N?D M!31NGIBA+I@;1,/[U#XBT_WD9AK??JT11)OK=3],%W9X,=5]%8+4-_].IR
MJ2;"@]+A!JC(>Q66@K6O)BZGZC&@+H=P507SL1CFJ02Y0'BLJ0X%+ -6)F!< MQGKC&J-2<06]-"%\QD'NH]_M'0)X%4?9ZUW4"LZ;+*CHFHF"F,Z)>/M&T"#R MQ6/GMB)WQ@
OT @,*&#O^D:]!HC)1#I^\V)5];IVA$I3G==7^Y(PG4-:U][#2.@+VMLH>CPVZ"Z-F41VENP7P#EB]P,$,Z':?U!C{QTR C MN;BOUW&5,26=
[#5AYRDN^\V1Y;J44W63H8D>WNZ2I$154[1N[BK7 MZ1&EZL90\;B9$GFLJS=V!2Q]RXQ9+7REUI>1]#8{0K,[0# MH_/YN?#8HMZ> M1,MR]G.R)O^1=WD
:=/OI:2^@T!#4#T/(.4;\&&3#-I'K9CE? MNLVT?FB@:.B7Z"7>[K;N%5=*0WG{8!"=J5.DN1<' M*N+P]D&VPD.WN@)ZNJO!T'JL+/+8!JC[$5H P#O<>?${TV1*M/Y4YD7JYE
MQ,$#6L6'LO7 X@%@;:1.='&G7YVS=-1V/'8V^'#'$<3]DRK(AP&N$-K21IE=7#;H_A[>Z[4QEJW53YQ$T M\;Z+D'2XQ\
{A#0!K&K*.V#OAL*Z1]}>@1LBS^#E>H725BY>G,I(F2P67) "P M &33!0F?90V.GSV([&F6"ULEC1"2V3*H'&?2K"@7 (),M3!F"JVHIT%8D.F8N'L; MDKD-D%RV-
Q7<'$=/9BNI2(%T0=8\PB?&Y/8Y]W=>TAX'GUP#"3F MPR05_SX#>QN7M1xO!O9O>T]&:<0(3'CIW6J4 MYG4?RFB 6YFU^-
-/KGN8F>BVW;+Y%V4J1QL4.WV'2E[%\7:C[,S4Y000R^XZ7 M%D;XO1:?\]VY&-S+(3P_2&/4TLY[FEP#S/U@T3 :YPB4]P)RP*@QRD;(OI4*A@-0$X%X29G%(\X M&.+%)'R?
H71E\1S;X()]-<<^3_E=.00$#;=S M[*)%0%UA"3!700#6B1H>Y-F@165\132V&JU.GE$6K5$3UU]>OJ:*>IQZUTNS M ?;'"' #CMC2:LSKQJ8A^O+QW<:N[]>PZF2S!Z &+
\>'+'W1:Q MZ7+LUPQU.S9KGEW/@:T;A/NQ*?UQ[D&J-,39QCFD\S&LWI8'TJY^=D,N['P4 MODA;!4&FT#5J==>4.ZZSWW&W\CK*6L[(H--?9ZK6^VT)CRFLU]HG[#@ MZ@V-
:'=^H9#7AO>'R_DFSP75ZCG@8L9.8P[F;HYTX>.5$W*VU^*%:SKHOF\(M$)UDU:,W$_5QB:.4X$WNR$G/4,J/9U&!+JC(X*Q^CFO0J KCV2:XI &J??8$% MJ_GH&[0E"OF)(F-
EM?^?Y/EN6VF.^-,O/-C@%4[P>I F<:R;T*]QK@=&9 M\1[4@CU !&M'0I1M/ !L-FE%75--5%%X#ML \?B QK+DO.%2MMY](3TJ MEQN_C?/?
+5*$+E,B%ID5WY+A;DHG+JMO"A?.K^]-N8<#FLZ=EYA6R("?W+6I MG,:%-D^J3.TL9/5-X2SX]\L^$*^K>TDF5Y^Q0EAD\3%ZZ$\!;_&
M*7T%6^/L+:8RW_'X"U9,\TVE^:QBW':15WN2.E*$^5XTS5Y(7YLE0^:../OM9 M;;N6VNB^#2)\ L^<03,$&# XELXU5G>3]!6#1IF_?.UZ,7:Z?QON-'J*BRBI
M!+TEBLV>T>H"9Q<[>I6@>9&9@;]Q^>%;LM#R1P+^L9J; OL&;9KB1>[0_9: M!,KD:7QMM-7R\O+@+ZK!W]?"4R!&_#";LF',BVUC&W2${[M=IJM=]=A[=78^
MO^LVO^MV#.^ZS8^/S(^/=-P0X^:XSXY(:>JV"V@\?:"]0{1${S1T8$W.?G M1>;G10);IASM\R)OY$K08+5X9,^+P(8ZP0Q;0<4?[CR(I[06.3RGZQ_O=E4@ M?S]RR?
P%ZHI4!-V4.W\^08W M-P,>]^;\^5,UYFUW>A^CQBSEJ_^SW:/T$%;<5[P+^["(\BFNY0MKGB^TS/?N M@WQ08KYW?^SW[OFA 70D2G,TW*?;^$?Q2U\@@*\17>D0Y5-
O**5T%8/;]L# M*-L[:1)*CX3D7ID'T4X"?:LMIK<2_5:Y2H MQ0:5<+B:@A@0FPC.+GPD%='Q%51!F-?34$+8K>F!1)3]CNC5!!G$H.2-2U62
M^P\N39$UD:7F'N0]JL\H)#&F1>@_7F!2_5-]D %(SG'1($,,-A4WM(&Q'F@&YMX^G(4GB,UVR4 M1%F,\J_1&M%5]N+Q,5ZB+.])
{;C;9%"TT99647NI3B5C"8V:V[SEZAK#O5;59@1#V3/1!!]WUSA]KHX]Z>"5W^,B2KK?3W%> M7./B'ZBX14N\3N-_#3+Z3UX/FR;2?CW!=9=#Z7Q<%YNPE\39EJ:(/\7I*J:%05-
<*S5(Y[PC:PBN M:TVOYV'CUA3M"S?!RV0^IOMTR:%&/%Z=4X]^_3J#ZZXN;.'IJ-AOL>4[.('W MYBH?S@7.ZI\H'9LHQ$WE4_=00>5S1]>QCJ<]7M!TRS>T@HU
';&C._EZQ!RL.GFP*OBU!WELJAF;02BJ M+AO_GC2:WW]Z8^_";T7-^H+2,V3AT?MZ:M%_->A]&0W?R=*64_@$^+YQ2BO
M)ZRC!\5)'XC2:]/;>@*+.E@$:@[L(M6D28,#C"4B2;&4'K5<.9X,BQ[=U[8 MYD'@X#@NW?@PRY^C92$&!;2I(,1;P&M#$Z)A4'Z<@$TI9YN83"PO ,XR%' MLXI'T%C64I
]}*NJ#?)>S2G>;G%:2G,:/<5%E%0=EEY0RYX1/:^XV!5D/*3Z MH($(#(:-R]?F,2@?!G;'*L8 MP953A%+XN,ZC7ODI#NY,ER?]-!S\I3%"1GD?[J(4^+AR=QE/N&9;.J4
M1'F^>*P;L\AN:,XQWAF.FK"9#$D(O9&0<]JBI)/)Y^[DA-L<[F$)@%(FHOTC MD9L,7>RHUVBZ OX P;2,SN?GVZT5,OA5>1)/UN0_\GX/(&TZOY34=R1H"*KG!J1\ M
U\TJT=KK#/B 13;G$U*F89[' F8WXDTJCQ6%/,6*C3@XT&N/(,UOFQ2)MH0 M4!';\].*A9!BQ>/'TD9ZEG.-0I6?M{[G!H4@IW&=0LXZMW3KPT3B?O_F[F@ MV9IW;EV"U
MJR,UBD?7%^Z[EZTZTE4E3"8TY94#3 (2_-+I1/M756WK/*FA4V[Z3U9 M=BX'HFUP(:?U$Q(:\@'0(.<6\/MUDB LS14HOPP@@"[0]:=47N/E)\O5_(DU MY]
ZW*.P8U.>&C]#>Y :G1EO\/;*4+ 'B&#MXV@DNOJ&NJB2H*+SG$ MB ?!#V$L2[DF#-X!GTBZ<'-F6E7^;9S_?I$A=)D2L5!>=)^ G*)R^J;PH7S MZWM3[N&
IG/G):85,MPM6:O*:5SH6?P(.>=,[.KNQX F'/%?:TM]@S_$)R'WF'/RS3>J?" M4 6?DFCY^]UR0YJ;E]^F'%V$E4TQPG J>U-]Z5!&"W^DX4@XQ2FF+Z?#!S]T M!)PM'Z)-
M4W_'. ,HHSBJ3)X$ %(D>IH%NT1/$S6BW2>Z*IG$@9#]\<,BF[M?Q-2IZR?MQK"/[%EZE$$W?=B-;,N=GWX91T#<(D=%Z" RJ7&@@2 M3K71?_;%Z-
U(P:.9B\=.EJ!&!DEX)J@<)TI34SJ>#<'+$=SZV> M3E@^)$*=0RX+1N^1>PDK32D-0\Q[#!L0!9B!"'BK$RMO4@+NT5YU,W,-V06> MB&O$M>2AOBW=3;YZHTFRP"F C--
@R6H(,='5+4KH"]S$"L5K9VJ=F^>S&CVZ MU4VZ89LD"/J%DM>65Y.[&-$%K3K9XEUYZT"\'C4H*=<$OZ0S+P V+QZCB[X_ M4-5)'8%672%ZAFM47.$\OT%9N55T4A19_+
KJ*N[QYTY]08G1#B7#N,\RE(R M']LW59 ;3T'6),,3DGDSU9^SW\W9[PZ0 ;Z9_]S%+]S\\+OS WZSG>_9NG# M3%D;\=YXD%*R9NQ3!&%HHEIFIN^RF".-VK2;3;-
$D_%.4QTO!]'&=UO^;0"< MKRX'$&\;$NYMPJ^(CKYH=?*,LFB-VJQV98;&SDDBM,M64/U IO=P+K+Y/(3+$?41 M.YJTS ^ABOBU7]\3YZ02XO?+2MV#MEP28L@'*_
M8A%3.CGW*)>T9&W;MHOF;5S%:1&G.X*WO5.=&R.O/]VB)4Z7<1)7_4EP"<8N MU^9/11-F'QPK;_0_]#W0/[]_P-02P$"% ,4 " "P10A9#N&KMU27_0#F MN!8 $@_@ $
968R,# R.38X,%\Q,'$N:'1M4$L! A0# M% @ L$4(6#,R+3$N:'1M4$L! A0#% @ L$4(6:+*J*J&! IA$!4 M (!>ZP! &5F,C P,CDV.#!?97@S,BTR+FAT;5!+ 0(4 Q0 M
(+!%"%G[R"07] \ (^T 1 " 32Q 0!F96UY+3(P M,C0P-C,P+GAS9%!+ 0(4 Q0 (+!%"%G)VGHCYP\ %C. 5 M " 5?! 0!F96UY+3(P,C0P-C,P7V-A;"YX;6Q02P$"% ,4
" "P M10A9+!XKRW2TR,#(T,#8S M,%]D968N>$UL4$L! A0#% @ L$4(6?S,7XK!E@ *)$(!4 M (!&_P! &9E;7DM,C R-# V,S!?;&%B+GAM;%!+ 0(4 Q0 (+!%
M"%G1E2YNI$P %!J!0 5 " 0^3 @!F96UY+3(P,C0P-C,P >7W!R92YX;6Q02P4& H "@"7 @ YM\" end XML 69 ef20029680_10q_htm.xml IDEA: XBRL DOCUMENT
0001339005 2024-01-01 2024-06-30 0001339005 2024-08-07 0001339005 2024-06-30 0001339005 2023-12-31 0001339005 2023-01-01 2023-06-30
0001339005 2024-04-01 2024-06-30 0001339005 2023-04-01 2023-06-30 0001339005 us-gaap:CommonStockMember 2023-03-31 0001339005 us-
gaap:AdditionalPaidInCapitalMember 2023-06-30 0001339005 2023-06-30 0001339005 us-gaap:RetainedEarningsMember 2023-03-31 0001339005 2024-
03-31 0001339005 femy:EquityWarrantsMember 2023-03-31 0001339005 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001339005 us-
gaap:CommonStockMember 2022-12-31 0001339005 us-gaap:RetainedEarningsMember 2022-12-31 0001339005 2023-03-31 0001339005 2022-12-31
0001339005 femy:EquityWarrantsMember 2023-06-30 0001339005 us-gaap:CommonStockMember 2024-03-31 0001339005 us-gaap:CommonStockMember
2023-06-30 0001339005 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0001339005 us-gaap:RetainedEarningsMember 2024-03-31 0001339005
femy:EquityWarrantsMember 2024-03-31 0001339005 us-gaap:RetainedEarningsMember 2023-06-30 0001339005 us-
gaap:AdditionalPaidInCapitalMember 2024-03-31 0001339005 femy:EquityWarrantsMember 2022-12-31 0001339005 us-gaap:CommonStockMember 2024-
06-30 0001339005 us-gaap:TreasuryStockCommonMember 2024-03-31 0001339005 us-gaap:TreasuryStockCommonMember 2023-12-31 0001339005 us-
gaap:TreasuryStockCommonMember 2022-12-31 0001339005 us-gaap:TreasuryStockCommonMember 2023-03-31 0001339005 us-
gaap:TreasuryStockCommonMember 2023-06-30 0001339005 femy:EquityWarrantsMember 2023-04-01 2023-06-30 0001339005 femy:EquityWarrantsMember
2023-01-01 2023-06-30 0001339005 us-gaap:RetainedEarningsMember 2023-01-01 2023-06-30 0001339005 us-gaap:TreasuryStockCommonMember 2023-
04-01 2023-06-30 0001339005 us-gaap:CommonStockMember 2023-01-01 2023-06-30 0001339005 us-gaap:TreasuryStockCommonMember 2023-01-01 2023-
06-30 0001339005 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-06-30 0001339005 us-gaap:AdditionalPaidInCapitalMember 2023-04-01
2023-06-30 0001339005 us-gaap:RetainedEarningsMember 2023-04-01 2023-06-30 0001339005 us-gaap:CommonStockMember 2023-04-01 2023-06-30
0001339005 us-gaap:AdditionalPaidInCapitalMember 2024-04-01 2024-06-30 0001339005 us-gaap:CommonStockMember 2024-01-01 2024-06-30
0001339005 us-gaap:CommonStockMember 2024-04-01 2024-06-30 0001339005 femy:EquityWarrantsMember 2024-04-01 2024-06-30 0001339005 us-
gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-06-30 0001339005 us-gaap:RetainedEarningsMember 2024-04-01 2024-06-30 0001339005 us-
gaap:RetainedEarningsMember 2024-01-01 2024-06-30 0001339005 us-gaap:TreasuryStockCommonMember 2024-01-01 2024-06-30 0001339005 us-

gaap:TreasuryStockCommonMember 2024-04-01 2024-06-30 0001339005 femy:EquityWarrantsMember 2024-01-01 2024-06-30 0001339005 us-gaap:TreasuryStockCommonMember 2024-06-30 0001339005 us-gaap:CommonStockMember 2023-12-31 0001339005 femy:EquityWarrantsMember 2024-06-30 0001339005 us-gaap:RetainedEarningsMember 2024-06-30 0001339005 us-gaap:AdditionalPaidInCapitalMember 2024-06-30 0001339005 us-gaap:RetainedEarningsMember 2023-12-31 0001339005 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001339005 femy:EquityWarrantsMember 2023-12-31 0001339005 femy:Two021StockOptionPlanMember 2024-01-01 2024-06-30 0001339005 femy:InducementGrantMember 2024-01-01 2024-06-30 0001339005 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member 2024-06-30 0001339005 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member 2023-12-31 0001339005 srt:MaximumMember 2024-01-01 2024-06-30 0001339005 srt:MinimumMember 2024-01-01 2024-06-30 0001339005 femy:FemVueMember 2024-04-01 2024-06-30 0001339005 femy:FemVueMember country:US 2023-01-01 2023-06-30 0001339005 femy:FemVueMember 2023-04-01 2023-06-30 0001339005 femy:FemVueMember country:US 2023-04-01 2023-06-30 0001339005 femy:FemVueMember us-gaap:NonUsMember 2023-04-01 2023-06-30 0001339005 femy:FemVueMember 2023-01-01 2023-06-30 0001339005 femy:FemVueMember us-gaap:NonUsMember 2024-04-01 2024-06-30 0001339005 femy:FemVueMember country:US 2024-01-01 2024-06-30 0001339005 femy:FemVueMember 2024-01-01 2024-06-30 0001339005 femy:FemVueMember us-gaap:NonUsMember 2024-01-01 2024-06-30 0001339005 femy:FemVueMember us-gaap:NonUsMember 2023-01-01 2023-06-30 0001339005 femy:FemVueMember country:US 2024-04-01 2024-06-30 0001339005 femy:JunePromissoryNoteMember femy:AFCOCreditCorporationMember 2022-06-01 2022-06-30 0001339005 femy:JulyPromissoryNoteMember femy:AFCOCreditCorporationMember 2023-07-01 2023-07-31 0001339005 femy:JunePromissoryNoteMember femy:AFCOCreditCorporationMember 2022-06-30 0001339005 femy:JulyPromissoryNoteMember femy:AFCOCreditCorporationMember 2023-07-31 0001339005 femy:JulyPromissoryNoteMember femy:AFCOCreditCorporationMember 2024-01-01 2024-06-30 0001339005 femy:JunePromissoryNoteMember femy:AFCOCreditCorporationMember 2024-01-01 2024-06-30 0001339005 femy:JulyPromissoryNoteMember femy:AFCOCreditCorporationMember 2023-12-31 0001339005 femy:JulyPromissoryNoteMember femy:AFCOCreditCorporationMember 2024-06-30 0001339005 femy:JulyPromissoryNoteMember femy:AFCOCreditCorporationMember 2024-04-01 2024-06-30 0001339005 femy:JulyPromissoryNoteMember femy:AFCOCreditCorporationMember 2023-01-01 2023-06-30 0001339005 femy:JulyPromissoryNoteMember femy:AFCOCreditCorporationMember 2023-04-01 2023-06-30 0001339005 femy:November2023FinancingMember us-gaap:ConvertibleDebtMember us-gaap:CommonStockMember 2023-11-21 0001339005 femy:November2023FinancingMember us-gaap:ConvertibleDebtMember femy:SeriesBWarrantsMember 2023-11-21 0001339005 femy:November2023FinancingMember femy:SeriesAWarrantsMember 2023-11-21 0001339005 femy:November2023FinancingMember 2023-11-21 2023-11-21 0001339005 femy:November2023FinancingMember us-gaap:ConvertibleDebtMember 2024-06-30 0001339005 femy:November2023FinancingMember us-gaap:ConvertibleDebtMember 2024-01-01 2024-06-30 0001339005 femy:November2023FinancingMember 2024-01-01 2024-06-30 0001339005 femy:November2023FinancingMember 2023-11-21 0001339005 femy:November2023FinancingMember femy:SeriesAWarrantsMember 2024-06-30 0001339005 femy:November2023FinancingMember femy:SeriesBWarrantsMember 2024-06-30 0001339005 femy:November2023FinancingMember femy:SeriesBWarrantsMember 2023-11-21 2023-11-21 0001339005 femy:November2023FinancingMember femy:SeriesAWarrantsMember 2023-11-21 2023-11-21 0001339005 femy:November2023FinancingMember femy:SeriesBWarrantsMember 2024-01-01 2024-06-30 0001339005 femy:November2023FinancingMember femy:SeriesAWarrantsMember 2024-01-01 2024-06-30 0001339005 femy:November2023FinancingMember us-gaap:ConvertibleDebtMember 2024-04-01 2024-06-30 0001339005 femy:November2023FinancingMember us-gaap:ConvertibleDebtMember 2023-12-31 0001339005 srt:MaximumMember 2022-07-01 0001339005 srt:MaximumMember femy:EquityDistributionAgreementMember 2023-10-31 0001339005 us-gaap:CommonStockMember 2023-04-01 2023-04-30 0001339005 femy:EquityDistributionAgreementMember 2024-01-01 2024-06-30 0001339005 srt:MaximumMember femy:PlacementAgentWarrantsMember 2023-04-30 0001339005 srt:MaximumMember femy:CommonWarrantsMember 2023-04-30 0001339005 srt:MaximumMember femy:PreFundedWarrantsMember 2023-04-30 0001339005 femy:PreFundedWarrantsMember 2023-04-30 0001339005 us-gaap:CommonStockMember 2023-04-30 0001339005 2023-04-01 2023-04-30 0001339005 femy:PlacementAgentWarrantsMember 2023-09-01 2023-09-30 0001339005 femy:PlacementAgentWarrantsMember 2023-10-01 2023-10-31 0001339005 femy:PlacementAgentWarrantsMember 2024-06-30 0001339005 femy:Two021StockOptionPlanMember 2023-12-31 0001339005 femy:Two021StockOptionPlanMember us-gaap:ShareBasedPaymentArrangementNonemployeeMember 2024-01-01 2024-06-30 0001339005 femy:Two021StockOptionPlanMember us-gaap:ShareBasedPaymentArrangementEmployeeMember 2024-01-01 2024-06-30 0001339005 femy:Two021StockOptionPlanMember 2024-06-30 0001339005 femy:InducementGrantMember 2024-02-12 2024-02-12 0001339005 femy:InducementGrantMember 2024-06-30 0001339005 femy:InducementGrantMember 2024-02-12 0001339005 us-gaap:ResearchAndDevelopmentExpenseMember 2023-01-01 2023-06-30 0001339005 us-gaap:GeneralAndAdministrativeExpenseMember 2024-04-01 2024-06-30 0001339005 us-gaap:GeneralAndAdministrativeExpenseMember 2024-01-01 2024-06-30 0001339005 us-gaap:SellingAndMarketingExpenseMember 2024-04-01 2024-06-30 0001339005 us-gaap:SellingAndMarketingExpenseMember 2023-01-01 2023-06-30 0001339005 us-gaap:GeneralAndAdministrativeExpenseMember 2023-04-01 2023-06-30 0001339005 us-gaap:SellingAndMarketingExpenseMember 2024-01-01 2024-06-30 0001339005 us-gaap:ResearchAndDevelopmentExpenseMember 2024-01-01 2024-06-30 0001339005 us-gaap:GeneralAndAdministrativeExpenseMember 2023-01-01 2023-06-30 0001339005 us-gaap:ResearchAndDevelopmentExpenseMember 2024-04-01 2024-06-30 0001339005 us-gaap:ResearchAndDevelopmentExpenseMember 2023-04-01 2023-06-30 0001339005 us-gaap:SellingAndMarketingExpenseMember 2023-04-01 2023-06-30 0001339005 femy:EmployeeStockPurchasePlanMember 2024-01-01 2024-06-30 0001339005 femy:EmployeeStockPurchasePlanMember 2023-01-01 2023-06-30 0001339005 femy:EmployeeStockPurchasePlanMember 2024-06-30 0001339005 2023-04-20 2023-04-20 0001339005 femy:CommonWarrantsMember 2023-04-20 0001339005 femy:PlacementAgentWarrantsMember 2023-04-20 0001339005 femy:PreFundedWarrantsMember 2023-04-20 0001339005 femy:CommonWarrantsMember 2024-06-30 0001339005 femy:PreFundedWarrantsMember 2023-04-20 2023-04-20 0001339005 femy:CommonWarrantsMember 2023-04-20 2023-04-20 0001339005 2023-11-01 2023-11-30 0001339005 femy:WarrantsSevenMember 2023-01-01 2023-06-30 0001339005 femy:WarrantsSixMember 2023-04-01 2023-06-30 0001339005 femy:WarrantsSixMember 2024-04-01 2024-06-30 0001339005 femy:WarrantsSevenMember 2024-01-01 2024-06-30 0001339005 femy:WarrantsSevenMember 2023-04-01 2023-06-30 0001339005 femy:WarrantsSixMember 2024-01-01 2024-06-30 0001339005 femy:WarrantsSevenMember 2024-04-01 2024-06-30 0001339005 femy:WarrantsSixMember 2023-01-01 2023-06-30 shares iso4217:USD iso4217:USD shares femy:Segment femy:Product femy:Women pure false --12-31 2024 Q2 0001339005 2023-03-31 NASDAQ 2023-11-30 10-Q true 2024-06-30 false 001-40492 Femasys Inc. DE 11-3713499 3950 Johns Creek Court Suite 100 Suwanee GA 30024 770 500-3910 Common stock, $0.001 par value FEMY Yes Yes Non-accelerated Filer true true true false 22232799 13525898 21716077 92535 98906 1315580 667118 997623 695879 15931636 23177980 1212417 1212417 47308 47308 429933 414303 2599994 2559356 651157 423077 4940809 4656461 3678450 3545422 1262359 1111039 2081054 2380225 44317 0 957078 1086581 3082449 3466806 20276444 27755825 951510 1137823 886352 1444296 92397 65300 533734 406636 2463993 3054055 32706 54935 4758017 4258179 1771487 2036067 6562210 6349181 9026203 9403236 0.001 0.001 200000000 200000000 22350022 22232799 21774604 21657381 22350 21775 117223 117223 60000 60000 2608642 2787137 125344962 123985306 -116665713 -108381629 11250241 18352589 20276444 27755825 221484 320514 492624 614498 73125 110469 161657 215589 1975875 1527172 3746606 3064611 975190 128899 1275677 373795 1611817 1356637 3114621 2671774 67628 133299 138856 266365 4630510 3146007 8275760 6376545 -4482151 -2935962 -7944793 -5977636 184138 42652 408822 139741 388311 198 749863 1870 -204173 42454 -341041 137871 -4686324 -2893508 -8285834 -5839765 -1750 0 -1750 0 -4684574 -2893508 -8284084 -5839765 -4684574 -4684574 -2893508 -2893508 -8284084 -8284084 -5839765 -5839765 -0.21 -0.21 -0.22 -0.22 -0.38 -0.38 -0.47 -0.47 22215516 22215516 13107590 13107590 21995436 21995436 12493334 12493334 22216570 22217 117223 60000 2631838 124994678 -111981139 15607594 121371 121 0 0 0 212697 0 212818 12081 12 0 0 0 10378 0 10390 0 0 -23196 23196 0 0 0 0 0 104013 0 104013 0 0 0 0 -4684574 -4684574 22350022 22350 117223 60000 2608642 125344962 -116665713 11250241 21774604 21775 117223 60000 2787137 123985306 -108381629 18352589 563337 563 0 0 0 989185 0 989748 12081 12 0 0 0 10378 0 10390 0 0 -178495 178495 0 0 0 0 0 181598 0 181598 0 0 0 0 -8284084 -8284084 22350022 22350 117223 60000 2608642 125344962 -116665713 11250241 11989796 11990 117223 60000 567972 108917384 -97080762 12356584 1318000 1318 0 2526664 818014 0 3345996 3858 3 0 0 0 1694 0 1697 1878722 1879 0 0 -1176533 1174842 0 188 0 0 0 65216 0 65216 0 0 0 0 -2893508 -2893508 15190376 15190 117223 60000 1918103 110977150 -99974270 12876173 11986927 11987 117223 60000 567972 108857065 -94134505 15242519 1318000 1318 0 2526664 818014 0 3345996 2869 3 0 0 0 3365 0 3368 3858 3 0 0 0 1694 0 1697 1878722 1879 0 0 -1176533 1174842 0 188 0 0 0 122170 0 122170 0 0 0 0 -5839765 -5839765 15190376 15190 117223 60000 1918103 110977150 -99974270 12876173 -8284084 -5839765 133028 264040 5828 2325 299171 148541 0 -44538 2830 1770 181598 122170 544363 0 -6371 78276 651292 146521 173828 -154065 -223682 36119 -557944 80116 -137482 -181065 -39657 3119 -8894780 -5388824 50145 0 246978 71849 -297123 -71849 0 3899813 0 547764 0 188 10390 1697 1021994 3373 30660 0 0 141298 0 12255 1001724 3203754 -8190179 -2256919 21716077 12961936 13525898 10705017 0 1870 4550 37370 0 0 6163 1586 0 <table cellpadding="0" cellspacing="0" class="DSPFListTable" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;"> <tr style="vertical-align: top;"> <td style="vertical-align: top; width: 27pt;"> (1) </td> <td style="align: left; vertical-align: top; width: auto;"> Organization, Nature of Business, and Liquidity </td> </tr> </table>   Organization and Nature of Business   <span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><span style="color: rgb(0, 0, 0); font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float:

none;">Femasys Inc. (the Company or Femasys) was incorporated in Delaware on February 19, 2004 and is headquartered in Suwanee, Georgia. The Company is a leading biomedical company focused on addressing significant unmet needs for women worldwide with a broad portfolio of in-office, accessible, and innovative therapeutic and diagnostic products, including a lead revolutionary product candidate and FDA-cleared products. <span style="color: rgb(0, 0, 0); font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial;">The Company's mission is to provide women with superior minimally-invasive, non-surgical product technologies, accessible in the office, improving patient care and overall health economics focused on servicing the reproductive health needs for those seeking solutions for infertility issues (FemaSeed® and FemVue®) or permanent birth control (FemBloc®). <span style="color: rgb(0, 0, 0); font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">The Company currently operates as one <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">segment with an initial focus on servicing the reproductive health needs for those seeking solutions for infertility issues or permanent birth control.
      <div style="margin-top: 0px; margin-bottom: 0px; letter-spacing: normal; white-space: normal; word-spacing: 0px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-weight: normal; text-align: left; text-transform: none; background-color: rgb(255, 255, 255); font-variant: normal;"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">Femasys has an expansive intellectual property portfolio which covers both design and utility patents in the U.S. and significant ex-U.S. markets for each product initiative. Femasys has taken concepts internally conceived and protected through development, including domestic and foreign regulatory approvals, and production, through in-house manufacturing.<span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial;"> FemaSeed, a solution which enables directed intratubal insemination to improve on traditional intrauterine insemination (IUI) and provides a lower cost and safer option to in vitro fertilization methods, received approval to sell FemaSeed in Canada in April 2023. In September 2023, the Company received 510(k) clearance from the FDA for FemaSeed for intratubal insemination to market in the United States. A pivotal clinical trial was still ongoing at the time of receiving regulatory clearance, however, enrollment was completed in November 2023. In June 2024, the Company received European Union Medical Device Regulation (EU MDR) certificates and CE Mark certification for four products: FemaSeed, FemVue, FemCerv® and FemCath®. FemVue, a solution that enables fallopian tube assessment with ultrasound as an alternative to the radiologic approach (hysterosalpingogram) for the diagnosis of infertility, is approved for sale in the U.S., Japan, and Canada. FemChec® allows for fallopian tube evaluation after a FemBloc procedure to confirm occlusion (or procedure success). FemCerv is a solution for complete tissue sampling with minimal contamination of the endocervical canal in a virtually pain-free procedure as an alternative to the single biopsy method for diagnosis of cervical cancer and is approved for sale in the U.S. and Canada. FemCath, allows for selective evaluation of an individual fallopian tube as an alternative to the traditional intrauterine catheter that is undirected, is approved for sale in the U.S. and Canada. FemBloc<span style="color: rgb(0, 0, 0); font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial;">®, the Company's solution for permanent birth control, is based on the Company's platform technology for delivery and in June 2023 Femasys received FDA approval of our IDE to evaluate the safety and efficacy of FemBloc, our non-surgical, non-implant, non-hormonal in-office solution for permanent birth control in a pivotal clinical trial. In August 2023 Femasys announced the initiation of enrollment in the FINALE [Prospective Multi-Center Trial for FemBloc Intratubal Occlusion for TranscervicAL Permanent Birth Control] pivotal trial designed to evaluate the safety and efficacy of FemBloc. This prospective, multi-center, open-label, single-arm study design includes pregnancy rate as the primary endpoint, which will be analyzed once 401 women have relied on FemBloc for one year for permanent birth control. In addition, the study is designed as a roll-in beginning with enrollment of 50 women for a clinical readout primarily of preliminary safety data prior to enrolling the remaining subjects. An interim analysis of clinical data endpoints is planned once 300 women have used FemBloc for permanent birth control for one year. Follow-up will continue annually for five years post-market.
       Basis of Presentation   <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: left; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial;">The <span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; text-align: left; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">Company has prepared the accompanying condensed financial statements pursuant to the rules and regulations of the U.S. Securities and Exchange Commission (SEC). Certain information and footnote disclosures normally included in the annual financial statements prepared in accordance with accounting principles generally accepted in the United States of America (U.S. GAAP) have been condensed or omitted pursuant to these rules and regulations. These condensed financial statements should be read in conjunction with the Company's audited financial statements and footnotes related thereto for the year ended December 31, 2023 included in our Annual Report on Form 10K filed with the SEC on March 28, 2024 (the Annual Report). There have been no material changes to the Company's significant accounting policies described in Note 2 to the financial statements included in the Annual Report.
 <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial;"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: left; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial;">In <span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; text-align: left; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">the opinion of management, the unaudited financial statements include all adjustments (consisting only of normal recurring adjustments) necessary to present fairly the Company's financial position and the results of its operations and cash flows at the dates for periods presented. The results of operations for such interim periods are not necessarily indicative of the results to be expected for the full year.
         Use of Estimates
   <span style="font-family:

'Times New Roman'; font-size: 10pt;">
      <div style="font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0);">The <span style="color: rgb(0, 0, 0); font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">preparation of financial statements in conformity with U.S. GAAP requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenue and expense during the reporting periods. Estimates for these and other items are subject to change and are reassessed by management in accordance with U.S. GAAP. Actual results could differ from those estimates.
     Liquidity   <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: left; text-transform: none; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">As of June 30, 2024, the Company had cash and cash equivalents of $13,525,898. <span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; text-align: left; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">The Company plans to finance its operations and development needs with its existing cash and cash equivalents, additional equity and/or debt financing arrangements, and revenue primarily anticipated from the sale of FemVue and FemaSeed to support the Company's research and development activities, primarily focused on FemBloc. There can be no assurance that the Company will be able to obtain additional financing on terms acceptable to the Company, on a timely basis, or at all. If the Company is not able to obtain sufficient funds on acceptable terms when needed, the Company's business, results of operations, and financial condition could be materially adversely impacted.
       <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: left; text-transform: none; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">For the six months ended June 30, 2024, the Company generated a net loss of $8,284,084. <span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; text-align: left; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">The Company expects such losses to increase over the next few years as the Company advances FemBloc through clinical development if and until FDA approval is received and is available to be marketed.
       The financial statements have been prepared on a going-concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Company has incurred net operating losses in every year since inception and has an accumulated deficit as of June 30, 2024 of $116,665,713 and expects to incur additional losses and negative operating cash flows for at least the next twelve months. The Company's ability to meet its obligations is dependent upon its ability to generate sufficient cash flows from operations and future financing transactions. Although management expects the Company will continue as a going concern, there is no assurance that management's plans will be successful since the availability and amount of such funding is not certain. Accordingly, substantial doubt exists about the Company's ability to continue as a going concern for at least one year from the issuance of these financial statements. The accompanying financial statements do not include any adjustments to reflect the possible future effects on the recoverability of assets or the amounts and classifications of liabilities that may result from the possible inability of the Company to continue as a going concern.

       <span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; font-variant: normal; text-transform: none;">Recently Issued Accounting Pronouncements – Recently Adopted

  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial;">In November 2023, the FASB issued ASU No. 2023-07, Segment Reporting (Topic 28): Improvements to Reportable Segment Disclosures. The ASU improves reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment expenses. The ASU improves financial reporting by requiring disclosure of incremental segment information on an annual and interim basis for all public entities to enable investors to develop more decision-useful financial analyses. The amendments in this update are effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted. The Company will adopt the ASU for the fiscal year ended December 31, 2024 and interim periods in fiscal 2025. The adoption of the ASU will result in additional disclosures to the Company's financial statements and footnote disclosures.   Recently Issued Accounting Pronouncements – Not Yet Adopted
     <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">In December 2023, the FASB issued ASU 2023-09, <span

*style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; font-style: italic;">Income Taxes (Topic 740): Improvements to Income Tax Disclosures<span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">. The ASU requires the annual financial statements to include consistent categories and greater disaggregation of information in the rate reconciliation, and income taxes paid disaggregated by jurisdiction. ASU 2023-09 is effective for the Company's annual reporting periods beginning after December 15, 2024. Adoption is either with a prospective method or a fully retrospective method of transition. Early adoption is permitted. The Company is currently evaluating the effect that adoption of ASU 2023-09 will have on its financial statements and expects to adopt the ASU on January 1, 2025.   <span style="color: rgb(0, 0, 0); font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">
             No <span style="color: rgb(0, 0, 0); font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">other new accounting pronouncement issued or effective has had, or is expected to have, a material impact on the Company's financial statements.   Organization and Nature of Business   <span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><span style="color: rgb(0, 0, 0); font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">Femasys Inc. (the Company or Femasys) was incorporated in Delaware on February 19, 2004 and is headquartered in Suwanee, Georgia. The Company is a leading biomedical company focused on addressing significant unmet needs for women worldwide with a broad portfolio of in-office, accessible, and innovative therapeutic and diagnostic products, including a lead revolutionary product candidate and FDA-cleared products. <span style="color: rgb(0, 0, 0); font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial;">The Company's mission is to provide women with superior minimally-invasive, non-surgical product technologies, accessible in the office, improving patient care and overall health economics focused on servicing the reproductive health needs for those seeking solutions for infertility issues (FemaSeed® and FemVue®) or permanent birth control (FemBloc®). <span style="color: rgb(0, 0, 0); font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">The Company currently operates as one <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">segment with an initial focus on servicing the reproductive health needs for those seeking solutions for infertility issues or permanent birth control.
     <div style="margin-top: 0px; margin-bottom: 0px; letter-spacing: normal; white-space: normal; word-spacing: 0px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-weight: normal; text-align: left; text-transform: none; background-color: rgb(255, 255, 255); font-variant: normal;"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">Femasys has an expansive intellectual property portfolio which covers both design and utility patents in the U.S. and significant ex-U.S. markets for each product initiative. Femasys has taken concepts internally conceived and protected through development, including domestic and foreign regulatory approvals, and production, through in-house manufacturing.<span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial;"> FemaSeed, a solution which enables directed intratubal insemination to improve on traditional intrauterine insemination (IUI) and provides a lower cost and safer option to in vitro fertilization methods, received approval to sell FemaSeed in Canada in April 2023. In September 2023, the Company received 510(k) clearance from the FDA for FemaSeed for intratubal insemination to market in the United States. A pivotal clinical trial was still ongoing at the time of receiving regulatory clearance, however, enrollment was completed in November 2023. In June 2024, the Company received European Union Medical Device Regulation (EU MDR) certificates and CE Mark certification for four products: FemaSeed, FemVue, FemCerv® and FemCath®. FemVue, a solution that enables fallopian tube assessment with ultrasound as an alternative to the radiologic approach (hysterosalpingogram) for the diagnosis of infertility, is approved for sale in the U.S., Japan, and Canada. FemChec® allows for fallopian tube evaluation after a FemBloc procedure to confirm occlusion (or procedure success). FemCerv is a solution for complete tissue sampling with minimal contamination of the endocervical canal in a virtually pain-free procedure as an alternative to the single biopsy method for diagnosis of cervical cancer and is approved for sale in the U.S. and Canada. FemCath, allows for selective evaluation of an individual fallopian tube as an alternative to the traditional intrauterine catheter that is undirected, is approved for sale in the U.S. and Canada. FemBloc<span style="color: rgb(0, 0, 0); font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial;">®, the Company's solution for permanent birth control, is based on the Company's platform technology for delivery and in June 2023 Femasys received FDA approval of our IDE to evaluate the safety and efficacy of FemBloc, our non-surgical, non-implant, non-hormonal in-office solution for permanent birth control in a pivotal clinical trial. In August 2023 Femasys announced the initiation of enrollment in the FINALE [Prospective Multi-Center Trial for FemBloc Intratubal Occlusion for TranscervicAL Permanent Birth Control] pivotal trial designed to evaluate the safety and efficacy of FemBloc. This prospective, multi-center, open-label, single-arm study design includes pregnancy rate as the primary endpoint, which will be analyzed once 401 women have relied on FemBloc for one year for permanent birth control. In addition, the study is designed as a roll-in beginning with enrollment of 50 women for a clinical readout primarily of preliminary safety data prior to enrolling the remaining subjects. An interim analysis of clinical data endpoints is planned once 300 women have used FemBloc for permanent birth control for one year. Follow-up will continue annually for five years post-market.   1 4 401 P1Y 50 300 P1Y P5Y   Basis of Presentation   <div style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style:*

normal; font-variant: normal; text-transform: none;">   <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: left; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial;">The <span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; text-align: left; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">Company has prepared the accompanying condensed financial statements pursuant to the rules and regulations of the U.S. Securities and Exchange Commission (SEC). Certain information and footnote disclosures normally included in the annual financial statements prepared in accordance with accounting principles generally accepted in the United States of America (U.S. GAAP) have been condensed or omitted pursuant to these rules and regulations. These condensed financial statements should be read in conjunction with the Company's audited financial statements and footnotes related thereto for the year ended December 31, 2023 included in our Annual Report on Form 10K filed with the SEC on March 28, 2024 (the Annual Report). There have been no material changes to the Company's significant accounting policies described in Note 2 to the financial statements included in the Annual Report.
 <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial;"> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: left; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial;">In <span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; text-align: left; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">the opinion of management, the unaudited financial statements include all adjustments (consisting only of normal recurring adjustments) necessary to present fairly the Company's financial position and the results of its operations and cash flows at the dates for periods presented. The results of operations for such interim periods are not necessarily indicative of the results to be expected for the full year.   Use of Estimates

      <div style="font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0);">The <span style="color: rgb(0, 0, 0); font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">preparation of financial statements in conformity with U.S. GAAP requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenue and expense during the reporting periods. Estimates for these and other items are subject to change and are reassessed by management in accordance with U.S. GAAP. Actual results could differ from those estimates.   Liquidity   <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: left; text-transform: none; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">As of June 30, 2024, the Company had cash and cash equivalents of $13,525,898. <span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; text-align: left; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">The Company plans to finance its operations and development needs with its existing cash and cash equivalents, additional equity and/or debt financing arrangements, and revenue primarily anticipated from the sale of FemVue and FemaSeed to support the Company's research and development activities, primarily focused on FemBloc. There can be no assurance that the Company will be able to obtain additional financing on terms acceptable to the Company, on a timely basis, or at all. If the Company is not able to obtain sufficient funds on acceptable terms when needed, the Company's business, results of operations, and financial condition could be materially adversely impacted.
         <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: left; text-transform: none; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">For the six months ended June 30, 2024, the Company generated a net loss of $8,284,084. <span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; text-align: left; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">The Company expects such losses to increase over the next few years as the Company advances FemBloc through clinical development if and until FDA approval is received and is available to be marketed.
       The financial statements have been prepared on a going-concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Company has incurred net operating losses in every year since inception and has an accumulated deficit as of June 30, 2024 of $116,665,713 and expects to incur additional losses and negative operating cash flows for at least the next twelve months. The Company's ability to meet its obligations is dependent upon its ability to generate sufficient cash flows from operations and future financing transactions. Although management expects the Company will continue as a going concern, there is no assurance that management's plans will be successful since the availability and amount of such funding is not certain. Accordingly, substantial doubt exists about the Company's ability to continue as a going concern for at least one year from the issuance of these financial statements. The accompanying financial statements do not include any adjustments to reflect the possible future effects on the recoverability of assets or the amounts and classifications of liabilities that may result from the possible inability of the Company to continue as a going concern.
   13525898 -8284084 -116665713   <span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; font-variant: normal; text-transform: none;">Recently Issued Accounting Pronouncements – Recently Adopted
  <span style="font-

family: 'Times New Roman'; font-size: 10pt;">
  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial;">In November 2023, the FASB issued ASU No. 2023-07, Segment Reporting (Topic 28): Improvements to Reportable Segment Disclosures. The ASU improves reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment expenses. The ASU improves financial reporting by requiring disclosure of incremental segment information on an annual and interim basis for all public entities to enable investors to develop more decision-useful financial analyses. The amendments in this update are effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted. The Company will adopt the ASU for the fiscal year ended December 31, 2024 and interim periods in fiscal 2025. The adoption of the ASU will result in additional disclosures to the Company's financial statements and footnote disclosures.   Recently Issued Accounting Pronouncements – Not Yet Adopted
     <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">In December 2023, the FASB issued ASU 2023-09, <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; font-style: italic;">Income Taxes (Topic 740): Improvements to Income Tax Disclosures<span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">. The ASU requires the annual financial statements to include consistent categories and greater disaggregation of information in the rate reconciliation, and income taxes paid disaggregated by jurisdiction. ASU 2023-09 is effective for the Company's annual reporting periods beginning after December 15, 2024. Adoption is either with a prospective method or a fully retrospective method of transition. Early adoption is permitted. The Company is currently evaluating the effect that adoption of ASU 2023-09 will have on its financial statements and expects to adopt the ASU on January 1, 2025.   <span style="color: rgb(0, 0, 0); font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">
            No <span style="color: rgb(0, 0, 0); font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">other new accounting pronouncement issued or effective has had, or is expected to have, a material impact on the Company's financial statements. <table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%;"> <tr style="vertical-align: top;"> <td style="text-align: right; vertical-align: top; width: 27pt;"> (2) </td> <td style="text-align: left; vertical-align: top; width: auto;"> Fair Value
  </td> </tr> </table>
  <span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">The Company applies a fair value hierarchy that requires the use of observable market data, when available, and prioritizes the inputs to valuation techniques used to measure fair value in the following categories:
  Level 1 – Valuation is based upon quoted prices for identical instruments traded in active markets.
  Level 2 – Valuation is based upon quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active, and model-based valuation techniques for which all significant assumptions are observable in the market.
  Level 3 – Valuation is generated from model-based techniques that use significant assumptions not observable in the market. These unobservable assumptions reflect the Company's own estimates of assumptions market participants would use in pricing the asset or liability.
  <span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Certain of the Company's financial instruments, including cash and other liabilities approximate their fair value because of the short-term maturity of these financial instruments. The fair value of stock options, convertible notes and warrants are based on Level 3 inputs.
   <table cellpadding="0" cellspacing="0" class="DSPFListTable" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;"> <tr style="vertical-align: top;"> <td style="vertical-align: top; width: 27pt;"> (3) </td> <td style="align: left; vertical-align: top; width: auto;"> Cash and Cash Equivalents </td> </tr> </table>   <div style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">As of June 30, 2024 and December 31, 2023, money market funds included in cash and cash equivalents on the balance sheets were $12,686,738 and $21,278,895, respectively, which represent level 1 within the fair value hierarchy where there are quoted prices in active markets for identical assets. 12686738 21278895 <table cellpadding="0" cellspacing="0" class="DSPFListTable" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;"> <tr style="vertical-align: top;"> <td style="vertical-align: top; width: 27pt;"> (4) </td> <td style="align: left; vertical-align: top; width: auto;"> Inventories </td> </tr> </table>   <div style="margin-right: 36pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Inventory stated at cost, net of reserve, consisted of the following:
 <table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"> <tr> <td rowspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom"> </td> <td colspan="2" rowspan="1" style="vertical-align: bottom; text-align: center; font-weight: bold; font-size: 10pt; white-space: nowrap;" valign="bottom"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 700; letter-spacing: normal; text-align: center; text-indent: 0px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">June 30,</td> <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: center; font-weight: bold; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: center; font-weight: bold; white-space: nowrap;" valign="bottom"> </td> <td colspan="2" rowspan="1" style="vertical-align: bottom; text-align: center; font-weight: bold; white-space: nowrap;" valign="bottom">December 31,</td> <td colspan="1" rowspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"> 2024
  </td> <td colspan="1" style="vertical-align:

bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); text-align: center; white-space: nowrap;" valign="bottom">2023
  </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> Materials </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> $</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0);">792,365</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0);">367,934</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; white-space: nowrap;" valign="bottom"> <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);">Work in progress</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0);">229,045</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0);">128,993</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);">Finished goods</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0);">294,170</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0);">170,191</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0);">Inventory, net</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0);">$ </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"> 1,315,580 </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"> 667,118 </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"> </td> </tr> </table> <div style="margin-right: 36pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Inventory stated at cost, net of reserve, consisted of the following:
 <table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"> <tr> <td rowspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom"> </td> <td colspan="2" rowspan="1" style="vertical-align: bottom; text-align: center; font-weight: bold; font-size: 10pt; white-space: nowrap;" valign="bottom"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 700; letter-spacing: normal; text-align: center; text-indent: 0px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">June 30,</td> <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: center; font-weight: bold; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: center; font-weight: bold; white-space: nowrap;" valign="bottom"> </td> <td colspan="2" rowspan="1" style="vertical-align: bottom; text-align: center; font-weight: bold; white-space: nowrap;" valign="bottom">December 31,</td> <td colspan="1" rowspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"> 2024
  </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); text-align: center; white-space: nowrap;" valign="bottom">2023
  </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> Materials </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> $ </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> 792,365 </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> 367,934 </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; white-space: nowrap;" valign="bottom"> Work in progress </td> <td colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"> 229,045 </td> <td colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"> 128,993 </td> <td colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> Finished goods </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> 294,170 </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"> 170,191 </td> <td

colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"> Inventory, net </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"> $</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0);">1,315,580</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0);">667,118</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"> </td> </tr> </table> 792365 367934 229045 128993 294170 170191 1315580 667118 <div> <table cellpadding="0" cellspacing="0" class="DSPFListTable" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;"> <tr style="vertical-align: top;"> <td style="vertical-align: top; width: 27pt;"> <div style="text-align: left; font-weight: bold;">(5)</div> </td> <td style="align: left; vertical-align: top; width: auto;"> <div style="text-align: left; font-weight: bold;">Accrued Expenses</div> </td> </tr> </table> </div> <div> </div> <div style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Accrued expenses consisted of the following:</div> <div>
 </div> <table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"> <tr> <td rowspan="1" style="vertical-align: bottom;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: center; font-weight: bold; vertical-align: bottom; white-space: nowrap;" valign="bottom"> </td> <td colspan="2" rowspan="1" style="vertical-align: bottom; text-align: center; font-weight: bold; white-space: nowrap;" valign="bottom">June 30,</td> <td colspan="1" rowspan="1" style="font-weight: bold; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: center; font-weight: bold; vertical-align: bottom; white-space: nowrap;" valign="bottom"> </td> <td colspan="2" rowspan="1" style="vertical-align: bottom; text-align: center; font-weight: bold; white-space: nowrap;" valign="bottom">December 31,</td> <td colspan="1" rowspan="1" style="font-weight: bold; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"> 2024 </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="font-weight: bold; text-align: center; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">2023</td> <td colspan="1" style="font-weight: bold; text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);">Clinical trial costs</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0);">$ </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> 334,799 </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> 276,141 </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td rowspan="1" style="vertical-align: bottom; width: 76%; white-space: nowrap;" valign="bottom">Accrued interest
 </td> <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">250,025</td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">–</td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td rowspan="1" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">Incentive and other compensation costs
 </td> <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">170,328</td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">1,082,606</td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td rowspan="1" style="vertical-align: bottom; width: 76%; white-space: nowrap;" valign="bottom">Director fees </td> <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">70,000</td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">60,210</td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td rowspan="1" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">Franchise taxes
 </td> <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">3,150</td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">12,160</td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> Other </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"> 58,050 </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"> 13,179 </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> Accrued expenses </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;

background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> $</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0);">886,352</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0);">1,444,296</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> </td> </tr> </table> <div style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Accrued expenses consisted of the following:</div> <div>
 </div> <table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"> <tr> <td rowspan="1" style="vertical-align: bottom;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: center; font-weight: bold; vertical-align: bottom; white-space: nowrap;" valign="bottom"> </td> <td colspan="2" rowspan="1" style="vertical-align: bottom; text-align: center; font-weight: bold; white-space: nowrap;" valign="bottom">June 30,</td> <td colspan="1" rowspan="1" style="font-weight: bold; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: center; font-weight: bold; vertical-align: bottom; white-space: nowrap;" valign="bottom"> </td> <td colspan="2" rowspan="1" style="vertical-align: bottom; text-align: center; font-weight: bold; white-space: nowrap;" valign="bottom">December 31,</td> <td colspan="1" rowspan="1" style="font-weight: bold; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"> 2024 </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="font-weight: bold; text-align: center; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">2023</td> <td colspan="1" style="font-weight: bold; text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);">Clinical trial costs</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0);">$ </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> 334,799 </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> 276,141 </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td rowspan="1" style="vertical-align: bottom; width: 76%; white-space: nowrap;" valign="bottom">Accrued interest
 </td> <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">250,025</td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td rowspan="1" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">Incentive and other compensation costs
 </td> <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">170,328</td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">1,082,606</td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td rowspan="1" style="vertical-align: bottom; width: 76%; white-space: nowrap;" valign="bottom">Director fees </td> <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">70,000</td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">60,210</td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td rowspan="1" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">Franchise taxes
 </td> <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">3,150</td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">12,160</td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> Other </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"> 58,050 </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"> 13,179 </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> Accrued expenses </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> $ </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;"

valign="bottom"> 886,352 </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> 1,444,296 </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> </td> </tr> </table> 334799 276141 250025 0 170328 1082606 70000 60210 3150 12160 58050 13179 886352 1444296 <table cellpadding="0" cellspacing="0" class="DSPFListTable" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;"> <tr style="vertical-align: top;"> <td style="vertical-align: top; width: 27pt;"> (6) </td> <td style="align: left; vertical-align: top; width: auto;"> Clinical Holdback </td> </tr> </table>   <div style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">The following table shows the activity within the clinical holdback liability accounts for the six months ended June 30, 2024:   <table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"> <tr> <td style="vertical-align: bottom; width: 88%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> Balance at December 31, 2023
  </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> $</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0);">120,235</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 88%; white-space: nowrap;" valign="bottom"> <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);">Clinical holdback retained</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"> <div>5,990</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 88%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);">Clinical holdback paid</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div>(1,122</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div>)</div> </td> </tr> <tr> <td style="vertical-align: bottom; width: 88%; white-space: nowrap;" valign="bottom"> <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);">Balance at June 30, 2024</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0);">$ </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"> 125,103 </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 88%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> Less: clinical holdback - current portion </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> (92,397 </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">) </td> </tr> <tr> <td style="vertical-align: bottom; width: 88%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> Clinical holdback - long-term portion </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"> $</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"> <div>32,706</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> </table> <div style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">The following table shows the activity within the clinical holdback liability accounts for the six months ended June 30, 2024:</div> <div> </div> <table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"> <tr> <td style="vertical-align: bottom; width: 88%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);">Balance at December 31, 2023
 </div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0);">$ </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> 120,235 </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 88%; white-space: nowrap;" valign="bottom"> Clinical holdback retained </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"> 5,990 </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 88%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> Clinical holdback paid </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> (1,122 </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">) </td> </tr> <tr> <td style="vertical-align: bottom; width: 88%; white-space: nowrap;" valign="bottom"> Balance at June 30, 2024 </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> $</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0);">125,103</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 88%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);">Less: clinical holdback - current portion</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div>(92,397</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div>)</div> </td> </tr> <tr> <td style="vertical-align: bottom; width: 88%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);">Clinical holdback - long-term portion</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"> <div>$ </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"> 32,706 </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> </table> 120235 5990

1122 125103 92397 32706 <table cellpadding="0" cellspacing="0" class="DSPFListTable" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;"> <tr style="vertical-align: top;"> <td style="vertical-align: top; width: 27pt;"> (7) </td> <td style="align: left; vertical-align: top; width: auto;"> Revenue Recognition </td> </tr> </table>   <div style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Revenue is recognized upon shipment of our goods based upon contractually stated pricing at standard payment terms ranging from 30 to 60 days. All revenue is recognized point in time and no revenue is recognized over time. For the three and six months ended June 30, 2024 and 2023, there was no revenue recognized from performance obligations satisfied or partially satisfied in prior periods, nor were there any unsatisfied performance obligations as of June 30, 2024 or 2023.   <div style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">The majority of products sold directly to U.S customers are shipped via common carrier, and the customer pays for shipping and handling and assumes control Free on Board (FOB) shipping point. Products shipped to our international distributors are in accordance with their respective agreements; however, the shipping terms are generally EX-Works, reflecting that control is assumed by the distributor at the shipping point. Returns are only accepted with prior authorization from the Company. Items to be returned must be in original unopened cartons and are subject to a 30% restocking fee. Throughout the periods presented, the Company has not had a history of significant returns. <span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> <div style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">The following table summarizes our sales, primarily from FemVue, by geographic region as follows: <div style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">
  <table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"> <tr> <td style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"> Three Months Ended June 30, </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"> Six Months Ended June 30, </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">Primary geographical markets
 </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> 2024
  </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> 2023
  </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> 2024
  </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> 2023
  </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> U.S. </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> $</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0);">221,484</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0);">262,469</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0);">492,624</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0);">556,453</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 52%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);">International</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0);">–</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0);">58,045</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0);">–</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0);">58,045</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 52%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="text-indent: -7.2pt; margin-left: 16.2pt; color: rgb(0, 0, 0);">Total</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0);">$ </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> 221,484 </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> 320,514 </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0,

 </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> 614,498 </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> </table> P30D P60D 0 0 0 0 0.30 <div style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">The following table summarizes our sales, primarily from FemVue, by geographic region as follows: <div style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">
  <table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"> <tr> <td style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"> Three Months Ended June 30, </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"> Six Months Ended June 30, </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">Primary geographical markets
 </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> 2024
  </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> 2023
  </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> 2024
  </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> 2023
  </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> U.S. </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> $</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0);">221,484</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0);">262,469</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0);">492,624</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0);">556,453</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 52%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);">International</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0);">–</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0);">58,045</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0);">–</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0);">58,045</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 52%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="text-indent: -7.2pt; margin-left: 16.2pt; color: rgb(0, 0, 0);">Total</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0);">$ </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> 221,484 </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> 320,514 </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> 492,624 </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> 614,498 </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> </table> 221484 262469 492624 556453 0 58045 0 58045 221484 320514 492624 614498 <table cellpadding="0" cellspacing="0" class="DSPFListTable" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;"> <tr style="vertical-align: top;"> <td style="vertical-align: top; width: 27pt;"> (8) </td> <td style="align: left; vertical-align: top; width: auto;"> <div style="text-align: left; font-

weight: bold;">Commitments and Contingencies </td> </tr> </table>
 <div style="font-style: italic; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Legal Claims   Occasionally, the Company may be a party to legal claims or proceedings of which the outcomes are subject to significant uncertainty. In accordance with <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial;">Accounting Standards Codification (ASC) 450, Contingencies, the Company will assess the likelihood of an adverse judgment for any outstanding claim as well as ranges of probable losses. When it has been determined that a loss is probable and the amount can be reasonably estimated, the Company will record a liability. For both periods presented, there were no material legal contingencies requiring accrual or disclosure.
    The Company, as permitted under Delaware law and in accordance with its bylaws, indemnifies its officers and directors for certain events or occurrences, subject to certain limits, while the officer or director is or was serving at the Company’s request in such capacity. The Company entered into employment agreements with its officers, which provides for indemnification protection in the executive’s capacity as an officer for actions taken within the scope of employment. The maximum amount of potential future indemnification is unlimited; however, the Company has obtained director and officer insurance that limits its exposure. The Company believes the fair value for these indemnification obligations is minimal. Accordingly, the Company has not recognized any liabilities relating to these obligations as of June 30, 2024 and December 31, 2023.   <table cellpadding="0" cellspacing="0" class="DSPFListTable" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;"> <tr style="vertical-align: top;"> <td style="vertical-align: top; width: 27pt;"> <div style="text-align: left; font-weight: bold; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">(9) </td> <td style="align: left; vertical-align: top; width: auto;"> Notes Payable </td> </tr> </table>
      <div style="font-style: normal; margin-right: 154.8pt; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">AFCO Credit Corporation (AFCO)   In June 2022, the Company executed a Promissory Note with AFCO to finance certain insurance premiums totaling $465,380, requiring the Company to pay $47,539 in a down payment and make monthly installment payments. The annual interest rate was 5.7% and the monthly installment payment was $47,539, which represents principal and interest. The final installment payment was paid in March of 2023. <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">
   <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">In July 2023, the Company executed a Promissory Note with AFCO to finance certain insurance premiums totaling $469,042, requiring the Company to pay $48,423 in a down payment and make monthly installment payments. The annual interest rate was 8.6% and the monthly installment is $48,423, which represents principal and interest. The Promissory Note was paid in full without penalty in November 2023.
    As of June 30, 2024, and December 31, 2023, there was no principal balance on the AFCO note in the accompanying balance sheets. Interest expense in connection with the AFCO promissory notes was $0 and $1,319 for the three and six months ended June 30, 2024 and 2023, respectively. 465380 47539 0.057 monthly 47539 469042 48423 0.086 monthly 48423 0 0 0 0 1319 1319 <table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%;"> <tr style="vertical-align: top;"> <td style="text-align: right; vertical-align: top; width: 27pt;"> (10) </td> <td style="text-align: left; vertical-align: top; width: auto;"> Convertible Notes with Warrants (November 2023 Financing) </td> </tr> </table>
   On November 21, 2023, the Company issued (i) senior unsecured convertible notes in an aggregate principal amount of $6,850,000, convertible into shares of common stock at a conversion price of $1.18 per share, (ii) Series A Warrants to purchase up to an aggregate of 5,805,083 shares of common stock at an exercise price of $1.18 per share, and (iii) Series B Warrants, together with the Series A Warrants, and, together with the convertible notes, to purchase up to an aggregate of 5,805,083 shares of common stock at an exercise price of $1.475 per share. The financing resulted in aggregate gross proceeds of $6,850,000, before $525,144 of transaction costs.
   The Notes accrue interest at a rate of 6.0% per annum, payable annually, in cash or shares of common stock at the Company’s option, and mature on November 21, 2025, unless earlier converted or redeemed.
   The Notes are convertible into shares of common stock at the election of the holder at any time at an initial conversion price of $1.18. The Company has agreed not to issue or sell any equity securities of the Company at a price below the then-current conversion price for a period of 18 months after closing, subject to certain exceptions. Beginning six months after issuance, the Company may require holders to convert their Notes into conversion shares if the closing price of the common stock exceeds $2.36 per share for 10 consecutive trading days and the daily dollar trading volume of the common stock exceeds $1,000,000 per day during the same period and certain equity conditions

described in the Notes are satisfied. The Notes provide for certain events of default, whereby each holder of Notes will be able to require the Company to redeem in cash any or all of the holder's Notes at a premium of 115%. The conversion feature did not meet the requirements for separate accounting and is not accounted for as a derivative instrument. As of June 30, 2024, the Convertible Notes have not been converted into shares of common stock.

 <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial;">
  <span style="font-style: italic; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">The Warrants The Series A Warrants are exercisable immediately and expire five years from the date of issuance. The Company has the right to call the exercise of the Series A Warrants if the closing price of the common stock exceeds 200% of the Series A Exercise Price for 10 consecutive trading days and the daily dollar trading volume of the common stock exceeds $1,000,000 per day during the same period and certain equity conditions are satisfied.
   The Series B Warrants are exercisable immediately, together with the Series A Warrant Shares, and expire one year from the date of issuance. The Company has the right to call the exercise of the Series B Warrants if the closing price of the common stock exceeds 200% of the Series B exercise price for 10 consecutive trading days and the daily dollar trading volume of the common stock exceeds $1,000,000 per day during the same period and certain equity conditions are satisfied. There is no established public trading market for the warrants and the Company does not intend to list the Warrants on any national securities exchange or nationally recognized trading system.
   The Series A Warrants and Series B Warrants are classified as a component of permanent equity because they are freestanding financial instruments that are legally detachable and separately exercisable from the shares of common stock from which they are issued, are immediately exercisable, do not embody an obligation for the Company to repurchase its shares, and permit the holders to receive a fixed number of shares of common stock upon exercise.
 <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial;">
   For the convertible notes for the three months ended June 30, 2024, the Company recognized total interest expense of $388,311, including coupon interest expense of $102,750 and amortization of debt discount and issuance costs of $285,561.<span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"> For the six months ended June 30, 2024, the Company recognized total interest expense of $749,863, including coupon interest expense of $205,500 and amortization of debt discount and issuance costs of $544,363. As of December 31, 2023, the Notes principal balance as $6,850,000, unamortized discount was $2,636,346 and accrued interest was $44,525. As of June 30, 2024, the Notes principal balance as $6,850,000, unamortized discount was $2,091,983 and accrued interest was $250,025. The fair value of the convertible notes on June 30, 2024, calculated using a discounted cash flow analysis, was $6,307,258. 6850000 1.18 5805083 1.18 5805083 1.475 6850000 525144 0.06 2025-11-21 1.18 P18M 2.36 P10D 1000000 1.15 P5Y 2 P10D 1000000 P1Y 2 P10D 1000000 388311 102750 285561 749863 205500 544363 6850000 2636346 44525 6850000 2091983 250025 6307258 <table cellpadding="0" cellspacing="0" class="DSPFListTable" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;"> <tr style="vertical-align: top;"> <td style="vertical-align: top; width: 27pt;"> (11) </td> <td style="vertical-align: top;"> Stockholders' Equity </td> </tr> </table>
  On July 1, 2022, we filed <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">shelf registration statement to sell up to $150 million in common and preferred stock, debt securities and warrants. Additionally, we entered into an Equity Distribution Agreement (the "Equity Distribution Agreement") with Piper Sandler & Co. ("Piper Sandler" or the "Sales Agent") and filed a related prospectus establishing an "at-the-market" facility, pursuant to which we may offer and sell shares of our common stock from time to time through the Sales Agent. In October 2023, the Sales Agent was authorized to sell shares for aggregate proceeds up to $16.7 million at current market prices until all shares are sold. As of June 30, 2024, 3.9 million shares of common stock have been sold for aggregate proceeds of <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; display: inline !important; float: none;">approximately $8.7 million under the Equity Distribution Agreement pursuant to the prospectus. As of June 30, 2024, the amount we are authorized to sell is subject to baby-shelf limitations.<br class="Apple-interchange-newline"/>
     In April 2023, the Company sold an aggregate of (i) 1,318,000 shares of common stock and (ii) pre-funded warrants to purchase up to 1,878,722 shares of common stock in a registered direct offering ("pre-funded warrants") and, in a concurrent private placement, warrants to purchase up to 3,196,722 shares of common stock ("common warrants"). Additionally, common warrants were issued to the placement agent to purchase up to 191,803 shares of common stock as compensation for services ("placement agent warrants"), collectively the ("April 2023 Financing"). The purchase price per share for the common stock, pre-funded warrants was $1.22 and $1.2199, respectively. The gross proceeds from the offering were $3,899,813, less placement agent fees and offering expenses of $547,764.

 <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial;">In June 2023, all pre-funded warrants were exercised for shares of common stock. In September and October 2023, all common warrants and 122,994 placement agent warrants were exercised for cash proceeds of $3,687,976. As of June 30, 2024, 68,809 placement agent warrants remain outstanding. <br class="Apple-interchange-newline"/>   <div style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">As of June 30, 2024, the Company had 22,232,799 shares of common stock outstanding, and no dividends have been declared or paid. 150000000 16700000 3900000 8700000 1318000 1878722 3196722 191803 1.22 1.2199 3899813 547764 122994 122994 3687976 3687976 68809 22232799 0 <table cellpadding="0" cellspacing="0" class="DSPFListTable" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;"> <tr style="vertical-align: top;"> <td style="vertical-align: top; width: 27pt;"> (12) </td> <td style="align: left; vertical-align: top; width: auto;"> <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 700; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; display: inline !important; float: none;">Equity Incentive Plans and Warrants </td> </tr> </table>
  Stock-Based Awards

   <table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;"> <tr> <td style="width: 18pt; font-weight: normal;">
  </td> <td style="width: 18pt; vertical-align: top; font-style: italic; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal;

text-transform: none;">(a)</td> <td style="width: auto; vertical-align: top;"> Stock Option Plans </td> </tr> </table>   Activity under the Company's stock option plans for the six months ended June 30, 2024 was as follows:
   <table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"> <tr> <td rowspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: center; font-weight: bold; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="2" rowspan="1" style="vertical-align: bottom; text-align: center; font-weight: bold; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"> Number of options </td> <td colspan="1" rowspan="1" style="font-weight: bold; text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: center; font-weight: bold; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="2" rowspan="1" style="vertical-align: bottom; text-align: center; font-weight: bold; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"> Weighted average exercise price </td> <td colspan="1" rowspan="1" style="font-weight: bold; text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td rowspan="1" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">Outstanding at December 31, 2023</td> <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">2,102,030</td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">$</td> <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">2.00</td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td rowspan="1" style="vertical-align: bottom; text-indent: 9pt; width: 76%; white-space: nowrap;" valign="bottom">Granted</td> <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">1,062,421</td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">1.06</td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td rowspan="1" style="vertical-align: bottom; text-indent: 9pt; width: 76%; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;" valign="bottom">Forfeited</td> <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">(243,312</td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;" valign="bottom">) </td> <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;" valign="bottom">2.09</td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td rowspan="1" style="vertical-align: bottom; width: 76%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">Outstanding at June 30, 2024</td> <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom">2,921,139</td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">$</td> <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">1.65</td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td rowspan="1" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td rowspan="1" style="vertical-align: bottom; width: 76%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">Vested and exercisable at June 30, 2024</td> <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">1,207,595</td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">$</td> <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">2.53</td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> </table>
  Options granted under our 2021 Stock Option Plan for the six months ended June 30, 2024 to employees and nonemployees were 1,059,921 and 2,500, respectively and the weighted average exercise prices were $1.06 and $0.79, respectively. The weighted-average fair values of the options granted to employees and nonemployees were $0.90 and $0.39, respectively and were estimated using the following Black-Scholes assumptions:
  <table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="letter-spacing: normal; word-spacing: 0px; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; text-transform: none; width: 100%;"> <tr> <td rowspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: center; font-weight: bold; vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="2" rowspan="1" style="vertical-align: bottom; text-align: center; font-weight: bold; border-bottom: #000000 solid 2px;" valign="bottom">Employee
 </td> <td colspan="1" rowspan="1"

style="font-weight: bold; text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: center; font-weight: bold; vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="2" rowspan="1" style="text-align: center; vertical-align: bottom; font-weight: bold; border-bottom: #000000 solid 2px;" valign="bottom"> Nonemployee</td> <td colspan="1" rowspan="1" style="font-weight: bold; text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-weight: normal; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; font-family: 'Times New Roman';">Expected term (in years) </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
  </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> 6.25 </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">1.50</td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; white-space: nowrap;" valign="bottom"> Risk-free interest rate </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"> 4.06 </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> % </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">4.53</td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">%</td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-weight: normal; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; font-family: 'Times New Roman';">Dividend yield </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> - </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> % </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">-</td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">%</td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; white-space: nowrap;" valign="bottom"> <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-weight: normal; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; font-family: 'Times New Roman';">Expected volatility </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"> 110.40 </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> % </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">105.34</td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">%</td> </tr> </table>
 <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: left; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">No options were exercised for the six months ended June 30, 2024 under our stock option plans.
   <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">
  <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: left; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">As of June 30, 2024, the total number of shares of common stock reserved for future awards under the 2021 Stock Option Plan was 676,741.

   <table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;"> <tr> <td style="width: 18pt; font-weight: normal;">
  </td> <td style="width: 18pt; vertical-align: top; font-style: italic; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> (b)</td> <td style="width: auto; vertical-align: top;"> Inducement Grants </td> </tr> </table>
   <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: left; text-transform: none; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">On February 12, 2024, the Company awarded, outside the 2021 Plan, our Chief Commercial Officer a stock option grant for the right to purchase 100,000 shares of common stock at an exercise price of $1.10 per share (inducement grant), which was approved by the Compensation committee. The inducement grant will vest in equal installments over four years provided the employee remains employed by the Company on the vesting date. The fair value of the inducement grant was $0.94 and was estimated using the following assumptions: <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">
 <table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"> <tr> <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">   </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> Inducement </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 88%; background-color: #CCEEFF;

white-space: nowrap;" valign="bottom"> Expected term (in years) </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
  </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> 6.25 </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 88%; white-space: nowrap;" valign="bottom"> Risk-free interest rate </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"> 4.10 </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> % </td> </tr> <tr> <td style="vertical-align: bottom; width: 88%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> Dividend yield </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> — </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> % </td> </tr> <tr> <td style="vertical-align: bottom; width: 88%; white-space: nowrap;" valign="bottom"> Expected volatility </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"> 109.64 </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> % </td> </tr> </table>
  As of June 30, 2024, inducement grant awards of 250,000 shares were outstanding with a weighted average exercise price of $1.89, and 62,500 shares were vested and exercisable with a weighted average exercise price of $2.64.</div> <div>
 </div> <table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;"> <tr> <td style="width: 18pt;">
  </td> <td style="width: 18pt; vertical-align: top; font-style: italic; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">(c)</td> <td style="width: auto; vertical-align: top;">Share-Based Compensation Expense</td> </tr> </table> <div>
 </div> <div style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">The following table shows the share-based compensation expense related to vested stock option grants to employees and nonemployees by financial statement line item on the accompanying condensed statement of comprehensive loss:</div> <div style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">
 </div> <div style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> <table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"> <tr> <td rowspan="1" style="vertical-align: bottom; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="6" rowspan="1" style="vertical-align: bottom; text-align: center; border-bottom: #000000 solid 2px;" valign="bottom">Three Months Ended June 30,</td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="6" rowspan="1" style="text-align: center; vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom">Six Months Ended June 30,</td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">2024 </div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">2023 </div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: center; font-weight: bold; vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="2" style="text-align: center; vertical-align: bottom; font-weight: bold; border-bottom: #000000 solid 2px;" valign="bottom">2024</td> <td colspan="1" style="font-weight: bold; text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: center; font-weight: bold; vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="2" style="text-align: center; vertical-align: bottom; font-weight: bold; border-bottom: #000000 solid 2px;" valign="bottom">2023</td> <td colspan="1" style="font-weight: bold; text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;" valign="bottom"> <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Research and development</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$ </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> 34,629 </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> 27,192 </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left;

vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">64,637</td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">52,251</td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 52%;" valign="bottom"> Sales and marketing </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"> 18,246 </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"> 602 </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">24,764</td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">(1,942</td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">)</td> </tr> <tr> <td style="vertical-align: bottom; width: 52%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"> General and administrative </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> 51,138 </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> 37,422 </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">92,197</td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">71,861</td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 52%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"> Total share-based compensation expense </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"> $ </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"> 104,013 </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"> 65,216 </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">181,598</td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">122,170</td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"> </td> </tr> </table>
   As of <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: left; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">June 30, 2024, the remaining share-based compensation expense that is expected to be recognized in future periods for employees and nonemployees is $1,516,737, which includes $155,222 of compensation expense to be recognized upon achieving certain performance conditions. For service-based awards, the $1,361,515 of unrecognized expense is expected to be recognized over a weighted average period of 3.3 years.   <table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;"> <tr> <td style="width: 18pt;">
  </td> <td style="width: 18pt; vertical-align: top; font-style: italic; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">(d)</td> <td style="width: auto; vertical-align: top;"> Employee Stock Purchase Plan (ESPP)
  </td> </tr> </table>   For the six months ended <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: left; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-

color: initial; display: inline ! important; float: none;">June 30, 2024, 12,081 shares of common stock were issued under the Company's ESPP Plan at a fair value of $10,390. For the six months ended June 30, 2023, 3,858 shares of common stock were issued under the ESPP plan at a fair value of $1,697. As of <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: left; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">June 30, 2024, the total number of shares of common stock reserved for future awards under the ESPP Plan was 591,437.
  <table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;"> <tr> <td style="width: 18pt; font-weight: normal;">
  </td> <td style="width: 18pt; vertical-align: top; font-style: italic; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">(e)</td> <td style="width: auto; vertical-align: top;"> April 2023 Financing </td> </tr> </table>   On April 20, 2023, the Company entered into a securities purchase agreement pursuant to which the Company sold (i) 1,318,000 shares of common stock (see Note 11, Stockholders' Equity), (ii) pre-funded warrants to purchase 1,878,722 shares of common stock, (iii) common warrants to purchase 3,196,722 shares of common stock. Additionally, common warrants to purchase 191,803 shares of common stock were issued to the placement agent compensation for services performed.
  The pre-funded warrants, common warrants and placement agent warrants were exercisable immediately following the closing date of the offering. The pre-funded warrants have an unlimited term and an exercise price of $0.0001 per share. The common warrants have a 5.5 year term and an exercise price of $1.095 per share. The placement agent warrants have a 5 year term and exercise price of $1.525 per share. The offering resulted in aggregate gross proceeds of $3,899,813, before $547,764 of transaction costs.
  The pre-funded warrants and common warrants are classified as a component of permanent equity because they are freestanding financial instruments that are legally detachable and separately exercisable from the shares of common stock with which they were issued, are immediately exercisable, do not embody an obligation for the Company to repurchase its shares, and permit the holders to receive a fixed number of shares of common stock upon exercise.

  The common stock was valued at $1,133,480, based on the Company's stock price. The pre-funded warrants and common warrants were valued at $1,615,701 and $1,854,099, respectively, using the following Black-Scholes assumptions:</div> <div>
 </div> <table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="letter-spacing: normal; word-spacing: 0px; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; text-align: left; text-transform: none; width: 100%;"> <tr> <td style="vertical-align: bottom; color: rgb(0, 0, 0); padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="color: rgb(0, 0, 0); vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; color: rgb(0, 0, 0); border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: center; font-weight: bold;">Pre-funded</div> <div style="text-align: center; font-weight: bold;">warrants</div> </td> <td colspan="1" style="color: rgb(0, 0, 0); text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="color: rgb(0, 0, 0); vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; color: rgb(0, 0, 0); border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: center; font-weight: bold;">Common</div> <div style="text-align: center; font-weight: bold;">warrants</div> </td> <td colspan="1" style="color: rgb(0, 0, 0); text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; color: rgb(0, 0, 0); width: 76%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div>Expected term (in years)</div> </td> <td colspan="1" style="color: rgb(0, 0, 0); text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="color: rgb(0, 0, 0); text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div>
 </div> </td> <td colspan="1" style="color: rgb(0, 0, 0); vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div>4</div> </td> <td colspan="1" style="color: rgb(0, 0, 0); text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="color: rgb(0, 0, 0); text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="color: rgb(0, 0, 0); text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="color: rgb(0, 0, 0); vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div>4</div> </td> <td colspan="1" style="color: rgb(0, 0, 0); text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; color: rgb(0, 0, 0); width: 76%; white-space: nowrap;" valign="bottom"> <div>Risk-free interest rate</div> </td> <td colspan="1" style="color: rgb(0, 0, 0); text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="color: rgb(0, 0, 0); text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="color: rgb(0, 0, 0); vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"> <div>3.83</div> </td> <td colspan="1" style="color: rgb(0, 0, 0); text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> <div>%</div> </td> <td colspan="1" style="color: rgb(0, 0, 0); text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="color: rgb(0, 0, 0); text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="color: rgb(0, 0, 0); vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"> <div>3.83</div> </td> <td colspan="1" style="color: rgb(0, 0, 0); text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> <div>%</div> </td> </tr> <tr> <td style="vertical-align: bottom; color: rgb(0, 0, 0); width: 76%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div>Dividend yield</div> </td> <td colspan="1" style="color: rgb(0, 0, 0); text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="color: rgb(0, 0, 0); text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="color: rgb(0, 0, 0); vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div>—</div> </td> <td colspan="1" style="color: rgb(0, 0, 0); text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">%</td> <td colspan="1" style="color: rgb(0, 0, 0); text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="color: rgb(0, 0, 0); text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="color: rgb(0, 0, 0); vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div>—</div> </td> <td colspan="1" style="color: rgb(0, 0, 0); text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">%</td> </tr> <tr> <td style="vertical-align: bottom; color: rgb(0, 0, 0); width: 76%; white-space: nowrap;" valign="bottom"> <div>Expected volatility</div> </td> <td colspan="1" style="color: rgb(0, 0, 0); text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="color: rgb(0, 0, 0); text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="color: rgb(0, 0, 0); vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"> <div>100.25</div> </td> <td colspan="1" style="color: rgb(0, 0, 0); text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> <div>%</div> </td> <td colspan="1" style="color: rgb(0, 0, 0); text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="color: rgb(0, 0, 0); text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="color: rgb(0, 0, 0); vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"> <div>100.25</div> </td> <td colspan="1" style="color: rgb(0, 0, 0); text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> <div>%</div> </td> </tr> <tr> <td style="vertical-align: bottom; color: rgb(0, 0, 0); width: 76%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div>Exercise price</div> </td> <td colspan="1" style="color: rgb(0, 0, 0); text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="color: rgb(0, 0, 0); text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div>$ </td> <td

colspan="1" style="color: rgb(0, 0, 0); vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> 0.0001 </td> <td colspan="1" style="color: rgb(0, 0, 0); text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="color: rgb(0, 0, 0); text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="color: rgb(0, 0, 0); text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> $</div> </td> <td colspan="1" style="color: rgb(0, 0, 0); vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div>1.095</div> </td> <td colspan="1" style="color: rgb(0, 0, 0); text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; color: rgb(0, 0, 0); width: 76%; white-space: nowrap;" valign="bottom"> <div>Stock price</div> </td> <td colspan="1" style="color: rgb(0, 0, 0); text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="color: rgb(0, 0, 0); text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> <div>$ </td> <td colspan="1" style="color: rgb(0, 0, 0); vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"> 0.86 </td> <td colspan="1" style="color: rgb(0, 0, 0); text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="color: rgb(0, 0, 0); text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="color: rgb(0, 0, 0); text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> $</div> </td> <td colspan="1" style="color: rgb(0, 0, 0); vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"> <div>0.86</div> </td> <td colspan="1" style="color: rgb(0, 0, 0); text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td rowspan="1" style="vertical-align: bottom; color: rgb(0, 0, 0); width: 76%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">Black-Scholes value
 </td> <td colspan="1" rowspan="1" style="color: rgb(0, 0, 0); text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="color: rgb(0, 0, 0); text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">$</td> <td colspan="1" rowspan="1" style="color: rgb(0, 0, 0); vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">0.86</td> <td colspan="1" rowspan="1" style="color: rgb(0, 0, 0); text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="color: rgb(0, 0, 0); text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="color: rgb(0, 0, 0); text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">$</td> <td colspan="1" rowspan="1" style="color: rgb(0, 0, 0); vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">0.58</td> <td colspan="1" rowspan="1" style="color: rgb(0, 0, 0); text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> </table>
  <div style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">The net proceeds of $3,352,049 were allocated to the common stock, pre-funded warrants and common warrants using the relative fair value method. The valuations were recorded to stockholders' equity. In June 2023, all pre-funded warrants were exercised for shares of common stock. In September and October 2023, all common warrants and 122,994 placement agent warrants were exercised for cash proceeds of $3,687,976. As of June 30, 2024, 68,809 placement agent warrants remain outstanding. </div> <div style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Activity under the Company's stock option plans for the six months ended June 30, 2024 was as follows:</div> <div>
 </div> <div> <table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"> <tr> <td rowspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: center; font-weight: bold; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="2" rowspan="1" style="vertical-align: bottom; text-align: center; font-weight: bold; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"> <div>Number of</div> <div> options</div> </td> <td colspan="1" rowspan="1" style="font-weight: bold; text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: center; font-weight: bold; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="2" rowspan="1" style="vertical-align: bottom; text-align: center; font-weight: bold; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"> <div>Weighted</div> <div>average</div> <div>exercise</div> <div> price</div> </td> <td colspan="1" rowspan="1" style="font-weight: bold; text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td rowspan="1" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">Outstanding at December 31, 2023</td> <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">2,102,030</td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">$</td> <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">2.00</td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td rowspan="1" style="vertical-align: bottom; text-indent: 9pt; width: 76%; white-space: nowrap;" valign="bottom">Granted</td> <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">1,062,421</td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">1.06</td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td rowspan="1" style="vertical-align: bottom; text-indent: 9pt; width: 76%; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;" valign="bottom">Forfeited</td> <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">(243,312</td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;" valign="bottom">)</td> <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;" valign="bottom">2.09</td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td rowspan="1" style="vertical-align: bottom; width: 76%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">Outstanding at June 30, 2024</td> <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="vertical-align: bottom;

text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom">2,921,139</td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">$</td> <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">1.65</td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td rowspan="1" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td rowspan="1" style="vertical-align: bottom; width: 76%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">Vested and exercisable at June 30, 2024</td> <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">1,207,595</td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">$</td> <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">2.53</td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> </table> 2102030 2 1062421 1.06 243312 2.09 2921139 1.65 1207595 2.53 Options granted under our 2021 Stock Option Plan for the six months ended June 30, 2024 to employees and nonemployees were 1,059,921 and 2,500, respectively and the weighted average exercise prices were $1.06 and $0.79, respectively. The weighted-average fair values of the options granted to employees and nonemployees were $0.90 and $0.39, respectively and were estimated using the following Black-Scholes assumptions:
  <table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="letter-spacing: normal; word-spacing: 0px; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; text-transform: none; width: 100%;"> <tr> <td rowspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: center; font-weight: bold; vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="2" rowspan="1" style="vertical-align: bottom; text-align: center; font-weight: bold; border-bottom: #000000 solid 2px;" valign="bottom">Employee
 </td> <td colspan="1" rowspan="1" style="font-weight: bold; text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: center; font-weight: bold; vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="2" rowspan="1" style="text-align: center; vertical-align: bottom; font-weight: bold; border-bottom: #000000 solid 2px;" valign="bottom"> Nonemployee</td> <td colspan="1" rowspan="1" style="font-weight: bold; text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-weight: normal; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; font-family: 'Times New Roman';">Expected term (in years) </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
  </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> 6.25 </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">1.50</td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; white-space: nowrap;" valign="bottom"> Risk-free interest rate </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"> 4.06 </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> % </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">4.53</td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">%</td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-weight: normal; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; font-family: 'Times New Roman';">Dividend yield </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> - </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> % </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">-</td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">%</td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; white-space: nowrap;" valign="bottom"> <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-weight: normal; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; font-family: 'Times New Roman';">Expected volatility </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"> 110.40 </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> % </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">105.34</td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">%</td> </tr> </table> 1059921 2500 1.06 0.79 0.9 0.39 P6Y3M P1Y6M 0.0406 0.0453 0 0 1.104

1.0534 0 676741 On February 12, 2024, the Company awarded, outside the 2021 Plan, our Chief Commercial Officer a stock option grant for the right to purchase 100,000 shares of common stock at an exercise price of $1.10 per share (inducement grant), which was approved by the Compensation committee. The inducement grant will vest in equal installments over four years provided the employee remains employed by the Company on the vesting date. The fair value of the inducement grant was $0.94 and was estimated using the following assumptions: </div> <div>
 </div> <table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"> <tr> <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> <div style="text-align: left; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;"> </div> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: center; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Inducement</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 88%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="text-align: left; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">Expected term (in years) </div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">
 </div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">6.25</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 88%; white-space: nowrap;" valign="bottom"> <div style="text-align: left; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">Risk-free interest rate</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">4.10</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">% </div> </td> </tr> <tr> <td style="vertical-align: bottom; width: 88%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="text-align: left; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">Dividend yield</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">- </div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">% </div> </td> </tr> <tr> <td style="vertical-align: bottom; width: 88%; white-space: nowrap;" valign="bottom"> <div style="text-align: left; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">Expected volatility</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">109.64</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">% </div> </td> </tr> </table> 100000 1.1 P4Y 0.94 P6Y3M 0.041 0 1.0964 250000 1.89 62500 2.64 <div style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">The following table shows the share-based compensation expense related to vested stock option grants to employees and nonemployees by financial statement line item on the accompanying condensed statement of comprehensive loss:</div> <div style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">
 </div> <div style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> <table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"> <tr> <td rowspan="1" style="vertical-align: bottom; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="6" rowspan="1" style="vertical-align: bottom; text-align: center; border-bottom: #000000 solid 2px;" valign="bottom">Three Months Ended June 30,</td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="6" rowspan="1" style="text-align: center; vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom">Six Months Ended June 30,</td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">2024 </div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">2023 </div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: center; font-weight: bold; vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="2" style="text-align: center; vertical-align: bottom; font-weight: bold; border-bottom: #000000 solid 2px;" valign="bottom">2024</td> <td colspan="1" style="font-weight: bold; text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: center; font-weight: bold; vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="2" style="text-align: center; vertical-align: bottom; font-weight: bold; border-bottom: #000000 solid 2px;" valign="bottom">2023</td> <td colspan="1" style="font-weight: bold; text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;" valign="bottom"> <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Research and development</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$ </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> 34,629 </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt;

font-variant: normal; text-transform: none;">27,192 </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">64,637</td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">52,251</td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 52%;" valign="bottom"> Sales and marketing </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"> 18,246 </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"> 602 </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">24,764</td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">(1,942</td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">)</td> </tr> <tr> <td style="vertical-align: bottom; width: 52%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"> General and administrative </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> 51,138 </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> 37,422 </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">92,197</td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">71,861</td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 52%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"> Total share-based compensation expense </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"> $ </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"> 104,013 </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"> 65,216 </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">181,598</td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">122,170</td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"> </td> </tr> </table>
   34629 27192 64637 52251 18246 602 24764 -1942 51138 37422 92197 71861 104013 65216 181598 122170 1516737 155222 1361515 P3Y3M18D 12081 10390 3858 1697 591437 1318000 1878722 3196722 191803 0.0001 P5Y6M 1.095 P5Y 1.525 3899813 547764 The common stock was valued at $1,133,480, based on the Company's stock price. The pre-funded warrants and common warrants were valued at $1,615,701 and $1,854,099, respectively, using the following Black-Scholes assumptions:
  <table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="letter-spacing: normal; word-spacing: 0px; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; text-align: left; text-transform: none; width: 100%;"> <tr> <td style="vertical-align: bottom; color: rgb(0, 0, 0); padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="color: rgb(0, 0, 0); vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; color: rgb(0, 0, 0); border-bottom: #000000 solid 2px;" valign="bottom"> Pre-funded warrants </td> <td colspan="1" style="color: rgb(0, 0, 0); text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="color: rgb(0, 0, 0); vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; color: rgb(0, 0, 0); border-bottom: #000000 solid 2px;" valign="bottom"> Common warrants </td> <td colspan="1" style="color: rgb(0, 0, 0); text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; color: rgb(0, 0, 0); width: 76%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> Expected term (in years) </td> <td

colspan="1" style="color: rgb(0, 0, 0); text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="color: rgb(0, 0, 0); text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
  </td> <td colspan="1" style="color: rgb(0, 0, 0); vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> 4 </td> <td colspan="1" style="color: rgb(0, 0, 0); text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="color: rgb(0, 0, 0); text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="color: rgb(0, 0, 0); text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="color: rgb(0, 0, 0); vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> 4 </td> <td colspan="1" style="color: rgb(0, 0, 0); text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; color: rgb(0, 0, 0); width: 76%; white-space: nowrap;" valign="bottom"> Risk-free interest rate </td> <td colspan="1" style="color: rgb(0, 0, 0); text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="color: rgb(0, 0, 0); text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="color: rgb(0, 0, 0); vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"> 3.83 </td> <td colspan="1" style="color: rgb(0, 0, 0); text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> % </td> <td colspan="1" style="color: rgb(0, 0, 0); text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="color: rgb(0, 0, 0); text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="color: rgb(0, 0, 0); vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"> 3.83 </td> <td colspan="1" style="color: rgb(0, 0, 0); text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> % </td> </tr> <tr> <td style="vertical-align: bottom; color: rgb(0, 0, 0); width: 76%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> Dividend yield </td> <td colspan="1" style="color: rgb(0, 0, 0); text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="color: rgb(0, 0, 0); text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="color: rgb(0, 0, 0); vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> – </td> <td colspan="1" style="color: rgb(0, 0, 0); text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">%
</td> <td colspan="1" style="color: rgb(0, 0, 0); text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="color: rgb(0, 0, 0); text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="color: rgb(0, 0, 0); vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> – </td> <td colspan="1" style="color: rgb(0, 0, 0); text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">%</td> </tr> <tr> <td style="vertical-align: bottom; color: rgb(0, 0, 0); width: 76%; white-space: nowrap;" valign="bottom"> Expected volatility </td> <td colspan="1" style="color: rgb(0, 0, 0); text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="color: rgb(0, 0, 0); text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="color: rgb(0, 0, 0); vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"> 100.25 </td> <td colspan="1" style="color: rgb(0, 0, 0); text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> % </td> <td colspan="1" style="color: rgb(0, 0, 0); text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="color: rgb(0, 0, 0); text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="color: rgb(0, 0, 0); vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"> 100.25 </td> <td colspan="1" style="color: rgb(0, 0, 0); text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> % </td> </tr> <tr> <td style="vertical-align: bottom; color: rgb(0, 0, 0); width: 76%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> Exercise price </td> <td colspan="1" style="color: rgb(0, 0, 0); text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="color: rgb(0, 0, 0); text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> $</div> </td> <td colspan="1" style="color: rgb(0, 0, 0); vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div>0.0001</div> </td> <td colspan="1" style="color: rgb(0, 0, 0); text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="color: rgb(0, 0, 0); text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="color: rgb(0, 0, 0); text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div>$ </td> <td colspan="1" style="color: rgb(0, 0, 0); vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> 1.095 </td> <td colspan="1" style="color: rgb(0, 0, 0); text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; color: rgb(0, 0, 0); width: 76%; white-space: nowrap;" valign="bottom"> Stock price </td> <td colspan="1" style="color: rgb(0, 0, 0); text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="color: rgb(0, 0, 0); text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> $</div> </td> <td colspan="1" style="color: rgb(0, 0, 0); vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"> <div>0.86</div> </td> <td colspan="1" style="color: rgb(0, 0, 0); text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="color: rgb(0, 0, 0); text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="color: rgb(0, 0, 0); text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> <div>$ </td> <td colspan="1" style="color: rgb(0, 0, 0); vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"> 0.86 </td> <td colspan="1" style="color: rgb(0, 0, 0); text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td rowspan="1" style="vertical-align: bottom; color: rgb(0, 0, 0); width: 76%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">Black-Scholes value
 </td> <td colspan="1" rowspan="1" style="color: rgb(0, 0, 0); text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="color: rgb(0, 0, 0); text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">$</td> <td colspan="1" rowspan="1" style="color: rgb(0, 0, 0); vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">0.86</td> <td colspan="1" rowspan="1" style="color: rgb(0, 0, 0); text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="color: rgb(0, 0, 0); text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="color: rgb(0, 0, 0); text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">$</td> <td colspan="1" rowspan="1" style="color: rgb(0, 0, 0); vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">0.58</td> <td colspan="1" rowspan="1" style="color: rgb(0, 0, 0); text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> </table>
 1133480 1615701 1854099 P4Y P4Y 0.0383 0.0383 0 0 1.0025 1.0025 0.0001 1.095 0.86 0.86 0.86 0.58 3352049 122994 122994 3687976 3687976 68809 <table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%;"> <tr style="vertical-align: top;"> <td style="text-align: right; vertical-align: top; width: 27pt;"> (13) </td> <td style="text-align: left; vertical-align: top; width: auto;"> Related-Party Transactions </td> </tr> </table>
  In November 2023, the Company issued unsecured convertible notes and accompanying Series A and Series B Warrants (see Note 10). The transaction included issuance of a $5 million convertible note and Series A and Series B Warrants to PharmaCyte Biotech, Inc. The interim CEO, President and Director of PharmaCyte Biotech, Inc., Joshua Silverman, serves on the Company’s board of directors. In addition, during the year ended December 31, 2023 and six months ended June 30, 2024 and 2023, a family member of the CEO was employed by the Company.
  5000000 <table cellpadding="0" cellspacing="0" class="DSPFListTable" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;"> <tr style="vertical-align: top;"> <td style="vertical-align: top; width: 27pt;"> (14) </td> <td style="align: left; vertical-align: top; width: auto;"> Net Loss per Share Attributable to Common Stockholders </td> </tr> </table>   <div style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">The following table sets forth the computation of the basic and diluted net loss per share:
  <table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"> <tr> <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;"

valign="bottom"> Three Months Ended June 30, </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"> Six Months Ended June 30, </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> 2024
  </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> 2023
  </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> 2024
  </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> 2023
  </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; white-space: nowrap;" valign="bottom">
 </td> <td colspan="1" style="vertical-align: bottom;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 52%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"> Net loss attributable to common stockholders, basic & diluted </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> $ </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> (4,684,574 </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">) </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> (2,893,508 </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">) </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> (8,284,084 </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">) </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> (5,839,765 </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">) </td> </tr> <tr> <td rowspan="1" style="vertical-align: bottom; width: 52%;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 52%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" valign="bottom"> Weighted average number of shares used in computing net loss per share attributable to common stockholders, basic and diluted </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> 22,215,516
  </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> 13,107,590 </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> 21,995,436 </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> 12,493,334 </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 52%; padding-bottom: 4px;" valign="bottom"> <div

style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);">Net loss per share attributable to common stockholders, basic and diluted </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom"> $ </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom"> (0.21 </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">) </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom"> (0.22 </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">) </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom"> (0.38 </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">) </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom"> (0.47 </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">) </td> </tr> </table>
  The following potentially dilutive securities have been excluded from the computations of diluted weighted average shares outstanding because they would be anti-dilutive: <table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; color: rgb(0, 0, 0); width: 100%;"> <tr> <td rowspan="1" style="vertical-align: bottom; padding-bottom: 2px; width: 52.03%;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="vertical-align: bottom; padding-bottom: 2px; width: 1.04%; white-space: nowrap;" valign="bottom"> </td> <td colspan="6" rowspan="1" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"> Three Months Ended June 30, </td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; width: 1.04%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="vertical-align: bottom; padding-bottom: 2px; width: 1.04%; white-space: nowrap;" valign="bottom"> </td> <td colspan="6" rowspan="1" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); width: 1.04%; white-space: nowrap;" valign="bottom"> Six Months Ended June 30, </td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; width: 1.04%; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td rowspan="1" style="vertical-align: bottom; padding-bottom: 2px; width: 52.03%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; width: 1.04%;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"> 2024 </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; width: 1.04%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; width: 1.04%;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"> 2023 </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; width: 1.04%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; width: 1.04%;" valign="bottom"> </td> <td colspan="2" rowspan="1" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); width: 1.04%;" valign="bottom"> 2024 </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; width: 1.04%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; width: 1.04%;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"> 2023 </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; width: 1.04%; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 52.03%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> Options to purchase common stock </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1.04%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1.04%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 8.99%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> 3,171,139 </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1.04%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1.04%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1.04%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 8.99%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> 1,169,671 </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1.04%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1.04%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1.04%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 8.99%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> 3,171,139 </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1.04%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1.04%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1.04%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 8.99%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> 1,169,671 </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1.04%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td rowspan="1" style="vertical-align: bottom; width: 52.03%; white-space: nowrap;" valign="bottom">Warrants to purchase common stock, in connection with April 2023 financing </td> <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1.04%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1.04%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 8.99%; white-space: nowrap;" valign="bottom">68,809</td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1.04%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1.04%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1.04%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 8.99%; white-space: nowrap;" valign="bottom">3,388,525</td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1.04%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1.04%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1.04%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 8.99%; white-space: nowrap;" valign="bottom">68,809</td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1.04%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1.04%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1.04%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 8.99%; white-space: nowrap;" valign="bottom">3,388,525</td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1.04%; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 52.03%; white-space: nowrap;" valign="bottom">Warrants to purchase common stock, in connection with November 2023 financing </td> <td colspan="1" style="text-align: right; vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1.04%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1.04%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; background-color: rgb(204, 238, 255); width: 8.99%; white-space: nowrap;" valign="bottom">11,610,166</td> <td colspan="1" style="text-align: left; vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1.04%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1.04%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1.04%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; background-color: rgb(204, 238, 255); width: 8.99%; white-space: nowrap;"

valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1.04%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1.04%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; background-color: rgb(204, 238, 255); width: 1.04%; white-space: nowrap;" valign="bottom"> </td> <td rowspan="1" style="vertical-align: bottom; text-align: right; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">11,610,166</td> <td colspan="1" style="text-align: left; vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1.04%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1.04%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1.04%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; background-color: rgb(204, 238, 255); width: 8.99%; white-space: nowrap;" valign="bottom">-</td> <td colspan="1" style="text-align: left; vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1.04%; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 52.03%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> Warrants to purchase common stock </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1.04%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1.04%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 8.99%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"> 196,816 </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1.04%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1.04%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1.04%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 8.99%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"> 233,460 </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1.04%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1.04%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1.04%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 8.99%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"> 196,816 </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1.04%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1.04%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1.04%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 8.99%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"> 233,460 </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1.04%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td rowspan="1" style="vertical-align: bottom; width: 52.03%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> Total potential shares </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1.04%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1.04%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 8.99%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> 15,046,930 </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1.04%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1.04%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1.04%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 8.99%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> 4,791,656 </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1.04%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1.04%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1.04%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 8.99%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> 15,046,930 </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1.04%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1.04%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1.04%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 8.99%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> 4,791,656 </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1.04%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> </td> </tr> </table> <div style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">The following table sets forth the computation of the basic and diluted net loss per share:
  <table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"> <tr> <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"> Three Months Ended June 30, </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"> Six Months Ended June 30, </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> 2024
  </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> 2023
  </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> 2024
  </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> 2023
  </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; white-space: nowrap;" valign="bottom">
 </td> <td colspan="1" style="vertical-align: bottom;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 52%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"> Net loss attributable to common stockholders, basic & diluted </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> $ </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space:

nowrap;" valign="bottom"> (4,684,574 </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">) </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> (2,893,508 </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">) </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> (8,284,084 </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">) </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> (5,839,765 </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">) </td> </tr> <tr> <td rowspan="1" style="vertical-align: bottom; width: 52%;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 52%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" valign="bottom"> Weighted average number of shares used in computing net loss per share attributable to common stockholders, basic and diluted </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> 22,215,516
  </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> 13,107,590 </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> 21,995,436 </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> 12,493,334 </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 52%; padding-bottom: 4px;" valign="bottom"> Net loss per share attributable to common stockholders, basic and diluted </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom"> $ </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom"> (0.21 </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">) </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom"> (0.22 </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">) </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom"> (0.38 </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">) </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom"> (0.47 </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">) </td> </tr> </table> -4684574 -4684574 -2893508 -2893508 -8284084 -8284084 -5839765 -5839765 22215516 22215516 13107590 13107590 21995436 21995436 12493334 12493334 -0.21 -0.21 -0.22 -0.22 -0.38 -0.38 -0.47 -0.47 The following potentially dilutive securities have been excluded from the computations of diluted weighted average shares outstanding because they would be anti-dilutive: <table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; color: rgb(0, 0, 0); width: 100%;"> <tr> <td rowspan="1" style="vertical-align: bottom; padding-bottom: 2px; width: 52.03%;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="vertical-align: bottom; padding-bottom: 2px; width: 1.04%; white-space: nowrap;" valign="bottom"> </td> <td colspan="6" rowspan="1" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"> Three Months Ended June 30, </td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; width: 1.04%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="vertical-align: bottom; padding-bottom: 2px; width: 1.04%; white-space: nowrap;" valign="bottom"> </td> <td colspan="6" rowspan="1" style="vertical-align: bottom; border-bottom: 2px solid

rgb(0, 0, 0); width: 1.04%; white-space: nowrap;" valign="bottom"> Six Months Ended June 30, </td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; width: 1.04%; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td rowspan="1" style="vertical-align: bottom; padding-bottom: 2px; width: 52.03%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; width: 1.04%;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"> 2024 </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; width: 1.04%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; width: 1.04%;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"> 2023 </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; width: 1.04%; white-space: nowrap;" valign="bottom"> </td> <td colspan="2" rowspan="1" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); width: 1.04%;" valign="bottom"> 2024 </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; width: 1.04%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; width: 1.04%;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"> 2023 </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; width: 1.04%; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 52.03%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> Options to purchase common stock </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1.04%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1.04%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 8.99%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> 3,171,139 </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1.04%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1.04%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1.04%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 8.99%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> 3,171,139 </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1.04%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1.04%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1.04%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 8.99%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> 1,169,671 </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1.04%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td rowspan="1" style="vertical-align: bottom; width: 52.03%; white-space: nowrap;" valign="bottom">Warrants to purchase common stock, in connection with April 2023 financing </td> <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1.04%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1.04%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 8.99%; white-space: nowrap;" valign="bottom">68,809</td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1.04%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1.04%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1.04%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 8.99%; white-space: nowrap;" valign="bottom">3,388,525</td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1.04%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1.04%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1.04%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 8.99%; white-space: nowrap;" valign="bottom">68,809</td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1.04%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1.04%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1.04%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 8.99%; white-space: nowrap;" valign="bottom">3,388,525</td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1.04%; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 52.03%; white-space: nowrap;" valign="bottom">Warrants to purchase common stock, in connection with November 2023 financing </td> <td colspan="1" style="text-align: right; vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1.04%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1.04%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; background-color: rgb(204, 238, 255); width: 8.99%; white-space: nowrap;" valign="bottom">11,610,166</td> <td colspan="1" style="text-align: left; vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1.04%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1.04%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1.04%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; background-color: rgb(204, 238, 255); width: 8.99%; white-space: nowrap;" valign="bottom">—</td> <td colspan="1" style="text-align: left; vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1.04%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1.04%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; background-color: rgb(204, 238, 255); width: 1.04%; white-space: nowrap;" valign="bottom"> </td> <td rowspan="1" style="vertical-align: bottom; text-align: right; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">11,610,166</td> <td colspan="1" style="text-align: left; vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1.04%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1.04%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1.04%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; background-color: rgb(204, 238, 255); width: 8.99%; white-space: nowrap;" valign="bottom">—</td> <td colspan="1" style="text-align: left; vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1.04%; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 52.03%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> Warrants to purchase common stock </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1.04%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1.04%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 8.99%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"> 196,816 </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1.04%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1.04%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1.04%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 8.99%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"> 233,460 </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1.04%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1.04%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1.04%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 8.99%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"> 196,816 </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1.04%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1.04%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1.04%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 8.99%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"> 233,460 </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1.04%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td rowspan="1"

style="vertical-align: bottom; width: 52.03%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> Total potential shares </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1.04%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1.04%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 8.99%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> 15,046,930 </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1.04%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1.04%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1.04%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 8.99%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> 4,791,656 </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1.04%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1.04%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1.04%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 8.99%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> 15,046,930 </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1.04%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1.04%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1.04%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1.04%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> 4,791,656 </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1.04%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> </td> </tr> </table> 3171139 1169671 3171139 1169671 68809 3388525 68809 3388525 11610166 0 11610166 0 196816 233460 196816 233460 15046930 4791656 15046930 4791656 <table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%;"> <tr style="vertical-align: top;"> <td style="text-align: right; vertical-align: top; width: 27pt;"> (15) </td> <td style="text-align: left; vertical-align: top; width: auto;"> Income Taxes
  </td> </tr> </table>
  The effective tax rate of 0% for the three and six months ended June 30, 2024 and 2023 was lower than the statutory rate due to the Company remaining in a full valuation allowance position. 0 0 0 0 false false false false

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{[VGG9\![.ZJBY#=VU#ALRG:%8-FVJ]NKB^NGKU%K&D\C]31,+@+F#;C=L\ M#-]E 9V3D8)'^_9XD5"(5:MOWB/'&? KU7V5MEW(Z1SF+2PC5:9 =KZM8'PK! M];6%%KM8I"G:!DE*N24HQ/1?'U<'.?[)<4+MTL+S/U4@3RK]U#QP@G!:Z:'F M@PH"' -TX), ?8445I#ARA_! M/WG@!]GA*@X#[R [H305K'A/>3,;'9!Q!0]))@1)%6"4;G/>.DJ*/7Y,L78$(QD]/23""#_7,U6/T7318 MSSDX$*A(?+ 55BR][M1[V;0;$0G:.&E_Y(G# 1@)D{[R,KG#4? _<00I\K]@ M50'[+DT(DFK2*-WF(TZ2 PMYQ-8$3LN=AEM,V7EL MWX,0M@61<5V*;\/@#HM[6D'DY0D[LLU+'. #.Y]_PK9",DQ%L0NR,?(*J2A€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|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{J=Z'^-A08004U_)&$]13Y'?R:_ND.W._)$8!QD#_CRB_!+\T##:1T,+#25H49\"#5U-#\2U_31+B49W&R_M*P97& (S+:R.S+7\V0\WRBEJ14KH/$92Q"Q_MP'@1,&MVG<** &*%X;LF!94_&$&X$9AHQN!@7<:'L.)]OB*:2PNM3I{(G2-_MKG?;!Y0M'@=7?WB^Q*ALD^%,KZS/_!NC!C#L- "MIP!C64;5_R+J+J2[^&9:6_M_U)<.D!(_E4Q%I3B:AI8CHU)^4B6]_H=3BK"3EYC=Z0+1LK+Q:1U?X?Z"J*-@Q!-^'U[6_M;KZ[OQXJ-056"R6X#LICRUS.;M@%>2V!8BPDEG? A&=C@8@0JIB14)6X_>_M.*I:W^3VY8)_1M(L3+DD_IL>(}JFU?D<1T0[.#[Z$23SY0(%1"M/EQP.='2$_MU<20@G60]PK8)+Y<_,F)!.F2PX$,2#Q-K(AX!AD!Q_AYAK=$- NYH)*#I#4<#_M&O\1_A'.:$_:L#2/5_$F-4Q_38GU%F@"+98\JXPO4EY!SOI;F:Z(QRBCF40K_MW_$!NZSM$#B*6:*S:W2&JC\OT^&VR"U.D@NF_M#BFUO*G%]//- :]:D2$)OX!^>4!9CNM69%0ZG_:?R?(B!YX0<_2>8R*,Q):S& M?.O_#V_=_?M>([!E].B7_;B4+X'I[%/T+_;<^_JRHTLX:1=G@"R4=H#&I*8T_MV,2PXL<$NZ%E0RM7> [;+R'JZPG/9.^C/]+V_,E%BXYQ/TE6SU\>;8(UDU9V*_M&;,*$:$6E6=G>F?F0,"\[[4EQOT%5NK#%(VDI^7I-_I{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{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{8R}V)E{&3"4*&EPBM\@N"_MV_TC/H(\PC#B9B*@(/;-A4)LBS5U_'*;DHK+_5]1H8OEI""_;S,W63Q6R35D_M;\:_:)DYI8_V5"1I:,_*D.3UA3Q9[/:1NF7W[;W

M&E87Y#XZWR%7><)^28E_E^2'E"@#D=48_\9&^70&(4MV*Z*Y,BO1XHE^@(VX_MENN2#MC6ZCJ"_C*U!:::+EAKK_DQ@G<]MI/D#]3K./32GM.C/RKTBS4Q'8)[
M=88;:]1,PBYP=HN>ZI>4I%@$%V_FR[("H:)15Q5-R\&'+AR[[N84VOH=<]#-W6*H-)@^W>[_M8S;4E."4V6TCINOOH$8$9W6;QK-I_X97G3W
M])24VHR21IN7Z2/.MA4*!>_]Z)5J$I!"2]D+;"OW/*)X=8$SR51>0-$9/_84_M;BZ4%XCTA((VYAH-L\YQO[87PYFO3LED,\6;,6_JKHAE6!ZRG>+/&_MPUF0V7BG-
VT!UQ%D,I1KG"Z)4/L;*^FJ/7LH'\$4W>?0+=>< (99V2B?^TC$6.^Y"W\15=G8%JPP%/H43F3!3:J#I(_M;GQCG#T5)@!^>:.U>3ODAOBY5"(/_W&CLDU:>+VR8<%VC&)&
%2S6F>0?HE6_M?'B[C?.3,/#8M*%ZZ18#,[',VH?_M#S5G%!:RK:EL!*3'M&&*%+0>+MY,EQ": 5;P6BQE"3SH_2+;!VE]0,OUU&Q_MRXAC_+3+XQ3E]
(&7JYA,&E8T5Z>+YSL[;30%:8Z3>%4!,%W==%30/DP3):TU_M1>M.JSR;AS[M\'3R0NJ8IM/7?Q*<$\S<$]!]2H:3K*G8VU_\E[TSIV<7EWAR_MU?
>=J)76EV^P6F^US27U03WS111GOT;)#KEPO6WE>YV*/"J$M+DA(B5U&_MTR*1,P/12B3UP>+P'J"':N[CV*Y_M?!![KU7A$X9*2O89;!ZETU>_U1T<0BH6TX=N#+$3UA*4?
2M!R+_WYK;E;NIN_MC.Z?M#GII?712MZ<^T6):&0&4.YS2X@IG3P?+3KC[+RGH>[_([FTIXB&7)QU_M>XCAL2WU]#V"I.KJ]-"PRF#']%-
"$R^CY.\X63U$1!1[1YD,9]'\7$'6S$J%_M9!8/7YDZA#-K%9V@S3[T/:6Z,5P^9HXLX%S.CL4<@^TYMXC,'G:(OC*^3LLC_M*A?#;=T*>N9[BM-
2X5_C8G.ZRPN\1:*P<K3"'!@J6;^/\KE6_5\";L'V.N)0_MGE%6T)>[R@Y()S#-*PG7^!EM'U!&0/53&TYE<86M6[5P8!_)IQW'C/G8C*#6_M;(1X2!_+R%0M/CB&\9C
%E7(3@$,VU9-!\S;%*R3*L._-S@AS<^K5SA<3!"J_MF@5.B/^QMC_[T4FN@8$.*7[44P/MJCJO5+1/GXI
MZN*&Q9N>KEW<<8>'VQZ/5@[/(2CK+SV%=KW!.HSR*AA:$;,5K_=$$3E104S?_M37&R#U^VY89MB__D_D;>[KNKR-V=.Z&U@W2R'(BRE*RO]FT4_M3#<49,W\0DCFPB.PK1'U?
R6=0#H?^K;2,!@N'S/*"SC3GBOA&&(_[>1\8Q_M:369)=_4FB=TH;&N;N*-[;_Y6OZPQL_OT7)5PWBYVJ.7_..W0=U$%E3>QQ[@_M5D78HE9,.+9OJN6YW27HPX\/?_Q
*CY9X2=R,BOBZ"S1DB8LKG$*0X::<)]_+51\@&74@8B,J;,<2".9@$5;;0=(_MKP)IDQ_39!-7\2G*XWSQ6%];(SZ\DDV.=+U"M:F@A8X'V49JF@C1T+98SA9_
M&!#_0M\U/\^+>M9S+_\4G43_M85R_59;>V7*5^.>^3)\PI_^9*A!QN4&K74(&XK9II[N,=K)2\<(_1,UB3>_A_MN)CO*8(,%:"5+@A>1XC'G$SJ('?]_$TD$-
IC:9A@!MC3H04'?5U=T/?,0,9*_MT$H&I%-+L*'#@\PLIOW^:+(_[\@$[JAF;0;?59>-UBB%+VH%G_M(#*O,-BN/4Q0Y&Y0G],4#15Q3JR9I5'2-
"S_]/H9X746/6WBY0E]N5GJ8"QP_M&BI,GU.@^8U&JLQ&RB/])H2XKE#AU<_M%SWY%F4K81*@:;@WR8-L@!3!>6#7.E_@Z*/!_MU\D%P^U3@E\1JESUMY18?
Q,_4:R>WRUN.J_.?'JE/YZ\Q&QDQ0@.S?S'A(-_MRJ)_GN%M%*=:&AH6_ZFE6\S>IM7]-_SCQP^=<9M6\Z5,9L0(!:"LY9!2NAL_M={V"=61F1@)@770HD-;AVXOGE^EJ5QU3?
Z9C&AJQDS//=MMHV_MT=Y*LUR39)5CK29W_LT>9_7[59:_T\!/:&0.NNX?3FY5DD;GF%]E+50$W"4'553_MZ'UH&I5;[576FACLO7C-=('N_HF..6G@'IILN^C]SR4!]%F<[_JT
KH](RX#_MEZ;)Q>MTA'9T_T]6:%Q?F%L3K;1?4;S>$+%.GE$6K='UCNYZUAX7.F@;\!A@_M5XM'(,@UUXL);K5JL[1>\#(CS!DJHCB9$\+P>_::$_:@&D_I6_H8MS.+IMLN
MGD@OIE=5[]"Z2F'9%UU)UUQ$%M-Y<>,88C8,%U=\>5A247D]6%R!;T?"35-O_M,KS:+8O\%BT164JMSG_YXV4IO_@]}BP88.FQ"!%S_M(Y0T&HYZ=3N+25,@]2LF7>D7LGR_0%LZ
;G_&9G+;*.4;F[&6;$I8_%Q(D"I_M;G$&H?#B(:+34#FCD0FOU[?L-(T$_T!1]G6#,E2*9990X_M&N$50>8]!32\LN45!AO3](H>2USVC6BG$5%),.=-A,>##68!(M*_M4T79_:E&
[35F_^@+9HD/CS'M72!P_JF;!"0JZI#@IB>Z,;Z4U=0_^I,O_+H@_M[AE_^^6I;;B.LS,K7.M8MW!(:!NE&&/PZ=9;8_'/@09T'SHOM&_3U4U"Z'UC_M?-
N4:T\?!%O5PN]LDE.WV\^G4;ZAVTOD#QJI\1PEI86*TRC+7N-T7<9;,*)I_ME6G2_\'*..ME8G-A,X'[_67_OGSO'L8VR_/G:U14[XW1V!5V\<#[UN91[7WS_M$P\R
0!V9XH'F1G\EIZYIFC5'%6?+)>[[:Y\N?4,/<;+>)@P"%J@37VC+N_G_M/+1%!6_&PM-R*&G('L1:"X5*0M1!$+)^<_M.)V8M<&N)WF.BBK>IHN4NR^@3463RC-.L^6?Y+_4O:8-U
MOLTZUQY?I^K^]-K^]>\QRHCOVKQ>H6>4PLDY5U_$$AI#6W;_K,YP+RO:'RZQX;@A,-78=O6LJ6A/D#L1'>%*_M79TF49[+!W,^W7#\9ND\F"=R3%_:^I<4/^0H>Z8F+
[TFS3U,5C))7_*J*XM_M=)^H&OXLTF(U+FSS!:?HE<;MH>)BEZYR[G1!3E3K143DBU^TCP<,U(S4+5IK_M%O62HN8

"